Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,22943969,C(max),"Plasma concentrations of lidocaine increased rapidly during the first 2 hours of application in each heated-patch group, and with mean (SD) C(max) values of 18.2 (5.1), 25.7 (5.9), and 30.3 (8.1) ng/mL in the 2-, 4-, and 12-hour groups, respectively.","Effects of application durations and heat on the pharmacokinetic properties of drug delivered by a lidocaine/tetracaine patch: a randomized, open-label, controlled study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943969/),[ng] / [ml],18.2,224,DB00281,Lidocaine
,22943969,C(max),"Plasma concentrations of lidocaine increased rapidly during the first 2 hours of application in each heated-patch group, and with mean (SD) C(max) values of 18.2 (5.1), 25.7 (5.9), and 30.3 (8.1) ng/mL in the 2-, 4-, and 12-hour groups, respectively.","Effects of application durations and heat on the pharmacokinetic properties of drug delivered by a lidocaine/tetracaine patch: a randomized, open-label, controlled study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943969/),[ng] / [ml],25.7,225,DB00281,Lidocaine
,22943969,C(max),"Plasma concentrations of lidocaine increased rapidly during the first 2 hours of application in each heated-patch group, and with mean (SD) C(max) values of 18.2 (5.1), 25.7 (5.9), and 30.3 (8.1) ng/mL in the 2-, 4-, and 12-hour groups, respectively.","Effects of application durations and heat on the pharmacokinetic properties of drug delivered by a lidocaine/tetracaine patch: a randomized, open-label, controlled study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943969/),[ng] / [ml],30.3,226,DB00281,Lidocaine
,8623997,highest measured plasma concentration,The highest measured plasma concentration was 15.3 micrograms.,Derivation and cross-validation of pharmacokinetic parameters for computer-controlled infusion of lidocaine in pain therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8623997/),μg,15.3,1197,DB00281,Lidocaine
,8623997,V1,"The final parameters ( +/- population variability expressed as %CV) were estimated as follows: V1 0.101 +/- 53% 1.kg-1, V2 0.452 +/- 33% 1.kg-1, Cl1 0.0215 +/- 25% 1.kg-1.min-1, and Cl2 0.0589 +/- 35% 1.kg-1.min-1.",Derivation and cross-validation of pharmacokinetic parameters for computer-controlled infusion of lidocaine in pain therapy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8623997/),[%·1] / [kg],0.101,1198,DB00281,Lidocaine
,8623997,V2,"The final parameters ( +/- population variability expressed as %CV) were estimated as follows: V1 0.101 +/- 53% 1.kg-1, V2 0.452 +/- 33% 1.kg-1, Cl1 0.0215 +/- 25% 1.kg-1.min-1, and Cl2 0.0589 +/- 35% 1.kg-1.min-1.",Derivation and cross-validation of pharmacokinetic parameters for computer-controlled infusion of lidocaine in pain therapy. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8623997/),[%·1] / [kg],0.452,1199,DB00281,Lidocaine
,8623997,Cl1,"The final parameters ( +/- population variability expressed as %CV) were estimated as follows: V1 0.101 +/- 53% 1.kg-1, V2 0.452 +/- 33% 1.kg-1, Cl1 0.0215 +/- 25% 1.kg-1.min-1, and Cl2 0.0589 +/- 35% 1.kg-1.min-1.",Derivation and cross-validation of pharmacokinetic parameters for computer-controlled infusion of lidocaine in pain therapy. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8623997/),[%·1] / [kg·min],0.0215,1200,DB00281,Lidocaine
,8623997,Cl2,"The final parameters ( +/- population variability expressed as %CV) were estimated as follows: V1 0.101 +/- 53% 1.kg-1, V2 0.452 +/- 33% 1.kg-1, Cl1 0.0215 +/- 25% 1.kg-1.min-1, and Cl2 0.0589 +/- 35% 1.kg-1.min-1.",Derivation and cross-validation of pharmacokinetic parameters for computer-controlled infusion of lidocaine in pain therapy. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8623997/),[%·1] / [kg·min],0.0589,1201,DB00281,Lidocaine
,25455873,maximum plasma concentration,"From the phase-I study (15 participants), mean pharmacokinetic values were: maximum plasma concentration: 351 ± 205 ng/mL; time taken to reach maximum concentration: 68 ± 41 minutes; and area under the concentration-time curve from 0 to 180 minutes: 717 ± 421 ng*h/mL.",Novel topical formulation of lidocaine provides significant pain relief for intrauterine device insertion: pharmacokinetic evaluation and randomized placebo-controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25455873/),[ng] / [ml],351,1235,DB00281,Lidocaine
,25455873,time taken to reach maximum concentration,"From the phase-I study (15 participants), mean pharmacokinetic values were: maximum plasma concentration: 351 ± 205 ng/mL; time taken to reach maximum concentration: 68 ± 41 minutes; and area under the concentration-time curve from 0 to 180 minutes: 717 ± 421 ng*h/mL.",Novel topical formulation of lidocaine provides significant pain relief for intrauterine device insertion: pharmacokinetic evaluation and randomized placebo-controlled trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25455873/),min,68,1236,DB00281,Lidocaine
,25455873,area under the concentration-time curve from 0 to 180 minutes,"From the phase-I study (15 participants), mean pharmacokinetic values were: maximum plasma concentration: 351 ± 205 ng/mL; time taken to reach maximum concentration: 68 ± 41 minutes; and area under the concentration-time curve from 0 to 180 minutes: 717 ± 421 ng*h/mL.",Novel topical formulation of lidocaine provides significant pain relief for intrauterine device insertion: pharmacokinetic evaluation and randomized placebo-controlled trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25455873/),[h·ng] / [ml],717,1237,DB00281,Lidocaine
,16454639,volume of distribution at steady state,"Mean +/- SD volume of distribution at steady state, total body clearance, and terminal half-life were 0.70 +/- 0.39 L/kg, 25 +/- 3 mL/kg/min, and 65 +/- 33 minutes, respectively.",Influence of gastrointestinal tract disease on pharmacokinetics of lidocaine after intravenous infusion in anesthetized horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454639/),[l] / [kg],0.70,1702,DB00281,Lidocaine
,16454639,total body clearance,"Mean +/- SD volume of distribution at steady state, total body clearance, and terminal half-life were 0.70 +/- 0.39 L/kg, 25 +/- 3 mL/kg/min, and 65 +/- 33 minutes, respectively.",Influence of gastrointestinal tract disease on pharmacokinetics of lidocaine after intravenous infusion in anesthetized horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454639/),[ml] / [kg·min],25,1703,DB00281,Lidocaine
,16454639,terminal half-life,"Mean +/- SD volume of distribution at steady state, total body clearance, and terminal half-life were 0.70 +/- 0.39 L/kg, 25 +/- 3 mL/kg/min, and 65 +/- 33 minutes, respectively.",Influence of gastrointestinal tract disease on pharmacokinetics of lidocaine after intravenous infusion in anesthetized horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454639/),min,65,1704,DB00281,Lidocaine
,16454639,HR,"Mean HR ranged from 36 +/- 1 beats/min to 43 +/- 9 beats/min, and mean MAP ranged from 74 +/- 18 mm Hg to 89 +/- 10 mm Hg.",Influence of gastrointestinal tract disease on pharmacokinetics of lidocaine after intravenous infusion in anesthetized horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454639/),[beats] / [min],36,1705,DB00281,Lidocaine
,16454639,HR,"Mean HR ranged from 36 +/- 1 beats/min to 43 +/- 9 beats/min, and mean MAP ranged from 74 +/- 18 mm Hg to 89 +/- 10 mm Hg.",Influence of gastrointestinal tract disease on pharmacokinetics of lidocaine after intravenous infusion in anesthetized horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16454639/),[beats] / [min],43,1706,DB00281,Lidocaine
,11851636,clearance,"Interestingly there was no significant change in the clearance of lignocaine (6.4 vs 5.8 (95% CI for the difference -2.74, -1.51) ml kg-1 min-1).",Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11851636/),kg·ml,6.4,2363,DB00281,Lidocaine
,11851636,clearance,"Interestingly there was no significant change in the clearance of lignocaine (6.4 vs 5.8 (95% CI for the difference -2.74, -1.51) ml kg-1 min-1).",Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11851636/),kg·ml,5.8,2364,DB00281,Lidocaine
≥,31572990,time to TOF,"With a TOF Watch SX device, the time to TOF ≥0.9 was recorded.","Effect of Concurrent Lidocaine, Remifentanil and Methylprednisolone Use on the Clinical Effect of Sugammadex under General Anaesthesia in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31572990/),,0.9,3123,DB00281,Lidocaine
≥,31572990,time to TOF,"However, in Group 2, time to TOF ≥0.9 was prolonged significantly when compared with the control group.","Effect of Concurrent Lidocaine, Remifentanil and Methylprednisolone Use on the Clinical Effect of Sugammadex under General Anaesthesia in Rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31572990/),,0.9,3124,DB00281,Lidocaine
,3857018,total plasma clearances,"After intravenous bolus injections of 0.5, 1, and 2 g of cefotiam to three healthy volunteers, the mean (+/- standard deviation) total plasma clearances measured for each dose were, respectively, 26.8 +/- 2.7, 22.8 +/- 0.8, and 17.8 +/- 0.9 liters/h; the terminal elimination half-lives were 54.0 +/- 0.1, 68 +/- 15, and 98 +/- 36 min; and the renal clearances were 16.0 +/- 2.9, 13.3 +/- 1.4, and 11.3 +/- 2.6 liters/h.",Pharmacokinetics of cefotiam in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3857018/),[l] / [h],26.8,3613,DB00281,Lidocaine
,3857018,total plasma clearances,"After intravenous bolus injections of 0.5, 1, and 2 g of cefotiam to three healthy volunteers, the mean (+/- standard deviation) total plasma clearances measured for each dose were, respectively, 26.8 +/- 2.7, 22.8 +/- 0.8, and 17.8 +/- 0.9 liters/h; the terminal elimination half-lives were 54.0 +/- 0.1, 68 +/- 15, and 98 +/- 36 min; and the renal clearances were 16.0 +/- 2.9, 13.3 +/- 1.4, and 11.3 +/- 2.6 liters/h.",Pharmacokinetics of cefotiam in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3857018/),[l] / [h],22.8,3614,DB00281,Lidocaine
,3857018,total plasma clearances,"After intravenous bolus injections of 0.5, 1, and 2 g of cefotiam to three healthy volunteers, the mean (+/- standard deviation) total plasma clearances measured for each dose were, respectively, 26.8 +/- 2.7, 22.8 +/- 0.8, and 17.8 +/- 0.9 liters/h; the terminal elimination half-lives were 54.0 +/- 0.1, 68 +/- 15, and 98 +/- 36 min; and the renal clearances were 16.0 +/- 2.9, 13.3 +/- 1.4, and 11.3 +/- 2.6 liters/h.",Pharmacokinetics of cefotiam in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3857018/),[l] / [h],17.8,3615,DB00281,Lidocaine
,3857018,terminal elimination half-lives,"After intravenous bolus injections of 0.5, 1, and 2 g of cefotiam to three healthy volunteers, the mean (+/- standard deviation) total plasma clearances measured for each dose were, respectively, 26.8 +/- 2.7, 22.8 +/- 0.8, and 17.8 +/- 0.9 liters/h; the terminal elimination half-lives were 54.0 +/- 0.1, 68 +/- 15, and 98 +/- 36 min; and the renal clearances were 16.0 +/- 2.9, 13.3 +/- 1.4, and 11.3 +/- 2.6 liters/h.",Pharmacokinetics of cefotiam in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3857018/),min,54.0,3616,DB00281,Lidocaine
,3857018,terminal elimination half-lives,"After intravenous bolus injections of 0.5, 1, and 2 g of cefotiam to three healthy volunteers, the mean (+/- standard deviation) total plasma clearances measured for each dose were, respectively, 26.8 +/- 2.7, 22.8 +/- 0.8, and 17.8 +/- 0.9 liters/h; the terminal elimination half-lives were 54.0 +/- 0.1, 68 +/- 15, and 98 +/- 36 min; and the renal clearances were 16.0 +/- 2.9, 13.3 +/- 1.4, and 11.3 +/- 2.6 liters/h.",Pharmacokinetics of cefotiam in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3857018/),min,68,3617,DB00281,Lidocaine
,3857018,terminal elimination half-lives,"After intravenous bolus injections of 0.5, 1, and 2 g of cefotiam to three healthy volunteers, the mean (+/- standard deviation) total plasma clearances measured for each dose were, respectively, 26.8 +/- 2.7, 22.8 +/- 0.8, and 17.8 +/- 0.9 liters/h; the terminal elimination half-lives were 54.0 +/- 0.1, 68 +/- 15, and 98 +/- 36 min; and the renal clearances were 16.0 +/- 2.9, 13.3 +/- 1.4, and 11.3 +/- 2.6 liters/h.",Pharmacokinetics of cefotiam in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3857018/),min,98,3618,DB00281,Lidocaine
,3857018,renal clearances,"After intravenous bolus injections of 0.5, 1, and 2 g of cefotiam to three healthy volunteers, the mean (+/- standard deviation) total plasma clearances measured for each dose were, respectively, 26.8 +/- 2.7, 22.8 +/- 0.8, and 17.8 +/- 0.9 liters/h; the terminal elimination half-lives were 54.0 +/- 0.1, 68 +/- 15, and 98 +/- 36 min; and the renal clearances were 16.0 +/- 2.9, 13.3 +/- 1.4, and 11.3 +/- 2.6 liters/h.",Pharmacokinetics of cefotiam in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3857018/),[l] / [h],16.0,3619,DB00281,Lidocaine
,3857018,renal clearances,"After intravenous bolus injections of 0.5, 1, and 2 g of cefotiam to three healthy volunteers, the mean (+/- standard deviation) total plasma clearances measured for each dose were, respectively, 26.8 +/- 2.7, 22.8 +/- 0.8, and 17.8 +/- 0.9 liters/h; the terminal elimination half-lives were 54.0 +/- 0.1, 68 +/- 15, and 98 +/- 36 min; and the renal clearances were 16.0 +/- 2.9, 13.3 +/- 1.4, and 11.3 +/- 2.6 liters/h.",Pharmacokinetics of cefotiam in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3857018/),[l] / [h],13.3,3620,DB00281,Lidocaine
,3857018,renal clearances,"After intravenous bolus injections of 0.5, 1, and 2 g of cefotiam to three healthy volunteers, the mean (+/- standard deviation) total plasma clearances measured for each dose were, respectively, 26.8 +/- 2.7, 22.8 +/- 0.8, and 17.8 +/- 0.9 liters/h; the terminal elimination half-lives were 54.0 +/- 0.1, 68 +/- 15, and 98 +/- 36 min; and the renal clearances were 16.0 +/- 2.9, 13.3 +/- 1.4, and 11.3 +/- 2.6 liters/h.",Pharmacokinetics of cefotiam in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3857018/),[l] / [h],11.3,3621,DB00281,Lidocaine
,3857018,peak concentration,"After intramuscular administration of 1 g of cefotiam to three healthy volunteers, a mean (+/- standard deviation) peak concentration of 16.6 +/- 5.1 micrograms/ml was reached at 0.75 to 1 h post dosing.",Pharmacokinetics of cefotiam in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3857018/),[μg] / [ml],16.6,3622,DB00281,Lidocaine
,29991403,area under the curve at 0-10 h,The area under the curve at 0-10 h of KM with and without lidocaine was respectively 147.7 and 143.6 μg·h/ml.,Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29991403/),[h·μg] / [ml],147.7,3753,DB00281,Lidocaine
,29991403,area under the curve at 0-10 h,The area under the curve at 0-10 h of KM with and without lidocaine was respectively 147.7 and 143.6 μg·h/ml.,Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29991403/),[h·μg] / [ml],143.6,3754,DB00281,Lidocaine
,3197750,elimination t1/2,"Between Trials 1 and 3, antipyrine elimination t1/2 (17.2 vs 17.4 h), clearance (0.44 vs 0.43 ml.min-1.kg-1) and 24-h recovery of antipyrine and metabolites (313 vs 293 mg) did not differ significantly.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,17.2,5484,DB00281,Lidocaine
,3197750,elimination t1/2,"Between Trials 1 and 3, antipyrine elimination t1/2 (17.2 vs 17.4 h), clearance (0.44 vs 0.43 ml.min-1.kg-1) and 24-h recovery of antipyrine and metabolites (313 vs 293 mg) did not differ significantly.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,17.4,5485,DB00281,Lidocaine
,3197750,clearance,"Between Trials 1 and 3, antipyrine elimination t1/2 (17.2 vs 17.4 h), clearance (0.44 vs 0.43 ml.min-1.kg-1) and 24-h recovery of antipyrine and metabolites (313 vs 293 mg) did not differ significantly.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],0.44,5486,DB00281,Lidocaine
,3197750,clearance,"Between Trials 1 and 3, antipyrine elimination t1/2 (17.2 vs 17.4 h), clearance (0.44 vs 0.43 ml.min-1.kg-1) and 24-h recovery of antipyrine and metabolites (313 vs 293 mg) did not differ significantly.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],0.43,5487,DB00281,Lidocaine
,3197750,clearance,"Between Trials 1 and 3, antipyrine elimination t1/2 (17.2 vs 17.4 h), clearance (0.44 vs 0.43 ml.min-1.kg-1) and 24-h recovery of antipyrine and metabolites (313 vs 293 mg) did not differ significantly.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),,24,5488,DB00281,Lidocaine
,3197750,VZ,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[l] / [kg],1.14,5489,DB00281,Lidocaine
,3197750,VZ,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[l] / [kg],1.00,5490,DB00281,Lidocaine
,3197750,t1/2,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,2.7,5491,DB00281,Lidocaine
,3197750,t1/2,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,3.3,5492,DB00281,Lidocaine
,3197750,clearance,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],4.8,5493,DB00281,Lidocaine
,3197750,clearance,"Between Trials 2 and 3, acetaminophen VZ was reduced (1.14 vs 1.00 l.kg-1), t1/2 prolonged (2.7 vs 3.3 h), clearance reduced (4.8 vs 3.6 ml.min-1.kg-1), and fractional urinary recovery of acetaminophen glucuronide reduced.",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],3.6,5494,DB00281,Lidocaine
,3197750,VZ,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[l] / [kg],2.6,5495,DB00281,Lidocaine
,3197750,VZ,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[l] / [kg],2.7,5496,DB00281,Lidocaine
,3197750,t1/2,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,2.0,5497,DB00281,Lidocaine
,3197750,t1/2,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),h,2.4,5498,DB00281,Lidocaine
,3197750,clearance,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],15.0,5499,DB00281,Lidocaine
,3197750,clearance,"The two trials did not differ significantly in lidocaine VZ (2.6 vs 2.7 l.kg-1), t1/2 (2.0 vs 2.4 h) or clearance (15.0 vs 13.5 ml.min-1.kg-1).",Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197750/),[ml] / [kg·min],13.5,5500,DB00281,Lidocaine
not exceed,19815946,peak lidocaine concentration,"As the peak lidocaine concentration did not exceed 5 microg/ml (commonly known as the toxic threshold), the results of our study indicate that the doses used (not exceeding 40 mg/kg b.w.) are completely safe for patients undergoing tumescent anesthesia in different body areas.",Optimization of lidocaine application in tumescent local anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19815946/),[μg] / [ml],5,5720,DB00281,Lidocaine
,7639374,steady-state concentration (Css),The infusion led to a high steady-state concentration (Css) of 5.91 +/- 2.46 mg/mL in Group TD-.,"Interpleural infusion of 2% lidocaine with 1:200,000 epinephrine for postthoracotomy analgesia. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639374/),[mg] / [ml],5.91,6020,DB00281,Lidocaine
,7639374,VAS score,The VAS score was slightly reduced after the bolus (6.6 +/- 1.0 vs 8.7 +/- 0.3; P < 0.05 vs the placebo group) but the cumulative doses of morphine were similar in both groups.,"Interpleural infusion of 2% lidocaine with 1:200,000 epinephrine for postthoracotomy analgesia. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639374/),,6.6,6021,DB00281,Lidocaine
,7639374,VAS score,The VAS score was slightly reduced after the bolus (6.6 +/- 1.0 vs 8.7 +/- 0.3; P < 0.05 vs the placebo group) but the cumulative doses of morphine were similar in both groups.,"Interpleural infusion of 2% lidocaine with 1:200,000 epinephrine for postthoracotomy analgesia. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639374/),,8.7,6022,DB00281,Lidocaine
above,67335,Plasma levels,Plasma levels above 2 microng/ml were achieved within 1 min and maintained for 1 h in all patients; in seven this level was maintained for 2 h.,Antiarrhythmic action of lignocaine in early myocardial infarction. Plasma levels after combined intramuscular and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/67335/),[μng] / [ml],2,6355,DB00281,Lidocaine
,9148343,Time until peak plasma concentration,Time until peak plasma concentration was 17.4 min.,[Pharmacokinetics of lidocaine in obstetric patients after its epidural single-dose administration]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9148343/),min,17.4,6488,DB00281,Lidocaine
,9148343,Peak concentrations,Peak concentrations ranged from 1.44 to 2.12 micrograms/ml.,[Pharmacokinetics of lidocaine in obstetric patients after its epidural single-dose administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9148343/),[μg] / [ml],1.44 to 2.12,6489,DB00281,Lidocaine
,9148343,rate,"Plasma clearance took place at a rate of 10.1 +/- 1.7 ml/min/kg, more slowly than in surgical patients.",[Pharmacokinetics of lidocaine in obstetric patients after its epidural single-dose administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9148343/),[ml] / [kg·min],10.1,6490,DB00281,Lidocaine
,9148343,plasma concentration,"At birth (25 +/- 5 min after epidural injection), plasma concentration was 1.67 +/- 0.28 micrograms/ml.",[Pharmacokinetics of lidocaine in obstetric patients after its epidural single-dose administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9148343/),μ,1,6491,DB00281,Lidocaine
,25687803,flow rate,"The mobile phase for separation consisted of 5mM ammonium acetate (pH 4.5)/methanol (4:1, v/v) and was delivered at a flow rate of 0.2mL/min.",Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687803/),[ml] / [min],0.2,6580,DB00281,Lidocaine
,25687803,m/,The ion transitions used to monitor analytes were m/z 273→m/z 110 for PLC and m/z 325→m/z 79 for quinidine.,Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687803/),,273,6581,DB00281,Lidocaine
,25687803,m/z,The ion transitions used to monitor analytes were m/z 273→m/z 110 for PLC and m/z 325→m/z 79 for quinidine.,Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687803/),,325,6582,DB00281,Lidocaine
,25687803,m/z,The ion transitions used to monitor analytes were m/z 273→m/z 110 for PLC and m/z 325→m/z 79 for quinidine.,Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687803/),,79,6583,DB00281,Lidocaine
less,25687803,total time for,The total time for chromatographic separation was less than 8min.,Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687803/),min,8,6584,DB00281,Lidocaine
,25687803,recoveries,"Mean recoveries of PLC in plasma, ultrafiltered plasma solution, and urine were 93.2-99.7%, 91.4-100.6%, and 93.9-104.7%, respectively.",Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687803/),%,93.2-99.7,6585,DB00281,Lidocaine
,25687803,recoveries,"Mean recoveries of PLC in plasma, ultrafiltered plasma solution, and urine were 93.2-99.7%, 91.4-100.6%, and 93.9-104.7%, respectively.",Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687803/),%,91.4-100.6,6586,DB00281,Lidocaine
,25687803,recoveries,"Mean recoveries of PLC in plasma, ultrafiltered plasma solution, and urine were 93.2-99.7%, 91.4-100.6%, and 93.9-104.7%, respectively.",Quantitation of pilsicainide in microscale samples of human biological fluids using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687803/),%,93.9-104.7,6587,DB00281,Lidocaine
,29934999,Cmax,"The pharmacokinetic parameters were: Cmax 141.15 ± 39.84 (μg/mL) and 55.02 ± 9.36 (ng/mL); tmax (h) 2.50 ± 0.50 and 1.5 ± 0.50; t½ (h) 7.30 ± 2.98 and 4.23 ± 1.96; and Kel (h-1 ) 0.10 ± 0.04 and 0.20 ± 0.13 for CFT and LDC, respectively.",Enhanced HPLC-MS/MS method for the quantitative determination of the co-administered drugs ceftriaxone sodium and lidocaine hydrochloride in human plasma following an intramuscular injection and application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29934999/),[ng] / [ml],141.15,7210,DB00281,Lidocaine
,29934999,Cmax,"The pharmacokinetic parameters were: Cmax 141.15 ± 39.84 (μg/mL) and 55.02 ± 9.36 (ng/mL); tmax (h) 2.50 ± 0.50 and 1.5 ± 0.50; t½ (h) 7.30 ± 2.98 and 4.23 ± 1.96; and Kel (h-1 ) 0.10 ± 0.04 and 0.20 ± 0.13 for CFT and LDC, respectively.",Enhanced HPLC-MS/MS method for the quantitative determination of the co-administered drugs ceftriaxone sodium and lidocaine hydrochloride in human plasma following an intramuscular injection and application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29934999/),[ng] / [ml],55.02,7211,DB00281,Lidocaine
,29934999,tmax,"The pharmacokinetic parameters were: Cmax 141.15 ± 39.84 (μg/mL) and 55.02 ± 9.36 (ng/mL); tmax (h) 2.50 ± 0.50 and 1.5 ± 0.50; t½ (h) 7.30 ± 2.98 and 4.23 ± 1.96; and Kel (h-1 ) 0.10 ± 0.04 and 0.20 ± 0.13 for CFT and LDC, respectively.",Enhanced HPLC-MS/MS method for the quantitative determination of the co-administered drugs ceftriaxone sodium and lidocaine hydrochloride in human plasma following an intramuscular injection and application to a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29934999/),h,2.50,7212,DB00281,Lidocaine
,29934999,tmax,"The pharmacokinetic parameters were: Cmax 141.15 ± 39.84 (μg/mL) and 55.02 ± 9.36 (ng/mL); tmax (h) 2.50 ± 0.50 and 1.5 ± 0.50; t½ (h) 7.30 ± 2.98 and 4.23 ± 1.96; and Kel (h-1 ) 0.10 ± 0.04 and 0.20 ± 0.13 for CFT and LDC, respectively.",Enhanced HPLC-MS/MS method for the quantitative determination of the co-administered drugs ceftriaxone sodium and lidocaine hydrochloride in human plasma following an intramuscular injection and application to a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29934999/),h,1.5,7213,DB00281,Lidocaine
,29934999,t½,"The pharmacokinetic parameters were: Cmax 141.15 ± 39.84 (μg/mL) and 55.02 ± 9.36 (ng/mL); tmax (h) 2.50 ± 0.50 and 1.5 ± 0.50; t½ (h) 7.30 ± 2.98 and 4.23 ± 1.96; and Kel (h-1 ) 0.10 ± 0.04 and 0.20 ± 0.13 for CFT and LDC, respectively.",Enhanced HPLC-MS/MS method for the quantitative determination of the co-administered drugs ceftriaxone sodium and lidocaine hydrochloride in human plasma following an intramuscular injection and application to a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29934999/),h,7.30,7214,DB00281,Lidocaine
,29934999,t½,"The pharmacokinetic parameters were: Cmax 141.15 ± 39.84 (μg/mL) and 55.02 ± 9.36 (ng/mL); tmax (h) 2.50 ± 0.50 and 1.5 ± 0.50; t½ (h) 7.30 ± 2.98 and 4.23 ± 1.96; and Kel (h-1 ) 0.10 ± 0.04 and 0.20 ± 0.13 for CFT and LDC, respectively.",Enhanced HPLC-MS/MS method for the quantitative determination of the co-administered drugs ceftriaxone sodium and lidocaine hydrochloride in human plasma following an intramuscular injection and application to a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29934999/),h,4.23,7215,DB00281,Lidocaine
,29934999,Kel,"The pharmacokinetic parameters were: Cmax 141.15 ± 39.84 (μg/mL) and 55.02 ± 9.36 (ng/mL); tmax (h) 2.50 ± 0.50 and 1.5 ± 0.50; t½ (h) 7.30 ± 2.98 and 4.23 ± 1.96; and Kel (h-1 ) 0.10 ± 0.04 and 0.20 ± 0.13 for CFT and LDC, respectively.",Enhanced HPLC-MS/MS method for the quantitative determination of the co-administered drugs ceftriaxone sodium and lidocaine hydrochloride in human plasma following an intramuscular injection and application to a pharmacokinetic study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29934999/),1/[h],0.10,7216,DB00281,Lidocaine
,29934999,Kel,"The pharmacokinetic parameters were: Cmax 141.15 ± 39.84 (μg/mL) and 55.02 ± 9.36 (ng/mL); tmax (h) 2.50 ± 0.50 and 1.5 ± 0.50; t½ (h) 7.30 ± 2.98 and 4.23 ± 1.96; and Kel (h-1 ) 0.10 ± 0.04 and 0.20 ± 0.13 for CFT and LDC, respectively.",Enhanced HPLC-MS/MS method for the quantitative determination of the co-administered drugs ceftriaxone sodium and lidocaine hydrochloride in human plasma following an intramuscular injection and application to a pharmacokinetic study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29934999/),1/[h],0.20,7217,DB00281,Lidocaine
,1610634,peak plasma concentrations,"The peak plasma concentrations of lignocaine were 2.28 (SD 0.29) micrograms ml-1 and 3.75 (0.79) micrograms ml-1 in groups I and II, respectively.",Plasma concentrations of lignocaine after obturator nerve block combined with spinal anaesthesia in patients undergoing transurethral resection procedures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610634/),[μg] / [ml],2.28,8411,DB00281,Lidocaine
,1610634,peak plasma concentrations,"The peak plasma concentrations of lignocaine were 2.28 (SD 0.29) micrograms ml-1 and 3.75 (0.79) micrograms ml-1 in groups I and II, respectively.",Plasma concentrations of lignocaine after obturator nerve block combined with spinal anaesthesia in patients undergoing transurethral resection procedures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610634/),[μg] / [ml],3.75,8412,DB00281,Lidocaine
,1610634,greatest plasma concentration,The greatest plasma concentration was 5.07 micrograms ml-1 in a patient of group II.,Plasma concentrations of lignocaine after obturator nerve block combined with spinal anaesthesia in patients undergoing transurethral resection procedures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610634/),[μg] / [ml],5.07,8413,DB00281,Lidocaine
,28078530,Apparent Clearance,"Apparent Clearance was estimated to be 48 L/h after application of two or fewer plasters, whereas its value increased to 67 L/h after application of three plasters.",Evaluation of the Population Pharmacokinetic Properties of Lidocaine and its Metabolites After Long-Term Multiple Applications of a Lidocaine Plaster in Post-Herpetic Neuralgia Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28078530/),[l] / [h],48,8721,DB00281,Lidocaine
,28078530,Apparent Clearance,"Apparent Clearance was estimated to be 48 L/h after application of two or fewer plasters, whereas its value increased to 67 L/h after application of three plasters.",Evaluation of the Population Pharmacokinetic Properties of Lidocaine and its Metabolites After Long-Term Multiple Applications of a Lidocaine Plaster in Post-Herpetic Neuralgia Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28078530/),[l] / [h],67,8722,DB00281,Lidocaine
,10491056,rates of infusion,The rates of infusion of tumescent anesthesia ranged from 27.1 mg/min up to 200 mg/min infused over a period of 5 minutes to 2 hours.,Lidocaine levels during the first two hours of infiltration of dilute anesthetic solution for tumescent liposuction: rapid versus slow delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10491056/),[mg] / [min],27.1,10545,DB00281,Lidocaine
,7351118,t1/2,"After intravenous administration the mean t1/2 was about 14 hr, volume of distribution about 3.0 l/kg, and corrected renal clearance about 140 ml/min.",Tocainide kinetics after intravenous and oral administration in healthy subjects and in patients with acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7351118/),h,14,11124,DB00281,Lidocaine
,7351118,volume of distribution,"After intravenous administration the mean t1/2 was about 14 hr, volume of distribution about 3.0 l/kg, and corrected renal clearance about 140 ml/min.",Tocainide kinetics after intravenous and oral administration in healthy subjects and in patients with acute myocardial infarction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7351118/),[l] / [kg],3.0,11125,DB00281,Lidocaine
,7351118,corrected renal clearance,"After intravenous administration the mean t1/2 was about 14 hr, volume of distribution about 3.0 l/kg, and corrected renal clearance about 140 ml/min.",Tocainide kinetics after intravenous and oral administration in healthy subjects and in patients with acute myocardial infarction. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7351118/),[ml] / [min],140,11126,DB00281,Lidocaine
,8910173,peak plasma lidocaine level,"In Group A, mean (+/- SD) peak plasma lidocaine level of 1.35 +/- 0.5 micrograms/ml (range 0.61 to 2.41 micrograms/ml) occurred 45 minutes after injection.",Lidocaine plasma levels following two techniques of obturator nerve block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8910173/),[μg] / [ml],1.35,11342,DB00281,Lidocaine
,8910173,peak,"In Group B, a peak of 3.63 +/- 2.07 micrograms/ml (0.75 to 7.21 micrograms/ml) occurred 15 minutes after injection.",Lidocaine plasma levels following two techniques of obturator nerve block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8910173/),[μg] / [ml],3.63,11343,DB00281,Lidocaine
,8910173,peak level,"Mean peak level in Group C of 2.08 +/- 0.77 micrograms/ml (0.84 to 3.21 micrograms/ml) occurred 60 minutes after injection Lidocaine concentrations were significantly higher in Groups B and C than in Group A, and they were higher in Group B than in Group C.",Lidocaine plasma levels following two techniques of obturator nerve block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8910173/),[μg] / [ml],2.08,11344,DB00281,Lidocaine
,6326558,systemic bioavailability,"Uptake and distribution of mexiletine are rapid, systemic bioavailability is about 90%, and tissue distribution is extensive.","Pharmacology, electrophysiology, and pharmacokinetics of mexiletine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6326558/),%,90,12552,DB00281,Lidocaine
,6326558,Elimination half-life,Elimination half-life is 9 to 11 hours after intravenous or oral administration.,"Pharmacology, electrophysiology, and pharmacokinetics of mexiletine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6326558/),h,9 to 11,12553,DB00281,Lidocaine
,17208404,flow rate,"The chromatographic separation was accomplished on a Xterra MS C18 Column (150 mm x 4.6 mm, 5 microm particle size) with the mobile phase consisting of methanol and water (40:60, v/v) (pH 2.0, adjusted with trifluoroacetic acid), and the flow rate was set at 0.6 mL/min.",LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),[ml] / [min],0.6,12778,DB00281,Lidocaine
,17208404,retention time,"Detection was performed on a single quadruple mass spectrometer by selected ion monitoring (SIM) mode (m/z 267.0 for trimetazidine and m/z 235.0 for lidocaine) with the retention time at about 3.47 and 5.05 min, respectively.",LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),min,3.47,12779,DB00281,Lidocaine
,17208404,retention time,"Detection was performed on a single quadruple mass spectrometer by selected ion monitoring (SIM) mode (m/z 267.0 for trimetazidine and m/z 235.0 for lidocaine) with the retention time at about 3.47 and 5.05 min, respectively.",LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),min,5.05,12780,DB00281,Lidocaine
,17208404,LOQ (,The LOQ (S/N=10) was accordingly 2.5 ng/mL.,LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),[ng] / [ml],10,12781,DB00281,Lidocaine
,17208404,LOQ (,The LOQ (S/N=10) was accordingly 2.5 ng/mL.,LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),[ng] / [ml],2.5,12782,DB00281,Lidocaine
,17208404,S/N,The LOQ (S/N=10) was accordingly 2.5 ng/mL.,LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),[ng] / [ml],10,12783,DB00281,Lidocaine
,17208404,S/N,The LOQ (S/N=10) was accordingly 2.5 ng/mL.,LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),[ng] / [ml],2.5,12784,DB00281,Lidocaine
,17208404,AUC(0-24),"After a single 20 mg dose for the test and reference product, the resulting mean of major pharmacokinetic parameters such as AUC(0-24), AUC(0-infinity), Cmax, Tmax and t(1/2) of trimetazidine were (673.1+/-117.6 ng h mL(-1) versus 652.3+/-121.9 ng h mL(-1)), (717.1+/-120.9 ng h mL(-1) versus 692+/-128.6 ng h mL(-1)), (74.85+/-12.13 ng mL(-1) versus 71.93+/-14.32 ng mL(-1)), (2.312+/-0.663 h versus 2.211+/-0.608 h) and (4.785+/-0.919 h versus 4.740+/-0.823 h), respectively, indicating that these two kinds of tablets were bioequivalent in the Chinese population.",LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),[h·ng] / [ml],673.1,12785,DB00281,Lidocaine
,17208404,t(1/2),"After a single 20 mg dose for the test and reference product, the resulting mean of major pharmacokinetic parameters such as AUC(0-24), AUC(0-infinity), Cmax, Tmax and t(1/2) of trimetazidine were (673.1+/-117.6 ng h mL(-1) versus 652.3+/-121.9 ng h mL(-1)), (717.1+/-120.9 ng h mL(-1) versus 692+/-128.6 ng h mL(-1)), (74.85+/-12.13 ng mL(-1) versus 71.93+/-14.32 ng mL(-1)), (2.312+/-0.663 h versus 2.211+/-0.608 h) and (4.785+/-0.919 h versus 4.740+/-0.823 h), respectively, indicating that these two kinds of tablets were bioequivalent in the Chinese population.",LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),h,2.312,12786,DB00281,Lidocaine
,17208404,t(1/2),"After a single 20 mg dose for the test and reference product, the resulting mean of major pharmacokinetic parameters such as AUC(0-24), AUC(0-infinity), Cmax, Tmax and t(1/2) of trimetazidine were (673.1+/-117.6 ng h mL(-1) versus 652.3+/-121.9 ng h mL(-1)), (717.1+/-120.9 ng h mL(-1) versus 692+/-128.6 ng h mL(-1)), (74.85+/-12.13 ng mL(-1) versus 71.93+/-14.32 ng mL(-1)), (2.312+/-0.663 h versus 2.211+/-0.608 h) and (4.785+/-0.919 h versus 4.740+/-0.823 h), respectively, indicating that these two kinds of tablets were bioequivalent in the Chinese population.",LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),h,2.211,12787,DB00281,Lidocaine
,17208404,t(1/2),"After a single 20 mg dose for the test and reference product, the resulting mean of major pharmacokinetic parameters such as AUC(0-24), AUC(0-infinity), Cmax, Tmax and t(1/2) of trimetazidine were (673.1+/-117.6 ng h mL(-1) versus 652.3+/-121.9 ng h mL(-1)), (717.1+/-120.9 ng h mL(-1) versus 692+/-128.6 ng h mL(-1)), (74.85+/-12.13 ng mL(-1) versus 71.93+/-14.32 ng mL(-1)), (2.312+/-0.663 h versus 2.211+/-0.608 h) and (4.785+/-0.919 h versus 4.740+/-0.823 h), respectively, indicating that these two kinds of tablets were bioequivalent in the Chinese population.",LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),h,4.785,12788,DB00281,Lidocaine
,17208404,t(1/2),"After a single 20 mg dose for the test and reference product, the resulting mean of major pharmacokinetic parameters such as AUC(0-24), AUC(0-infinity), Cmax, Tmax and t(1/2) of trimetazidine were (673.1+/-117.6 ng h mL(-1) versus 652.3+/-121.9 ng h mL(-1)), (717.1+/-120.9 ng h mL(-1) versus 692+/-128.6 ng h mL(-1)), (74.85+/-12.13 ng mL(-1) versus 71.93+/-14.32 ng mL(-1)), (2.312+/-0.663 h versus 2.211+/-0.608 h) and (4.785+/-0.919 h versus 4.740+/-0.823 h), respectively, indicating that these two kinds of tablets were bioequivalent in the Chinese population.",LC/ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17208404/),h,4.740,12789,DB00281,Lidocaine
more,27733484,recoveries,The recoveries at three levels were more than 66.2%.,"Determination of the Metabolite of Ephedrine, 4-Hydroxyephedrine, by LC-MS-MS in Rat Urine and Its Application in Excretion Profiles After Oral Administration of Ephedra sinica Stapf and Processing Ephedra sinica Stapf. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27733484/),%,66.2,13361,DB00281,Lidocaine
,2809817,Maximum systemic concentrations,"Maximum systemic concentrations were seen at 20-30 min and ranged from 100 to 1,100 ng/ml, well below the toxic threshold of 5,000 ng/ml.",Plasma lidocaine levels following hematoma block for distal radius fractures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2809817/),[ng] / [ml],"100 to 1,100",13641,DB00281,Lidocaine
,8013159,volume of distribution,The volume of distribution is between 8 and 13L and is not different from other cephalosporins.,Clinical pharmacokinetics of cefotetan. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8013159/),l,8 and 13,14964,DB00281,Lidocaine
,8013159,Total body clearance,Total body clearance is 1.8 to 2.9 L/h.,Clinical pharmacokinetics of cefotetan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8013159/),[l] / [h],1.8 to 2.9,14965,DB00281,Lidocaine
,8013159,plasma elimination half-life,The plasma elimination half-life is between 3 and 4 hours after intravenous and intramuscular doses.,Clinical pharmacokinetics of cefotetan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8013159/),h,3 and 4,14966,DB00281,Lidocaine
up to,8013159,Half-life,Half-life is considerably prolonged in patients with renal impairment (up to 10 hours).,Clinical pharmacokinetics of cefotetan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8013159/),h,10,14967,DB00281,Lidocaine
,9584343,onset time,The mean onset time of surgical analgesia of articaine was 2.5 +/- 1.1 min and that of lidocaine 11.2 +/- 5.1 min (p = 0.0006).,Comparison of the effects and disposition kinetics of articaine and lidocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9584343/),min,2.5,15096,DB00281,Lidocaine
,9584343,onset time,The mean onset time of surgical analgesia of articaine was 2.5 +/- 1.1 min and that of lidocaine 11.2 +/- 5.1 min (p = 0.0006).,Comparison of the effects and disposition kinetics of articaine and lidocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9584343/),min,11.2,15097,DB00281,Lidocaine
,9584343,t1/2 alpha,"After releasing the tourniquet, articaine appears in the blood and is rapidly eliminated with a t1/2 alpha of 5 +/- 3 min and a t1/2 beta of 59 +/- 39 min due to hydrolysis.",Comparison of the effects and disposition kinetics of articaine and lidocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9584343/),min,5,15098,DB00281,Lidocaine
,9584343,t1/2 beta,"After releasing the tourniquet, articaine appears in the blood and is rapidly eliminated with a t1/2 alpha of 5 +/- 3 min and a t1/2 beta of 59 +/- 39 min due to hydrolysis.",Comparison of the effects and disposition kinetics of articaine and lidocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9584343/),min,59,15099,DB00281,Lidocaine
,9584343,half-lives of t1/2 alpha,Lidocaine is rapidly and biexponentially eliminated with similar half-lives of t1/2 alpha of 4 +/- 2 min and a t1/2 beta of 79 +/- 31 min.,Comparison of the effects and disposition kinetics of articaine and lidocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9584343/),min,4,15100,DB00281,Lidocaine
,9584343,t1/2 beta,Lidocaine is rapidly and biexponentially eliminated with similar half-lives of t1/2 alpha of 4 +/- 2 min and a t1/2 beta of 79 +/- 31 min.,Comparison of the effects and disposition kinetics of articaine and lidocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9584343/),min,79,15101,DB00281,Lidocaine
,9584343,Total body clearance,Total body clearance of articaine (8.9 +/- 3.5 L/min) is ten times greater than that of lidocaine (0.9 +/- 0.4 L/min; p = 0.0005).,Comparison of the effects and disposition kinetics of articaine and lidocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9584343/),[l] / [min],8.9,15102,DB00281,Lidocaine
,9584343,Total body clearance,Total body clearance of articaine (8.9 +/- 3.5 L/min) is ten times greater than that of lidocaine (0.9 +/- 0.4 L/min; p = 0.0005).,Comparison of the effects and disposition kinetics of articaine and lidocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9584343/),[l] / [min],0.9,15103,DB00281,Lidocaine
,9584343,t1/2 beta,"After releasing the tourniquet, articaine is eliminated with a t1/2 beta of 60 min and lidocaine with a t1/2 beta of 80 min.",Comparison of the effects and disposition kinetics of articaine and lidocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9584343/),min,60,15104,DB00281,Lidocaine
,9584343,t1/2 beta,"After releasing the tourniquet, articaine is eliminated with a t1/2 beta of 60 min and lidocaine with a t1/2 beta of 80 min.",Comparison of the effects and disposition kinetics of articaine and lidocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9584343/),min,80,15105,DB00281,Lidocaine
,3933983,peak plasma concentrations,The peak plasma concentrations in the patients with pyelonephritis (3.80 micrograms/ml) and interstitial nephritis (3.74 micrograms/ml) but not in those with glomerulonephritis (3.17 micrograms/ml) differed from that in healthy volunteers (3.24 micrograms/ml).,Pharmacokinetics of tocainide in patients with severe renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3933983/),[μg] / [ml],3.80,15205,DB00281,Lidocaine
,3933983,peak plasma concentrations,The peak plasma concentrations in the patients with pyelonephritis (3.80 micrograms/ml) and interstitial nephritis (3.74 micrograms/ml) but not in those with glomerulonephritis (3.17 micrograms/ml) differed from that in healthy volunteers (3.24 micrograms/ml).,Pharmacokinetics of tocainide in patients with severe renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3933983/),[μg] / [ml],3.74,15206,DB00281,Lidocaine
,3933983,peak plasma concentrations,The peak plasma concentrations in the patients with pyelonephritis (3.80 micrograms/ml) and interstitial nephritis (3.74 micrograms/ml) but not in those with glomerulonephritis (3.17 micrograms/ml) differed from that in healthy volunteers (3.24 micrograms/ml).,Pharmacokinetics of tocainide in patients with severe renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3933983/),[μg] / [ml],3.17,15207,DB00281,Lidocaine
,3933983,peak plasma concentrations,The peak plasma concentrations in the patients with pyelonephritis (3.80 micrograms/ml) and interstitial nephritis (3.74 micrograms/ml) but not in those with glomerulonephritis (3.17 micrograms/ml) differed from that in healthy volunteers (3.24 micrograms/ml).,Pharmacokinetics of tocainide in patients with severe renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3933983/),[μg] / [ml],3.24,15208,DB00281,Lidocaine
,3922392,plasma level,The mean plasma level of tocainide achieved was 2.95 micrograms/ml (15.37 mmol/l).,Pharmacokinetics and haemodynamic effects of tocainide in patients with acute myocardial infarction complicated by left ventricular failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3922392/),,15.37,15243,DB00281,Lidocaine
,3922392,plasma half-life,The mean plasma half-life was 15.6 h.,Pharmacokinetics and haemodynamic effects of tocainide in patients with acute myocardial infarction complicated by left ventricular failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3922392/),h,15.6,15244,DB00281,Lidocaine
,3922392,cardiac index,"The mean cardiac index was reduced 5 min after completion of the infusion, from 2.24 1 min-1 m-2 (+/- 0.40) to 2.07 1 min-1 m-2 (+/- 0.29) (P less than 0.01).",Pharmacokinetics and haemodynamic effects of tocainide in patients with acute myocardial infarction complicated by left ventricular failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3922392/),[1] / [(m)^2·min],2.24,15245,DB00281,Lidocaine
,3922392,cardiac index,"The mean cardiac index was reduced 5 min after completion of the infusion, from 2.24 1 min-1 m-2 (+/- 0.40) to 2.07 1 min-1 m-2 (+/- 0.29) (P less than 0.01).",Pharmacokinetics and haemodynamic effects of tocainide in patients with acute myocardial infarction complicated by left ventricular failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3922392/),[1] / [(m)^2·min],2.07,15246,DB00281,Lidocaine
,8549031,clearance rate,A lower vinorelbine clearance rate was observed in the five patients with more than 75% LVRT (22.9 L/hr/m2) compared with the 10 patients with no liver metastases (48.0 L/hr/m2) and the 12 patients with 25% to 75% LVRT (45.3 L/hr/m2).,Pharmacokinetics of vinorelbine in patients with liver metastases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549031/),[l] / [h·m2],22.9,16945,DB00281,Lidocaine
,8549031,clearance rate,A lower vinorelbine clearance rate was observed in the five patients with more than 75% LVRT (22.9 L/hr/m2) compared with the 10 patients with no liver metastases (48.0 L/hr/m2) and the 12 patients with 25% to 75% LVRT (45.3 L/hr/m2).,Pharmacokinetics of vinorelbine in patients with liver metastases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549031/),[l] / [h·m2],48.0,16946,DB00281,Lidocaine
,8549031,clearance rate,A lower vinorelbine clearance rate was observed in the five patients with more than 75% LVRT (22.9 L/hr/m2) compared with the 10 patients with no liver metastases (48.0 L/hr/m2) and the 12 patients with 25% to 75% LVRT (45.3 L/hr/m2).,Pharmacokinetics of vinorelbine in patients with liver metastases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549031/),[l] / [h],45,16947,DB00281,Lidocaine
,8803524,apparent oral clearance,"Accordingly, apparent oral clearance was markedly reduced (from 9.1 to 4.5 and 4.1 ml.min-1.kg-1 in nonascitic and ascitic patients, respectively).",Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803524/),[ml] / [kg·min],9.1,17941,DB00281,Lidocaine
,8803524,apparent oral clearance,"Accordingly, apparent oral clearance was markedly reduced (from 9.1 to 4.5 and 4.1 ml.min-1.kg-1 in nonascitic and ascitic patients, respectively).",Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803524/),[ml] / [kg·min],4.5,17942,DB00281,Lidocaine
,8803524,apparent oral clearance,"Accordingly, apparent oral clearance was markedly reduced (from 9.1 to 4.5 and 4.1 ml.min-1.kg-1 in nonascitic and ascitic patients, respectively).",Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803524/),[ml] / [kg·min],4.1,17943,DB00281,Lidocaine
,8803524,Terminal half-life (t1/2),"Terminal half-life (t1/2), was significantly longer in nonascitic patients than in control subjects (32 vs 22 min).",Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803524/),min,32,17944,DB00281,Lidocaine
,8803524,Terminal half-life (t1/2),"Terminal half-life (t1/2), was significantly longer in nonascitic patients than in control subjects (32 vs 22 min).",Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803524/),min,22,17945,DB00281,Lidocaine
,8803524,t1/2,"A further significant prolongation of t1/2, most likely due to an increased distribution volume, was observed in patients with ascites (56 min).",Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803524/),min,56,17946,DB00281,Lidocaine
,8803524,time to Cmax,The time to Cmax increased from 30 to 45 min in both cirrhotic groups.,Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803524/),min,30,17947,DB00281,Lidocaine
,8803524,time to Cmax,The time to Cmax increased from 30 to 45 min in both cirrhotic groups.,Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803524/),min,45,17948,DB00281,Lidocaine
,931206,half-life of the elimination phase,In this group of patients the mean half-life of the elimination phase was found to be 3.22 h.,Pharmacokinetics of lidocaine after prolonged intravenous infusions in uncomplicated myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/931206/),h,3.22,18083,DB00281,Lidocaine
,931206,half-life,This is significantly different from the half-life of 100 min that has been reported after bolus injections or infusions lasting less than 12 h.,Pharmacokinetics of lidocaine after prolonged intravenous infusions in uncomplicated myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/931206/),min,100,18084,DB00281,Lidocaine
less,2754714,biological half-life,"In an effort to find a replacement for the iv antiarrhythmic drug lidocaine having reduced systemic and central nervous system effects, activity against supraventricular as well as ventricular arrhythmias, and a biological half-life of less than 15 min, derivatives of the orally active class Ic clinical agent 2,6-bis(1-pyrrolidinylmethyl)-4-benzamidophenol, 1 (ACC-9358), were synthesized and tested.","Ester derivatives of 2,6-bis(1-pyrrolidinylmethyl)-4-benzamidophenol as short-acting antiarrhythmic agents. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2754714/),min,15,20852,DB00281,Lidocaine
,16426206,pseudo-steady-state plasma concentrations,"In experiment 2, data from experiment 1 were used to calculate appropriate doses of lidocaine that would achieve predetermined plasma lidocaine concentrations in the cats; lidocaine (or an equivalent volume of saline [0.9% NaCl] solution as the control treatment) was administered IV to target pseudo-steady-state plasma concentrations of 0, 0.5, 1, 2, 5, and 8 microg/mL.",Effects of intravenous administration of lidocaine on the thermal threshold in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426206/),[μg] / [ml],0,21071,DB00281,Lidocaine
,16426206,pseudo-steady-state plasma concentrations,"In experiment 2, data from experiment 1 were used to calculate appropriate doses of lidocaine that would achieve predetermined plasma lidocaine concentrations in the cats; lidocaine (or an equivalent volume of saline [0.9% NaCl] solution as the control treatment) was administered IV to target pseudo-steady-state plasma concentrations of 0, 0.5, 1, 2, 5, and 8 microg/mL.",Effects of intravenous administration of lidocaine on the thermal threshold in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426206/),[μg] / [ml],0.5,21072,DB00281,Lidocaine
,16426206,pseudo-steady-state plasma concentrations,"In experiment 2, data from experiment 1 were used to calculate appropriate doses of lidocaine that would achieve predetermined plasma lidocaine concentrations in the cats; lidocaine (or an equivalent volume of saline [0.9% NaCl] solution as the control treatment) was administered IV to target pseudo-steady-state plasma concentrations of 0, 0.5, 1, 2, 5, and 8 microg/mL.",Effects of intravenous administration of lidocaine on the thermal threshold in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426206/),[μg] / [ml],1,21073,DB00281,Lidocaine
,16426206,pseudo-steady-state plasma concentrations,"In experiment 2, data from experiment 1 were used to calculate appropriate doses of lidocaine that would achieve predetermined plasma lidocaine concentrations in the cats; lidocaine (or an equivalent volume of saline [0.9% NaCl] solution as the control treatment) was administered IV to target pseudo-steady-state plasma concentrations of 0, 0.5, 1, 2, 5, and 8 microg/mL.",Effects of intravenous administration of lidocaine on the thermal threshold in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426206/),[μg] / [ml],2,21074,DB00281,Lidocaine
,16426206,pseudo-steady-state plasma concentrations,"In experiment 2, data from experiment 1 were used to calculate appropriate doses of lidocaine that would achieve predetermined plasma lidocaine concentrations in the cats; lidocaine (or an equivalent volume of saline [0.9% NaCl] solution as the control treatment) was administered IV to target pseudo-steady-state plasma concentrations of 0, 0.5, 1, 2, 5, and 8 microg/mL.",Effects of intravenous administration of lidocaine on the thermal threshold in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426206/),[μg] / [ml],5,21075,DB00281,Lidocaine
,16426206,pseudo-steady-state plasma concentrations,"In experiment 2, data from experiment 1 were used to calculate appropriate doses of lidocaine that would achieve predetermined plasma lidocaine concentrations in the cats; lidocaine (or an equivalent volume of saline [0.9% NaCl] solution as the control treatment) was administered IV to target pseudo-steady-state plasma concentrations of 0, 0.5, 1, 2, 5, and 8 microg/mL.",Effects of intravenous administration of lidocaine on the thermal threshold in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16426206/),[μg] / [ml],8,21076,DB00281,Lidocaine
,9651106,constant flow rate,The liver was perfused with a recirculating system at a constant flow rate of 20 ml/min.,The pharmacokinetic change of lidocaine by catecholamines using isolated perfused rat liver (IPRL). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9651106/),[ml] / [min],20,22690,DB00281,Lidocaine
,3348074,peak concentrations (Cmax),"The mean peak concentrations (Cmax) of lidocaine in the three groups were 0.57, 1.39 and 0.73 micrograms/ml, respectively.",Venous blood concentration of lidocaine after nasopharyngeal application of 2% lidocaine gel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348074/),[μg] / [ml],0.57,22756,DB00281,Lidocaine
,3348074,peak concentrations (Cmax),"The mean peak concentrations (Cmax) of lidocaine in the three groups were 0.57, 1.39 and 0.73 micrograms/ml, respectively.",Venous blood concentration of lidocaine after nasopharyngeal application of 2% lidocaine gel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348074/),[μg] / [ml],1.39,22757,DB00281,Lidocaine
,3348074,peak concentrations (Cmax),"The mean peak concentrations (Cmax) of lidocaine in the three groups were 0.57, 1.39 and 0.73 micrograms/ml, respectively.",Venous blood concentration of lidocaine after nasopharyngeal application of 2% lidocaine gel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348074/),[μg] / [ml],0.73,22758,DB00281,Lidocaine
,3348074,length of time,The mean length of time between the nasopharyngeal application of lidocaine gel and the time when Cmax was reached (tpeak) was the same in all three groups (60-70 min).,Venous blood concentration of lidocaine after nasopharyngeal application of 2% lidocaine gel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348074/),min,60-70,22759,DB00281,Lidocaine
,3348074,tpeak,The mean length of time between the nasopharyngeal application of lidocaine gel and the time when Cmax was reached (tpeak) was the same in all three groups (60-70 min).,Venous blood concentration of lidocaine after nasopharyngeal application of 2% lidocaine gel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348074/),min,60-70,22760,DB00281,Lidocaine
,3777457,peak plasma concentrations,"Addition of epinephrine to the local anesthetic solutions reduced the mean peak plasma concentrations of lidocaine and bupivacaine from 2.2 to 1.7 micrograms/ml (23%) and from 0.73 to 0.53 microgram/ml (28%), respectively, but did not alter the times at which the peak concentrations were reached.",Epidural anesthesia with lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777457/),[μg] / [ml],2.2 to 1.7,23243,DB00281,Lidocaine
,3777457,peak plasma concentrations,"Addition of epinephrine to the local anesthetic solutions reduced the mean peak plasma concentrations of lidocaine and bupivacaine from 2.2 to 1.7 micrograms/ml (23%) and from 0.73 to 0.53 microgram/ml (28%), respectively, but did not alter the times at which the peak concentrations were reached.",Epidural anesthesia with lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777457/),[μg] / [ml],0.73 to 0.53,23244,DB00281,Lidocaine
,1425890,clearance,"The clearance of the drug was significantly higher, (39.9 vs 16.7 ml.min-1.kg-1) associated with a decreased elimination half-life and mean residence time.",Altered pharmacokinetics of lignocaine after epidural injection in type II diabetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425890/),[ml] / [kg·min],39.9,23830,DB00281,Lidocaine
,1425890,clearance,"The clearance of the drug was significantly higher, (39.9 vs 16.7 ml.min-1.kg-1) associated with a decreased elimination half-life and mean residence time.",Altered pharmacokinetics of lignocaine after epidural injection in type II diabetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425890/),[ml] / [kg·min],16.7,23831,DB00281,Lidocaine
,10741624,apparent oral clearance,"Concomitant administration of cimetidine significantly increased the area under the plasma concentration-time curve of pilsicainide by a mean of 33%, prolonged elimination half-life by a mean of 24% (from 5 to 6.2 hours), reduced apparent oral clearance by a mean of 26% (from 14.7 +/- 0.1 to 10.8 +/- 0.8 L/h) and reduced renal clearance by a mean of 28% (from 196.8 +/- 53.9 to 141.8 +/- 25.9 mL/min).",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[l] / [h],14.7,24634,DB00281,Lidocaine
,10741624,apparent oral clearance,"Concomitant administration of cimetidine significantly increased the area under the plasma concentration-time curve of pilsicainide by a mean of 33%, prolonged elimination half-life by a mean of 24% (from 5 to 6.2 hours), reduced apparent oral clearance by a mean of 26% (from 14.7 +/- 0.1 to 10.8 +/- 0.8 L/h) and reduced renal clearance by a mean of 28% (from 196.8 +/- 53.9 to 141.8 +/- 25.9 mL/min).",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[l] / [h],10.8,24635,DB00281,Lidocaine
,10741624,renal clearance,"Concomitant administration of cimetidine significantly increased the area under the plasma concentration-time curve of pilsicainide by a mean of 33%, prolonged elimination half-life by a mean of 24% (from 5 to 6.2 hours), reduced apparent oral clearance by a mean of 26% (from 14.7 +/- 0.1 to 10.8 +/- 0.8 L/h) and reduced renal clearance by a mean of 28% (from 196.8 +/- 53.9 to 141.8 +/- 25.9 mL/min).",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[ml] / [min],196.8,24636,DB00281,Lidocaine
,10741624,renal clearance,"Concomitant administration of cimetidine significantly increased the area under the plasma concentration-time curve of pilsicainide by a mean of 33%, prolonged elimination half-life by a mean of 24% (from 5 to 6.2 hours), reduced apparent oral clearance by a mean of 26% (from 14.7 +/- 0.1 to 10.8 +/- 0.8 L/h) and reduced renal clearance by a mean of 28% (from 196.8 +/- 53.9 to 141.8 +/- 25.9 mL/min).",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[ml] / [min],141.8,24637,DB00281,Lidocaine
,10741624,net renal clearance by tubular secretion,"The net renal clearance by tubular secretion was significantly reduced by a mean value of 38%, from 151.4 +/- 62.9 to 93.0 +/- 31.1 mL/min.",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[ml] / [min],151.4,24638,DB00281,Lidocaine
,10741624,net renal clearance by tubular secretion,"The net renal clearance by tubular secretion was significantly reduced by a mean value of 38%, from 151.4 +/- 62.9 to 93.0 +/- 31.1 mL/min.",Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741624/),[ml] / [min],93.0,24639,DB00281,Lidocaine
,3800032,peak venous plasma concentrations,"All subjects experienced mild CNS toxicity, consisting of tinnitus, facial tingling, or subtle visual disturbances, associated with peak venous plasma concentrations of 0.81 to 2.7 micrograms/ml.",Propranolol reduces bupivacaine clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),[μg] / [ml],0.81 to 2.7,25303,DB00281,Lidocaine
,3800032,clearance,"Mean bupivacaine clearance was 0.33 +/- 0.12 l/min for the control session and 0.21 +/- 0.12 l/min during propranolol use, a significant 35% reduction (P less than 0.01).",Propranolol reduces bupivacaine clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),[l] / [min],0.33,25304,DB00281,Lidocaine
,3800032,clearance,"Mean bupivacaine clearance was 0.33 +/- 0.12 l/min for the control session and 0.21 +/- 0.12 l/min during propranolol use, a significant 35% reduction (P less than 0.01).",Propranolol reduces bupivacaine clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),[l] / [min],0.21,25305,DB00281,Lidocaine
,3800032,terminal elimination rate constant (beta),"The terminal elimination rate constant (beta) was 0.27 +/- 0.16 h-1 for the control session and 0.14 +/- 0.069 h-1 with propranolol (P less than 0.05); terminal elimination half-lives were 2.6 and 4.9 h, respectively.",Propranolol reduces bupivacaine clearance. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),1/[h],0.27,25306,DB00281,Lidocaine
,3800032,terminal elimination rate constant (beta),"The terminal elimination rate constant (beta) was 0.27 +/- 0.16 h-1 for the control session and 0.14 +/- 0.069 h-1 with propranolol (P less than 0.05); terminal elimination half-lives were 2.6 and 4.9 h, respectively.",Propranolol reduces bupivacaine clearance. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),1/[h],0.14,25307,DB00281,Lidocaine
,3800032,terminal elimination half-lives,"The terminal elimination rate constant (beta) was 0.27 +/- 0.16 h-1 for the control session and 0.14 +/- 0.069 h-1 with propranolol (P less than 0.05); terminal elimination half-lives were 2.6 and 4.9 h, respectively.",Propranolol reduces bupivacaine clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),h,2.6,25308,DB00281,Lidocaine
,3800032,terminal elimination half-lives,"The terminal elimination rate constant (beta) was 0.27 +/- 0.16 h-1 for the control session and 0.14 +/- 0.069 h-1 with propranolol (P less than 0.05); terminal elimination half-lives were 2.6 and 4.9 h, respectively.",Propranolol reduces bupivacaine clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),h,4.9,25309,DB00281,Lidocaine
,3091779,peak ulcers,"These doses produced peak ulcers of 0.15 to 0.22 cm2, respectively, one to five days after injection.",Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2,0.15,26156,DB00281,Lidocaine
,3091779,peak ulcers,"These doses produced peak ulcers of 0.15 to 0.22 cm2, respectively, one to five days after injection.",Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2,0.22,26157,DB00281,Lidocaine
,3091779,area X time,The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,0.89,26158,DB00281,Lidocaine
,3091779,area X time,The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,3.11,26159,DB00281,Lidocaine
,3091779,area under the curve [AUC],The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,0.89,26160,DB00281,Lidocaine
,3091779,area under the curve [AUC],The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,3.11,26161,DB00281,Lidocaine
,3091779,AUC,DMSO significantly increased the AUC for MMC in skin from 0.89 to 2.25 ng/h/mL of tissue (P less than .05).,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),[ng] / [h·ml],0.89,26162,DB00281,Lidocaine
,3091779,AUC,DMSO significantly increased the AUC for MMC in skin from 0.89 to 2.25 ng/h/mL of tissue (P less than .05).,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),[ng] / [h·ml],2,26163,DB00281,Lidocaine
<,18173612,maximum concentrations,"Because of the lack of concentrations above the limit of quantification, it was not possible to determine the pharmacokinetic parameters, other than the maximum concentrations of < 100 ng/mL for lidocaine and < 5 ng/mL for tetracaine.",Systemic exposure to lidocaine and tetracaine is low after an application of a lidocaine 7%-tetracaine 7% peel in adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18173612/),[ng] / [ml],100,26926,DB00281,Lidocaine
<,18173612,maximum concentrations,"Because of the lack of concentrations above the limit of quantification, it was not possible to determine the pharmacokinetic parameters, other than the maximum concentrations of < 100 ng/mL for lidocaine and < 5 ng/mL for tetracaine.",Systemic exposure to lidocaine and tetracaine is low after an application of a lidocaine 7%-tetracaine 7% peel in adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18173612/),[ng] / [ml],5,26927,DB00281,Lidocaine
,32606902,Cmax,"Exposure to external heat resulted in increased peak plasma concentration of lidocaine with a mean Cmax of 160.3±100.1 ng/mL vs 97.6±36.9 ng/mL under normal conditions, with no effect on the extent of exposure (AUC).","A Randomized, Crossover, Pharmacokinetic and Adhesion Performance Study of a Lidocaine Topical System 1.8% During Physical Activity and Heat Treatment in Healthy Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32606902/),[ng] / [ml],160.3,27167,DB00281,Lidocaine
,32606902,Cmax,"Exposure to external heat resulted in increased peak plasma concentration of lidocaine with a mean Cmax of 160.3±100.1 ng/mL vs 97.6±36.9 ng/mL under normal conditions, with no effect on the extent of exposure (AUC).","A Randomized, Crossover, Pharmacokinetic and Adhesion Performance Study of a Lidocaine Topical System 1.8% During Physical Activity and Heat Treatment in Healthy Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32606902/),[ng] / [ml],97.6,27168,DB00281,Lidocaine
,32606902,Cmax,No clinically relevant differences in absorption were observed under exercise conditions with a mean Cmax of 90.5±25.4 ng/mL and no effect on the extent (AUC) of lidocaine exposure was observed relative to normal conditions.,"A Randomized, Crossover, Pharmacokinetic and Adhesion Performance Study of a Lidocaine Topical System 1.8% During Physical Activity and Heat Treatment in Healthy Subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32606902/),[ng] / [ml],90.5,27169,DB00281,Lidocaine
,1122677,elimination phase half-life,"The total volume of GX distribution in man is similar to that of lidocaine but the plasma clearance is less, so that the 10-hr elimination phase half-life of GX is much longer than the 1 1/2 hr half-life reported in normal subjects for lidocaine.","Pharmacological activity, metabolism, and pharmacokinetics of glycinexylidide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1122677/),h,10,27902,DB00281,Lidocaine
,1122677,elimination phase half-life,"The total volume of GX distribution in man is similar to that of lidocaine but the plasma clearance is less, so that the 10-hr elimination phase half-life of GX is much longer than the 1 1/2 hr half-life reported in normal subjects for lidocaine.","Pharmacological activity, metabolism, and pharmacokinetics of glycinexylidide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1122677/),h,1 1/2,27903,DB00281,Lidocaine
,1122677,half-life,"The total volume of GX distribution in man is similar to that of lidocaine but the plasma clearance is less, so that the 10-hr elimination phase half-life of GX is much longer than the 1 1/2 hr half-life reported in normal subjects for lidocaine.","Pharmacological activity, metabolism, and pharmacokinetics of glycinexylidide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1122677/),h,1 1/2,27904,DB00281,Lidocaine
exceeded,7416554,bioavailability,The bioavailability of EO0122 by the oral route exceeded 80% of the oral dose.,"A preclinical study of EO-122, a new lidocaine-like antiarrhythmic drug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7416554/),%,80,28638,DB00281,Lidocaine
,7416554,LD50,"The IV LD50 in mice was 22 mg/kg, and in rabbits 8.5 mg/kg.","A preclinical study of EO-122, a new lidocaine-like antiarrhythmic drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7416554/),[mg] / [kg],22,28639,DB00281,Lidocaine
,7416554,LD50,"The IV LD50 in mice was 22 mg/kg, and in rabbits 8.5 mg/kg.","A preclinical study of EO-122, a new lidocaine-like antiarrhythmic drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7416554/),[mg] / [kg],8.5,28640,DB00281,Lidocaine
,7416554,t1/2,"The pharmacokinetic profile of the drug fits a two-compartment open model, with t1/2 congruent to 150 min and Vd (SS) congruent to 1.5 l/kg.","A preclinical study of EO-122, a new lidocaine-like antiarrhythmic drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7416554/),min,150,28641,DB00281,Lidocaine
,7416554,Vd,"The pharmacokinetic profile of the drug fits a two-compartment open model, with t1/2 congruent to 150 min and Vd (SS) congruent to 1.5 l/kg.","A preclinical study of EO-122, a new lidocaine-like antiarrhythmic drug. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7416554/),[l] / [kg],1.5,28642,DB00281,Lidocaine
,7152740,maximum concentrations,The mean duration for exceeding a threshold concentration of 1.5 mg/l after 300 mg lidocaine i.m. was about 2 h; maximum concentrations were reached after 10 min and amounted to 3.2 mg/l (n = 10).,Plasma levels of lidocaine after intramuscular injection and subsequent infusion in patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7152740/),[mg] / [l],3.2,29128,DB00281,Lidocaine
,7152740,steady-state plasma levels,"By varying the infusion onset after i.m. injection (1 or 2 h later) and the infusion rates from 0.029-0.039 mg/kg X min, steady-state plasma levels of lidocaine were found to be in the therapeutic range (1.5-6 mg/l) for 5 h of observation.",Plasma levels of lidocaine after intramuscular injection and subsequent infusion in patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7152740/),[mg] / [l],1.5-6,29129,DB00281,Lidocaine
,3125767,steady-state maternal plasma lidocaine concentration,"kg-1.min-1 over a period of 180 min, in order to reach a steady-state maternal plasma lidocaine concentration of approximately 2 micrograms/ml.",Does gestational age affect the pharmacokinetics and pharmacodynamics of lidocaine in mother and fetus? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125767/),[μg] / [ml],2,30477,DB00281,Lidocaine
,3125767,steady-state plasma concentrations,"In both groups, the steady-state plasma concentrations of lidocaine were similar; namely, 2.3 +/- 0.17 and 2.1 +/- 0.21 micrograms/ml in preterm and term ewes, respectively.",Does gestational age affect the pharmacokinetics and pharmacodynamics of lidocaine in mother and fetus? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125767/),[μg] / [ml],2.3,30478,DB00281,Lidocaine
,3125767,steady-state plasma concentrations,"In both groups, the steady-state plasma concentrations of lidocaine were similar; namely, 2.3 +/- 0.17 and 2.1 +/- 0.21 micrograms/ml in preterm and term ewes, respectively.",Does gestational age affect the pharmacokinetics and pharmacodynamics of lidocaine in mother and fetus? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125767/),[μg] / [ml],2.1,30479,DB00281,Lidocaine
,3125767,steady-state plasma drug concentrations,There were also no significant differences in steady-state plasma drug concentrations in preterm and term fetuses (1.3 +/- 0.11 and 1.2 +/- 0.15 micrograms/ml).,Does gestational age affect the pharmacokinetics and pharmacodynamics of lidocaine in mother and fetus? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125767/),[μg] / [ml],1.3,30480,DB00281,Lidocaine
,3125767,steady-state plasma drug concentrations,There were also no significant differences in steady-state plasma drug concentrations in preterm and term fetuses (1.3 +/- 0.11 and 1.2 +/- 0.15 micrograms/ml).,Does gestational age affect the pharmacokinetics and pharmacodynamics of lidocaine in mother and fetus? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125767/),[μg] / [ml],1.2,30481,DB00281,Lidocaine
,3125767,concentration ratios (F/M),"The mean fetal maternal concentration ratios (F/M) were the same; namely, 0.6.",Does gestational age affect the pharmacokinetics and pharmacodynamics of lidocaine in mother and fetus? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125767/),,0.6,30482,DB00281,Lidocaine
,3188822,elimination half-life,"Increases in elimination half-life only achieved statistical significance in mepivacaine-treated animals (non-convulsing 45.2 min, convulsing 105.4 min, P less than 0.01).",Alterations in the pharmacokinetic properties of amide local anaesthetics following local anaesthetic induced convulsions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3188822/),min,45.2,30834,DB00281,Lidocaine
,3188822,elimination half-life,"Increases in elimination half-life only achieved statistical significance in mepivacaine-treated animals (non-convulsing 45.2 min, convulsing 105.4 min, P less than 0.01).",Alterations in the pharmacokinetic properties of amide local anaesthetics following local anaesthetic induced convulsions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3188822/),min,105.4,30835,DB00281,Lidocaine
,15365654,Maximum lidocaine concentrations,Maximum lidocaine concentrations at the median times of 15 min were 3.22 microg/ml.,Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15365654/),[μg] / [ml],3.22,31021,DB00281,Lidocaine
,15365654,half-life t1/2alpha,"The pharmacokinetic parameters were: half-life t1/2alpha 24.0 min, area under the curve (AUC)0-infinity 460.2 microg/min per ml, t1/2beta 180.0 min, clearance 12.2 ml/min per kg and volume distribution 3.1 l/kg.",Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15365654/),min,24.0,31022,DB00281,Lidocaine
,15365654,area under the curve (AUC)0-infinity,"The pharmacokinetic parameters were: half-life t1/2alpha 24.0 min, area under the curve (AUC)0-infinity 460.2 microg/min per ml, t1/2beta 180.0 min, clearance 12.2 ml/min per kg and volume distribution 3.1 l/kg.",Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15365654/),[μg] / [min·ml],460.2,31023,DB00281,Lidocaine
,15365654,t1/2beta,"The pharmacokinetic parameters were: half-life t1/2alpha 24.0 min, area under the curve (AUC)0-infinity 460.2 microg/min per ml, t1/2beta 180.0 min, clearance 12.2 ml/min per kg and volume distribution 3.1 l/kg.",Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15365654/),min,180.0,31024,DB00281,Lidocaine
,15365654,clearance,"The pharmacokinetic parameters were: half-life t1/2alpha 24.0 min, area under the curve (AUC)0-infinity 460.2 microg/min per ml, t1/2beta 180.0 min, clearance 12.2 ml/min per kg and volume distribution 3.1 l/kg.",Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15365654/),[ml] / [kg·min],12.2,31025,DB00281,Lidocaine
,15365654,volume distribution,"The pharmacokinetic parameters were: half-life t1/2alpha 24.0 min, area under the curve (AUC)0-infinity 460.2 microg/min per ml, t1/2beta 180.0 min, clearance 12.2 ml/min per kg and volume distribution 3.1 l/kg.",Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15365654/),[l] / [kg],3.1,31026,DB00281,Lidocaine
,15365654,fetal/maternal ratio,"The fetal/maternal ratio for lidocaine at delivery was 0.46, with the latency time between drug administration and delivery being 11.0 min.",Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15365654/),,0.46,31027,DB00281,Lidocaine
,15365654,latency time,"The fetal/maternal ratio for lidocaine at delivery was 0.46, with the latency time between drug administration and delivery being 11.0 min.",Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15365654/),min,11.0,31028,DB00281,Lidocaine
,15365654,Maximum MEGX concentrations,Maximum MEGX concentrations at the median time of 90 min were 229.0 ng/ml.,Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15365654/),[ng] / [ml],229.0,31029,DB00281,Lidocaine
,15365654,t1/2,"The t1/2 for MEGX was 240 min, and AUC0-infinity was 82.4 microg min/ml.",Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15365654/),min,240,31030,DB00281,Lidocaine
,15365654,AUC0-infinity,"The t1/2 for MEGX was 240 min, and AUC0-infinity was 82.4 microg min/ml.",Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15365654/),[min·μg] / [ml],82.4,31031,DB00281,Lidocaine
,15365654,tmax,"Lidocaine administered by the perineal route presented a tmax of 15 min, significantly lower than when the drug was administered peridurally, revealing that the time between administration and the occurrence of the analgesic effect was shorter.",Pharmacokinetics and transplacental transfer of lidocaine and its metabolite for perineal analgesic assistance to pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15365654/),min,15,31032,DB00281,Lidocaine
,6746155,infusion time,The lidocaine dose was 100 mg and the infusion time 12 minutes.,Pharmacokinetics of lidocaine in healthy individuals pretreated with multiple doses of metoprolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6746155/),min,12,31189,DB00281,Lidocaine
,9812455,peak concentration,The mean peak concentration of lidocaine that was 1.16 ug/mg with a range of 0.67 to 2.84 ug/mg occurred 4-13 hours after lidocaine administration.,[A pharmacokinetic study of lidocaine in patients undergoing liposuction with tumescent technique]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812455/),[ug] / [mg],1.16,31326,DB00281,Lidocaine
,3592861,peak concentrations (Cmax,"Concomitant administration of H caused a significant (p less than 0.05) increase in P peak concentrations (Cmax, 34 +/- 5: 73 +/- 10 ng/ml) and the area under plasma concentration time curve (AUC, 142 +/- 18: 254 +/- 56 ng/ml X hr) of P with significant (p less than 0.05) 24% reduction of the apparent oral clearance.",Influence of hydralazine on the pharmacokinetics of orally administered d-propranolol and lidocaine in conscious dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592861/),[ng] / [ml],34,32740,DB00281,Lidocaine
,3592861,peak concentrations (Cmax,"Concomitant administration of H caused a significant (p less than 0.05) increase in P peak concentrations (Cmax, 34 +/- 5: 73 +/- 10 ng/ml) and the area under plasma concentration time curve (AUC, 142 +/- 18: 254 +/- 56 ng/ml X hr) of P with significant (p less than 0.05) 24% reduction of the apparent oral clearance.",Influence of hydralazine on the pharmacokinetics of orally administered d-propranolol and lidocaine in conscious dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592861/),[ng] / [ml],73,32741,DB00281,Lidocaine
,3592861,area under plasma concentration time curve (AUC,"Concomitant administration of H caused a significant (p less than 0.05) increase in P peak concentrations (Cmax, 34 +/- 5: 73 +/- 10 ng/ml) and the area under plasma concentration time curve (AUC, 142 +/- 18: 254 +/- 56 ng/ml X hr) of P with significant (p less than 0.05) 24% reduction of the apparent oral clearance.",Influence of hydralazine on the pharmacokinetics of orally administered d-propranolol and lidocaine in conscious dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592861/),[ng] / [h·ml],142,32742,DB00281,Lidocaine
,3592861,area under plasma concentration time curve (AUC,"Concomitant administration of H caused a significant (p less than 0.05) increase in P peak concentrations (Cmax, 34 +/- 5: 73 +/- 10 ng/ml) and the area under plasma concentration time curve (AUC, 142 +/- 18: 254 +/- 56 ng/ml X hr) of P with significant (p less than 0.05) 24% reduction of the apparent oral clearance.",Influence of hydralazine on the pharmacokinetics of orally administered d-propranolol and lidocaine in conscious dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592861/),[ng] / [h·ml],254,32743,DB00281,Lidocaine
,14715049,Protein binding,"Protein binding ranges from 65% (lidocaine) to more than 95% (bupivacaine, ropivacaine).",Pharmacokinetics of local anaesthetics in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14715049/),%,65,32796,DB00281,Lidocaine
more,14715049,Protein binding,"Protein binding ranges from 65% (lidocaine) to more than 95% (bupivacaine, ropivacaine).",Pharmacokinetics of local anaesthetics in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14715049/),%,95,32797,DB00281,Lidocaine
,14715049,time to C(max),The time to C(max) decreases from 90-120 minutes in infants aged less than 6 months to 30 minutes in children aged more than 8 years.,Pharmacokinetics of local anaesthetics in infants and children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14715049/),min,90-120,32798,DB00281,Lidocaine
,14715049,time to C(max),The time to C(max) decreases from 90-120 minutes in infants aged less than 6 months to 30 minutes in children aged more than 8 years.,Pharmacokinetics of local anaesthetics in infants and children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14715049/),min,30,32799,DB00281,Lidocaine
,8017592,areas under the curve at infinity,"The mean (95% CI) areas under the curve at infinity for lignocaine after pretreatment with omeprazole or placebo were 6.67 (4.90-8.45) mumol.h.l-1 and 6.14 (5.05-7.23) mumol.h.l-1, respectively (p = 0.44).",The effect of oral omeprazole on the disposition of lignocaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8017592/),[h·μM] / [l],6.67,33472,DB00281,Lidocaine
,8017592,areas under the curve at infinity,"The mean (95% CI) areas under the curve at infinity for lignocaine after pretreatment with omeprazole or placebo were 6.67 (4.90-8.45) mumol.h.l-1 and 6.14 (5.05-7.23) mumol.h.l-1, respectively (p = 0.44).",The effect of oral omeprazole on the disposition of lignocaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8017592/),[h·μM] / [l],6.14,33473,DB00281,Lidocaine
,8017592,areas,The respective areas for monoethylglycinexylidine were 1.85 (1.25-2.45) mumol.h.l-1 and 1.79 (1.44-2.14) mumol.h.l-1 (p = 0.78).,The effect of oral omeprazole on the disposition of lignocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8017592/),[h·μM] / [l],1.85,33474,DB00281,Lidocaine
,8017592,areas,The respective areas for monoethylglycinexylidine were 1.85 (1.25-2.45) mumol.h.l-1 and 1.79 (1.44-2.14) mumol.h.l-1 (p = 0.78).,The effect of oral omeprazole on the disposition of lignocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8017592/),[h·μM] / [l],1.79,33475,DB00281,Lidocaine
,3061720,systemic bioavailability,"It is well absorbed after oral administration, but systemic bioavailability is only 12% after a 300-mg dose.",Propafenone: a new antiarrhythmic agent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),%,12,37633,DB00281,Lidocaine
,3061720,elimination half-life,"Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers.",Propafenone: a new antiarrhythmic agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),h,5.5,37634,DB00281,Lidocaine
,3061720,elimination half-life,"Elimination is primarily hepatic, with a mean elimination half-life after oral administration of 5.5 hours in extensive metabolizers and 17.2 hours in poor metabolizers.",Propafenone: a new antiarrhythmic agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3061720/),h,17.2,37635,DB00281,Lidocaine
,11847940,maximum concentrations,"For days 1, 2, and 3, the mean +/- SD maximum concentrations were 145.1 +/- 42.4, 153.0 +/- 40.7, and 153.8 +/- 51.4 ng/mL, respectively; the median times to peak plasma concentration were 18.0, 16.5, and 16.5 hours, respectively; the mean +/- SD trough concentrations were 83.0 +/- 29.0, 85.7 +/- 31.1, and 77.0 +/- 26.9 ng/mL, respectively; and the mean +/- SD AUCs over 24 hours were 2089.2 +/- 632.5, 2659.2 +/- 726.8, and 2675.7 +/- 819.2 ng.h/mL, respectively.",Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847940/),[ng] / [ml],145.1,37849,DB00281,Lidocaine
,11847940,maximum concentrations,"For days 1, 2, and 3, the mean +/- SD maximum concentrations were 145.1 +/- 42.4, 153.0 +/- 40.7, and 153.8 +/- 51.4 ng/mL, respectively; the median times to peak plasma concentration were 18.0, 16.5, and 16.5 hours, respectively; the mean +/- SD trough concentrations were 83.0 +/- 29.0, 85.7 +/- 31.1, and 77.0 +/- 26.9 ng/mL, respectively; and the mean +/- SD AUCs over 24 hours were 2089.2 +/- 632.5, 2659.2 +/- 726.8, and 2675.7 +/- 819.2 ng.h/mL, respectively.",Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847940/),[ng] / [ml],153.0,37850,DB00281,Lidocaine
,11847940,maximum concentrations,"For days 1, 2, and 3, the mean +/- SD maximum concentrations were 145.1 +/- 42.4, 153.0 +/- 40.7, and 153.8 +/- 51.4 ng/mL, respectively; the median times to peak plasma concentration were 18.0, 16.5, and 16.5 hours, respectively; the mean +/- SD trough concentrations were 83.0 +/- 29.0, 85.7 +/- 31.1, and 77.0 +/- 26.9 ng/mL, respectively; and the mean +/- SD AUCs over 24 hours were 2089.2 +/- 632.5, 2659.2 +/- 726.8, and 2675.7 +/- 819.2 ng.h/mL, respectively.",Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847940/),[ng] / [ml],153.8,37851,DB00281,Lidocaine
,11847940,times to peak plasma concentration,"For days 1, 2, and 3, the mean +/- SD maximum concentrations were 145.1 +/- 42.4, 153.0 +/- 40.7, and 153.8 +/- 51.4 ng/mL, respectively; the median times to peak plasma concentration were 18.0, 16.5, and 16.5 hours, respectively; the mean +/- SD trough concentrations were 83.0 +/- 29.0, 85.7 +/- 31.1, and 77.0 +/- 26.9 ng/mL, respectively; and the mean +/- SD AUCs over 24 hours were 2089.2 +/- 632.5, 2659.2 +/- 726.8, and 2675.7 +/- 819.2 ng.h/mL, respectively.",Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847940/),h,18.0,37852,DB00281,Lidocaine
,11847940,times to peak plasma concentration,"For days 1, 2, and 3, the mean +/- SD maximum concentrations were 145.1 +/- 42.4, 153.0 +/- 40.7, and 153.8 +/- 51.4 ng/mL, respectively; the median times to peak plasma concentration were 18.0, 16.5, and 16.5 hours, respectively; the mean +/- SD trough concentrations were 83.0 +/- 29.0, 85.7 +/- 31.1, and 77.0 +/- 26.9 ng/mL, respectively; and the mean +/- SD AUCs over 24 hours were 2089.2 +/- 632.5, 2659.2 +/- 726.8, and 2675.7 +/- 819.2 ng.h/mL, respectively.",Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847940/),h,16.5,37853,DB00281,Lidocaine
,11847940,trough concentrations,"For days 1, 2, and 3, the mean +/- SD maximum concentrations were 145.1 +/- 42.4, 153.0 +/- 40.7, and 153.8 +/- 51.4 ng/mL, respectively; the median times to peak plasma concentration were 18.0, 16.5, and 16.5 hours, respectively; the mean +/- SD trough concentrations were 83.0 +/- 29.0, 85.7 +/- 31.1, and 77.0 +/- 26.9 ng/mL, respectively; and the mean +/- SD AUCs over 24 hours were 2089.2 +/- 632.5, 2659.2 +/- 726.8, and 2675.7 +/- 819.2 ng.h/mL, respectively.",Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847940/),[ng] / [ml],83.0,37854,DB00281,Lidocaine
,11847940,trough concentrations,"For days 1, 2, and 3, the mean +/- SD maximum concentrations were 145.1 +/- 42.4, 153.0 +/- 40.7, and 153.8 +/- 51.4 ng/mL, respectively; the median times to peak plasma concentration were 18.0, 16.5, and 16.5 hours, respectively; the mean +/- SD trough concentrations were 83.0 +/- 29.0, 85.7 +/- 31.1, and 77.0 +/- 26.9 ng/mL, respectively; and the mean +/- SD AUCs over 24 hours were 2089.2 +/- 632.5, 2659.2 +/- 726.8, and 2675.7 +/- 819.2 ng.h/mL, respectively.",Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847940/),[ng] / [ml],85.7,37855,DB00281,Lidocaine
,11847940,trough concentrations,"For days 1, 2, and 3, the mean +/- SD maximum concentrations were 145.1 +/- 42.4, 153.0 +/- 40.7, and 153.8 +/- 51.4 ng/mL, respectively; the median times to peak plasma concentration were 18.0, 16.5, and 16.5 hours, respectively; the mean +/- SD trough concentrations were 83.0 +/- 29.0, 85.7 +/- 31.1, and 77.0 +/- 26.9 ng/mL, respectively; and the mean +/- SD AUCs over 24 hours were 2089.2 +/- 632.5, 2659.2 +/- 726.8, and 2675.7 +/- 819.2 ng.h/mL, respectively.",Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847940/),[ng] / [ml],77.0,37856,DB00281,Lidocaine
,11847940,AUCs,"For days 1, 2, and 3, the mean +/- SD maximum concentrations were 145.1 +/- 42.4, 153.0 +/- 40.7, and 153.8 +/- 51.4 ng/mL, respectively; the median times to peak plasma concentration were 18.0, 16.5, and 16.5 hours, respectively; the mean +/- SD trough concentrations were 83.0 +/- 29.0, 85.7 +/- 31.1, and 77.0 +/- 26.9 ng/mL, respectively; and the mean +/- SD AUCs over 24 hours were 2089.2 +/- 632.5, 2659.2 +/- 726.8, and 2675.7 +/- 819.2 ng.h/mL, respectively.",Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847940/),[h·ng] / [ml],2089.2,37857,DB00281,Lidocaine
,11847940,AUCs,"For days 1, 2, and 3, the mean +/- SD maximum concentrations were 145.1 +/- 42.4, 153.0 +/- 40.7, and 153.8 +/- 51.4 ng/mL, respectively; the median times to peak plasma concentration were 18.0, 16.5, and 16.5 hours, respectively; the mean +/- SD trough concentrations were 83.0 +/- 29.0, 85.7 +/- 31.1, and 77.0 +/- 26.9 ng/mL, respectively; and the mean +/- SD AUCs over 24 hours were 2089.2 +/- 632.5, 2659.2 +/- 726.8, and 2675.7 +/- 819.2 ng.h/mL, respectively.",Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847940/),[h·ng] / [ml],2659.2,37858,DB00281,Lidocaine
,11847940,AUCs,"For days 1, 2, and 3, the mean +/- SD maximum concentrations were 145.1 +/- 42.4, 153.0 +/- 40.7, and 153.8 +/- 51.4 ng/mL, respectively; the median times to peak plasma concentration were 18.0, 16.5, and 16.5 hours, respectively; the mean +/- SD trough concentrations were 83.0 +/- 29.0, 85.7 +/- 31.1, and 77.0 +/- 26.9 ng/mL, respectively; and the mean +/- SD AUCs over 24 hours were 2089.2 +/- 632.5, 2659.2 +/- 726.8, and 2675.7 +/- 819.2 ng.h/mL, respectively.",Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11847940/),[h·ng] / [ml],2675.7,37859,DB00281,Lidocaine
,2127569,total body clearance,"In the healthy subjects, the total body clearance of R(-)-tocainide was significantly greater than that of S(+)-tocainide (2.62 vs 1.70 ml.min-1.kg-1).",Stereoselective pharmacokinetics of tocainide in human uraemic patients and in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2127569/),[ml] / [kg·min],2.62,38180,DB00281,Lidocaine
,2127569,total body clearance,"In the healthy subjects, the total body clearance of R(-)-tocainide was significantly greater than that of S(+)-tocainide (2.62 vs 1.70 ml.min-1.kg-1).",Stereoselective pharmacokinetics of tocainide in human uraemic patients and in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2127569/),[ml] / [kg·min],1.70,38181,DB00281,Lidocaine
,8431344,peak plasma lignocaine concentration,"The mean (SD) peak plasma lignocaine concentration was 0.57 (0.29) microgram ml-1 after glycopyrronium and 0.31 (0.10) microgram ml-1 after saline (P < 0.05) and were attained in 17 min (range 10-40 min) and 29 min (range 8-40 min), respectively.",Glycopyrronium prolongs topical anaesthesia of oral mucosa and enhances absorption of lignocaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431344/),[μg] / [ml],0.57,39973,DB00281,Lidocaine
,8431344,peak plasma lignocaine concentration,"The mean (SD) peak plasma lignocaine concentration was 0.57 (0.29) microgram ml-1 after glycopyrronium and 0.31 (0.10) microgram ml-1 after saline (P < 0.05) and were attained in 17 min (range 10-40 min) and 29 min (range 8-40 min), respectively.",Glycopyrronium prolongs topical anaesthesia of oral mucosa and enhances absorption of lignocaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431344/),[μg] / [ml],0.31,39974,DB00281,Lidocaine
,9249105,elimination half-life,"After the bolus injection, the elimination half-life for LD was 0.87-5.44 h.",Lidocaine pharmacokinetics and toxicity in newborn pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9249105/),h,0.87-5.44,40464,DB00281,Lidocaine
,9249105,unbound LD(pl),The unbound LD(pl) at seizures was 4.4 +/- 2.4 mg/L. Younger animals convulsed at higher LD(conv) (r2 = 0.85).,Lidocaine pharmacokinetics and toxicity in newborn pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9249105/),[mg] / [l],4.4,40465,DB00281,Lidocaine
,7812627,plasma osmolality,"3. In dehydrated and hyperosmolal-hydrated rabbits, plasma osmolality was 321 +/- 1 and 313 +/- 1 mOsm kg-1, respectively (P < 0.01 compared to controls, 285 +/- 1 mOsm kg-1).",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[mosm] / [kg],321,40565,DB00281,Lidocaine
,7812627,plasma osmolality,"3. In dehydrated and hyperosmolal-hydrated rabbits, plasma osmolality was 321 +/- 1 and 313 +/- 1 mOsm kg-1, respectively (P < 0.01 compared to controls, 285 +/- 1 mOsm kg-1).",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[mosm] / [kg],313,40566,DB00281,Lidocaine
,7812627,plasma osmolality,"3. In dehydrated and hyperosmolal-hydrated rabbits, plasma osmolality was 321 +/- 1 and 313 +/- 1 mOsm kg-1, respectively (P < 0.01 compared to controls, 285 +/- 1 mOsm kg-1).",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[mosm] / [kg],285,40567,DB00281,Lidocaine
,7812627,systemic clearance,"4. Under both experimental conditions, lignocaine plasma concentrations were almost double (P < 0.01) those in controls, due to a lower systemic clearance, e.g. 54 +/- 3 and 59 +/- 1 vs. 96 +/- 5 ml min-1 kg-1, respectively.",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[ml] / [kg·min],54,40568,DB00281,Lidocaine
,7812627,systemic clearance,"4. Under both experimental conditions, lignocaine plasma concentrations were almost double (P < 0.01) those in controls, due to a lower systemic clearance, e.g. 54 +/- 3 and 59 +/- 1 vs. 96 +/- 5 ml min-1 kg-1, respectively.",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[ml] / [kg·min],59,40569,DB00281,Lidocaine
,7812627,systemic clearance,"4. Under both experimental conditions, lignocaine plasma concentrations were almost double (P < 0.01) those in controls, due to a lower systemic clearance, e.g. 54 +/- 3 and 59 +/- 1 vs. 96 +/- 5 ml min-1 kg-1, respectively.",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[ml] / [kg·min],96,40570,DB00281,Lidocaine
,7812627,hepatic plasma flow,AVP reduced hepatic plasma flow from 38.9 +/-2.7 ml min-1 to 19.6 +/-2.5 ml min-1 (P<0.01).,Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[ml] / [min],38.9,40571,DB00281,Lidocaine
,7812627,hepatic plasma flow,AVP reduced hepatic plasma flow from 38.9 +/-2.7 ml min-1 to 19.6 +/-2.5 ml min-1 (P<0.01).,Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[ml] / [min],19.6,40572,DB00281,Lidocaine
,7812627,Emax,"The predicted maximal AVP-induced decrease in hepatic plasma flow was 19.6 ml min-1 kg- 1(Emax), and AVP concentration eliciting 50% of Em.. (ED50) was 28.7 pg ml-1.6",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[1·kg-·ml] / [min],19.6,40573,DB00281,Lidocaine
,7812627,Em.. (,"The predicted maximal AVP-induced decrease in hepatic plasma flow was 19.6 ml min-1 kg- 1(Emax), and AVP concentration eliciting 50% of Em.. (ED50) was 28.7 pg ml-1.6",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[pg] / [ml],28.7,40574,DB00281,Lidocaine
,7812627,ED50),"The predicted maximal AVP-induced decrease in hepatic plasma flow was 19.6 ml min-1 kg- 1(Emax), and AVP concentration eliciting 50% of Em.. (ED50) was 28.7 pg ml-1.6",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[pg] / [ml],28.7,40575,DB00281,Lidocaine
,2613837,Analytical recoveries,"Analytical recoveries were 88.6 +/- 3.6 and 77.4 +/- 3.0% (mean +/- S.E.), respectively, at levels ranging from 25 to 200 ng/ml.",Sensitive high-performance liquid chromatographic assay using 9-fluorenylmethylchloroformate for monitoring controlled-release lidocaine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2613837/),%,88.6,40682,DB00281,Lidocaine
,2613837,Analytical recoveries,"Analytical recoveries were 88.6 +/- 3.6 and 77.4 +/- 3.0% (mean +/- S.E.), respectively, at levels ranging from 25 to 200 ng/ml.",Sensitive high-performance liquid chromatographic assay using 9-fluorenylmethylchloroformate for monitoring controlled-release lidocaine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2613837/),%,77.4,40683,DB00281,Lidocaine
,2613837,lower detection limit,The lower detection limit was 1 ng/ml lidocaine.,Sensitive high-performance liquid chromatographic assay using 9-fluorenylmethylchloroformate for monitoring controlled-release lidocaine in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2613837/),[ng] / [ml],1,40684,DB00281,Lidocaine
,2914337,Cmax plasma levels,Cmax plasma levels for normal patients (5.6 +/- 1.1 micrograms.ml-1) and for patients with chronic renal failure (6.6 +/- 1.6 micrograms.,Interscalene brachial plexus blockade with lidocaine in chronic renal failure--a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2914337/),[μg] / [ml],5.6,41981,DB00281,Lidocaine
,2914337,Cmax plasma levels,Cmax plasma levels for normal patients (5.6 +/- 1.1 micrograms.ml-1) and for patients with chronic renal failure (6.6 +/- 1.6 micrograms.,Interscalene brachial plexus blockade with lidocaine in chronic renal failure--a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2914337/),μg,6.6,41982,DB00281,Lidocaine
,33859140,plasma concentrations,"Mean plasma concentrations of lidocaine were not statistically different between groups, ranging from 0.245 to 2.28 ng/ml after administration of lidocaine with epinephrine (immediate post-iontophoresis to 230 min post-iontophoresis), compared with 1.35 to 2.14 ng/ml after administration of lidocaine alone.",Pharmacokinetics of Single Dose Lidocaine and Epinephrine Following Iontophoresis of the Tympanic Membrane in a Double-Blinded Randomized Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33859140/),[ng] / [ml],0.245 to 2.28,42078,DB00281,Lidocaine
,33859140,plasma concentrations,"Mean plasma concentrations of lidocaine were not statistically different between groups, ranging from 0.245 to 2.28 ng/ml after administration of lidocaine with epinephrine (immediate post-iontophoresis to 230 min post-iontophoresis), compared with 1.35 to 2.14 ng/ml after administration of lidocaine alone.",Pharmacokinetics of Single Dose Lidocaine and Epinephrine Following Iontophoresis of the Tympanic Membrane in a Double-Blinded Randomized Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33859140/),[ng] / [ml],1.35 to 2.14,42079,DB00281,Lidocaine
,33859140,Cmax,Lidocaine levels (Cmax 2.24 ng/ml) were approximately 2000-fold lower than the threshold for minor lidocaine toxicity.,Pharmacokinetics of Single Dose Lidocaine and Epinephrine Following Iontophoresis of the Tympanic Membrane in a Double-Blinded Randomized Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33859140/),[ng] / [ml],2.24,42080,DB00281,Lidocaine
,6883930,total amount,"The total amount of lidocaine removed was 8.9 and 12.5 mg for patients A and B, respectively.",Hemodialysis clearance of total and unbound lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),,8.9,42254,DB00281,Lidocaine
,6883930,total amount,"The total amount of lidocaine removed was 8.9 and 12.5 mg for patients A and B, respectively.",Hemodialysis clearance of total and unbound lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),,12.5,42255,DB00281,Lidocaine
,6883930,plasma dialysis clearance (Clp),"For patient A, the mean plasma dialysis clearance (Clp) was 28.2 +/- 6.3 ml/min for total lidocaine and 41.3 +/- 15.6 ml/min for unbound lidocaine.",Hemodialysis clearance of total and unbound lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),[ml] / [min],28.2,42256,DB00281,Lidocaine
,6883930,plasma dialysis clearance (Clp),"For patient A, the mean plasma dialysis clearance (Clp) was 28.2 +/- 6.3 ml/min for total lidocaine and 41.3 +/- 15.6 ml/min for unbound lidocaine.",Hemodialysis clearance of total and unbound lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),[ml] / [min],41.3,42257,DB00281,Lidocaine
,6883930,dial,"The mean dialysate clearance (Cld) of total lidocaine was 28.6 +/- 7.8 and 26.3 +/- 6.5 ml/min for patients A and B, respectively.",Hemodialysis clearance of total and unbound lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),[ml] / [min],28.6,42258,DB00281,Lidocaine
,6883930,Cld,"The Cld of unbound lidocaine was 42.7 +/- 6.7 and 44.5 +/- 9.9 for patients A and B, respectively.",Hemodialysis clearance of total and unbound lidocaine. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),,42.7,42259,DB00281,Lidocaine
,6883930,Cld,"The Cld of unbound lidocaine was 42.7 +/- 6.7 and 44.5 +/- 9.9 for patients A and B, respectively.",Hemodialysis clearance of total and unbound lidocaine. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),,44.5,42260,DB00281,Lidocaine
,6883930,unbound fractions,"Although both patients A and B had substantial elevations in AAG concentrations (254 and 247 mg/dl, respectively), they exhibited high lidocaine unbound fractions of 0.55 and 0.68 before dialysis.",Hemodialysis clearance of total and unbound lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),,0.55,42261,DB00281,Lidocaine
,6883930,unbound fractions,"Although both patients A and B had substantial elevations in AAG concentrations (254 and 247 mg/dl, respectively), they exhibited high lidocaine unbound fractions of 0.55 and 0.68 before dialysis.",Hemodialysis clearance of total and unbound lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883930/),,0.68,42262,DB00281,Lidocaine
,10071979,bioavailability [F,"We found slightly high etoposide bioavailability [F, 61% (17-95%)] and clearance [CL, 1.1 (0.7-2.3)l h(-1) m(-2)] resulting in a normal degree of systemic exposure (AUC(oral) 27 microg h ml(-1)).",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),%,61,43362,DB00281,Lidocaine
,10071979,clearance [CL,"We found slightly high etoposide bioavailability [F, 61% (17-95%)] and clearance [CL, 1.1 (0.7-2.3)l h(-1) m(-2)] resulting in a normal degree of systemic exposure (AUC(oral) 27 microg h ml(-1)).",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),[l] / [(m)^2·h],1.1,43363,DB00281,Lidocaine
,10071979,AUC(oral),"We found slightly high etoposide bioavailability [F, 61% (17-95%)] and clearance [CL, 1.1 (0.7-2.3)l h(-1) m(-2)] resulting in a normal degree of systemic exposure (AUC(oral) 27 microg h ml(-1)).",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),[h·μg] / [ml],27,43364,DB00281,Lidocaine
,10071979,"AUC(f, oral)","Normal protein binding [PB 93.2% (84.4-98.1%)] contributed to a normal level of exposure to free drug (AUC(f, oral) 1.9 microg h ml(-1)).",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),[h·μg] / [ml],1.9,43365,DB00281,Lidocaine
,10071979,distribution volume [V(SS),"The distribution volume [V(SS) 8.4 (6.1-13.2) l/m2] and the effective half-life [t1/2eff, 5.1 (3.0-9.6) h] were normal.",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),[l] / [m2],8.4,43366,DB00281,Lidocaine
,10071979,effective half-life [t1/2eff,"The distribution volume [V(SS) 8.4 (6.1-13.2) l/m2] and the effective half-life [t1/2eff, 5.1 (3.0-9.6) h] were normal.",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),h,5.1,43367,DB00281,Lidocaine
,10071979,CL,"Median CL and protein binding did not differ in the seven patients with total bilirubin value of > 1.2 mg/dl as compared with the ten patients with total bilirubin levels of < or = 1.2 mg/dl (1.3 versus 1.01 h(-1) m(-2) and 92.5% versus 93.4%, respectively).",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),1/[(m)^2·h],1.3,43368,DB00281,Lidocaine
,10071979,CL,"Median CL and protein binding did not differ in the seven patients with total bilirubin value of > 1.2 mg/dl as compared with the ten patients with total bilirubin levels of < or = 1.2 mg/dl (1.3 versus 1.01 h(-1) m(-2) and 92.5% versus 93.4%, respectively).",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),1/[(m)^2·h],1.01,43369,DB00281,Lidocaine
,10071979,protein binding,"Median CL and protein binding did not differ in the seven patients with total bilirubin value of > 1.2 mg/dl as compared with the ten patients with total bilirubin levels of < or = 1.2 mg/dl (1.3 versus 1.01 h(-1) m(-2) and 92.5% versus 93.4%, respectively).",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),%,92.5,43370,DB00281,Lidocaine
,10071979,protein binding,"Median CL and protein binding did not differ in the seven patients with total bilirubin value of > 1.2 mg/dl as compared with the ten patients with total bilirubin levels of < or = 1.2 mg/dl (1.3 versus 1.01 h(-1) m(-2) and 92.5% versus 93.4%, respectively).",Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071979/),%,93.4,43371,DB00281,Lidocaine
,17571567,Cmax,"Some pharmacokinetic parameters of lidocaine were statistically significant higher (p < 0.05, ANOVA) for the rats treated with atenolol compared with control group: Cmax (196.97 +/- 2.15 ng/ml vs. 125.29 +/- 2.90 ng/ml), AUD (7734.07 +/- 129.06 ng/ ml x min vs. 4478.57 +/- 296.61 ng/ml x min), AUC1 after 5 minutes (314.23 +/- 6.59 ng/ml x min vs. 190.71 +/- 19.75 ng/ml x min).",[Research on the effect of atenolol on lidocaine pharmacokinetics in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17571567/),[ng] / [ml],196.97,43563,DB00281,Lidocaine
,17571567,Cmax,"Some pharmacokinetic parameters of lidocaine were statistically significant higher (p < 0.05, ANOVA) for the rats treated with atenolol compared with control group: Cmax (196.97 +/- 2.15 ng/ml vs. 125.29 +/- 2.90 ng/ml), AUD (7734.07 +/- 129.06 ng/ ml x min vs. 4478.57 +/- 296.61 ng/ml x min), AUC1 after 5 minutes (314.23 +/- 6.59 ng/ml x min vs. 190.71 +/- 19.75 ng/ml x min).",[Research on the effect of atenolol on lidocaine pharmacokinetics in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17571567/),[ng] / [ml],125.29,43564,DB00281,Lidocaine
,17571567,AUD,"Some pharmacokinetic parameters of lidocaine were statistically significant higher (p < 0.05, ANOVA) for the rats treated with atenolol compared with control group: Cmax (196.97 +/- 2.15 ng/ml vs. 125.29 +/- 2.90 ng/ml), AUD (7734.07 +/- 129.06 ng/ ml x min vs. 4478.57 +/- 296.61 ng/ml x min), AUC1 after 5 minutes (314.23 +/- 6.59 ng/ml x min vs. 190.71 +/- 19.75 ng/ml x min).",[Research on the effect of atenolol on lidocaine pharmacokinetics in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17571567/),[ng] / [min·ml],7734.07,43565,DB00281,Lidocaine
,17571567,AUD,"Some pharmacokinetic parameters of lidocaine were statistically significant higher (p < 0.05, ANOVA) for the rats treated with atenolol compared with control group: Cmax (196.97 +/- 2.15 ng/ml vs. 125.29 +/- 2.90 ng/ml), AUD (7734.07 +/- 129.06 ng/ ml x min vs. 4478.57 +/- 296.61 ng/ml x min), AUC1 after 5 minutes (314.23 +/- 6.59 ng/ml x min vs. 190.71 +/- 19.75 ng/ml x min).",[Research on the effect of atenolol on lidocaine pharmacokinetics in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17571567/),[ng] / [min·ml],4478.57,43566,DB00281,Lidocaine
,17571567,AUC1,"Some pharmacokinetic parameters of lidocaine were statistically significant higher (p < 0.05, ANOVA) for the rats treated with atenolol compared with control group: Cmax (196.97 +/- 2.15 ng/ml vs. 125.29 +/- 2.90 ng/ml), AUD (7734.07 +/- 129.06 ng/ ml x min vs. 4478.57 +/- 296.61 ng/ml x min), AUC1 after 5 minutes (314.23 +/- 6.59 ng/ml x min vs. 190.71 +/- 19.75 ng/ml x min).",[Research on the effect of atenolol on lidocaine pharmacokinetics in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17571567/),[ng] / [min·ml],314.23,43567,DB00281,Lidocaine
,17571567,AUC1,"Some pharmacokinetic parameters of lidocaine were statistically significant higher (p < 0.05, ANOVA) for the rats treated with atenolol compared with control group: Cmax (196.97 +/- 2.15 ng/ml vs. 125.29 +/- 2.90 ng/ml), AUD (7734.07 +/- 129.06 ng/ ml x min vs. 4478.57 +/- 296.61 ng/ml x min), AUC1 after 5 minutes (314.23 +/- 6.59 ng/ml x min vs. 190.71 +/- 19.75 ng/ml x min).",[Research on the effect of atenolol on lidocaine pharmacokinetics in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17571567/),[ng] / [min·ml],190.71,43568,DB00281,Lidocaine
,17571567,Tmax,"Tmax was 20 minutes, similar for both groups.",[Research on the effect of atenolol on lidocaine pharmacokinetics in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17571567/),min,20,43569,DB00281,Lidocaine
,6854732,elimination rate constant,"The mean elimination rate constant and the mean specific clearance determined for the intravenous portion of the study were 0.786 h-1 and 2.40 1/kg/h, respectively.",Pharmacokinetics of lidocaine and its active metabolites in dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6854732/),1/[h],0.786,46182,DB00281,Lidocaine
,6854732,specific clearance,"The mean elimination rate constant and the mean specific clearance determined for the intravenous portion of the study were 0.786 h-1 and 2.40 1/kg/h, respectively.",Pharmacokinetics of lidocaine and its active metabolites in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6854732/),[1] / [h·kg],2.40,46183,DB00281,Lidocaine
,6854732,absorption rate constant,Following intramuscular administration the mean absorption rate constant was 7.74 h-1.,Pharmacokinetics of lidocaine and its active metabolites in dogs. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6854732/),1/[h],7.74,46184,DB00281,Lidocaine
,19574726,C(max),"After application of the patch (9.8 mg/kg), pilsicainide was continuously absorbed through the skin with a C(max) of 0.49 +/- 0.13 microg/ml, while its plasma concentration was kept above the clinically reported minimum effective plasma concentration for 2 - 8 h.",Simultaneous assessment of pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects on atria of chronic atrioventricular block dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574726/),[μg] / [ml],0.49,46625,DB00281,Lidocaine
,12483453,C(max),"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[ng] / [ml],3.9,47136,DB00281,Lidocaine
,12483453,C(max),"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[ng] / [ml],0.7,47137,DB00281,Lidocaine
,12483453,AUC(0-24),"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[h·ng] / [ml],51.5,47138,DB00281,Lidocaine
,12483453,AUC(0-24),"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[h·ng] / [ml],9.4,47139,DB00281,Lidocaine
,12483453,Cl/f,"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],3.6,47140,DB00281,Lidocaine
,12483453,Cl/f,"The following differences were observed between the (+)-N and (-)-N enantiomers, respectively, in the patients presenting with DM (means and ranges): C(max) 3.9 (1.7-6.1) ng ml(-1) versus 0.7 (0.4-1.0) ng ml(-1), AUC(0-24) 51.5 (29.0-74.0) ng ml(-1) h versus 9.4 (5.9-12.8) ng ml(-1) h, and Cl/f 3.6 (1.9-5.4) l h(-1) kg(-1) versus 18.7 (11.7-25.7) l h(-1) kg(-1).",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],18.7,47141,DB00281,Lidocaine
,12483453,Cl/f,The Cl/f value of (+)-N was lower (Mann-Whitney test) in patients with DM: 6.0 (4.3-7.5) l h(-1) kg(-1) versus 3.6 (1.9-5.4) l h(-1) kg(-1).,Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],6.0,47142,DB00281,Lidocaine
,12483453,Cl/f,The Cl/f value of (+)-N was lower (Mann-Whitney test) in patients with DM: 6.0 (4.3-7.5) l h(-1) kg(-1) versus 3.6 (1.9-5.4) l h(-1) kg(-1).,Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],3.6,47143,DB00281,Lidocaine
,12483453,Cl/f,"The same observation was made for the (-)-N, with Cl/f reaching 38.8 (26.8-51.0) l h(-1) kg(-1) and 18.7 (11.7-25.7) l h(-1) kg(-1) for the non-diabetic and DM groups, respectively.",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],38.8,47144,DB00281,Lidocaine
,12483453,Cl/f,"The same observation was made for the (-)-N, with Cl/f reaching 38.8 (26.8-51.0) l h(-1) kg(-1) and 18.7 (11.7-25.7) l h(-1) kg(-1) for the non-diabetic and DM groups, respectively.",Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[l] / [h·kg],18.7,47145,DB00281,Lidocaine
,12483453,plasma concentrations,The data also demonstrated that the plasma concentrations of noradrenaline 30 min after N administration were lower (P < 0.05) in diabetic (mean 2.86 pmol ml(-1)) than in non-diabetic patients (4.80 pmol ml(-1)).,Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),pm,2.86,47146,DB00281,Lidocaine
,12483453,plasma concentrations,The data also demonstrated that the plasma concentrations of noradrenaline 30 min after N administration were lower (P < 0.05) in diabetic (mean 2.86 pmol ml(-1)) than in non-diabetic patients (4.80 pmol ml(-1)).,Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483453/),[pM] / [ml],4.80,47147,DB00281,Lidocaine
,30127249,plasma,"The mean plasma concentration and mean total dose that produced convulsions in goat kids were 13.59 ± 2.34 µg/mL and 12.31 ± 1.42 mg/kg BW (mean ± S.D.), respectively.","Toxicity and Pharmacokinetic Studies of Lidocaine and Its Active Metabolite, Monoethylglycinexylidide, in Goat Kids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30127249/),[μg] / [ml],13.59,47213,DB00281,Lidocaine
,30127249,total dose,"The mean plasma concentration and mean total dose that produced convulsions in goat kids were 13.59 ± 2.34 µg/mL and 12.31 ± 1.42 mg/kg BW (mean ± S.D.), respectively.","Toxicity and Pharmacokinetic Studies of Lidocaine and Its Active Metabolite, Monoethylglycinexylidide, in Goat Kids. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30127249/),[mg] / [kg],12.31,47214,DB00281,Lidocaine
,30127249,Cmax,"The absorption of lidocaine following subcutaneous administration was rapid with Cmax and Tmax of 2.12 ± 0.81 µg/mL and 0.33 ± 0.11 h, respectively.","Toxicity and Pharmacokinetic Studies of Lidocaine and Its Active Metabolite, Monoethylglycinexylidide, in Goat Kids. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30127249/),[μg] / [ml],2.12,47215,DB00281,Lidocaine
,30127249,Tmax,"The absorption of lidocaine following subcutaneous administration was rapid with Cmax and Tmax of 2.12 ± 0.81 µg/mL and 0.33 ± 0.11 h, respectively.","Toxicity and Pharmacokinetic Studies of Lidocaine and Its Active Metabolite, Monoethylglycinexylidide, in Goat Kids. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30127249/),h,0.33,47216,DB00281,Lidocaine
,30127249,elimination half-lives (t½λz),"The elimination half-lives (t½λz) of lidocaine hydrochloride and MGX were 1.71 ± 0.51 h and 3.19 ± 1.21 h, respectively.","Toxicity and Pharmacokinetic Studies of Lidocaine and Its Active Metabolite, Monoethylglycinexylidide, in Goat Kids. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30127249/),h,1.71,47217,DB00281,Lidocaine
,30127249,elimination half-lives (t½λz),"The elimination half-lives (t½λz) of lidocaine hydrochloride and MGX were 1.71 ± 0.51 h and 3.19 ± 1.21 h, respectively.","Toxicity and Pharmacokinetic Studies of Lidocaine and Its Active Metabolite, Monoethylglycinexylidide, in Goat Kids. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30127249/),h,3.19,47218,DB00281,Lidocaine
,19558370,MAC,The MAC of Sevo was 2.30 +/- 0.19%.,Effect of lidocaine on the minimum alveolar concentration of sevoflurane in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19558370/),%,2.30,47868,DB00281,Lidocaine
,19558370,plasma concentration,Lidocaine plasma concentration was 0.84 +/- 0.18 for LCRI and 1.89 +/- 0.37 microg mL(-1) for HCRI.,Effect of lidocaine on the minimum alveolar concentration of sevoflurane in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19558370/),[μg] / [ml],0.84,47869,DB00281,Lidocaine
,19558370,plasma concentration,Lidocaine plasma concentration was 0.84 +/- 0.18 for LCRI and 1.89 +/- 0.37 microg mL(-1) for HCRI.,Effect of lidocaine on the minimum alveolar concentration of sevoflurane in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19558370/),[μg] / [ml],1.89,47870,DB00281,Lidocaine
,7486273,plasma peak concentration,"The median plasma peak concentration was 1.74 mg.L-1 after 10 min for lidocaine, and 0.52 mg.L-1 after 7.5 min for bupivacaine respectively.",[Pharmacokinetics of lidocaine and bupivacaine after peribulbar block with additional hyaluronidase]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486273/),[mg] / [l],1.74,49113,DB00281,Lidocaine
,7486273,plasma peak concentration,"The median plasma peak concentration was 1.74 mg.L-1 after 10 min for lidocaine, and 0.52 mg.L-1 after 7.5 min for bupivacaine respectively.",[Pharmacokinetics of lidocaine and bupivacaine after peribulbar block with additional hyaluronidase]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486273/),[mg] / [l],0.52,49114,DB00281,Lidocaine
,12486694,Pa(O2),"In a randomized cross-over design, iv lidocaine (100 mg over 2 min) was administered to conscious instrumented sheep in a control state (C) or when the sheep were rendered hypoxic (H) by the addition of nitrogen to their inspired air (average Pa(O2) = 26 mmHg).",The effect of hypoxic hypoxia on the systemic and myocardial pharmacokinetics and dynamics of lidocaine in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12486694/),mmhg,26,50396,DB00281,Lidocaine
,17929146,bioavailability,The bioavailability value was estimated as 0.31 after the first-pass elimination.,Pharmacokinetic modeling of absorption behavior of 9-aminocamptothecin (9-AC) released from colon-specific HPMA copolymer-9-AC conjugate in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17929146/),,0.31,50662,DB00281,Lidocaine
,17178261,clearance,"In patients not undergoing hemodialysis, lidocaine kinetic parameters were altered in proportion to the degree of renal function impairment, but only in patients with severe renal insufficiency were differences statistically significant: clearance was about half that of control subjects (mean +/- SD, 6.01 +/- 2.54 mL/min x kg versus 11.87 +/- 2.97 mL/min x kg; P < .001), and half-life was approximately doubled (4.55 +/- 1.71 hours versus 2.24 +/- 0.55 hours, P < .001).",Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178261/),[ml] / [kg·min],6.01,50840,DB00281,Lidocaine
,17178261,clearance,"In patients not undergoing hemodialysis, lidocaine kinetic parameters were altered in proportion to the degree of renal function impairment, but only in patients with severe renal insufficiency were differences statistically significant: clearance was about half that of control subjects (mean +/- SD, 6.01 +/- 2.54 mL/min x kg versus 11.87 +/- 2.97 mL/min x kg; P < .001), and half-life was approximately doubled (4.55 +/- 1.71 hours versus 2.24 +/- 0.55 hours, P < .001).",Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178261/),[ml] / [kg·min],11.87,50841,DB00281,Lidocaine
,17178261,half-life,"In patients not undergoing hemodialysis, lidocaine kinetic parameters were altered in proportion to the degree of renal function impairment, but only in patients with severe renal insufficiency were differences statistically significant: clearance was about half that of control subjects (mean +/- SD, 6.01 +/- 2.54 mL/min x kg versus 11.87 +/- 2.97 mL/min x kg; P < .001), and half-life was approximately doubled (4.55 +/- 1.71 hours versus 2.24 +/- 0.55 hours, P < .001).",Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178261/),h,4.55,50842,DB00281,Lidocaine
,17178261,half-life,"In patients not undergoing hemodialysis, lidocaine kinetic parameters were altered in proportion to the degree of renal function impairment, but only in patients with severe renal insufficiency were differences statistically significant: clearance was about half that of control subjects (mean +/- SD, 6.01 +/- 2.54 mL/min x kg versus 11.87 +/- 2.97 mL/min x kg; P < .001), and half-life was approximately doubled (4.55 +/- 1.71 hours versus 2.24 +/- 0.55 hours, P < .001).",Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178261/),h,2.24,50843,DB00281,Lidocaine
,17178261,apparent inhibition constant,"GX was found to be a competitive inhibitor, but its apparent inhibition constant value (52 +/- 6 micromol/L) was 2 orders of magnitude higher than its concentrations in vivo.",Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178261/),[μM] / [l],52,50844,DB00281,Lidocaine
,18085156,peak levels,"The lowest mean peak levels of plasma cortisol (82.53 +/- 6.04 nmol l(-1)), the most rapid return of plasma cortisol levels to baseline values (1.92 +/- 1.11 h), and the lowest occurrence of stress behaviours (2.38 +/- 5.83%) were noted in the SLA group.",Stress responses in adult cattle due to surgical dehorning using three different types of anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18085156/),[nM] / [l],82.53,50856,DB00281,Lidocaine
,18085156,peak levels,"The highest mean peak levels plasma cortisol (113.86 +/- 25.65 nmol l(-1)), the slowest return of plasma cortisol levels to baseline values (3.83 +/- 2.18 h) and the most frequent occurrence of stress behaviours (65.48 +/- 28.72%) were observed in the LA group.",Stress responses in adult cattle due to surgical dehorning using three different types of anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18085156/),[nM] / [l],113.86,50857,DB00281,Lidocaine
,1195128,systemic availability,"The systemic availability of antipyrine was not altered significantly by the surgical procedure whereas the availability of lidocaine and salicylamide, drugs with a marked first-pass effect, was increased from 14.8 +/- 2.8 to 81.3 +/- 5.2% and from 21.8 +/- 7.8 to 57.5 +/- 2.5%, respectively.",Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1195128/),%,14.8,51039,DB00281,Lidocaine
,1195128,availability,"The systemic availability of antipyrine was not altered significantly by the surgical procedure whereas the availability of lidocaine and salicylamide, drugs with a marked first-pass effect, was increased from 14.8 +/- 2.8 to 81.3 +/- 5.2% and from 21.8 +/- 7.8 to 57.5 +/- 2.5%, respectively.",Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1195128/),%,14.8,51040,DB00281,Lidocaine
,1195128,availability,"The systemic availability of antipyrine was not altered significantly by the surgical procedure whereas the availability of lidocaine and salicylamide, drugs with a marked first-pass effect, was increased from 14.8 +/- 2.8 to 81.3 +/- 5.2% and from 21.8 +/- 7.8 to 57.5 +/- 2.5%, respectively.",Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1195128/),%,81.3,51041,DB00281,Lidocaine
,1195128,availability,"The systemic availability of antipyrine was not altered significantly by the surgical procedure whereas the availability of lidocaine and salicylamide, drugs with a marked first-pass effect, was increased from 14.8 +/- 2.8 to 81.3 +/- 5.2% and from 21.8 +/- 7.8 to 57.5 +/- 2.5%, respectively.",Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1195128/),%,21.8,51042,DB00281,Lidocaine
,1195128,availability,"The systemic availability of antipyrine was not altered significantly by the surgical procedure whereas the availability of lidocaine and salicylamide, drugs with a marked first-pass effect, was increased from 14.8 +/- 2.8 to 81.3 +/- 5.2% and from 21.8 +/- 7.8 to 57.5 +/- 2.5%, respectively.",Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1195128/),%,57.5,51043,DB00281,Lidocaine
,8352015,VFT,"kg-1 x min-1 in rats, the VFT were 1.64-3.17 or 1.60-2.11 V, respectively.",[First-pass effect of dauricine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352015/),v,1.64-3.17,51805,DB00281,Lidocaine
,8352015,VFT,"kg-1 x min-1 in rats, the VFT were 1.64-3.17 or 1.60-2.11 V, respectively.",[First-pass effect of dauricine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352015/),v,1.60-2.11,51806,DB00281,Lidocaine
,8352015,VFT,"kg-1 x min-1, the VFT were 1.69-4.79 or 1.67-2.80 V, respectively, after ear vein (iev) or imv infusion of Dau at a rate of 0.5 mg.",[First-pass effect of dauricine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352015/),v,1.69-4.79,51807,DB00281,Lidocaine
,8352015,VFT,"kg-1 x min-1, the VFT were 1.69-4.79 or 1.67-2.80 V, respectively, after ear vein (iev) or imv infusion of Dau at a rate of 0.5 mg.",[First-pass effect of dauricine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352015/),v,1.67-2.80,51808,DB00281,Lidocaine
,8352015,VFT,"kg-1 x min-1 in rabbits, the VFT were 6.50-12.14 or 5.81-7.43 V, respectively.",[First-pass effect of dauricine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352015/),v,6.50-12.14,51809,DB00281,Lidocaine
,8352015,VFT,"kg-1 x min-1 in rabbits, the VFT were 6.50-12.14 or 5.81-7.43 V, respectively.",[First-pass effect of dauricine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352015/),v,5.81-7.43,51810,DB00281,Lidocaine
,9619036,conversion time,"Successful conversion was obtained within 90 minutes in 44% and 3 hours in 56% of episodes, with a mean conversion time of 119.2 +/- 107.5 minutes after the administration of pilsicainide.",[Efficacy and safety of a single oral dose of pilsicainide in supraventricular arrhythmia after coronary artery bypass grafting]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9619036/),min,119.2,52263,DB00281,Lidocaine
,9619036,ventricular rate,"The ventricular rate was significantly reduced from 123.3 +/- 29.5 beats/min to 85.6 +/- 19.9 beats/min (p < 0.0001), however no significant changes in blood pressure or no significant side effects were observed.",[Efficacy and safety of a single oral dose of pilsicainide in supraventricular arrhythmia after coronary artery bypass grafting]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9619036/),[beats] / [min],123.3,52264,DB00281,Lidocaine
,9619036,ventricular rate,"The ventricular rate was significantly reduced from 123.3 +/- 29.5 beats/min to 85.6 +/- 19.9 beats/min (p < 0.0001), however no significant changes in blood pressure or no significant side effects were observed.",[Efficacy and safety of a single oral dose of pilsicainide in supraventricular arrhythmia after coronary artery bypass grafting]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9619036/),[beats] / [min],85.6,52265,DB00281,Lidocaine
,22450529,total ropivacaine,"Median total ropivacaine concentrations were 1.0, 1.6 and 1.7 μg ml(-1) at 10, 30 and 60 min, respectively.",Potentially toxic concentrations in blood of total ropivacaine after bilateral transversus abdominis plane blocks; a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22450529/),[μg] / [ml],1.0,55307,DB00281,Lidocaine
,22450529,total ropivacaine,"Median total ropivacaine concentrations were 1.0, 1.6 and 1.7 μg ml(-1) at 10, 30 and 60 min, respectively.",Potentially toxic concentrations in blood of total ropivacaine after bilateral transversus abdominis plane blocks; a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22450529/),[μg] / [ml],1.6,55308,DB00281,Lidocaine
,22450529,total ropivacaine,"Median total ropivacaine concentrations were 1.0, 1.6 and 1.7 μg ml(-1) at 10, 30 and 60 min, respectively.",Potentially toxic concentrations in blood of total ropivacaine after bilateral transversus abdominis plane blocks; a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22450529/),[μg] / [ml],1.7,55309,DB00281,Lidocaine
,22450529,concentrations,"Median total ropivacaine concentrations were 1.0, 1.6 and 1.7 μg ml(-1) at 10, 30 and 60 min, respectively.",Potentially toxic concentrations in blood of total ropivacaine after bilateral transversus abdominis plane blocks; a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22450529/),[μg] / [ml],1.0,55310,DB00281,Lidocaine
,22450529,concentrations,"Median total ropivacaine concentrations were 1.0, 1.6 and 1.7 μg ml(-1) at 10, 30 and 60 min, respectively.",Potentially toxic concentrations in blood of total ropivacaine after bilateral transversus abdominis plane blocks; a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22450529/),[μg] / [ml],1.6,55311,DB00281,Lidocaine
,22450529,concentrations,"Median total ropivacaine concentrations were 1.0, 1.6 and 1.7 μg ml(-1) at 10, 30 and 60 min, respectively.",Potentially toxic concentrations in blood of total ropivacaine after bilateral transversus abdominis plane blocks; a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22450529/),[μg] / [ml],1.7,55312,DB00281,Lidocaine
above,22450529,Cmax,Six patients (33%) had Cmax values above 2.2 μg ml(-1) and the highest concentration measured was 5.1 μg ml(-1).,Potentially toxic concentrations in blood of total ropivacaine after bilateral transversus abdominis plane blocks; a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22450529/),[μg] / [ml],2.2,55313,DB00281,Lidocaine
,17083453,plasma concentrations,The range of plasma concentrations during the infusion was 1.21-3.13 microg/mL.,The disposition of lidocaine during a 12-hour intravenous infusion to postoperative horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083453/),[μg] / [ml],1.21-3.13,56762,DB00281,Lidocaine
,17083453,protein binding,"The in vitro protein binding of lidocaine in equine plasma at 2 microg/mL was 53.06+/-10.28% and decreased to 27.33+/-9.72% and 29.52+/-6.44% when in combination with ceftiofur or the combination of ceftiofur and flunixin, respectively.",The disposition of lidocaine during a 12-hour intravenous infusion to postoperative horses. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083453/),%,53.06,56763,DB00281,Lidocaine
,17083453,protein binding,"The in vitro protein binding of lidocaine in equine plasma at 2 microg/mL was 53.06+/-10.28% and decreased to 27.33+/-9.72% and 29.52+/-6.44% when in combination with ceftiofur or the combination of ceftiofur and flunixin, respectively.",The disposition of lidocaine during a 12-hour intravenous infusion to postoperative horses. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083453/),%,27.33,56764,DB00281,Lidocaine
,17083453,protein binding,"The in vitro protein binding of lidocaine in equine plasma at 2 microg/mL was 53.06+/-10.28% and decreased to 27.33+/-9.72% and 29.52+/-6.44% when in combination with ceftiofur or the combination of ceftiofur and flunixin, respectively.",The disposition of lidocaine during a 12-hour intravenous infusion to postoperative horses. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083453/),%,29.52,56765,DB00281,Lidocaine
,22814850,overall responder rate,Global response assessment showed an overall responder rate of 64% at day 14 and a sustained overall responder rate of 64% 2 weeks later.,Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22814850/),%,64,56844,DB00281,Lidocaine
,2732141,Cmax,"Plasma concentrations were fitted to a two-compartment model and the mean pharmacokinetic parameters determined after iv bolus were: Cmax 117 mg/l, T1/2 beta 36 min, Vss 181, AUC 2179 mg/min/l with urinary recoveries of FCE 22101 37%, P1 36% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),[mg] / [l],117,57047,DB00281,Lidocaine
,2732141,T1/2 beta,"Plasma concentrations were fitted to a two-compartment model and the mean pharmacokinetic parameters determined after iv bolus were: Cmax 117 mg/l, T1/2 beta 36 min, Vss 181, AUC 2179 mg/min/l with urinary recoveries of FCE 22101 37%, P1 36% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),min,36,57048,DB00281,Lidocaine
,2732141,Vss,"Plasma concentrations were fitted to a two-compartment model and the mean pharmacokinetic parameters determined after iv bolus were: Cmax 117 mg/l, T1/2 beta 36 min, Vss 181, AUC 2179 mg/min/l with urinary recoveries of FCE 22101 37%, P1 36% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),,181,57049,DB00281,Lidocaine
,2732141,AUC,"Plasma concentrations were fitted to a two-compartment model and the mean pharmacokinetic parameters determined after iv bolus were: Cmax 117 mg/l, T1/2 beta 36 min, Vss 181, AUC 2179 mg/min/l with urinary recoveries of FCE 22101 37%, P1 36% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),[mg] / [l·min],2179,57050,DB00281,Lidocaine
,2732141,Cmax,"With probenecid the values were Cmax 116 mg/l, T1/2 beta 47 min, Vss 141, AUC 4540 mg/min/l and urinary recoveries of FCE 22101 20%, P1 40% and P2 7%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),[mg] / [l],116,57051,DB00281,Lidocaine
,2732141,T1/2 beta,"With probenecid the values were Cmax 116 mg/l, T1/2 beta 47 min, Vss 141, AUC 4540 mg/min/l and urinary recoveries of FCE 22101 20%, P1 40% and P2 7%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),min,47,57052,DB00281,Lidocaine
,2732141,Vss,"With probenecid the values were Cmax 116 mg/l, T1/2 beta 47 min, Vss 141, AUC 4540 mg/min/l and urinary recoveries of FCE 22101 20%, P1 40% and P2 7%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),,141,57053,DB00281,Lidocaine
,2732141,AUC,"With probenecid the values were Cmax 116 mg/l, T1/2 beta 47 min, Vss 141, AUC 4540 mg/min/l and urinary recoveries of FCE 22101 20%, P1 40% and P2 7%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),[mg] / [l·min],4540,57054,DB00281,Lidocaine
,2732141,Cmax,"Following im injection the mean values were Cmax 15 mg/l, Tmax 30 min, T1/2abs 14 min, T1/2 beta 61 min, AUC 2117 mg/min/l and urinary recoveries of FCE 22101 33%, P1 37% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),[mg] / [l],15,57055,DB00281,Lidocaine
,2732141,Tmax,"Following im injection the mean values were Cmax 15 mg/l, Tmax 30 min, T1/2abs 14 min, T1/2 beta 61 min, AUC 2117 mg/min/l and urinary recoveries of FCE 22101 33%, P1 37% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),min,30,57056,DB00281,Lidocaine
,2732141,T1/2abs,"Following im injection the mean values were Cmax 15 mg/l, Tmax 30 min, T1/2abs 14 min, T1/2 beta 61 min, AUC 2117 mg/min/l and urinary recoveries of FCE 22101 33%, P1 37% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),min,14,57057,DB00281,Lidocaine
,2732141,T1/2 beta,"Following im injection the mean values were Cmax 15 mg/l, Tmax 30 min, T1/2abs 14 min, T1/2 beta 61 min, AUC 2117 mg/min/l and urinary recoveries of FCE 22101 33%, P1 37% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),min,61,57058,DB00281,Lidocaine
,2732141,AUC,"Following im injection the mean values were Cmax 15 mg/l, Tmax 30 min, T1/2abs 14 min, T1/2 beta 61 min, AUC 2117 mg/min/l and urinary recoveries of FCE 22101 33%, P1 37% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),[mg] / [l·min],2117,57059,DB00281,Lidocaine
,2732141,urinary recoveries,"Following im injection the mean values were Cmax 15 mg/l, Tmax 30 min, T1/2abs 14 min, T1/2 beta 61 min, AUC 2117 mg/min/l and urinary recoveries of FCE 22101 33%, P1 37% and P2 6%.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),%,33,57060,DB00281,Lidocaine
,2732141,Css,"At steady state during continuous infusion, mean values were Css 12.7 mg/l, Vss 131 and T1/2 beta after steady state was 22 min.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),[mg] / [l],12.7,57061,DB00281,Lidocaine
,2732141,Vss,"At steady state during continuous infusion, mean values were Css 12.7 mg/l, Vss 131 and T1/2 beta after steady state was 22 min.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),,131,57062,DB00281,Lidocaine
,2732141,T1/2 beta after steady state,"At steady state during continuous infusion, mean values were Css 12.7 mg/l, Vss 131 and T1/2 beta after steady state was 22 min.",Pharmacokinetics of FCE 22101 in man following different modes of administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2732141/),min,22,57063,DB00281,Lidocaine
,14749694,clearance,"Lidocaine clearance was decreased on average by 60% (from 12.1 mL/min.kg to 4.85 mL/min.kg, P <.001) in healthy subjects and by 44% (from 9.83 mL/min.kg to 5.06 mL/min.kg, P <.001) in patients with mild liver dysfunction, with proportional increases in terminal half-lives, whereas virtually no effect was produced in patients with severe liver dysfunction (4.21 mL/min.kg versus 3.65 mL/min.kg, P >.05).",Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749694/),[ml] / [kg·min],12.1,57491,DB00281,Lidocaine
,14749694,clearance,"Lidocaine clearance was decreased on average by 60% (from 12.1 mL/min.kg to 4.85 mL/min.kg, P <.001) in healthy subjects and by 44% (from 9.83 mL/min.kg to 5.06 mL/min.kg, P <.001) in patients with mild liver dysfunction, with proportional increases in terminal half-lives, whereas virtually no effect was produced in patients with severe liver dysfunction (4.21 mL/min.kg versus 3.65 mL/min.kg, P >.05).",Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749694/),[ml] / [kg·min],4.85,57492,DB00281,Lidocaine
,14749694,clearance,"Lidocaine clearance was decreased on average by 60% (from 12.1 mL/min.kg to 4.85 mL/min.kg, P <.001) in healthy subjects and by 44% (from 9.83 mL/min.kg to 5.06 mL/min.kg, P <.001) in patients with mild liver dysfunction, with proportional increases in terminal half-lives, whereas virtually no effect was produced in patients with severe liver dysfunction (4.21 mL/min.kg versus 3.65 mL/min.kg, P >.05).",Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749694/),[ml] / [kg·min],9.83,57493,DB00281,Lidocaine
,14749694,clearance,"Lidocaine clearance was decreased on average by 60% (from 12.1 mL/min.kg to 4.85 mL/min.kg, P <.001) in healthy subjects and by 44% (from 9.83 mL/min.kg to 5.06 mL/min.kg, P <.001) in patients with mild liver dysfunction, with proportional increases in terminal half-lives, whereas virtually no effect was produced in patients with severe liver dysfunction (4.21 mL/min.kg versus 3.65 mL/min.kg, P >.05).",Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749694/),[ml] / [kg·min],5.06,57494,DB00281,Lidocaine
,14749694,terminal half-lives,"Lidocaine clearance was decreased on average by 60% (from 12.1 mL/min.kg to 4.85 mL/min.kg, P <.001) in healthy subjects and by 44% (from 9.83 mL/min.kg to 5.06 mL/min.kg, P <.001) in patients with mild liver dysfunction, with proportional increases in terminal half-lives, whereas virtually no effect was produced in patients with severe liver dysfunction (4.21 mL/min.kg versus 3.65 mL/min.kg, P >.05).",Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749694/),[ml] / [kg·min],4.21,57495,DB00281,Lidocaine
,14749694,terminal half-lives,"Lidocaine clearance was decreased on average by 60% (from 12.1 mL/min.kg to 4.85 mL/min.kg, P <.001) in healthy subjects and by 44% (from 9.83 mL/min.kg to 5.06 mL/min.kg, P <.001) in patients with mild liver dysfunction, with proportional increases in terminal half-lives, whereas virtually no effect was produced in patients with severe liver dysfunction (4.21 mL/min.kg versus 3.65 mL/min.kg, P >.05).",Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749694/),[ml] / [kg·min],3.65,57496,DB00281,Lidocaine
>,26895001,Cmax,"For any given milligram per kilogram dosage, the probability that Cmax >6 μg/mL, the threshold for mild lidocaine toxicity was estimated using tolerance interval analysis.",Estimated Maximal Safe Dosages of Tumescent Lidocaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895001/),[μg] / [ml],6,57667,DB00281,Lidocaine
,26895001,maximum safe dosages,Preliminary estimates for maximum safe dosages of tumescent lidocaine are 28 mg/kg without liposuction and 45 mg/kg with liposuction.,Estimated Maximal Safe Dosages of Tumescent Lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895001/),[mg] / [kg],28,57668,DB00281,Lidocaine
,26895001,maximum safe dosages,Preliminary estimates for maximum safe dosages of tumescent lidocaine are 28 mg/kg without liposuction and 45 mg/kg with liposuction.,Estimated Maximal Safe Dosages of Tumescent Lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895001/),mg,45,57669,DB00281,Lidocaine
,7060324,steady-state concentration,Phase 2 consisted of a long-term (30 hr) lidocaine infusion designed to produce a steady-state concentration equal to 1.5 microgram/ml.,Influence of long-term infusions on lidocaine kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060324/),[μg] / [ml],1.5,59279,DB00281,Lidocaine
,7060324,steady-state lidocaine concentration,Phase 3 differed from phase 2 in that target steady-state lidocaine concentration was 4 microgram/ml and the stable isotope lidocaine dose was reduced to 40 mg.,Influence of long-term infusions on lidocaine kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060324/),[μg] / [ml],4,59280,DB00281,Lidocaine
,2310001,maximum concentrations,"Median maximum concentrations of lidocaine after i.v. (3.2 range 1.3-9.6 micrograms/ml) and e.b. administration (3.1 range 1.1-8.6) were measured after 5.5 min (range i.v. = 4-10 min, e.b. = 3-7 min).",[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),[μg] / [ml],3.2,59388,DB00281,Lidocaine
,2310001,maximum concentrations,"Median maximum concentrations of lidocaine after i.v. (3.2 range 1.3-9.6 micrograms/ml) and e.b. administration (3.1 range 1.1-8.6) were measured after 5.5 min (range i.v. = 4-10 min, e.b. = 3-7 min).",[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),[μg] / [ml],3.1,59389,DB00281,Lidocaine
,2310001,absorption half-life,"The absorption half-life of e.b. lidocaine was 3.9 min, and mean bioavailability was 90%.",[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),min,3.9,59390,DB00281,Lidocaine
,2310001,bioavailability,"The absorption half-life of e.b. lidocaine was 3.9 min, and mean bioavailability was 90%.",[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),%,90,59391,DB00281,Lidocaine
,2310001,elimination half-lives,"Elimination pharmacokinetics of i.v. and e.b. lidocaine were nearly identical, with elimination half-lives of 25 min (e.b.) and 42 min (i.v.).",[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),min,25,59392,DB00281,Lidocaine
,2310001,elimination half-lives,"Elimination pharmacokinetics of i.v. and e.b. lidocaine were nearly identical, with elimination half-lives of 25 min (e.b.) and 42 min (i.v.).",[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),min,42,59393,DB00281,Lidocaine
,2310001,Total body clearances,Total body clearances were 401 ml/min (e.b.) and 362 ml/min (i.v.).,[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),[ml] / [min],401,59394,DB00281,Lidocaine
,2310001,Total body clearances,Total body clearances were 401 ml/min (e.b.) and 362 ml/min (i.v.).,[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),[ml] / [min],362,59395,DB00281,Lidocaine
,2310001,minimum dosage,"During CPR without i.v. access the e.b. instillation of lidocaine can be recommended, but to ensure therapeutic concentrations a minimum dosage of 2 mg/kg is suggested.",[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),[mg] / [kg],2,59396,DB00281,Lidocaine
,9832299,elimination half-life,The area under the lignocaine concentration-time curve was similar during all three phases but erythromycin significantly increased the elimination half-life of lignocaine from 2.5 to 2.9 (0.7) h compared with placebo.,Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832299/),h,2.5,59428,DB00281,Lidocaine
,9832299,elimination half-life,The area under the lignocaine concentration-time curve was similar during all three phases but erythromycin significantly increased the elimination half-life of lignocaine from 2.5 to 2.9 (0.7) h compared with placebo.,Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832299/),h,2.9,59429,DB00281,Lidocaine
,9832299,t1/2,"Following itraconazole administration, t1/2 was 2.6 h.",Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832299/),h,2.6,59430,DB00281,Lidocaine
,3602088,clearance,"Results showed that mean (+/- SD, n = 3) acetaminophen clearance was similar in both horses (4.84 +/- 0.637 ml/min/kg) and humans (4.68 +/- 0.691 ml/min/kg).",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],4.84,61109,DB00281,Lidocaine
,3602088,clearance,"Results showed that mean (+/- SD, n = 3) acetaminophen clearance was similar in both horses (4.84 +/- 0.637 ml/min/kg) and humans (4.68 +/- 0.691 ml/min/kg).",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],4.68,61110,DB00281,Lidocaine
,3602088,clearance,"However, antipyrine clearance was 10 times greater in horses (5.83 +/- 2.21 ml/min/kg) than in humans (0.536 +/- 0.110 ml/min/kg), which may reflect enhanced hepatic microsomal activity in horses.",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],5.83,61111,DB00281,Lidocaine
,3602088,clearance,"However, antipyrine clearance was 10 times greater in horses (5.83 +/- 2.21 ml/min/kg) than in humans (0.536 +/- 0.110 ml/min/kg), which may reflect enhanced hepatic microsomal activity in horses.",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],0.536,61112,DB00281,Lidocaine
,3602088,clearance,"Although lidocaine clearance in humans was similar to estimated hepatic blood flow (20.6 +/- 5.81 ml/min/kg), clearance in horses was more than 2 times greater (52.0 +/- 11.7 ml/min/kg).",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],20.6,61113,DB00281,Lidocaine
,3602088,clearance,"Although lidocaine clearance in humans was similar to estimated hepatic blood flow (20.6 +/- 5.81 ml/min/kg), clearance in horses was more than 2 times greater (52.0 +/- 11.7 ml/min/kg).",Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3602088/),[ml] / [kg·min],52.0,61114,DB00281,Lidocaine
,8864326,Total body clearance,"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],7.15,61881,DB00281,Lidocaine
,8864326,apparent volume of distribution,"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],7.15,61882,DB00281,Lidocaine
,8864326,maximum observed concentration (Cmax),"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],7.15,61883,DB00281,Lidocaine
,8864326,maximum observed concentration (Cmax),"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],3.11,61884,DB00281,Lidocaine
,8864326,maximum observed concentration (Cmax),"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],4.48,61885,DB00281,Lidocaine
,8864326,maximum observed concentration (Cmax),"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],4.06,61886,DB00281,Lidocaine
,9010944,onset time of sensory block,"The onset time of sensory block was significantly shorter (2.5 minutes) in the articaine group than in the lidocaine group (11.1 minutes) or the prilocaine group (10.9 minutes) (Scheffe, P < .05).","Intravenous regional anesthesia with 0.5% articaine, 0.5% lidocaine, or 0.5% prilocaine. A double-blind randomized clinical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010944/),min,2.5,62083,DB00281,Lidocaine
,9010944,onset time of sensory block,"The onset time of sensory block was significantly shorter (2.5 minutes) in the articaine group than in the lidocaine group (11.1 minutes) or the prilocaine group (10.9 minutes) (Scheffe, P < .05).","Intravenous regional anesthesia with 0.5% articaine, 0.5% lidocaine, or 0.5% prilocaine. A double-blind randomized clinical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010944/),min,11.1,62084,DB00281,Lidocaine
,9010944,onset time of sensory block,"The onset time of sensory block was significantly shorter (2.5 minutes) in the articaine group than in the lidocaine group (11.1 minutes) or the prilocaine group (10.9 minutes) (Scheffe, P < .05).","Intravenous regional anesthesia with 0.5% articaine, 0.5% lidocaine, or 0.5% prilocaine. A double-blind randomized clinical study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010944/),min,10.9,62085,DB00281,Lidocaine
,9010944,Maximum concentrations,"Maximum concentrations of articaine, lidocaine, and prilocaine were, 1.85, 8.5, and 4.4 micrograms/mL, respectively.","Intravenous regional anesthesia with 0.5% articaine, 0.5% lidocaine, or 0.5% prilocaine. A double-blind randomized clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010944/),[μg] / [ml],1.85,62086,DB00281,Lidocaine
,9010944,Maximum concentrations,"Maximum concentrations of articaine, lidocaine, and prilocaine were, 1.85, 8.5, and 4.4 micrograms/mL, respectively.","Intravenous regional anesthesia with 0.5% articaine, 0.5% lidocaine, or 0.5% prilocaine. A double-blind randomized clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010944/),[μg] / [ml],8.5,62087,DB00281,Lidocaine
,9010944,Maximum concentrations,"Maximum concentrations of articaine, lidocaine, and prilocaine were, 1.85, 8.5, and 4.4 micrograms/mL, respectively.","Intravenous regional anesthesia with 0.5% articaine, 0.5% lidocaine, or 0.5% prilocaine. A double-blind randomized clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010944/),[μg] / [ml],4.4,62088,DB00281,Lidocaine
,430178,total excretion,"The total excretion of radioactivity over a 70-min period amounted to 95.7% and 42.8% of the dose of Tc-99m HIDA and Tc-99m PG, respectively.",Pharmacokinetics of hepatobiliary imaging agents in rats: concise communication. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/430178/),%,95.7,62461,DB00281,Lidocaine
,430178,total excretion,"The total excretion of radioactivity over a 70-min period amounted to 95.7% and 42.8% of the dose of Tc-99m HIDA and Tc-99m PG, respectively.",Pharmacokinetics of hepatobiliary imaging agents in rats: concise communication. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/430178/),%,42.8,62462,DB00281,Lidocaine
,2068827,peak plasma lidocaine concentrations,"No differences in peak plasma lidocaine concentrations, 2.09 +/- 1.28 mumol/L (1 microgram/mL = 4.27 mumol/L) in young subjects, and 2.35 +/- 0.85 mumol/L in young-elderly subjects, or lidocaine AUC were seen between the two age groups.",Lidocaine absorption and metabolism after oropharyngeal application in young and young-elderly adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2068827/),[μM] / [l],2.09,62979,DB00281,Lidocaine
,2068827,peak plasma lidocaine concentrations,"No differences in peak plasma lidocaine concentrations, 2.09 +/- 1.28 mumol/L (1 microgram/mL = 4.27 mumol/L) in young subjects, and 2.35 +/- 0.85 mumol/L in young-elderly subjects, or lidocaine AUC were seen between the two age groups.",Lidocaine absorption and metabolism after oropharyngeal application in young and young-elderly adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2068827/),[μM] / [l],2.35,62980,DB00281,Lidocaine
greater,3710065,extraction ratio,The patients were divided into two groups according to severity of disease: 14 patients (group 1) had slight liver dysfunction (ICG extraction ratio greater than 0.25) and 21 patients (group 2) had severe liver disease (ICG extraction ratio less than 0.25).,Effect of portacaval shunt on drug disposition in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710065/),,0.25,64173,DB00281,Lidocaine
,3710065,systemic clearance,"In group 1, ICG systemic clearance decreased from 9.10 +/- 0.68 to 4.40 +/- 0.34 ml/min . kg (p less than 0.05), whereas ICG intrinsic clearance remained unchanged; lidocaine systemic clearance decreased from 7.93 +/- 0.93 to 5.09 +/- 0.33 ml/min . kg (p less than 0.05), whereas lidocaine intrinsic clearance remained unchanged; bioavailability increased from 0.601 +/- 0.076 to 1, resulting in an abrupt reduction of oral clearance from 18.01 +/- 4.90 to 5.09 +/- 0.33 ml/min . kg (p less than 0.05).",Effect of portacaval shunt on drug disposition in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710065/),[ml] / [kg·min],9.10,64174,DB00281,Lidocaine
,3710065,systemic clearance,"In group 1, ICG systemic clearance decreased from 9.10 +/- 0.68 to 4.40 +/- 0.34 ml/min . kg (p less than 0.05), whereas ICG intrinsic clearance remained unchanged; lidocaine systemic clearance decreased from 7.93 +/- 0.93 to 5.09 +/- 0.33 ml/min . kg (p less than 0.05), whereas lidocaine intrinsic clearance remained unchanged; bioavailability increased from 0.601 +/- 0.076 to 1, resulting in an abrupt reduction of oral clearance from 18.01 +/- 4.90 to 5.09 +/- 0.33 ml/min . kg (p less than 0.05).",Effect of portacaval shunt on drug disposition in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710065/),[ml] / [kg·min],4.40,64175,DB00281,Lidocaine
,3710065,systemic clearance,"In group 1, ICG systemic clearance decreased from 9.10 +/- 0.68 to 4.40 +/- 0.34 ml/min . kg (p less than 0.05), whereas ICG intrinsic clearance remained unchanged; lidocaine systemic clearance decreased from 7.93 +/- 0.93 to 5.09 +/- 0.33 ml/min . kg (p less than 0.05), whereas lidocaine intrinsic clearance remained unchanged; bioavailability increased from 0.601 +/- 0.076 to 1, resulting in an abrupt reduction of oral clearance from 18.01 +/- 4.90 to 5.09 +/- 0.33 ml/min . kg (p less than 0.05).",Effect of portacaval shunt on drug disposition in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710065/),[ml] / [kg·min],7.93,64176,DB00281,Lidocaine
,3710065,systemic clearance,"In group 1, ICG systemic clearance decreased from 9.10 +/- 0.68 to 4.40 +/- 0.34 ml/min . kg (p less than 0.05), whereas ICG intrinsic clearance remained unchanged; lidocaine systemic clearance decreased from 7.93 +/- 0.93 to 5.09 +/- 0.33 ml/min . kg (p less than 0.05), whereas lidocaine intrinsic clearance remained unchanged; bioavailability increased from 0.601 +/- 0.076 to 1, resulting in an abrupt reduction of oral clearance from 18.01 +/- 4.90 to 5.09 +/- 0.33 ml/min . kg (p less than 0.05).",Effect of portacaval shunt on drug disposition in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710065/),[ml] / [kg·min],5.09,64177,DB00281,Lidocaine
,3710065,bioavailability,"In group 1, ICG systemic clearance decreased from 9.10 +/- 0.68 to 4.40 +/- 0.34 ml/min . kg (p less than 0.05), whereas ICG intrinsic clearance remained unchanged; lidocaine systemic clearance decreased from 7.93 +/- 0.93 to 5.09 +/- 0.33 ml/min . kg (p less than 0.05), whereas lidocaine intrinsic clearance remained unchanged; bioavailability increased from 0.601 +/- 0.076 to 1, resulting in an abrupt reduction of oral clearance from 18.01 +/- 4.90 to 5.09 +/- 0.33 ml/min . kg (p less than 0.05).",Effect of portacaval shunt on drug disposition in patients with cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710065/),,0.601,64178,DB00281,Lidocaine
,3710065,bioavailability,"In group 1, ICG systemic clearance decreased from 9.10 +/- 0.68 to 4.40 +/- 0.34 ml/min . kg (p less than 0.05), whereas ICG intrinsic clearance remained unchanged; lidocaine systemic clearance decreased from 7.93 +/- 0.93 to 5.09 +/- 0.33 ml/min . kg (p less than 0.05), whereas lidocaine intrinsic clearance remained unchanged; bioavailability increased from 0.601 +/- 0.076 to 1, resulting in an abrupt reduction of oral clearance from 18.01 +/- 4.90 to 5.09 +/- 0.33 ml/min . kg (p less than 0.05).",Effect of portacaval shunt on drug disposition in patients with cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710065/),,1,64179,DB00281,Lidocaine
,3710065,oral clearance,"In group 1, ICG systemic clearance decreased from 9.10 +/- 0.68 to 4.40 +/- 0.34 ml/min . kg (p less than 0.05), whereas ICG intrinsic clearance remained unchanged; lidocaine systemic clearance decreased from 7.93 +/- 0.93 to 5.09 +/- 0.33 ml/min . kg (p less than 0.05), whereas lidocaine intrinsic clearance remained unchanged; bioavailability increased from 0.601 +/- 0.076 to 1, resulting in an abrupt reduction of oral clearance from 18.01 +/- 4.90 to 5.09 +/- 0.33 ml/min . kg (p less than 0.05).",Effect of portacaval shunt on drug disposition in patients with cirrhosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710065/),[ml] / [kg·min],18.01,64180,DB00281,Lidocaine
,3710065,oral clearance,"In group 1, ICG systemic clearance decreased from 9.10 +/- 0.68 to 4.40 +/- 0.34 ml/min . kg (p less than 0.05), whereas ICG intrinsic clearance remained unchanged; lidocaine systemic clearance decreased from 7.93 +/- 0.93 to 5.09 +/- 0.33 ml/min . kg (p less than 0.05), whereas lidocaine intrinsic clearance remained unchanged; bioavailability increased from 0.601 +/- 0.076 to 1, resulting in an abrupt reduction of oral clearance from 18.01 +/- 4.90 to 5.09 +/- 0.33 ml/min . kg (p less than 0.05).",Effect of portacaval shunt on drug disposition in patients with cirrhosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710065/),[ml] / [kg·min],5.09,64181,DB00281,Lidocaine
,3710065,systemic clearance,"In group 2, ICG systemic clearance decreased slightly from 3.90 +/- 0.39 to 2.28 +/- 0.16 ml/min . kg (p less than 0.01) and ICG intrinsic clearance was not modified; lidocaine systemic and intrinsic clearance remained unchanged; and bioavailability increased from 0.779 +/- 0.229 to 1, resulting in a decrease of oral clearance from 7.68 +/- 1.65 to 4.23 +/- 0.37 ml/min X kg (p less than 0.05).",Effect of portacaval shunt on drug disposition in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710065/),[ml] / [kg·min],3.90,64182,DB00281,Lidocaine
,3710065,systemic clearance,"In group 2, ICG systemic clearance decreased slightly from 3.90 +/- 0.39 to 2.28 +/- 0.16 ml/min . kg (p less than 0.01) and ICG intrinsic clearance was not modified; lidocaine systemic and intrinsic clearance remained unchanged; and bioavailability increased from 0.779 +/- 0.229 to 1, resulting in a decrease of oral clearance from 7.68 +/- 1.65 to 4.23 +/- 0.37 ml/min X kg (p less than 0.05).",Effect of portacaval shunt on drug disposition in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710065/),[ml] / [kg·min],2.28,64183,DB00281,Lidocaine
,3710065,bioavailability,"In group 2, ICG systemic clearance decreased slightly from 3.90 +/- 0.39 to 2.28 +/- 0.16 ml/min . kg (p less than 0.01) and ICG intrinsic clearance was not modified; lidocaine systemic and intrinsic clearance remained unchanged; and bioavailability increased from 0.779 +/- 0.229 to 1, resulting in a decrease of oral clearance from 7.68 +/- 1.65 to 4.23 +/- 0.37 ml/min X kg (p less than 0.05).",Effect of portacaval shunt on drug disposition in patients with cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710065/),,0.779,64184,DB00281,Lidocaine
,3710065,bioavailability,"In group 2, ICG systemic clearance decreased slightly from 3.90 +/- 0.39 to 2.28 +/- 0.16 ml/min . kg (p less than 0.01) and ICG intrinsic clearance was not modified; lidocaine systemic and intrinsic clearance remained unchanged; and bioavailability increased from 0.779 +/- 0.229 to 1, resulting in a decrease of oral clearance from 7.68 +/- 1.65 to 4.23 +/- 0.37 ml/min X kg (p less than 0.05).",Effect of portacaval shunt on drug disposition in patients with cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710065/),,1,64185,DB00281,Lidocaine
,3710065,oral clearance,"In group 2, ICG systemic clearance decreased slightly from 3.90 +/- 0.39 to 2.28 +/- 0.16 ml/min . kg (p less than 0.01) and ICG intrinsic clearance was not modified; lidocaine systemic and intrinsic clearance remained unchanged; and bioavailability increased from 0.779 +/- 0.229 to 1, resulting in a decrease of oral clearance from 7.68 +/- 1.65 to 4.23 +/- 0.37 ml/min X kg (p less than 0.05).",Effect of portacaval shunt on drug disposition in patients with cirrhosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710065/),[ml] / [kg·min],7.68,64186,DB00281,Lidocaine
,3710065,oral clearance,"In group 2, ICG systemic clearance decreased slightly from 3.90 +/- 0.39 to 2.28 +/- 0.16 ml/min . kg (p less than 0.01) and ICG intrinsic clearance was not modified; lidocaine systemic and intrinsic clearance remained unchanged; and bioavailability increased from 0.779 +/- 0.229 to 1, resulting in a decrease of oral clearance from 7.68 +/- 1.65 to 4.23 +/- 0.37 ml/min X kg (p less than 0.05).",Effect of portacaval shunt on drug disposition in patients with cirrhosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3710065/),[ml] / [kg·min],4.23,64187,DB00281,Lidocaine
,30811630,Cmax,"Mean values of Cmax were 14.20 and 5.36 ng/ml and tmax were 3.5 and 1.8 hour for lidocaine and prilocaine, respectively.","Randomized, double-blind, phase III clinical study of a novel nanotechnological topical anesthetic formulation containing lidocaine 25 mg/g and prilocaine 25 mg/g (nanorap) in skin phototypes I-III patients with ablative fractional CO2 laser treatment indication in the forehead. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30811630/),[ng] / [ml],14.20,65603,DB00281,Lidocaine
,30811630,Cmax,"Mean values of Cmax were 14.20 and 5.36 ng/ml and tmax were 3.5 and 1.8 hour for lidocaine and prilocaine, respectively.","Randomized, double-blind, phase III clinical study of a novel nanotechnological topical anesthetic formulation containing lidocaine 25 mg/g and prilocaine 25 mg/g (nanorap) in skin phototypes I-III patients with ablative fractional CO2 laser treatment indication in the forehead. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30811630/),[ng] / [ml],5.36,65604,DB00281,Lidocaine
,30811630,tmax,"Mean values of Cmax were 14.20 and 5.36 ng/ml and tmax were 3.5 and 1.8 hour for lidocaine and prilocaine, respectively.","Randomized, double-blind, phase III clinical study of a novel nanotechnological topical anesthetic formulation containing lidocaine 25 mg/g and prilocaine 25 mg/g (nanorap) in skin phototypes I-III patients with ablative fractional CO2 laser treatment indication in the forehead. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30811630/),h,3.5,65605,DB00281,Lidocaine
,30811630,tmax,"Mean values of Cmax were 14.20 and 5.36 ng/ml and tmax were 3.5 and 1.8 hour for lidocaine and prilocaine, respectively.","Randomized, double-blind, phase III clinical study of a novel nanotechnological topical anesthetic formulation containing lidocaine 25 mg/g and prilocaine 25 mg/g (nanorap) in skin phototypes I-III patients with ablative fractional CO2 laser treatment indication in the forehead. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30811630/),h,1.8,65606,DB00281,Lidocaine
,8479004,extraction ratio,The lidocaine extraction ratio of 0.60 in the pig was found to be similar to that determined by others in man.,Lidocaine decay and hepatic extraction in the pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8479004/),,0.60,66663,DB00281,Lidocaine
,10193676,oral bioavailability,"Lignocaine is metabolized by cytochrome P450 3A4 enzyme (CYP3A4), and has a moderate to high extraction ratio resulting in oral bioavailability of 30%.",Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10193676/),%,30,66836,DB00281,Lidocaine
,6686773,volume of distribution,"Lidocaine volume of distribution was significantly increased during penbutolol treatment (4.9 vs 3.4 l/kg, p less than 0.005), resulting in a significant prolongation of elimination half-life (2.5 vs 2.0 h, p less than 0.025).",Effect of penbutolol on lidocaine kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6686773/),[l] / [kg],4.9,68988,DB00281,Lidocaine
,6686773,volume of distribution,"Lidocaine volume of distribution was significantly increased during penbutolol treatment (4.9 vs 3.4 l/kg, p less than 0.005), resulting in a significant prolongation of elimination half-life (2.5 vs 2.0 h, p less than 0.025).",Effect of penbutolol on lidocaine kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6686773/),[l] / [kg],3.4,68989,DB00281,Lidocaine
,6686773,elimination half-life,"Lidocaine volume of distribution was significantly increased during penbutolol treatment (4.9 vs 3.4 l/kg, p less than 0.005), resulting in a significant prolongation of elimination half-life (2.5 vs 2.0 h, p less than 0.025).",Effect of penbutolol on lidocaine kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6686773/),h,2.5,68990,DB00281,Lidocaine
,6686773,elimination half-life,"Lidocaine volume of distribution was significantly increased during penbutolol treatment (4.9 vs 3.4 l/kg, p less than 0.005), resulting in a significant prolongation of elimination half-life (2.5 vs 2.0 h, p less than 0.025).",Effect of penbutolol on lidocaine kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6686773/),h,2.0,68991,DB00281,Lidocaine
,6686773,Total metabolic clearance,"Total metabolic clearance of lidocaine, however, was not significantly altered by penbutolol (23.0 vs 19.4 ml/min/kg).",Effect of penbutolol on lidocaine kinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6686773/),[ml] / [kg·min],23.0,68992,DB00281,Lidocaine
,6686773,Total metabolic clearance,"Total metabolic clearance of lidocaine, however, was not significantly altered by penbutolol (23.0 vs 19.4 ml/min/kg).",Effect of penbutolol on lidocaine kinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6686773/),[ml] / [kg·min],19.4,68993,DB00281,Lidocaine
,2452320,effective dose,"SR tocainide prevented the arrhythmia in three of six dogs (mean effective dose, 21.3 mg/kg), one remained unchanged, and two died.",Effects of tocainide enantiomers on experimental arrhythmias produced by programmed electrical stimulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452320/),[mg] / [kg],21.3,69025,DB00281,Lidocaine
,2722118,Maximal plasma concentration,Maximal plasma concentration was 0.73 +/- 0.33 micrograms.,Pharmacokinetics of lidocaine and bupivacaine in retrobulbar and facial block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2722118/),μg,0.73,69112,DB00281,Lidocaine
,2722118,CSF/plasma ratio,CSF/plasma ratio was in the range 0.05-0.26 for lidocaine and 0.56-1.33 for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine in retrobulbar and facial block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2722118/),,0.05-0.26,69113,DB00281,Lidocaine
,2722118,CSF/plasma ratio,CSF/plasma ratio was in the range 0.05-0.26 for lidocaine and 0.56-1.33 for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine in retrobulbar and facial block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2722118/),,0.56-1.33,69114,DB00281,Lidocaine
,25428796,maximum serum concentration,"The maximum serum concentration of lidocaine ranged from 0.50 to 3.01 μg/mL (mean ± SD: 2.18 ± 0.91 μg/mL), and the time to reach it was 28.75 ± 15.74 min.",Intra-articular administration of lidocaine in anaesthetized dogs: pharmacokinetic profile and safety on cardiovascular and nervous systems. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25428796/),[μg] / [ml],0.50 to 3.01,69696,DB00281,Lidocaine
,25428796,maximum serum concentration,"The maximum serum concentration of lidocaine ranged from 0.50 to 3.01 μg/mL (mean ± SD: 2.18 ± 0.91 μg/mL), and the time to reach it was 28.75 ± 15.74 min.",Intra-articular administration of lidocaine in anaesthetized dogs: pharmacokinetic profile and safety on cardiovascular and nervous systems. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25428796/),[μg] / [ml],2.18,69697,DB00281,Lidocaine
,25428796,time to reach it,"The maximum serum concentration of lidocaine ranged from 0.50 to 3.01 μg/mL (mean ± SD: 2.18 ± 0.91 μg/mL), and the time to reach it was 28.75 ± 15.74 min.",Intra-articular administration of lidocaine in anaesthetized dogs: pharmacokinetic profile and safety on cardiovascular and nervous systems. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25428796/),min,28.75,69698,DB00281,Lidocaine
,4006366,absorption t1/2,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),h,0.20,69837,DB00281,Lidocaine
,4006366,absorption t1/2,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),h,0.61,69838,DB00281,Lidocaine
,4006366,time to peak mexi,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),h,1.13,69839,DB00281,Lidocaine
,4006366,time to peak mexi,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),h,1.88,69840,DB00281,Lidocaine
,4006366,plasma concentration,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),mg,0.74,69841,DB00281,Lidocaine
,4006366,plasma concentration,"Cimetidine did have a significant effect on mexiletine absorption, as demonstrated by a longer mean absorption t1/2 (from 0.20 +/- 0.14 to 0.61 +/- 0.35 hours), a longer mean time to peak mexiletine concentration (from 1.13 +/- 0.31 to 1.88 +/- 0.83 hours), and decreased mexiletine plasma concentration (from 0.74 +/- 0.19 to 0.59 +/- 0.15 mg/ml).",Mexiletine kinetics in healthy subjects taking cimetidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4006366/),mg,0.59,69842,DB00281,Lidocaine
,32677407,Time to peak concerntration (Tmax),Time to peak concerntration (Tmax) ranged from 12 to 13 min.,[Pharmacokinetics Study of Phentolamine Mesylate Injection in Healthy Volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32677407/),min,12 to 13,70619,DB00281,Lidocaine
,32677407,Half-time of elimination (t1/2),"Half-time of elimination (t1/2) ranged from 3.84 to 4.07 h, with a clearance (CL) of 190 L/h.",[Pharmacokinetics Study of Phentolamine Mesylate Injection in Healthy Volunteers]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32677407/),h,3.84 to 4.07,70620,DB00281,Lidocaine
,32677407,clearance (CL),"Half-time of elimination (t1/2) ranged from 3.84 to 4.07 h, with a clearance (CL) of 190 L/h.",[Pharmacokinetics Study of Phentolamine Mesylate Injection in Healthy Volunteers]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32677407/),[l] / [h],190,70621,DB00281,Lidocaine
below,19247757,Total plasma concentrations,Total plasma concentrations of lidocaine remained below 4 microg ml(-1) throughout the study period.,Intranasal lidocaine plus naphazoline nitrate improves surgical conditions and perioperative analgesia in septorhinoplasty surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19247757/),[μg] / [ml],4,71699,DB00281,Lidocaine
,2751122,plasma concentrations at steady state,"Maternal and fetal lidocaine plasma concentrations at steady state were 2.32 +/- 0.12 and 1.23 +/- 0.17 microgram/ml, respectively, similar to those seen during human epidural anesthesia.",Adverse effects of maternally administered lidocaine on the asphyxiated preterm fetal lamb. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751122/),[μg] / [ml],2.32,72176,DB00281,Lidocaine
,2751122,plasma concentrations at steady state,"Maternal and fetal lidocaine plasma concentrations at steady state were 2.32 +/- 0.12 and 1.23 +/- 0.17 microgram/ml, respectively, similar to those seen during human epidural anesthesia.",Adverse effects of maternally administered lidocaine on the asphyxiated preterm fetal lamb. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751122/),[μg] / [ml],1.23,72177,DB00281,Lidocaine
,27283723,plasma concentration,"The plasma concentration of dexamethasone for the CS interventions was 226 ± 47 ng/ml at 30-min and 316 ± 81.6 ng/ml at 60-min post injection, and for SS, it was 221 ± 81.6 ng/ml at 30-min and 340 ± 105 ng/ml at 60-min post injection.","High performance liquid chromatography determination of dexamethasone in plasma to evaluate its systemic absorption following intra-space pterygomandibular injection of twin-mix (mixture of 2 % lignocaine with 1:200,000 epinephrine and 4 mg dexamethasone): randomized control trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283723/),[ng] / [ml],226,72462,DB00281,Lidocaine
,27283723,plasma concentration,"The plasma concentration of dexamethasone for the CS interventions was 226 ± 47 ng/ml at 30-min and 316 ± 81.6 ng/ml at 60-min post injection, and for SS, it was 221 ± 81.6 ng/ml at 30-min and 340 ± 105 ng/ml at 60-min post injection.","High performance liquid chromatography determination of dexamethasone in plasma to evaluate its systemic absorption following intra-space pterygomandibular injection of twin-mix (mixture of 2 % lignocaine with 1:200,000 epinephrine and 4 mg dexamethasone): randomized control trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283723/),[ng] / [ml],221,72463,DB00281,Lidocaine
,27283723,plasma concentration,"The plasma concentration of dexamethasone for the CS interventions was 226 ± 47 ng/ml at 30-min and 316 ± 81.6 ng/ml at 60-min post injection, and for SS, it was 221 ± 81.6 ng/ml at 30-min and 340 ± 105 ng/ml at 60-min post injection.","High performance liquid chromatography determination of dexamethasone in plasma to evaluate its systemic absorption following intra-space pterygomandibular injection of twin-mix (mixture of 2 % lignocaine with 1:200,000 epinephrine and 4 mg dexamethasone): randomized control trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283723/),[ng] / [ml],340,72464,DB00281,Lidocaine
,8408724,milk: plasma ratios,"The milk: plasma ratios for lignocaine and monoethylglycinexylidide were 1.1 and 1.8, respectively.",Excretion of lignocaine and its metabolite monoethylglycinexylidide in breast milk following its use in a dental procedure. A case report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8408724/),,1.1,73848,DB00281,Lidocaine
,8408724,milk: plasma ratios,"The milk: plasma ratios for lignocaine and monoethylglycinexylidide were 1.1 and 1.8, respectively.",Excretion of lignocaine and its metabolite monoethylglycinexylidide in breast milk following its use in a dental procedure. A case report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8408724/),,1.8,73849,DB00281,Lidocaine
,10680103,clearance,"Morphine clearance 2.5 to 10 ml/kg/min (6 +/- 2.6, mean +/- SD) and volume of distribution 0.28 to 3.30 L/kg (1.4 +/- 1.0) were found to be lower than values described previously for healthy volunteers (33.5 +/- 9 ml/kg/min and 5.16 +/- 1.40 L/kg, respectively), and are similar to those described in trauma patients (5 +/- 2.9 ml/kg/min and 0.9 +/- 0.2 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[ml] / [kg·min],2.5 to 10,74847,DB00281,Lidocaine
,10680103,clearance,"Morphine clearance 2.5 to 10 ml/kg/min (6 +/- 2.6, mean +/- SD) and volume of distribution 0.28 to 3.30 L/kg (1.4 +/- 1.0) were found to be lower than values described previously for healthy volunteers (33.5 +/- 9 ml/kg/min and 5.16 +/- 1.40 L/kg, respectively), and are similar to those described in trauma patients (5 +/- 2.9 ml/kg/min and 0.9 +/- 0.2 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[ml] / [kg·min],6,74848,DB00281,Lidocaine
,10680103,volume of distribution,"Morphine clearance 2.5 to 10 ml/kg/min (6 +/- 2.6, mean +/- SD) and volume of distribution 0.28 to 3.30 L/kg (1.4 +/- 1.0) were found to be lower than values described previously for healthy volunteers (33.5 +/- 9 ml/kg/min and 5.16 +/- 1.40 L/kg, respectively), and are similar to those described in trauma patients (5 +/- 2.9 ml/kg/min and 0.9 +/- 0.2 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[l] / [kg],0.28 to 3.30,74849,DB00281,Lidocaine
,10680103,volume of distribution,"Morphine clearance 2.5 to 10 ml/kg/min (6 +/- 2.6, mean +/- SD) and volume of distribution 0.28 to 3.30 L/kg (1.4 +/- 1.0) were found to be lower than values described previously for healthy volunteers (33.5 +/- 9 ml/kg/min and 5.16 +/- 1.40 L/kg, respectively), and are similar to those described in trauma patients (5 +/- 2.9 ml/kg/min and 0.9 +/- 0.2 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),,1.4,74850,DB00281,Lidocaine
,10680103,volume of distribution,"Morphine clearance 2.5 to 10 ml/kg/min (6 +/- 2.6, mean +/- SD) and volume of distribution 0.28 to 3.30 L/kg (1.4 +/- 1.0) were found to be lower than values described previously for healthy volunteers (33.5 +/- 9 ml/kg/min and 5.16 +/- 1.40 L/kg, respectively), and are similar to those described in trauma patients (5 +/- 2.9 ml/kg/min and 0.9 +/- 0.2 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[l] / [kg],5.16,74851,DB00281,Lidocaine
,10680103,volume of distribution,"Morphine clearance 2.5 to 10 ml/kg/min (6 +/- 2.6, mean +/- SD) and volume of distribution 0.28 to 3.30 L/kg (1.4 +/- 1.0) were found to be lower than values described previously for healthy volunteers (33.5 +/- 9 ml/kg/min and 5.16 +/- 1.40 L/kg, respectively), and are similar to those described in trauma patients (5 +/- 2.9 ml/kg/min and 0.9 +/- 0.2 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[ml] / [kg·min],5,74852,DB00281,Lidocaine
,10680103,volume of distribution,"Morphine clearance 2.5 to 10 ml/kg/min (6 +/- 2.6, mean +/- SD) and volume of distribution 0.28 to 3.30 L/kg (1.4 +/- 1.0) were found to be lower than values described previously for healthy volunteers (33.5 +/- 9 ml/kg/min and 5.16 +/- 1.40 L/kg, respectively), and are similar to those described in trauma patients (5 +/- 2.9 ml/kg/min and 0.9 +/- 0.2 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[l] / [kg],0.9,74853,DB00281,Lidocaine
,10680103,clearance,"In contrast, lidocaine clearance 4.5 to 9.4 ml/kg/min (6.7 +/- 1.7) and volume of distribution 0.39 to 1.20 L/kg (0.72 +/- 0.28) were similar to the value described in healthy volunteers (10 ml/kg/min and 1.32 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[ml] / [kg·min],4.5 to 9.4,74854,DB00281,Lidocaine
,10680103,clearance,"In contrast, lidocaine clearance 4.5 to 9.4 ml/kg/min (6.7 +/- 1.7) and volume of distribution 0.39 to 1.20 L/kg (0.72 +/- 0.28) were similar to the value described in healthy volunteers (10 ml/kg/min and 1.32 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[ml] / [kg·min],6.7,74855,DB00281,Lidocaine
,10680103,volume of distribution,"In contrast, lidocaine clearance 4.5 to 9.4 ml/kg/min (6.7 +/- 1.7) and volume of distribution 0.39 to 1.20 L/kg (0.72 +/- 0.28) were similar to the value described in healthy volunteers (10 ml/kg/min and 1.32 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[l] / [kg],0.39 to 1.20,74856,DB00281,Lidocaine
,10680103,volume of distribution,"In contrast, lidocaine clearance 4.5 to 9.4 ml/kg/min (6.7 +/- 1.7) and volume of distribution 0.39 to 1.20 L/kg (0.72 +/- 0.28) were similar to the value described in healthy volunteers (10 ml/kg/min and 1.32 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[l] / [kg],0.72,74857,DB00281,Lidocaine
,10680103,volume of distribution,"In contrast, lidocaine clearance 4.5 to 9.4 ml/kg/min (6.7 +/- 1.7) and volume of distribution 0.39 to 1.20 L/kg (0.72 +/- 0.28) were similar to the value described in healthy volunteers (10 ml/kg/min and 1.32 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[ml] / [kg·min],10,74858,DB00281,Lidocaine
,10680103,volume of distribution,"In contrast, lidocaine clearance 4.5 to 9.4 ml/kg/min (6.7 +/- 1.7) and volume of distribution 0.39 to 1.20 L/kg (0.72 +/- 0.28) were similar to the value described in healthy volunteers (10 ml/kg/min and 1.32 L/kg, respectively).",The pharmacokinetics of morphine and lidocaine in nine severe trauma patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10680103/),[l] / [kg],1.32,74859,DB00281,Lidocaine
,27088998,Peak plasma concentrations,Peak plasma concentrations were larger using the mucosal atomization device (median [range]: 1.9 [1.4-3.2] μg/mL) than the spray tube (1.1 [0.6-2.0] μg/mL; P = 0.0021).,The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),[μg] / [ml],1.9,75318,DB00281,Lidocaine
,27088998,Peak plasma concentrations,Peak plasma concentrations were larger using the mucosal atomization device (median [range]: 1.9 [1.4-3.2] μg/mL) than the spray tube (1.1 [0.6-2.0] μg/mL; P = 0.0021).,The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),[μg] / [ml],1.1,75319,DB00281,Lidocaine
,27088998,bioavailability,"Our pharmacokinetic model estimated a difference of bioavailability between the atomized and the nonatomized lidocaine (0.801 and 0.559 respectively, P = 0.0005), whereas our model estimated no difference in the absorption rate constant (0.00688/min).",The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),,0.801,75320,DB00281,Lidocaine
,27088998,bioavailability,"Our pharmacokinetic model estimated a difference of bioavailability between the atomized and the nonatomized lidocaine (0.801 and 0.559 respectively, P = 0.0005), whereas our model estimated no difference in the absorption rate constant (0.00688/min).",The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),,0.559,75321,DB00281,Lidocaine
,27088998,absorption rate constant,"Our pharmacokinetic model estimated a difference of bioavailability between the atomized and the nonatomized lidocaine (0.801 and 0.559 respectively, P = 0.0005), whereas our model estimated no difference in the absorption rate constant (0.00688/min).",The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),1/[min],0.00688,75322,DB00281,Lidocaine
,2711965,plasma concentrations,"Mean plasma concentrations of lidocaine, MEGX, and GX at the start of the study were 1.02, 0.86, and 0.62 micrograms/ml, respectively.",Therapeutic serum lidocaine and metabolite concentrations in patients undergoing electrophysiologic study after discontinuation of intravenous lidocaine infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2711965/),[μg] / [ml],1.02,75927,DB00281,Lidocaine
,2711965,plasma concentrations,"Mean plasma concentrations of lidocaine, MEGX, and GX at the start of the study were 1.02, 0.86, and 0.62 micrograms/ml, respectively.",Therapeutic serum lidocaine and metabolite concentrations in patients undergoing electrophysiologic study after discontinuation of intravenous lidocaine infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2711965/),[μg] / [ml],0.86,75928,DB00281,Lidocaine
,2711965,plasma concentrations,"Mean plasma concentrations of lidocaine, MEGX, and GX at the start of the study were 1.02, 0.86, and 0.62 micrograms/ml, respectively.",Therapeutic serum lidocaine and metabolite concentrations in patients undergoing electrophysiologic study after discontinuation of intravenous lidocaine infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2711965/),[μg] / [ml],0.62,75929,DB00281,Lidocaine
,2711965,half-life,Thus using the reported half-life of 90 minutes and discontinuing lidocaine 5 half-lives prior to electrophysiologic evaluation does not ensure lack of electrophysiologic effects of the parent compound or its metabolites.,Therapeutic serum lidocaine and metabolite concentrations in patients undergoing electrophysiologic study after discontinuation of intravenous lidocaine infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2711965/),min,90,75930,DB00281,Lidocaine
,7784724,FiO2,"Anesthesia was induced with propofol (2 mg/kg), sufentanil (0.5 micrograms/kg), and vecuronium (0.08 mg/kg) and continued as total intravenous anesthesia with propofol (8 mg/kg/h) and oxygen in air (FiO2 = 0.33).",The technique of endobronchial lidocaine administration does not influence plasma concentration profiles and pharmacokinetic parameters in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784724/),,0.,78336,DB00281,Lidocaine
,7784724,maximal mean plasma concentrations,Asorption of lidocaine in groups 1-3 resulted in maximal mean plasma concentrations ranging from 0.78 to 0.85 micrograms/ml after 16.9 to 22.4 min.,The technique of endobronchial lidocaine administration does not influence plasma concentration profiles and pharmacokinetic parameters in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784724/),[μg] / [ml],0.78 to 0.85,78337,DB00281,Lidocaine
,26730802,t(1/2),"Pharmacokinetics parameters of lidocaine hydrochloride showed that there were no significant difference between the native Han and Tibetan volunteers, but the t(1/2) was 29.8 and 29.8% higher in 2 groups, respectively, than in the LA group.",Pharmacokinetics of Lidocaine Hydrochloride Metabolized by CYP3A4 in Chinese Han Volunteers Living at Low Altitude and in Native Han and Tibetan Chinese Volunteers Living at High Altitude. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26730802/),%,29.8,78682,DB00281,Lidocaine
,25031074,C max,"The test result showed that the maximum concentration (C max) of lidocaine in different ocular tissues and plasma were all achieved within 20 min after drug administration, and the data of C max were (2,987 ± 1814) μg/g, (44.67 ± 12.91) μg/g, (26.26 ± 7.19) μg/g, (11,046 ± 2,734) ng/mL, and (160.3 ± 61.0) ng/mL for tear fluid, cornea, conjunctiva, aqueous humor, and plasma, respectively.",Ocular and systemic pharmacokinetics of lidocaine hydrochloride ophthalmic gel in rabbits after topical ocular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25031074/),[μg] / [g],"2,987",78997,DB00281,Lidocaine
,25031074,C max,"The test result showed that the maximum concentration (C max) of lidocaine in different ocular tissues and plasma were all achieved within 20 min after drug administration, and the data of C max were (2,987 ± 1814) μg/g, (44.67 ± 12.91) μg/g, (26.26 ± 7.19) μg/g, (11,046 ± 2,734) ng/mL, and (160.3 ± 61.0) ng/mL for tear fluid, cornea, conjunctiva, aqueous humor, and plasma, respectively.",Ocular and systemic pharmacokinetics of lidocaine hydrochloride ophthalmic gel in rabbits after topical ocular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25031074/),[μg] / [g],44.67,78998,DB00281,Lidocaine
,25031074,C max,"The test result showed that the maximum concentration (C max) of lidocaine in different ocular tissues and plasma were all achieved within 20 min after drug administration, and the data of C max were (2,987 ± 1814) μg/g, (44.67 ± 12.91) μg/g, (26.26 ± 7.19) μg/g, (11,046 ± 2,734) ng/mL, and (160.3 ± 61.0) ng/mL for tear fluid, cornea, conjunctiva, aqueous humor, and plasma, respectively.",Ocular and systemic pharmacokinetics of lidocaine hydrochloride ophthalmic gel in rabbits after topical ocular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25031074/),[μg] / [g],26.26,78999,DB00281,Lidocaine
,25031074,C max,"The test result showed that the maximum concentration (C max) of lidocaine in different ocular tissues and plasma were all achieved within 20 min after drug administration, and the data of C max were (2,987 ± 1814) μg/g, (44.67 ± 12.91) μg/g, (26.26 ± 7.19) μg/g, (11,046 ± 2,734) ng/mL, and (160.3 ± 61.0) ng/mL for tear fluid, cornea, conjunctiva, aqueous humor, and plasma, respectively.",Ocular and systemic pharmacokinetics of lidocaine hydrochloride ophthalmic gel in rabbits after topical ocular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25031074/),[ng] / [ml],"11,046",79000,DB00281,Lidocaine
,25031074,C max,"The test result showed that the maximum concentration (C max) of lidocaine in different ocular tissues and plasma were all achieved within 20 min after drug administration, and the data of C max were (2,987 ± 1814) μg/g, (44.67 ± 12.91) μg/g, (26.26 ± 7.19) μg/g, (11,046 ± 2,734) ng/mL, and (160.3 ± 61.0) ng/mL for tear fluid, cornea, conjunctiva, aqueous humor, and plasma, respectively.",Ocular and systemic pharmacokinetics of lidocaine hydrochloride ophthalmic gel in rabbits after topical ocular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25031074/),[ng] / [ml],160.3,79001,DB00281,Lidocaine
,25031074,elimination half-life,"The data of the elimination half-life in these tissues were 1.5, 3.2, 3.5, 1.9, and 1.7 h for tear fluid, cornea, conjunctiva, aqueous humor, and plasma, respectively.",Ocular and systemic pharmacokinetics of lidocaine hydrochloride ophthalmic gel in rabbits after topical ocular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25031074/),h,1.5,79002,DB00281,Lidocaine
,25031074,elimination half-life,"The data of the elimination half-life in these tissues were 1.5, 3.2, 3.5, 1.9, and 1.7 h for tear fluid, cornea, conjunctiva, aqueous humor, and plasma, respectively.",Ocular and systemic pharmacokinetics of lidocaine hydrochloride ophthalmic gel in rabbits after topical ocular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25031074/),h,3.2,79003,DB00281,Lidocaine
,25031074,elimination half-life,"The data of the elimination half-life in these tissues were 1.5, 3.2, 3.5, 1.9, and 1.7 h for tear fluid, cornea, conjunctiva, aqueous humor, and plasma, respectively.",Ocular and systemic pharmacokinetics of lidocaine hydrochloride ophthalmic gel in rabbits after topical ocular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25031074/),h,3.5,79004,DB00281,Lidocaine
,25031074,elimination half-life,"The data of the elimination half-life in these tissues were 1.5, 3.2, 3.5, 1.9, and 1.7 h for tear fluid, cornea, conjunctiva, aqueous humor, and plasma, respectively.",Ocular and systemic pharmacokinetics of lidocaine hydrochloride ophthalmic gel in rabbits after topical ocular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25031074/),h,1.9,79005,DB00281,Lidocaine
,25031074,elimination half-life,"The data of the elimination half-life in these tissues were 1.5, 3.2, 3.5, 1.9, and 1.7 h for tear fluid, cornea, conjunctiva, aqueous humor, and plasma, respectively.",Ocular and systemic pharmacokinetics of lidocaine hydrochloride ophthalmic gel in rabbits after topical ocular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25031074/),h,1.7,79006,DB00281,Lidocaine
,12534644,clearance,"In healthy volunteers, lignocaine clearance was decreased from 9.93 to 8.15 ml kg-1 min-1[mean percentage ratio (95% CI), 82 (65-98)] and the half-life was prolonged from 2.23 to 02.80 h [mean percentage ratio (95% CI), 130 (109-151)]; MEGX area under the concentration-time curve from 0 h to 12 h was increased from 665 to 886 ng ml-1 h [mean percentage ratio (95% CI), 129 (102-156)].",Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534644/),[ml] / [kg·min],9.93 to 8.15,80305,DB00281,Lidocaine
,12534644,half-life,"In healthy volunteers, lignocaine clearance was decreased from 9.93 to 8.15 ml kg-1 min-1[mean percentage ratio (95% CI), 82 (65-98)] and the half-life was prolonged from 2.23 to 02.80 h [mean percentage ratio (95% CI), 130 (109-151)]; MEGX area under the concentration-time curve from 0 h to 12 h was increased from 665 to 886 ng ml-1 h [mean percentage ratio (95% CI), 129 (102-156)].",Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534644/),h,2.23 to 02.80,80306,DB00281,Lidocaine
,12534644,area under the concentration-time curve from 0 h to 12 h,"In healthy volunteers, lignocaine clearance was decreased from 9.93 to 8.15 ml kg-1 min-1[mean percentage ratio (95% CI), 82 (65-98)] and the half-life was prolonged from 2.23 to 02.80 h [mean percentage ratio (95% CI), 130 (109-151)]; MEGX area under the concentration-time curve from 0 h to 12 h was increased from 665 to 886 ng ml-1 h [mean percentage ratio (95% CI), 129 (102-156)].",Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12534644/),[h·ng] / [ml],665 to 886,80307,DB00281,Lidocaine
,3082345,ratios,Mean +/- s.d. ratios increased from 1.03 +/- 0.05 at 2 min to 1.76 +/- 0.35 at 48.5 h.,The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082345/),,1.03,80319,DB00281,Lidocaine
,3082345,ratios,Mean +/- s.d. ratios increased from 1.03 +/- 0.05 at 2 min to 1.76 +/- 0.35 at 48.5 h.,The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082345/),,1.,80320,DB00281,Lidocaine
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],378,80807,DB00281,Lidocaine
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],309,80808,DB00281,Lidocaine
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],66.7,80809,DB00281,Lidocaine
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],48,80810,DB00281,Lidocaine
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],42.9,80811,DB00281,Lidocaine
,4025891,peak concentration,"The initial dose (320-400 mg without epinephrine) followed by top-up injections of about 60% of the mean initial dose every 35-55 min resulted in a plasma accumulation of lidocaine: the peak concentration increased from 2.30 +/- 0.46 (mean +/- SD) microgram/ml following the first injection and 3.34 +/- 0.76 microgram/ml after the second, to 4.11 +/- 0.72 microgram/ml following the third.",Plasma concentrations of lidocaine and its principal metabolites during intermittent epidural anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025891/),[μg] / [ml],2.30,81713,DB00281,Lidocaine
,4025891,peak concentration,"The initial dose (320-400 mg without epinephrine) followed by top-up injections of about 60% of the mean initial dose every 35-55 min resulted in a plasma accumulation of lidocaine: the peak concentration increased from 2.30 +/- 0.46 (mean +/- SD) microgram/ml following the first injection and 3.34 +/- 0.76 microgram/ml after the second, to 4.11 +/- 0.72 microgram/ml following the third.",Plasma concentrations of lidocaine and its principal metabolites during intermittent epidural anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025891/),[μg] / [ml],3.34,81714,DB00281,Lidocaine
,4025891,peak concentration,"The initial dose (320-400 mg without epinephrine) followed by top-up injections of about 60% of the mean initial dose every 35-55 min resulted in a plasma accumulation of lidocaine: the peak concentration increased from 2.30 +/- 0.46 (mean +/- SD) microgram/ml following the first injection and 3.34 +/- 0.76 microgram/ml after the second, to 4.11 +/- 0.72 microgram/ml following the third.",Plasma concentrations of lidocaine and its principal metabolites during intermittent epidural anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025891/),[μg] / [ml],4.11,81715,DB00281,Lidocaine
,4025891,maximum concentrations,"The maximum concentrations of MEGX and GX were 0.66 +/- 0.22 and 0.28 +/- 0.08 microgram/ml, respectively.",Plasma concentrations of lidocaine and its principal metabolites during intermittent epidural anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025891/),[μg] / [ml],0.66,81716,DB00281,Lidocaine
,4025891,maximum concentrations,"The maximum concentrations of MEGX and GX were 0.66 +/- 0.22 and 0.28 +/- 0.08 microgram/ml, respectively.",Plasma concentrations of lidocaine and its principal metabolites during intermittent epidural anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025891/),[μg] / [ml],0.28,81717,DB00281,Lidocaine
,4025891,elimination half-life (t1/2,"Such pharmacokinetic variables as elimination half-life (t1/2, 2.33 +/- 0.43 h), apparent volume of distribution divided by bioavailability (Vd/F, 2.51 +/- 0.61 l/kg), and clearance divided by bioavailability (Cl/F, 11.65 +/- 1.21 ml X kg-1 X min-1) obtained from the female patients were in reasonable agreement with those reported from healthy females receiving the intravenous lidocaine HCl.",Plasma concentrations of lidocaine and its principal metabolites during intermittent epidural anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025891/),h,2.33,81718,DB00281,Lidocaine
,4025891,apparent volume of distribution divided by bioavailability (Vd/F,"Such pharmacokinetic variables as elimination half-life (t1/2, 2.33 +/- 0.43 h), apparent volume of distribution divided by bioavailability (Vd/F, 2.51 +/- 0.61 l/kg), and clearance divided by bioavailability (Cl/F, 11.65 +/- 1.21 ml X kg-1 X min-1) obtained from the female patients were in reasonable agreement with those reported from healthy females receiving the intravenous lidocaine HCl.",Plasma concentrations of lidocaine and its principal metabolites during intermittent epidural anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025891/),[l] / [kg],2.51,81719,DB00281,Lidocaine
,4025891,clearance divided by bioavailability (Cl/F,"Such pharmacokinetic variables as elimination half-life (t1/2, 2.33 +/- 0.43 h), apparent volume of distribution divided by bioavailability (Vd/F, 2.51 +/- 0.61 l/kg), and clearance divided by bioavailability (Cl/F, 11.65 +/- 1.21 ml X kg-1 X min-1) obtained from the female patients were in reasonable agreement with those reported from healthy females receiving the intravenous lidocaine HCl.",Plasma concentrations of lidocaine and its principal metabolites during intermittent epidural anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025891/),[ml] / [kg·min],11.65,81720,DB00281,Lidocaine
,10445735,cell viability,"The average yield of hepatocytes was 2.4 +/- 0.6 x 10(10) cells per liver, with a cell viability of 89.6 +/- 3.9%.",In vitro evaluation of metabolic functions of a bioartificial liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445735/),%,89.6,83053,DB00281,Lidocaine
,10445735,intrinsic clearance,The average intrinsic clearance of the BAL device was found to be 46 ml/min for lidocaine and 8.8 ml/min for ammonia.,In vitro evaluation of metabolic functions of a bioartificial liver. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445735/),[ml] / [min],46,83054,DB00281,Lidocaine
,10445735,intrinsic clearance,The average intrinsic clearance of the BAL device was found to be 46 ml/min for lidocaine and 8.8 ml/min for ammonia.,In vitro evaluation of metabolic functions of a bioartificial liver. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445735/),[ml] / [min],8.8,83055,DB00281,Lidocaine
,10445735,elimination capacity,The galactose elimination capacity of the BAL device was 1.34 mg/min.,In vitro evaluation of metabolic functions of a bioartificial liver. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445735/),[mg] / [min],1.34,83056,DB00281,Lidocaine
,30028024,elimination micro-constants (Ke ),"Median (range) elimination micro-constants (Ke ) for LD, 3-OH, 4-OH, and MEXG were 4.12 (2.62-6.23), 1.25 (1.10-2.15), 1.79 (1.22-2.39), and 1.69 (1.03-1.99)/hr, respectively.","Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),1/[h],4.12,83213,DB00281,Lidocaine
,30028024,elimination micro-constants (Ke ),"Median (range) elimination micro-constants (Ke ) for LD, 3-OH, 4-OH, and MEXG were 4.12 (2.62-6.23), 1.25 (1.10-2.15), 1.79 (1.22-2.39), and 1.69 (1.03-1.99)/hr, respectively.","Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),1/[h],1.25,83214,DB00281,Lidocaine
,30028024,elimination micro-constants (Ke ),"Median (range) elimination micro-constants (Ke ) for LD, 3-OH, 4-OH, and MEXG were 4.12 (2.62-6.23), 1.25 (1.10-2.15), 1.79 (1.22-2.39), and 1.69 (1.03-1.99)/hr, respectively.","Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),1/[h],1.79,83215,DB00281,Lidocaine
,30028024,elimination micro-constants (Ke ),"Median (range) elimination micro-constants (Ke ) for LD, 3-OH, 4-OH, and MEXG were 4.12 (2.62-6.23), 1.25 (1.10-2.15), 1.79 (1.22-2.39), and 1.69 (1.03-1.99)/hr, respectively.","Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),1/[h],1.69,83216,DB00281,Lidocaine
,30028024,alpha (t½α ),"Median (range) values of alpha (t½α ), beta (t½β ), and gamma (t½γ ) half-lives were 0.08 (0.07-0.13), 0.57 (0.15-1.25), and 4.11 (0.52-7.36) hr.","Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),h,0.08,83217,DB00281,Lidocaine
,30028024,beta (t½β ),"Median (range) values of alpha (t½α ), beta (t½β ), and gamma (t½γ ) half-lives were 0.08 (0.07-0.13), 0.57 (0.15-1.25), and 4.11 (0.52-7.36) hr.","Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),h,0.57,83218,DB00281,Lidocaine
,30028024,gamma (t½γ ) half-lives,"Median (range) values of alpha (t½α ), beta (t½β ), and gamma (t½γ ) half-lives were 0.08 (0.07-0.13), 0.57 (0.15-1.25), and 4.11 (0.52-7.36) hr.","Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),h,4.11,83219,DB00281,Lidocaine
,30028024,absorption half-life (t½ab ),The median (range) of the LD absorption half-life (t½ab ) was 0.47 (0.29-0.61) hr.,"Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),h,0.47,83220,DB00281,Lidocaine
,30028024,Ke,"The Ke for LD, 3-OH, 4-OH, and MEXG was 3.91 (1.48-9.25), 1.00 (0.78-1.08), 1.76 (0.96-2.11), and 1.13 (0.69-1.33)/hr.","Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),1/[h],3.91,83221,DB00281,Lidocaine
,30028024,Ke,"The Ke for LD, 3-OH, 4-OH, and MEXG was 3.91 (1.48-9.25), 1.00 (0.78-1.08), 1.76 (0.96-2.11), and 1.13 (0.69-1.33)/hr.","Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),1/[h],1.00,83222,DB00281,Lidocaine
,30028024,Ke,"The Ke for LD, 3-OH, 4-OH, and MEXG was 3.91 (1.48-9.25), 1.00 (0.78-1.08), 1.76 (0.96-2.11), and 1.13 (0.69-1.33)/hr.","Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),1/[h],1.76,83223,DB00281,Lidocaine
,30028024,Ke,"The Ke for LD, 3-OH, 4-OH, and MEXG was 3.91 (1.48-9.25), 1.00 (0.78-1.08), 1.76 (0.96-2.11), and 1.13 (0.69-1.33)/hr.","Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),1/[h],1.13,83224,DB00281,Lidocaine
,30028024,t½α,The median (range) of t½α and t½β was 0.15 (0.06-0.27) and 3.04 (2.53-6.39) hr.,"Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),h,0.15,83225,DB00281,Lidocaine
,30028024,t½β,The median (range) of t½α and t½β was 0.15 (0.06-0.27) and 3.04 (2.53-6.39) hr.,"Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),h,3.04,83226,DB00281,Lidocaine
,30028024,t½ab,Plasma concentrations of LD after tp (400 mg) application were described by one-compartment model with a t½ab of 8.49 (5.16-11.80) hr.,"Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),h,8.49,83227,DB00281,Lidocaine
,30028024,Ke,"The Ke for LD, 3-OH, and MEXG was 0.24 (0.10-0.81), 0.41 (0.08-0.93), and 0.38 (0.26-1.14)/hr.","Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),1/[h],0.24,83228,DB00281,Lidocaine
,30028024,Ke,"The Ke for LD, 3-OH, and MEXG was 0.24 (0.10-0.81), 0.41 (0.08-0.93), and 0.38 (0.26-1.14)/hr.","Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),1/[h],0.41,83229,DB00281,Lidocaine
,30028024,Ke,"The Ke for LD, 3-OH, and MEXG was 0.24 (0.10-0.81), 0.41 (0.08-0.93), and 0.38 (0.26-1.14)/hr.","Pharmacokinetics of intravenous, subcutaneous, and topical administration of lidocaine hydrochloride and metabolites 3-hydroxylidocaine, monoethylglycinexylidide, and 4-hydroxylidocaine in horse. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30028024/),1/[h],0.38,83230,DB00281,Lidocaine
,15845683,elimination half-life,Fluvoxamine alone decreased the clearance of lidocaine by 41% (P < 0.001) and prolonged its elimination half-life from 2.6 to 3.5 h (P < 0.01).,The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845683/),h,2.6,83700,DB00281,Lidocaine
,15845683,elimination half-life,Fluvoxamine alone decreased the clearance of lidocaine by 41% (P < 0.001) and prolonged its elimination half-life from 2.6 to 3.5 h (P < 0.01).,The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845683/),h,3.5,83701,DB00281,Lidocaine
,15845683,half-life,During the combination phase the half-life of lidocaine (4.3 h) was longer than during the placebo (2.6 h; P < 0.001) or fluvoxamine (3.5 h; P < 0.01).,The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845683/),h,4.3,83702,DB00281,Lidocaine
,15845683,half-life,During the combination phase the half-life of lidocaine (4.3 h) was longer than during the placebo (2.6 h; P < 0.001) or fluvoxamine (3.5 h; P < 0.01).,The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845683/),h,2.6,83703,DB00281,Lidocaine
,15845683,half-life,During the combination phase the half-life of lidocaine (4.3 h) was longer than during the placebo (2.6 h; P < 0.001) or fluvoxamine (3.5 h; P < 0.01).,The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845683/),h,3.5,83704,DB00281,Lidocaine
,19840530,maximum serum concentration of morphine (Cmax,"Administration of EREM 3 minutes after a lidocaine-epinephrine test dose, with or without a flush, resulted in an increased mean maximum serum concentration of morphine (Cmax; flush, 30.2 +/- 8.5 ng/ml; no flush, 25.6 +/- 10.1 ng/ml; EREM alone, 11.5 +/- 7.3 ng/ml) and a decreased median time to Cmax (tmax; flush, 0.2 h; no flush, 0.2 h; EREM alone, 2.0 h) compared with administration of EREM alone, without affecting relative morphine bioavailability.",A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),[ng] / [ml],30.2,83715,DB00281,Lidocaine
,19840530,maximum serum concentration of morphine (Cmax,"Administration of EREM 3 minutes after a lidocaine-epinephrine test dose, with or without a flush, resulted in an increased mean maximum serum concentration of morphine (Cmax; flush, 30.2 +/- 8.5 ng/ml; no flush, 25.6 +/- 10.1 ng/ml; EREM alone, 11.5 +/- 7.3 ng/ml) and a decreased median time to Cmax (tmax; flush, 0.2 h; no flush, 0.2 h; EREM alone, 2.0 h) compared with administration of EREM alone, without affecting relative morphine bioavailability.",A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),[ng] / [ml],25.6,83716,DB00281,Lidocaine
,19840530,maximum serum concentration of morphine (Cmax,"Administration of EREM 3 minutes after a lidocaine-epinephrine test dose, with or without a flush, resulted in an increased mean maximum serum concentration of morphine (Cmax; flush, 30.2 +/- 8.5 ng/ml; no flush, 25.6 +/- 10.1 ng/ml; EREM alone, 11.5 +/- 7.3 ng/ml) and a decreased median time to Cmax (tmax; flush, 0.2 h; no flush, 0.2 h; EREM alone, 2.0 h) compared with administration of EREM alone, without affecting relative morphine bioavailability.",A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),[ng] / [ml],11.5,83717,DB00281,Lidocaine
,19840530,time to Cmax (tmax,"Administration of EREM 3 minutes after a lidocaine-epinephrine test dose, with or without a flush, resulted in an increased mean maximum serum concentration of morphine (Cmax; flush, 30.2 +/- 8.5 ng/ml; no flush, 25.6 +/- 10.1 ng/ml; EREM alone, 11.5 +/- 7.3 ng/ml) and a decreased median time to Cmax (tmax; flush, 0.2 h; no flush, 0.2 h; EREM alone, 2.0 h) compared with administration of EREM alone, without affecting relative morphine bioavailability.",A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),h,0.2,83718,DB00281,Lidocaine
,19840530,time to Cmax (tmax,"Administration of EREM 3 minutes after a lidocaine-epinephrine test dose, with or without a flush, resulted in an increased mean maximum serum concentration of morphine (Cmax; flush, 30.2 +/- 8.5 ng/ml; no flush, 25.6 +/- 10.1 ng/ml; EREM alone, 11.5 +/- 7.3 ng/ml) and a decreased median time to Cmax (tmax; flush, 0.2 h; no flush, 0.2 h; EREM alone, 2.0 h) compared with administration of EREM alone, without affecting relative morphine bioavailability.",A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),h,2.0,83719,DB00281,Lidocaine
,19840530,Cmax,Flushing the catheter and waiting 15 minutes normalized the Cmax (11.4 +/- 6.4 ng/ml) but not the median tmax (0.5 h).,A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),[ng] / [ml],11.4,83720,DB00281,Lidocaine
,19840530,tmax,Flushing the catheter and waiting 15 minutes normalized the Cmax (11.4 +/- 6.4 ng/ml) but not the median tmax (0.5 h).,A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),h,0.5,83721,DB00281,Lidocaine
,14581721,absolute clearance (CL),"Drug elimination rate constant (gammaz) increased by 68% in rats with experimental diabetes which had an effect on the shortening of lidocaine half-life in those animals (t1/2 by 39%) and on the increase in absolute clearance (CL) to 1.46 l/h comparing to control group (0.95 l/h), i.e. by 54%.",Effect of experimental diabetes on pharmacokinetic parameters of lidocaine and MEGX in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581721/),[l] / [h],1.46,84285,DB00281,Lidocaine
,14581721,absolute clearance (CL),"Drug elimination rate constant (gammaz) increased by 68% in rats with experimental diabetes which had an effect on the shortening of lidocaine half-life in those animals (t1/2 by 39%) and on the increase in absolute clearance (CL) to 1.46 l/h comparing to control group (0.95 l/h), i.e. by 54%.",Effect of experimental diabetes on pharmacokinetic parameters of lidocaine and MEGX in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581721/),[l] / [h],0.95,84286,DB00281,Lidocaine
,14581721,half-life (t1/2),"The MEGX half-life (t1/2) increased from 0.34 h in the control group to 0.89 h in the rats with diabetes, i.e. by 165%.",Effect of experimental diabetes on pharmacokinetic parameters of lidocaine and MEGX in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581721/),h,0.34,84287,DB00281,Lidocaine
,14581721,half-life (t1/2),"The MEGX half-life (t1/2) increased from 0.34 h in the control group to 0.89 h in the rats with diabetes, i.e. by 165%.",Effect of experimental diabetes on pharmacokinetic parameters of lidocaine and MEGX in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581721/),h,0.89,84288,DB00281,Lidocaine
greater,6966453,apparent volume of distribution (Vd),The apparent volume of distribution (Vd) is greater than 500 1.,Pharmacokinetics of mexiletine in renal insufficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6966453/),1,500,84404,DB00281,Lidocaine
,6966453,plasma half-time,The plasma half-time is 10 to 12 hours in healthy volunteers with a 70% plasma protein fixation.,Pharmacokinetics of mexiletine in renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6966453/),h,10 to 12,84405,DB00281,Lidocaine
,6966453,plasma half-time,The mean plasma half-time for these patients is 11.1 +/- 1.7 hours after a single i.v. injection of 1.5 mg/kg.,Pharmacokinetics of mexiletine in renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6966453/),h,11.1,84406,DB00281,Lidocaine
,6966453,plasma half-time,Our control group containing convalescents from acute myocardial infarct has a plasma half-time of only 5.9 hours.,Pharmacokinetics of mexiletine in renal insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6966453/),h,5.9,84407,DB00281,Lidocaine
<,19021619,peak serum lidocaine concentration,"The peak serum lidocaine concentration during the study was <2 microg/mL, and well below the toxic level (>5 microg/mL).",Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19021619/),[μg] / [ml],2,85716,DB00281,Lidocaine
,7355759,elimination half-life,Pharmacokinetic analysis indicated a mean elimination half-life of 12.6 +/- 1.6 hours following oral administration of mexiletine.,Mexiletine therapy in 15 patients with drug-resistant ventricular tachycardia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7355759/),h,12.6,85876,DB00281,Lidocaine
,470315,clearance,In ten of them the main pharmacokinetic parameters were determined; the average value of lidocain clearance was 0.45 1/min.,[Lidocaine pharmacokinetics and substantiation of the new method of its administration in myocardial infarct]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/470315/),[1] / [min],0.45,87759,DB00281,Lidocaine
,470315,rate of continuous drip infusion,The optimum rate of continuous drip infusion was calculated (1.35 mg/min).,[Lidocaine pharmacokinetics and substantiation of the new method of its administration in myocardial infarct]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/470315/),[mg] / [min],1.35,87760,DB00281,Lidocaine
,10486075,half-life,Pharmacokinetic evaluation indicated a single compartment first-order elimination with a methaemoglobin half-life of 8 h.,Toxic methaemoglobin concentrations in premature infants after application of a prilocaine-containing cream and peridural prilocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10486075/),h,8,87924,DB00281,Lidocaine
,6287931,peak plasma concentration,"The mean peak plasma concentration, time to attain the peak, area under the plasma curve from time zero to infinity, and elimination half-life were 45 micrograms/ml, 2.5 h, 578 micrograms .",Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6287931/),[μg] / [ml],45,88524,DB00281,Lidocaine
,6287931,time to attain the peak,"The mean peak plasma concentration, time to attain the peak, area under the plasma curve from time zero to infinity, and elimination half-life were 45 micrograms/ml, 2.5 h, 578 micrograms .",Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6287931/),h,2.5,88525,DB00281,Lidocaine
,6287931,area under the plasma curve from time zero to infinity,"The mean peak plasma concentration, time to attain the peak, area under the plasma curve from time zero to infinity, and elimination half-life were 45 micrograms/ml, 2.5 h, 578 micrograms .",Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6287931/),h,2.5,88526,DB00281,Lidocaine
,6287931,elimination half-life,"The mean peak plasma concentration, time to attain the peak, area under the plasma curve from time zero to infinity, and elimination half-life were 45 micrograms/ml, 2.5 h, 578 micrograms .",Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6287931/),μg,578,88527,DB00281,Lidocaine
,9481979,maximum concentration,"The maximum concentration measured in any subject was 418 ng/ml for lidocaine and 223 ng/ml for prilocaine, well below known toxic levels.",Pharmacokinetics of EMLA cream 5% application to oral mucosa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9481979/),[ng] / [ml],418,89258,DB00281,Lidocaine
,9481979,maximum concentration,"The maximum concentration measured in any subject was 418 ng/ml for lidocaine and 223 ng/ml for prilocaine, well below known toxic levels.",Pharmacokinetics of EMLA cream 5% application to oral mucosa. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9481979/),[ng] / [ml],223,89259,DB00281,Lidocaine
,2107608,total body clearance,"There was no significant difference in the means (+/- SEM) of total body clearance [7.70 +/- 0.70 (PN) versus 6.78 +/- 0.79 (D10W) versus 7.86 +/- 0.93 (control) ml/min kg], half-life [74.0 +/- 12.2 (PN) versus 89.6 +/- 4.35 (D10W) versus 79.2 +/- 7.22 (control) min], volume of distribution [0.82 +/- 0.15 (PN) versus 0.88 +/- 0.13 (D10W) versus 0.78 +/- 0.13 (control) L/kg], and the fraction of unbound lidocaine in the serum [0.34 +/- 0.025 (PN) versus 0.36 +/- 0.019 (D10W) versus 0.33 +/- 0.020 (control)] among the three nutrient regimens.",Lack of acute effect on lidocaine pharmacokinetics from parenteral nutrition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107608/),[ml] / [kg·min],7.70,89585,DB00281,Lidocaine
,2107608,total body clearance,"There was no significant difference in the means (+/- SEM) of total body clearance [7.70 +/- 0.70 (PN) versus 6.78 +/- 0.79 (D10W) versus 7.86 +/- 0.93 (control) ml/min kg], half-life [74.0 +/- 12.2 (PN) versus 89.6 +/- 4.35 (D10W) versus 79.2 +/- 7.22 (control) min], volume of distribution [0.82 +/- 0.15 (PN) versus 0.88 +/- 0.13 (D10W) versus 0.78 +/- 0.13 (control) L/kg], and the fraction of unbound lidocaine in the serum [0.34 +/- 0.025 (PN) versus 0.36 +/- 0.019 (D10W) versus 0.33 +/- 0.020 (control)] among the three nutrient regimens.",Lack of acute effect on lidocaine pharmacokinetics from parenteral nutrition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107608/),[ml] / [kg·min],6.78,89586,DB00281,Lidocaine
,2107608,total body clearance,"There was no significant difference in the means (+/- SEM) of total body clearance [7.70 +/- 0.70 (PN) versus 6.78 +/- 0.79 (D10W) versus 7.86 +/- 0.93 (control) ml/min kg], half-life [74.0 +/- 12.2 (PN) versus 89.6 +/- 4.35 (D10W) versus 79.2 +/- 7.22 (control) min], volume of distribution [0.82 +/- 0.15 (PN) versus 0.88 +/- 0.13 (D10W) versus 0.78 +/- 0.13 (control) L/kg], and the fraction of unbound lidocaine in the serum [0.34 +/- 0.025 (PN) versus 0.36 +/- 0.019 (D10W) versus 0.33 +/- 0.020 (control)] among the three nutrient regimens.",Lack of acute effect on lidocaine pharmacokinetics from parenteral nutrition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107608/),[ml] / [kg·min],7.86,89587,DB00281,Lidocaine
,2107608,half-life,"There was no significant difference in the means (+/- SEM) of total body clearance [7.70 +/- 0.70 (PN) versus 6.78 +/- 0.79 (D10W) versus 7.86 +/- 0.93 (control) ml/min kg], half-life [74.0 +/- 12.2 (PN) versus 89.6 +/- 4.35 (D10W) versus 79.2 +/- 7.22 (control) min], volume of distribution [0.82 +/- 0.15 (PN) versus 0.88 +/- 0.13 (D10W) versus 0.78 +/- 0.13 (control) L/kg], and the fraction of unbound lidocaine in the serum [0.34 +/- 0.025 (PN) versus 0.36 +/- 0.019 (D10W) versus 0.33 +/- 0.020 (control)] among the three nutrient regimens.",Lack of acute effect on lidocaine pharmacokinetics from parenteral nutrition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107608/),min,74.0,89588,DB00281,Lidocaine
,2107608,half-life,"There was no significant difference in the means (+/- SEM) of total body clearance [7.70 +/- 0.70 (PN) versus 6.78 +/- 0.79 (D10W) versus 7.86 +/- 0.93 (control) ml/min kg], half-life [74.0 +/- 12.2 (PN) versus 89.6 +/- 4.35 (D10W) versus 79.2 +/- 7.22 (control) min], volume of distribution [0.82 +/- 0.15 (PN) versus 0.88 +/- 0.13 (D10W) versus 0.78 +/- 0.13 (control) L/kg], and the fraction of unbound lidocaine in the serum [0.34 +/- 0.025 (PN) versus 0.36 +/- 0.019 (D10W) versus 0.33 +/- 0.020 (control)] among the three nutrient regimens.",Lack of acute effect on lidocaine pharmacokinetics from parenteral nutrition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107608/),min,89.6,89589,DB00281,Lidocaine
,2107608,half-life,"There was no significant difference in the means (+/- SEM) of total body clearance [7.70 +/- 0.70 (PN) versus 6.78 +/- 0.79 (D10W) versus 7.86 +/- 0.93 (control) ml/min kg], half-life [74.0 +/- 12.2 (PN) versus 89.6 +/- 4.35 (D10W) versus 79.2 +/- 7.22 (control) min], volume of distribution [0.82 +/- 0.15 (PN) versus 0.88 +/- 0.13 (D10W) versus 0.78 +/- 0.13 (control) L/kg], and the fraction of unbound lidocaine in the serum [0.34 +/- 0.025 (PN) versus 0.36 +/- 0.019 (D10W) versus 0.33 +/- 0.020 (control)] among the three nutrient regimens.",Lack of acute effect on lidocaine pharmacokinetics from parenteral nutrition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107608/),min,79.2,89590,DB00281,Lidocaine
,2107608,volume of distribution,"There was no significant difference in the means (+/- SEM) of total body clearance [7.70 +/- 0.70 (PN) versus 6.78 +/- 0.79 (D10W) versus 7.86 +/- 0.93 (control) ml/min kg], half-life [74.0 +/- 12.2 (PN) versus 89.6 +/- 4.35 (D10W) versus 79.2 +/- 7.22 (control) min], volume of distribution [0.82 +/- 0.15 (PN) versus 0.88 +/- 0.13 (D10W) versus 0.78 +/- 0.13 (control) L/kg], and the fraction of unbound lidocaine in the serum [0.34 +/- 0.025 (PN) versus 0.36 +/- 0.019 (D10W) versus 0.33 +/- 0.020 (control)] among the three nutrient regimens.",Lack of acute effect on lidocaine pharmacokinetics from parenteral nutrition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107608/),[l] / [kg],0.82,89591,DB00281,Lidocaine
,2107608,volume of distribution,"There was no significant difference in the means (+/- SEM) of total body clearance [7.70 +/- 0.70 (PN) versus 6.78 +/- 0.79 (D10W) versus 7.86 +/- 0.93 (control) ml/min kg], half-life [74.0 +/- 12.2 (PN) versus 89.6 +/- 4.35 (D10W) versus 79.2 +/- 7.22 (control) min], volume of distribution [0.82 +/- 0.15 (PN) versus 0.88 +/- 0.13 (D10W) versus 0.78 +/- 0.13 (control) L/kg], and the fraction of unbound lidocaine in the serum [0.34 +/- 0.025 (PN) versus 0.36 +/- 0.019 (D10W) versus 0.33 +/- 0.020 (control)] among the three nutrient regimens.",Lack of acute effect on lidocaine pharmacokinetics from parenteral nutrition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107608/),[l] / [kg],0.88,89592,DB00281,Lidocaine
,2107608,volume of distribution,"There was no significant difference in the means (+/- SEM) of total body clearance [7.70 +/- 0.70 (PN) versus 6.78 +/- 0.79 (D10W) versus 7.86 +/- 0.93 (control) ml/min kg], half-life [74.0 +/- 12.2 (PN) versus 89.6 +/- 4.35 (D10W) versus 79.2 +/- 7.22 (control) min], volume of distribution [0.82 +/- 0.15 (PN) versus 0.88 +/- 0.13 (D10W) versus 0.78 +/- 0.13 (control) L/kg], and the fraction of unbound lidocaine in the serum [0.34 +/- 0.025 (PN) versus 0.36 +/- 0.019 (D10W) versus 0.33 +/- 0.020 (control)] among the three nutrient regimens.",Lack of acute effect on lidocaine pharmacokinetics from parenteral nutrition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107608/),[l] / [kg],0.78,89593,DB00281,Lidocaine
,2107608,fraction of unbound lidocaine in,"There was no significant difference in the means (+/- SEM) of total body clearance [7.70 +/- 0.70 (PN) versus 6.78 +/- 0.79 (D10W) versus 7.86 +/- 0.93 (control) ml/min kg], half-life [74.0 +/- 12.2 (PN) versus 89.6 +/- 4.35 (D10W) versus 79.2 +/- 7.22 (control) min], volume of distribution [0.82 +/- 0.15 (PN) versus 0.88 +/- 0.13 (D10W) versus 0.78 +/- 0.13 (control) L/kg], and the fraction of unbound lidocaine in the serum [0.34 +/- 0.025 (PN) versus 0.36 +/- 0.019 (D10W) versus 0.33 +/- 0.020 (control)] among the three nutrient regimens.",Lack of acute effect on lidocaine pharmacokinetics from parenteral nutrition. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107608/),,0.34,89594,DB00281,Lidocaine
,2107608,fraction of unbound lidocaine in,"There was no significant difference in the means (+/- SEM) of total body clearance [7.70 +/- 0.70 (PN) versus 6.78 +/- 0.79 (D10W) versus 7.86 +/- 0.93 (control) ml/min kg], half-life [74.0 +/- 12.2 (PN) versus 89.6 +/- 4.35 (D10W) versus 79.2 +/- 7.22 (control) min], volume of distribution [0.82 +/- 0.15 (PN) versus 0.88 +/- 0.13 (D10W) versus 0.78 +/- 0.13 (control) L/kg], and the fraction of unbound lidocaine in the serum [0.34 +/- 0.025 (PN) versus 0.36 +/- 0.019 (D10W) versus 0.33 +/- 0.020 (control)] among the three nutrient regimens.",Lack of acute effect on lidocaine pharmacokinetics from parenteral nutrition. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107608/),,0.36,89595,DB00281,Lidocaine
,2107608,fraction of unbound lidocaine in,"There was no significant difference in the means (+/- SEM) of total body clearance [7.70 +/- 0.70 (PN) versus 6.78 +/- 0.79 (D10W) versus 7.86 +/- 0.93 (control) ml/min kg], half-life [74.0 +/- 12.2 (PN) versus 89.6 +/- 4.35 (D10W) versus 79.2 +/- 7.22 (control) min], volume of distribution [0.82 +/- 0.15 (PN) versus 0.88 +/- 0.13 (D10W) versus 0.78 +/- 0.13 (control) L/kg], and the fraction of unbound lidocaine in the serum [0.34 +/- 0.025 (PN) versus 0.36 +/- 0.019 (D10W) versus 0.33 +/- 0.020 (control)] among the three nutrient regimens.",Lack of acute effect on lidocaine pharmacokinetics from parenteral nutrition. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107608/),,0.33,89596,DB00281,Lidocaine
,1595915,Recovery time,Recovery time from the epidural block in the liposomal lidocaine group (170 +/- 49.5 min) was approximately three times longer than that in the free lidocaine group (61 +/- 18.1 min).,Prolongation of canine epidural anesthesia by liposome encapsulation of lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1595915/),min,170,90617,DB00281,Lidocaine
,1595915,Recovery time,Recovery time from the epidural block in the liposomal lidocaine group (170 +/- 49.5 min) was approximately three times longer than that in the free lidocaine group (61 +/- 18.1 min).,Prolongation of canine epidural anesthesia by liposome encapsulation of lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1595915/),min,61,90618,DB00281,Lidocaine
,1911010,clearance,The hepatic clearance of R(+)- was greater than that of S(-)-bupivacaine (P less than 0.05) with mean (SD) clearance at the two respective time periods being 1.37 (0.78) and 1.47 (0.57) litre min-1 and 1.01 (0.72) and 1.29 (0.47) litre min-1.,Cardiovascular effects and regional clearances of i.v. bupivacaine in sheep: enantiomeric analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911010/),[l] / [min],1.37,91642,DB00281,Lidocaine
,1911010,clearance,The hepatic clearance of R(+)- was greater than that of S(-)-bupivacaine (P less than 0.05) with mean (SD) clearance at the two respective time periods being 1.37 (0.78) and 1.47 (0.57) litre min-1 and 1.01 (0.72) and 1.29 (0.47) litre min-1.,Cardiovascular effects and regional clearances of i.v. bupivacaine in sheep: enantiomeric analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911010/),[l] / [min],1.47,91643,DB00281,Lidocaine
,1911010,clearance,The hepatic clearance of R(+)- was greater than that of S(-)-bupivacaine (P less than 0.05) with mean (SD) clearance at the two respective time periods being 1.37 (0.78) and 1.47 (0.57) litre min-1 and 1.01 (0.72) and 1.29 (0.47) litre min-1.,Cardiovascular effects and regional clearances of i.v. bupivacaine in sheep: enantiomeric analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911010/),[l] / [min],1.01,91644,DB00281,Lidocaine
,1911010,clearance,The hepatic clearance of R(+)- was greater than that of S(-)-bupivacaine (P less than 0.05) with mean (SD) clearance at the two respective time periods being 1.37 (0.78) and 1.47 (0.57) litre min-1 and 1.01 (0.72) and 1.29 (0.47) litre min-1.,Cardiovascular effects and regional clearances of i.v. bupivacaine in sheep: enantiomeric analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911010/),[l] / [min],1.29,91645,DB00281,Lidocaine
,10458175,maximum dexamethasone concentration,"The estimated maximum dexamethasone concentration in the aqueous was 858 ng per ml at 2.5 hours after injection, and in the vitreous, 72.5 ng per ml at 3 hours.",High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10458175/),[ng] / [ml],858,95100,DB00281,Lidocaine
,10458175,maximum dexamethasone concentration,"The estimated maximum dexamethasone concentration in the aqueous was 858 ng per ml at 2.5 hours after injection, and in the vitreous, 72.5 ng per ml at 3 hours.",High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10458175/),[ng] / [ml],72.5,95101,DB00281,Lidocaine
,10458175,maximum concentration,"In serum, a mean maximum concentration of 32.4 ng per ml was measured at approximately 30 minutes after injection.",High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10458175/),[ng] / [ml],32.4,95102,DB00281,Lidocaine
,4028631,t1/2,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),h,3.60,95919,DB00281,Lidocaine
,4028631,t1/2,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),h,4.30,95920,DB00281,Lidocaine
,4028631,volume of distribution,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[l] / [kg],5.8,95921,DB00281,Lidocaine
,4028631,volume of distribution,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[l] / [kg],6.6,95922,DB00281,Lidocaine
,4028631,total clearance,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ml] / [kg·min],19.2,95923,DB00281,Lidocaine
,4028631,total clearance,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ml] / [kg·min],18.4,95924,DB00281,Lidocaine
,4028631,t1/2,"After oral doses, the t1/2 (4.25 +/- 0.57 vs.",Lack of interaction between verapamil and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),,4.25,95925,DB00281,Lidocaine
,4028631,plasma AUC,"4.60 +/- 0.70 hours), plasma AUC (585 +/- 113 vs. 506 +/- 82 ng/ml X hr) and absolute bioavailability (35% +/- 7% vs. 30% +/- 5%) did not differ between control and cimetidine trials, respectively.",Lack of interaction between verapamil and cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ng] / [h·ml],585,95926,DB00281,Lidocaine
,4028631,plasma AUC,"4.60 +/- 0.70 hours), plasma AUC (585 +/- 113 vs. 506 +/- 82 ng/ml X hr) and absolute bioavailability (35% +/- 7% vs. 30% +/- 5%) did not differ between control and cimetidine trials, respectively.",Lack of interaction between verapamil and cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ng] / [h·ml],506,95927,DB00281,Lidocaine
,4028631,absolute bioavailability,"4.60 +/- 0.70 hours), plasma AUC (585 +/- 113 vs. 506 +/- 82 ng/ml X hr) and absolute bioavailability (35% +/- 7% vs. 30% +/- 5%) did not differ between control and cimetidine trials, respectively.",Lack of interaction between verapamil and cimetidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),%,35,95928,DB00281,Lidocaine
,4028631,absolute bioavailability,"4.60 +/- 0.70 hours), plasma AUC (585 +/- 113 vs. 506 +/- 82 ng/ml X hr) and absolute bioavailability (35% +/- 7% vs. 30% +/- 5%) did not differ between control and cimetidine trials, respectively.",Lack of interaction between verapamil and cimetidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),%,30,95929,DB00281,Lidocaine
,4028631,clearance,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ml] / [min],665,95930,DB00281,Lidocaine
,4028631,clearance,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ml] / [min],527,95931,DB00281,Lidocaine
,4028631,t1/2,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),h,1.81,95932,DB00281,Lidocaine
,4028631,t1/2,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),h,2.44,95933,DB00281,Lidocaine
,4028631,volume of distribution,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[l] / [kg],1.77,95934,DB00281,Lidocaine
,4028631,volume of distribution,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[l] / [kg],1.99,95935,DB00281,Lidocaine
,4028631,heart rate,A decrease in mean arterial pressure (8 +/- 1 vs. 9 +/- 2 mm Hg) and a reflex increase in heart rate (14 +/- 3 vs. 17 +/- 2 bpm) were no different in the control and cimetidine trials.,Lack of interaction between verapamil and cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),bpm,14,95936,DB00281,Lidocaine
,4028631,heart rate,A decrease in mean arterial pressure (8 +/- 1 vs. 9 +/- 2 mm Hg) and a reflex increase in heart rate (14 +/- 3 vs. 17 +/- 2 bpm) were no different in the control and cimetidine trials.,Lack of interaction between verapamil and cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),bpm,17,95937,DB00281,Lidocaine
,10088519,peak plasma concentrations,The peak plasma concentrations of lidocaine varied between 0.96 and 3.12 microg/ml (mean 1.49 microg/ml) and occurred between 4 and 12 hours (mean 7.3 hours) postoperatively.,Plasma concentrations of lidocaine and alpha1-acid glycoprotein during and after breast augmentation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10088519/),[μg] / [ml],1.49,96802,DB00281,Lidocaine
,10496655,tissue retention half lives,"Diclofenac had estimated tissue retention half lives of 18.1 hr and 3.5 hr for the dextran and BSA containing perfusates, respectively.",A physiological pharmacokinetic model for solute disposition in tissues below a topical below a topical application site. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496655/),h,18.1,99194,DB00281,Lidocaine
,10496655,tissue retention half lives,"Diclofenac had estimated tissue retention half lives of 18.1 hr and 3.5 hr for the dextran and BSA containing perfusates, respectively.",A physiological pharmacokinetic model for solute disposition in tissues below a topical below a topical application site. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496655/),h,3.5,99195,DB00281,Lidocaine
,19754910,serum T(max),"Following administration via inverted L nerve block, serum T(max) was 0.521 +/- 0.226 h and serum C(max) was 572 +/- 207 ng/mL.",Pharmacokinetics of lidocaine in serum and milk of mature Holstein cows. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754910/),h,0.521,99653,DB00281,Lidocaine
,19754910,serum C(max),"Following administration via inverted L nerve block, serum T(max) was 0.521 +/- 0.226 h and serum C(max) was 572 +/- 207 ng/mL.",Pharmacokinetics of lidocaine in serum and milk of mature Holstein cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754910/),[ng] / [ml],572,99654,DB00281,Lidocaine
,19754910,Serum AUC,Serum AUC was 1348 +/- 335 ng.h/mL.,Pharmacokinetics of lidocaine in serum and milk of mature Holstein cows. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754910/),[h·ng] / [ml],1348,99655,DB00281,Lidocaine
,19754910,Apparent serum t((1/2)beta),Apparent serum t((1/2)beta) was 4.19 +/- 1.69 h and MRT was 5.13 +/- 2.33 h with clearance uncorrected for the extent of absorption of 2.75 +/- 0.68 L/kg/h.,Pharmacokinetics of lidocaine in serum and milk of mature Holstein cows. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754910/),h,4.19,99656,DB00281,Lidocaine
,19754910,MRT,Apparent serum t((1/2)beta) was 4.19 +/- 1.69 h and MRT was 5.13 +/- 2.33 h with clearance uncorrected for the extent of absorption of 2.75 +/- 0.68 L/kg/h.,Pharmacokinetics of lidocaine in serum and milk of mature Holstein cows. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754910/),h,5.13,99657,DB00281,Lidocaine
,19754910,clearance,Apparent serum t((1/2)beta) was 4.19 +/- 1.69 h and MRT was 5.13 +/- 2.33 h with clearance uncorrected for the extent of absorption of 2.75 +/- 0.68 L/kg/h.,Pharmacokinetics of lidocaine in serum and milk of mature Holstein cows. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754910/),[l] / [h·kg],2.75,99658,DB00281,Lidocaine
,19754910,last measurable time,The last measurable time of lidocaine detection in serum was 8.5 +/- 1.4 h with a mean concentration of 51 +/- 30 ng/mL.,Pharmacokinetics of lidocaine in serum and milk of mature Holstein cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754910/),h,8.5,99659,DB00281,Lidocaine
,19754910,T(max),Milk T(max) was detected at 1.75 +/- 0.46 h with C(max) of 300 +/- 139 ng/mL.,Pharmacokinetics of lidocaine in serum and milk of mature Holstein cows. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754910/),h,1.75,99660,DB00281,Lidocaine
,19754910,C(max),Milk T(max) was detected at 1.75 +/- 0.46 h with C(max) of 300 +/- 139 ng/mL.,Pharmacokinetics of lidocaine in serum and milk of mature Holstein cows. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754910/),[ng] / [ml],300,99661,DB00281,Lidocaine
,19754910,AUC,Milk AUC till the last time was 1869 +/- 450 ng.h/mL with the mean AUC milk to AUC serum ratio of 1.439 +/- 0.374.,Pharmacokinetics of lidocaine in serum and milk of mature Holstein cows. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754910/),[h·ng] / [ml],1869,99662,DB00281,Lidocaine
,19754910,AUC milk to AUC serum ratio,Milk AUC till the last time was 1869 +/- 450 ng.h/mL with the mean AUC milk to AUC serum ratio of 1.439 +/- 0.374.,Pharmacokinetics of lidocaine in serum and milk of mature Holstein cows. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754910/),,1.439,99663,DB00281,Lidocaine
,19754910,last measurable time,The last measurable time of lidocaine detection in milk was 32.5 +/- 16.2 h with a mean concentration of 46 +/- 30 ng/mL.,Pharmacokinetics of lidocaine in serum and milk of mature Holstein cows. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19754910/),h,32.5,99664,DB00281,Lidocaine
,10051088,clearance (Cl),"The clearance (Cl) was found to be 5.7+/-2.3 ml/kg per min, volume of distribution of the central compartment (Vc) 0.16+/-0.12 l/kg and volume of distribution at steady state (Vss) 1.08+/-0.69 l/kg.",The pharmacokinetics of morphine and lidocaine in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051088/),[ml] / [kg·min],5.7,100220,DB00281,Lidocaine
,10051088,volume of distribution of the central compartment (Vc),"The clearance (Cl) was found to be 5.7+/-2.3 ml/kg per min, volume of distribution of the central compartment (Vc) 0.16+/-0.12 l/kg and volume of distribution at steady state (Vss) 1.08+/-0.69 l/kg.",The pharmacokinetics of morphine and lidocaine in critically ill patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051088/),[l] / [kg],0.16,100221,DB00281,Lidocaine
,10051088,volume of distribution at steady state (Vss),"The clearance (Cl) was found to be 5.7+/-2.3 ml/kg per min, volume of distribution of the central compartment (Vc) 0.16+/-0.12 l/kg and volume of distribution at steady state (Vss) 1.08+/-0.69 l/kg.",The pharmacokinetics of morphine and lidocaine in critically ill patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051088/),[l] / [kg],1.08,100222,DB00281,Lidocaine
,10051088,Cl,"The Cl was 6.9+/-3.8 ml/kg per min, Vc 0.25+/-0.1 l/kg and Vss 0.78+/-0.26 l/kg.",The pharmacokinetics of morphine and lidocaine in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051088/),[ml] / [kg·min],6.9,100223,DB00281,Lidocaine
,10051088,Vc,"The Cl was 6.9+/-3.8 ml/kg per min, Vc 0.25+/-0.1 l/kg and Vss 0.78+/-0.26 l/kg.",The pharmacokinetics of morphine and lidocaine in critically ill patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051088/),[l] / [kg],0.25,100224,DB00281,Lidocaine
,10051088,Vss,"The Cl was 6.9+/-3.8 ml/kg per min, Vc 0.25+/-0.1 l/kg and Vss 0.78+/-0.26 l/kg.",The pharmacokinetics of morphine and lidocaine in critically ill patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051088/),[l] / [kg],0.78,100225,DB00281,Lidocaine
,28881313,flow rate,"After a simple protein precipitation procedure, analysis was performed on an Extend C18 column (100mm×3mm, 3.5μm) by isocratic elution with 0.05% formic acid/acetonitrile (78:22, v/v) at a flow rate of 0.3mL/min.","LC-MS/MS method for preclinical pharmacokinetic study of QX-OH, a novel long-acting local anesthetic, in sciatic nerve blockade in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28881313/),[ml] / [min],0.3,101022,DB00281,Lidocaine
,17341004,"AUC(tau,sd)","After a single dose of 125 mg lidocaine the average extent of exposure in terms of the AUC(tau,sd) during a 6 h dosage interval amounted to 397.7 ng/ml x h (geometric mean).",Proof of systemic safety of a lidocaine ointment in the treatment of patients with anorectal pain. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17341004/),[ng] / [h·ml],397.7,103146,DB00281,Lidocaine
,17341004,"C(max,sd)","C(max,sd) reached a mean value of 131.8 ng/ml (geometric mean).",Proof of systemic safety of a lidocaine ointment in the treatment of patients with anorectal pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17341004/),[ng] / [ml],131.8,103147,DB00281,Lidocaine
,17341004,"AUC(tau,md)","The geometric mean of the AUC(tau,md) (503.8 ng/ml x h, tau = 6 h) and the geometric mean of C(max,md) (145.9 ng/ml) were slightly higher than the corresponding single dose values.",Proof of systemic safety of a lidocaine ointment in the treatment of patients with anorectal pain. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17341004/),[ng] / [h·ml],503.8,103148,DB00281,Lidocaine
,17341004,"C(max,md)","The geometric mean of the AUC(tau,md) (503.8 ng/ml x h, tau = 6 h) and the geometric mean of C(max,md) (145.9 ng/ml) were slightly higher than the corresponding single dose values.",Proof of systemic safety of a lidocaine ointment in the treatment of patients with anorectal pain. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17341004/),[ng] / [ml],145.9,103149,DB00281,Lidocaine
,17341004,AUC accumulation ratio,The AUC accumulation ratio was calculated as 127% (90% CI: 108-148%) and the C(max) accumulation ratio reached 120% (90% CI: 101-139%).,Proof of systemic safety of a lidocaine ointment in the treatment of patients with anorectal pain. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17341004/),%,127,103150,DB00281,Lidocaine
,10379661,flow-rate,The flow-rate was maintained at 0.5 ml min(-1).,Simple liquid chromatographic method for the analysis of the blood brain barrier permeability characteristics of ceftriaxone in an experimental rabbit meningitis model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379661/),[ml] / [min],0.5,103353,DB00281,Lidocaine
,18546903,Ramsay sedation score,"At the start of laryngoscopy, the patient had a Ramsay sedation score of 6.",[Dexmedetomidine infusion for sedation during awake intubation]. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18546903/),,6,103526,DB00281,Lidocaine
,2085708,Terminal half-life,Terminal half-life was 11.0 +/- 2.9 min.,Myocardial uptake of lignocaine: pharmacokinetics and pharmacodynamics in the isolated perfused heart of the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085708/),min,11.0,103733,DB00281,Lidocaine
,2085708,T1/2.12,The unidirectional transfer was slower from central to peripheral compartment than from peripheral to central compartment (T1/2.12 = 42.6 +/- 10.5 min whereas T1/2.21 = 10.7 +/- 2.8 min).,Myocardial uptake of lignocaine: pharmacokinetics and pharmacodynamics in the isolated perfused heart of the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085708/),min,42.6,103734,DB00281,Lidocaine
,2085708,T1/2.21,The unidirectional transfer was slower from central to peripheral compartment than from peripheral to central compartment (T1/2.12 = 42.6 +/- 10.5 min whereas T1/2.21 = 10.7 +/- 2.8 min).,Myocardial uptake of lignocaine: pharmacokinetics and pharmacodynamics in the isolated perfused heart of the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085708/),min,10.7,103735,DB00281,Lidocaine
,2085708,my,The myocardium/perfusate concentration-ratio was 4.7 +/- 0.4.,Myocardial uptake of lignocaine: pharmacokinetics and pharmacodynamics in the isolated perfused heart of the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085708/),,4.7,103736,DB00281,Lidocaine
,2085708,concentration-ratio,The myocardium/perfusate concentration-ratio was 4.7 +/- 0.4.,Myocardial uptake of lignocaine: pharmacokinetics and pharmacodynamics in the isolated perfused heart of the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085708/),,4.7,103737,DB00281,Lidocaine
,2085708,maximum QRS duration (Emax),Calculated maximum QRS duration (Emax) was 77 +/- 8 ms.,Myocardial uptake of lignocaine: pharmacokinetics and pharmacodynamics in the isolated perfused heart of the rabbit. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085708/),ms,77,103738,DB00281,Lidocaine
,2085708,Emax,"Emax was also directly measured in four additional rabbits by infusing ten times the dose of lignocaine used in the main experiment: the value of Emax measured in these conditions was 92.5 +/- 9.6 ms, i.e. a QRS widening of 150%.",Myocardial uptake of lignocaine: pharmacokinetics and pharmacodynamics in the isolated perfused heart of the rabbit. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085708/),ms,92.5,103739,DB00281,Lidocaine
,2085708,steady-state perfusate concentration producing half the effect (C50),The steady-state perfusate concentration producing half the effect (C50) was 15.7 +/- 7.6 micrograms ml-1.,Myocardial uptake of lignocaine: pharmacokinetics and pharmacodynamics in the isolated perfused heart of the rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085708/),[μg] / [ml],15.7,103740,DB00281,Lidocaine
,17296334,limit of quantification (LOQ),"The limit of quantification (LOQ) in dog plasma for lidocaine, MEGX and GX was set at 2.5 ng ml(-1), 20 ng ml(-1) and 200 ng ml(-1), respectively.",Determination of lidocaine and its two N-desethylated metabolites in dog and horse plasma by high-performance liquid chromatography combined with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296334/),[ng] / [ml],2.5,103797,DB00281,Lidocaine
,17296334,limit of quantification (LOQ),"The limit of quantification (LOQ) in dog plasma for lidocaine, MEGX and GX was set at 2.5 ng ml(-1), 20 ng ml(-1) and 200 ng ml(-1), respectively.",Determination of lidocaine and its two N-desethylated metabolites in dog and horse plasma by high-performance liquid chromatography combined with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296334/),[ng] / [ml],20,103798,DB00281,Lidocaine
,17296334,limit of quantification (LOQ),"The limit of quantification (LOQ) in dog plasma for lidocaine, MEGX and GX was set at 2.5 ng ml(-1), 20 ng ml(-1) and 200 ng ml(-1), respectively.",Determination of lidocaine and its two N-desethylated metabolites in dog and horse plasma by high-performance liquid chromatography combined with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296334/),[ng] / [ml],200,103799,DB00281,Lidocaine
,17296334,limit of quantification,"For horse plasma a limit of quantification of 2.5 ng ml(-1), 5 ng ml(-1) and 200 ng ml(-1) was achieved for lidocaine, MEGX and GX, respectively.",Determination of lidocaine and its two N-desethylated metabolites in dog and horse plasma by high-performance liquid chromatography combined with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296334/),[ng] / [ml],2.5,103800,DB00281,Lidocaine
,17296334,limit of quantification,"For horse plasma a limit of quantification of 2.5 ng ml(-1), 5 ng ml(-1) and 200 ng ml(-1) was achieved for lidocaine, MEGX and GX, respectively.",Determination of lidocaine and its two N-desethylated metabolites in dog and horse plasma by high-performance liquid chromatography combined with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296334/),[ng] / [ml],5,103801,DB00281,Lidocaine
,17296334,limit of quantification,"For horse plasma a limit of quantification of 2.5 ng ml(-1), 5 ng ml(-1) and 200 ng ml(-1) was achieved for lidocaine, MEGX and GX, respectively.",Determination of lidocaine and its two N-desethylated metabolites in dog and horse plasma by high-performance liquid chromatography combined with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296334/),[ng] / [ml],200,103802,DB00281,Lidocaine
,17296334,limit of detection (LOD),"In dog plasma, the limit of detection (LOD) was found to be 0.8 ng ml(-1), 2.3 ng ml(-1) and 55 ng ml(-1) for lidocaine, MEGX and GX, respectively.",Determination of lidocaine and its two N-desethylated metabolites in dog and horse plasma by high-performance liquid chromatography combined with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296334/),[ng] / [ml],0.8,103803,DB00281,Lidocaine
,17296334,limit of detection (LOD),"In dog plasma, the limit of detection (LOD) was found to be 0.8 ng ml(-1), 2.3 ng ml(-1) and 55 ng ml(-1) for lidocaine, MEGX and GX, respectively.",Determination of lidocaine and its two N-desethylated metabolites in dog and horse plasma by high-performance liquid chromatography combined with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296334/),[ng] / [ml],2.3,103804,DB00281,Lidocaine
,17296334,limit of detection (LOD),"In dog plasma, the limit of detection (LOD) was found to be 0.8 ng ml(-1), 2.3 ng ml(-1) and 55 ng ml(-1) for lidocaine, MEGX and GX, respectively.",Determination of lidocaine and its two N-desethylated metabolites in dog and horse plasma by high-performance liquid chromatography combined with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296334/),[ng] / [ml],55,103805,DB00281,Lidocaine
,17296334,LOD's,"In horse plasma the LOD's found for lidocaine, MEGX and GX, were 1.1 ng ml(-1), 0.5 ng ml(-1) and 13 ng ml(-1), respectively.",Determination of lidocaine and its two N-desethylated metabolites in dog and horse plasma by high-performance liquid chromatography combined with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296334/),[ng] / [ml],1.1,103806,DB00281,Lidocaine
,17296334,LOD's,"In horse plasma the LOD's found for lidocaine, MEGX and GX, were 1.1 ng ml(-1), 0.5 ng ml(-1) and 13 ng ml(-1), respectively.",Determination of lidocaine and its two N-desethylated metabolites in dog and horse plasma by high-performance liquid chromatography combined with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296334/),[ng] / [ml],0.5,103807,DB00281,Lidocaine
,17296334,LOD's,"In horse plasma the LOD's found for lidocaine, MEGX and GX, were 1.1 ng ml(-1), 0.5 ng ml(-1) and 13 ng ml(-1), respectively.",Determination of lidocaine and its two N-desethylated metabolites in dog and horse plasma by high-performance liquid chromatography combined with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296334/),[ng] / [ml],13,103808,DB00281,Lidocaine
,9627591,formation,"MEGX formation at 15 minutes was decreased in patients with sickle cell disease compared with formation in the control subjects (39.9 +/- 18.0 vs 65.6 +/- 50.0 micrograms/L, respectively, p < 0.02).",Hepatic function as assessed by lidocaine metabolism in sickle cell disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9627591/),[μg] / [l],39.9,104484,DB00281,Lidocaine
,9627591,formation,"MEGX formation at 15 minutes was decreased in patients with sickle cell disease compared with formation in the control subjects (39.9 +/- 18.0 vs 65.6 +/- 50.0 micrograms/L, respectively, p < 0.02).",Hepatic function as assessed by lidocaine metabolism in sickle cell disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9627591/),[μg] / [l],65.6,104485,DB00281,Lidocaine
,9627591,volume of distribution,"The volume of distribution of ICG was increased in patients with sickle cell disease compared with that in the control subjects (0.21 +/- 0.09 vs 0.11 +/- 0.03 L/kg, p < 0.01).",Hepatic function as assessed by lidocaine metabolism in sickle cell disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9627591/),[l] / [kg],0.21,104486,DB00281,Lidocaine
,9627591,volume of distribution,"The volume of distribution of ICG was increased in patients with sickle cell disease compared with that in the control subjects (0.21 +/- 0.09 vs 0.11 +/- 0.03 L/kg, p < 0.01).",Hepatic function as assessed by lidocaine metabolism in sickle cell disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9627591/),[l] / [kg],0.11,104487,DB00281,Lidocaine
,9627591,half-life,The ICG half-life was similar in both groups (3.8 +/- 1.5 vs 3.1 +/- 1.0 min).,Hepatic function as assessed by lidocaine metabolism in sickle cell disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9627591/),min,3.8,104488,DB00281,Lidocaine
,9627591,half-life,The ICG half-life was similar in both groups (3.8 +/- 1.5 vs 3.1 +/- 1.0 min).,Hepatic function as assessed by lidocaine metabolism in sickle cell disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9627591/),min,3.1,104489,DB00281,Lidocaine
,9627591,Hepatic blood flow,"Hepatic blood flow, derived from ICG clearance, was increased in sickle cell patients compared with that of the control subjects (12.2 +/- 4.5 vs 8.1 +/- 2.1 ml/kg/min, p < 0.01).",Hepatic function as assessed by lidocaine metabolism in sickle cell disease. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9627591/),[ml] / [kg·min],12.2,104490,DB00281,Lidocaine
,9627591,Hepatic blood flow,"Hepatic blood flow, derived from ICG clearance, was increased in sickle cell patients compared with that of the control subjects (12.2 +/- 4.5 vs 8.1 +/- 2.1 ml/kg/min, p < 0.01).",Hepatic function as assessed by lidocaine metabolism in sickle cell disease. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9627591/),[ml] / [kg·min],8.1,104491,DB00281,Lidocaine
,10077095,Maximum tissue pressure,"Maximum tissue pressure during injection was 339 +/- 63 mmHg and 27 +/- 9 mmHg using high- and low-pressure techniques, respectively.",The tumescent technique: the effect of high tissue pressure and dilute epinephrine on absorption of lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10077095/),mmhg,339,104894,DB00281,Lidocaine
,10077095,Maximum tissue pressure,"Maximum tissue pressure during injection was 339 +/- 63 mmHg and 27 +/- 9 mmHg using high- and low-pressure techniques, respectively.",The tumescent technique: the effect of high tissue pressure and dilute epinephrine on absorption of lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10077095/),mmhg,27,104895,DB00281,Lidocaine
greater,10077095,Peak plasma concentrations,Peak plasma concentrations greater than 1 mcg/ml were seen in 11 subjects.,The tumescent technique: the effect of high tissue pressure and dilute epinephrine on absorption of lidocaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10077095/),[mcg] / [ml],1,104896,DB00281,Lidocaine
>,16691409,maximal lidocaine plasma concentrations,In most of the treatments (13 out of 20) maximal lidocaine plasma concentrations were >9 mg/L.,Development of an optimal lidocaine infusion strategy for neonatal seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16691409/),[mg] / [l],9,105302,DB00281,Lidocaine
<,16691409,maximal lidocaine plasma concentrations,"Secondly, we developed the optimal dosing regimen, which was defined as an infusion regimen at which maximal lidocaine plasma concentrations are <9 mg/L.",Development of an optimal lidocaine infusion strategy for neonatal seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16691409/),[mg] / [l],9,105303,DB00281,Lidocaine
<,16691409,maximal lidocaine plasma concentrations,In most of the treatments (11 out of 16) maximal lidocaine plasma concentrations were <9 mg/L.,Development of an optimal lidocaine infusion strategy for neonatal seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16691409/),[mg] / [l],9,105304,DB00281,Lidocaine
,15277825,peak (maximal) concentration,The peak (maximal) concentration of lidocaine plus monoethylglycinexylidide was 2.2 to 2.7 microg/ml.,Pharmacokinetics and safety of lidocaine and monoethylglycinexylidide in liposuction: a microdialysis study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15277825/),[μg] / [ml],2.2 to 2.7,105786,DB00281,Lidocaine
,15277825,Time to peak lid,Time to peak lidocaine plus monoethylglycinexylidide was 8 to 28 hours after infiltration began.,Pharmacokinetics and safety of lidocaine and monoethylglycinexylidide in liposuction: a microdialysis study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15277825/),h,8 to 28,105787,DB00281,Lidocaine
,11403247,oxygen saturation,Mean oxygen saturation was 98.9 +/- 0.01%.,Safety and pharmacokinetics of EMLA in the treatment of postburn pruritus in pediatric patients: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11403247/),%,98.9,107650,DB00281,Lidocaine
,2050177,apparent volume of distribution at steady state,"The apparent volume of distribution at steady state was 1.48 l.kg-1, the absorption rate constant was 2.2 h-1, and plasma protein binding was 26.8% in subjects with normal renal function.","Pharmacokinetics of SUN 1165, a new antiarrhythmic agent, in renal dysfunction. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050177/),[l] / [kg],1.48,107775,DB00281,Lidocaine
,2050177,absorption rate constant,"The apparent volume of distribution at steady state was 1.48 l.kg-1, the absorption rate constant was 2.2 h-1, and plasma protein binding was 26.8% in subjects with normal renal function.","Pharmacokinetics of SUN 1165, a new antiarrhythmic agent, in renal dysfunction. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050177/),1/[h],2.2,107776,DB00281,Lidocaine
,2050177,plasma protein binding,"The apparent volume of distribution at steady state was 1.48 l.kg-1, the absorption rate constant was 2.2 h-1, and plasma protein binding was 26.8% in subjects with normal renal function.","Pharmacokinetics of SUN 1165, a new antiarrhythmic agent, in renal dysfunction. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050177/),%,26.8,107777,DB00281,Lidocaine
,2050177,half-time of elimination,The half-time of elimination was 3.4 h in normal subjects and it was prolonged to 23.7 h in severe renal failure (creatinine clearance below 20 ml.min-1.1.48 m-2).,"Pharmacokinetics of SUN 1165, a new antiarrhythmic agent, in renal dysfunction. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050177/),h,3.4,107778,DB00281,Lidocaine
,2050177,half-time of elimination,The half-time of elimination was 3.4 h in normal subjects and it was prolonged to 23.7 h in severe renal failure (creatinine clearance below 20 ml.min-1.1.48 m-2).,"Pharmacokinetics of SUN 1165, a new antiarrhythmic agent, in renal dysfunction. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050177/),h,23.7,107779,DB00281,Lidocaine
,8745970,Cmax,The Cmax was 859 +/- 503 ng.,[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),ng,859,108253,DB00281,Lidocaine
,8745970,Tmax,mL-1 after a Tmax to 47 +/- 17 min.,[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),min,47,108254,DB00281,Lidocaine
,8745970,elimination half-life,The mean elimination half-life was 87 +/- 19 min (mean +/- SD).,[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),min,87,108255,DB00281,Lidocaine
,8745970,total clearance,"The total clearance and the volume of distribution were respectively 4,521 +/- 1,858 mL.min-1 and 568 +/- 273 L.",[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),[ml] / [min],"4,521",108256,DB00281,Lidocaine
,8745970,volume of distribution,"The total clearance and the volume of distribution were respectively 4,521 +/- 1,858 mL.min-1 and 568 +/- 273 L.",[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),l,568,108257,DB00281,Lidocaine
,32622712,concentrations,Lidocaine concentrations ranged from 0.50- to- 1.68 μg/mL in the CPB group and 0.86- to- 2.07 μg/mL in the no- CPB group.,Systemic Absorption of Lidocaine from Continuous Erector Spinae Plane Catheters After Congenital Cardiac Surgery: A Retrospective Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32622712/),[μg] / [ml],0.50,109648,DB00281,Lidocaine
,32622712,peak level,"There was a normally distributed overall mean peak level of 1.818 ± standard deviation of 0.624 μg/mL, with 95% confidence interval of 0.57- to- 3.06 μg/mL.",Systemic Absorption of Lidocaine from Continuous Erector Spinae Plane Catheters After Congenital Cardiac Surgery: A Retrospective Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32622712/),[μg] / [ml],1.818,109649,DB00281,Lidocaine
,3740386,elimination rate constant k10,The elimination rate constant k10 was significantly lower in Group 1 (3-16 days) than all other groups and Group 2 (37-57 days) was lower than Group 4 (178-191 days).,The influence of age on lignocaine pharmacokinetics in young puppies. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740386/),d,3-16,109870,DB00281,Lidocaine
,3740386,elimination rate constant k10,The elimination rate constant k10 was significantly lower in Group 1 (3-16 days) than all other groups and Group 2 (37-57 days) was lower than Group 4 (178-191 days).,The influence of age on lignocaine pharmacokinetics in young puppies. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740386/),d,37-57,109871,DB00281,Lidocaine
,3740386,elimination rate constant k10,The elimination rate constant k10 was significantly lower in Group 1 (3-16 days) than all other groups and Group 2 (37-57 days) was lower than Group 4 (178-191 days).,The influence of age on lignocaine pharmacokinetics in young puppies. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740386/),d,178-191,109872,DB00281,Lidocaine
,21256961,AUC,"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],3058 to 3447,110524,DB00281,Lidocaine
,21256961,T(max),"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),h,∼6,110525,DB00281,Lidocaine
,21256961,T(max),"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),h,.0,110526,DB00281,Lidocaine
,21256961,C(max),"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[mg] / [ml],168 to 265,110527,DB00281,Lidocaine
,21256961,T(max),"Generally, the addition of polysorbate 80 shortened the time to reach C(max) (T(max) ranged 1.3-4.5h), but had limited effect on the bioavailability from F6H8 or MCT in combination with polysorbate 80 (4:1) (AUC ranged from 3807 to 4403 (hng/ml)).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),h,1.3-4.5,110528,DB00281,Lidocaine
,21256961,AUC,"Generally, the addition of polysorbate 80 shortened the time to reach C(max) (T(max) ranged 1.3-4.5h), but had limited effect on the bioavailability from F6H8 or MCT in combination with polysorbate 80 (4:1) (AUC ranged from 3807 to 4403 (hng/ml)).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],3807 to 4403,110529,DB00281,Lidocaine
,21256961,AUC,"Although a synergistic effect was obtained with halofantrine in F6H8:MCT:polysorbate 80 (2:2:1) (AUC 5574±675hng/ml; mean±SEM), it was not superior to dosing halofantrine in pure polysorbarte 80 (AUC 7370±579hng/ml; mean±SEM).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],5574,110530,DB00281,Lidocaine
,21256961,AUC,"Although a synergistic effect was obtained with halofantrine in F6H8:MCT:polysorbate 80 (2:2:1) (AUC 5574±675hng/ml; mean±SEM), it was not superior to dosing halofantrine in pure polysorbarte 80 (AUC 7370±579hng/ml; mean±SEM).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],7370,110531,DB00281,Lidocaine
,2709609,lung uptake,"After general anesthesia with thiamylal, enflurane, nitrous oxide and oxygen, the lung uptake was 30 approximately 40% following initial and additional administrations.",[Pharmacokinetics and the lung uptake of lidocaine during epidural anesthesia]. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2709609/),%,40,110647,DB00281,Lidocaine
,19151302,onset,The onset of bupivacaine-lidocaine was 16 +/- 9 min versus 28 +/- 12 min for bupivacaine alone.,"A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151302/),min,16,110784,DB00281,Lidocaine
,19151302,onset,The onset of bupivacaine-lidocaine was 16 +/- 9 min versus 28 +/- 12 min for bupivacaine alone.,"A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151302/),min,28,110785,DB00281,Lidocaine
,19151302,onset,The onset of ropivacaine-lidocaine was 16 +/- 12 min versus 23 +/- 12 for ropivacaine alone.,"A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151302/),min,16,110786,DB00281,Lidocaine
,19151302,onset,The onset of ropivacaine-lidocaine was 16 +/- 12 min versus 23 +/- 12 for ropivacaine alone.,"A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151302/),,23,110787,DB00281,Lidocaine
,17898657,peak concentration,"Pharmacokinetic analysis was peak concentration 1.41 +/- 0.4 microg/mL, time to reach peak concentration 9.3 +/- 1.6 hours, terminal half-life 6.2 +/- 1.5 hours, area under the curve from time zero to last data point 1379.8 +/- 470 microg/min/mL, and area under the curve from time zero to infinity 1530.6 +/- 471.6 microg/min/mL.",Pharmacokinetics of high-dose diluted lidocaine in local anesthesia for facelift procedures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898657/),[μg] / [ml],1.41,111384,DB00281,Lidocaine
,17898657,time to reach peak concentration,"Pharmacokinetic analysis was peak concentration 1.41 +/- 0.4 microg/mL, time to reach peak concentration 9.3 +/- 1.6 hours, terminal half-life 6.2 +/- 1.5 hours, area under the curve from time zero to last data point 1379.8 +/- 470 microg/min/mL, and area under the curve from time zero to infinity 1530.6 +/- 471.6 microg/min/mL.",Pharmacokinetics of high-dose diluted lidocaine in local anesthesia for facelift procedures. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898657/),h,9.3,111385,DB00281,Lidocaine
,17898657,terminal half-life,"Pharmacokinetic analysis was peak concentration 1.41 +/- 0.4 microg/mL, time to reach peak concentration 9.3 +/- 1.6 hours, terminal half-life 6.2 +/- 1.5 hours, area under the curve from time zero to last data point 1379.8 +/- 470 microg/min/mL, and area under the curve from time zero to infinity 1530.6 +/- 471.6 microg/min/mL.",Pharmacokinetics of high-dose diluted lidocaine in local anesthesia for facelift procedures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898657/),h,6.2,111386,DB00281,Lidocaine
,17898657,area under the curve from time zero to last data point,"Pharmacokinetic analysis was peak concentration 1.41 +/- 0.4 microg/mL, time to reach peak concentration 9.3 +/- 1.6 hours, terminal half-life 6.2 +/- 1.5 hours, area under the curve from time zero to last data point 1379.8 +/- 470 microg/min/mL, and area under the curve from time zero to infinity 1530.6 +/- 471.6 microg/min/mL.",Pharmacokinetics of high-dose diluted lidocaine in local anesthesia for facelift procedures. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898657/),[μg] / [min·ml],1379.8,111387,DB00281,Lidocaine
,17898657,area under the curve from time zero to infinity,"Pharmacokinetic analysis was peak concentration 1.41 +/- 0.4 microg/mL, time to reach peak concentration 9.3 +/- 1.6 hours, terminal half-life 6.2 +/- 1.5 hours, area under the curve from time zero to last data point 1379.8 +/- 470 microg/min/mL, and area under the curve from time zero to infinity 1530.6 +/- 471.6 microg/min/mL.",Pharmacokinetics of high-dose diluted lidocaine in local anesthesia for facelift procedures. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898657/),[μg] / [min·ml],1530.6,111388,DB00281,Lidocaine
,27382279,entrapment efficiency,"Particle size and entrapment efficiency of the optimized SLN ""S8"" were determined as 98.23 nm and 84.36%, respectively.",Development of transmucosal patch loaded with anesthetic and analgesic for dental procedures and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27382279/),%,84.36,111749,DB00281,Lidocaine
,6629320,systemic availability,Lidocaine systemic availability was also found to vary widely from 0.2 to 1.0.,Determinants of drug disposition in patients with cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6629320/),,0.2,112407,DB00281,Lidocaine
,6629320,systemic availability,Lidocaine systemic availability was also found to vary widely from 0.2 to 1.0.,Determinants of drug disposition in patients with cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6629320/),,1.0,112408,DB00281,Lidocaine
less,6629320,f,"In 28 patients, f was less than 0.1 indicating minimal extrahepatic shunting and in these patients, lidocaine systemic availability was related to its intrinsic clearance (r = -0.717, p less than 0.001); in the 25 other patients with significant extrahepatic shunting (f greater than 0.1), the extent of lidocaine systemic availability was related to both intrinsic clearance (r = -0.819, p less than 0.001) and extrahepatic shunting (r = 0.913, p less than 0.001).",Determinants of drug disposition in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6629320/),,0.1,112409,DB00281,Lidocaine
greater,6629320,f,"In 28 patients, f was less than 0.1 indicating minimal extrahepatic shunting and in these patients, lidocaine systemic availability was related to its intrinsic clearance (r = -0.717, p less than 0.001); in the 25 other patients with significant extrahepatic shunting (f greater than 0.1), the extent of lidocaine systemic availability was related to both intrinsic clearance (r = -0.819, p less than 0.001) and extrahepatic shunting (r = 0.913, p less than 0.001).",Determinants of drug disposition in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6629320/),,0.1,112410,DB00281,Lidocaine
,12224866,maximum plasma concentration,"In the other 4 cats, the median maximum plasma concentration was 149.5 ng/ml, the median time to maximum plasma concentration was 2 hours, and the median area under the concentration versus time curve from zero to infinity was 1014.5 ng.h/ml.",Transdermal absorption of a liposome-encapsulated formulation of lidocaine following topical administration in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12224866/),[ng] / [ml],149.5,112915,DB00281,Lidocaine
,12224866,time to maximum plasma concentration,"In the other 4 cats, the median maximum plasma concentration was 149.5 ng/ml, the median time to maximum plasma concentration was 2 hours, and the median area under the concentration versus time curve from zero to infinity was 1014.5 ng.h/ml.",Transdermal absorption of a liposome-encapsulated formulation of lidocaine following topical administration in cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12224866/),h,2,112916,DB00281,Lidocaine
,12224866,area under the concentration versus time curve from zero to infinity,"In the other 4 cats, the median maximum plasma concentration was 149.5 ng/ml, the median time to maximum plasma concentration was 2 hours, and the median area under the concentration versus time curve from zero to infinity was 1014.5 ng.h/ml.",Transdermal absorption of a liposome-encapsulated formulation of lidocaine following topical administration in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12224866/),[h·ng] / [ml],1014.5,112917,DB00281,Lidocaine
,1296183,%Qa,The mean %Qa for patients with Child A cirrhosis was significantly higher than that for 8 healthy subjects (34.8 +/- 7.9% vs 18.1 +/- 4.0; P < 0.01).,Clinical utility of quantitative assessment of liver haemodynamics in cirrhosis provided by dynamic hepatoscintigraphy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1296183/),%,34.8,113628,DB00281,Lidocaine
,1296183,%Qa,The mean %Qa for patients with Child A cirrhosis was significantly higher than that for 8 healthy subjects (34.8 +/- 7.9% vs 18.1 +/- 4.0; P < 0.01).,Clinical utility of quantitative assessment of liver haemodynamics in cirrhosis provided by dynamic hepatoscintigraphy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1296183/),,18.1,113629,DB00281,Lidocaine
,3780330,peak plasma concentration,The results were that the peak plasma concentration after the bolus during mechanical ventilation was 3.22 +/- 0.37 mg/L (mean +/- SE) vs 2.40 +/- 0.35 mg/L during spontaneous ventilation (p less than 0.02).,Effect of mechanical ventilation on hepatic drug pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780330/),[mg] / [l],3.22,113953,DB00281,Lidocaine
,3780330,peak plasma concentration,The results were that the peak plasma concentration after the bolus during mechanical ventilation was 3.22 +/- 0.37 mg/L (mean +/- SE) vs 2.40 +/- 0.35 mg/L during spontaneous ventilation (p less than 0.02).,Effect of mechanical ventilation on hepatic drug pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780330/),[mg] / [l],2.40,113954,DB00281,Lidocaine
,3780330,Steady-state plasma concentration,Steady-state plasma concentration during mechanical ventilation was 2.10 +/- 0.20 mg/L vs 1.64 +/- 0.16 mg/L during spontaneous ventilation (p less than 0.01).,Effect of mechanical ventilation on hepatic drug pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780330/),[mg] / [l],2.10,113955,DB00281,Lidocaine
,3780330,Steady-state plasma concentration,Steady-state plasma concentration during mechanical ventilation was 2.10 +/- 0.20 mg/L vs 1.64 +/- 0.16 mg/L during spontaneous ventilation (p less than 0.01).,Effect of mechanical ventilation on hepatic drug pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780330/),[mg] / [l],1.64,113956,DB00281,Lidocaine
,3780330,Total clearance,Total clearance was 604.2 +/- 87.0 ml/min during mechanical ventilation vs 775.0 +/- 112.1 ml/min during spontaneous ventilation (p less than 0.01).,Effect of mechanical ventilation on hepatic drug pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780330/),[ml] / [min],604.2,113957,DB00281,Lidocaine
,3780330,Total clearance,Total clearance was 604.2 +/- 87.0 ml/min during mechanical ventilation vs 775.0 +/- 112.1 ml/min during spontaneous ventilation (p less than 0.01).,Effect of mechanical ventilation on hepatic drug pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780330/),[ml] / [min],775.0,113958,DB00281,Lidocaine
,3780330,Elimination half-life,Elimination half-life was 245.2 +/- 50.6 minutes during mechanical ventilation vs 160.0 +/- 40.6 minutes during spontaneous ventilation (p less than 0.05).,Effect of mechanical ventilation on hepatic drug pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780330/),min,245.2,113959,DB00281,Lidocaine
,3780330,Elimination half-life,Elimination half-life was 245.2 +/- 50.6 minutes during mechanical ventilation vs 160.0 +/- 40.6 minutes during spontaneous ventilation (p less than 0.05).,Effect of mechanical ventilation on hepatic drug pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780330/),min,160.0,113960,DB00281,Lidocaine
,3780330,Distribution volume,Distribution volume was 188.6 +/- 50.2 L during mechanical ventilation and 183.0 +/- 50.8 L during spontaneous ventilation (not significant).,Effect of mechanical ventilation on hepatic drug pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780330/),l,188.6,113961,DB00281,Lidocaine
,3780330,Distribution volume,Distribution volume was 188.6 +/- 50.2 L during mechanical ventilation and 183.0 +/- 50.8 L during spontaneous ventilation (not significant).,Effect of mechanical ventilation on hepatic drug pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780330/),l,183.0,113962,DB00281,Lidocaine
,3729087,greatest concentrations,The greatest concentrations observed between 15 and 30 min after the injection were of 2.40 +/- 0.86 micrograms .,[Plasma determination of lidocaine and bupivacaine after caudal anesthesia in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3729087/),μg,2.40,114322,DB00281,Lidocaine
,453562,elimination half-lives,"The elimination half-lives of lidocaine in the bloods of nonpregnant ewe, neonate and fetus were 31, 51 and 33 min, respectively.",Pharmacokinetics of lidocaine in fetal and neonatal lambs and adult sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/453562/),min,31,114818,DB00281,Lidocaine
,453562,elimination half-lives,"The elimination half-lives of lidocaine in the bloods of nonpregnant ewe, neonate and fetus were 31, 51 and 33 min, respectively.",Pharmacokinetics of lidocaine in fetal and neonatal lambs and adult sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/453562/),min,51,114819,DB00281,Lidocaine
,453562,elimination half-lives,"The elimination half-lives of lidocaine in the bloods of nonpregnant ewe, neonate and fetus were 31, 51 and 33 min, respectively.",Pharmacokinetics of lidocaine in fetal and neonatal lambs and adult sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/453562/),min,33,114820,DB00281,Lidocaine
,453562,Total-body clearances,Total-body clearances in the neonate and adult were 53 and 41 ml/min/kg.,Pharmacokinetics of lidocaine in fetal and neonatal lambs and adult sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/453562/),[ml] / [kg·min],53,114821,DB00281,Lidocaine
,453562,Total-body clearances,Total-body clearances in the neonate and adult were 53 and 41 ml/min/kg.,Pharmacokinetics of lidocaine in fetal and neonatal lambs and adult sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/453562/),[ml] / [kg·min],41,114822,DB00281,Lidocaine
,23394846,duration of,The duration of anaesthesia was 86.9 ± 66.0 min with the LIDO-BUPI combination.,"Comparing lidocaine, bupivacaine and a lidocaine-bupivacaine mixture as a metacarpal block in sheep. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23394846/),min,86.9,117304,DB00281,Lidocaine
,10551971,elimination half-life,The calculated elimination half-life was 10.2 h and the molecule and/or its metabolites were found up to 90 h after ingestion.,Orphenadrine poisoning in a child: clinical and analytical data. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551971/),h,10.2,119192,DB00281,Lidocaine
,11578889,peak plasma concentrations,The highest peak plasma concentrations of lidocaine were 5.02 and 6.28 microg.,Absorption of lidocaine during aspiration anesthesia of the airway. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11578889/),μg,5.02,120420,DB00281,Lidocaine
,11578889,peak plasma concentrations,The highest peak plasma concentrations of lidocaine were 5.02 and 6.28 microg.,Absorption of lidocaine during aspiration anesthesia of the airway. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11578889/),μg,6.28,120421,DB00281,Lidocaine
,23357844,Xu0-24h,Mean Xu0-24h values were 114.03 ±23.13 mg and 55.22 ±9.73 mg for clodronate 200 mg and 100 mg.,"Pharmacokinetic and tolerability of i.m. disodium clodronate 200 mg/lidocaine 1%, given twice monthly, in comparison with i.m. disodium clodronate 100 mg/lidocaine 1%, given weekly, in healthy postmenopausal female patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357844/),mg,114.03,120680,DB00281,Lidocaine
,23357844,Xu0-24h,Mean Xu0-24h values were 114.03 ±23.13 mg and 55.22 ±9.73 mg for clodronate 200 mg and 100 mg.,"Pharmacokinetic and tolerability of i.m. disodium clodronate 200 mg/lidocaine 1%, given twice monthly, in comparison with i.m. disodium clodronate 100 mg/lidocaine 1%, given weekly, in healthy postmenopausal female patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23357844/),mg,55.22,120681,DB00281,Lidocaine
below,6510884,peak concentrations,"During epidural anesthesia of longer duration (maximum 11 h), the peak concentrations remained below 5 micrograms/ml which was seen after the 9th supplementation.",[Pharmacokinetic study on the lidocaine concentration in serum during epidural anesthesia]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510884/),[μg] / [ml],5,121773,DB00281,Lidocaine
,9915145,apparent volume of distribution,Mean apparent volume of distribution was 0.77+/-0.02 litre kg(-1) and the harmonic mean half-life was three hours.,"Pharmacokinetics of oxytetracycline after intramuscular administration with lidocaine in sheep, comparison with a conventional formulation. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9915145/),[l] / [kg],0.77,122574,DB00281,Lidocaine
,9915145,half-life,Mean apparent volume of distribution was 0.77+/-0.02 litre kg(-1) and the harmonic mean half-life was three hours.,"Pharmacokinetics of oxytetracycline after intramuscular administration with lidocaine in sheep, comparison with a conventional formulation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9915145/),h,three,122575,DB00281,Lidocaine
,9915145,half-lives,"After intramuscular administrations of both formulations, half-lives were longer than after intravenous administration (mean values of 14.1 and 58.2 hours for T-100 and OTC-L respectively).","Pharmacokinetics of oxytetracycline after intramuscular administration with lidocaine in sheep, comparison with a conventional formulation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9915145/),h,14.1,122576,DB00281,Lidocaine
,9915145,half-lives,"After intramuscular administrations of both formulations, half-lives were longer than after intravenous administration (mean values of 14.1 and 58.2 hours for T-100 and OTC-L respectively).","Pharmacokinetics of oxytetracycline after intramuscular administration with lidocaine in sheep, comparison with a conventional formulation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9915145/),h,58.2,122577,DB00281,Lidocaine
,9915145,minimum inhibitory concentration,OTC-L provided therapeutic plasma concentrations over 0.5 microg ml(-1) (the minimum inhibitory concentration for most susceptible pathogens) for a longer period of time than T-100 (72 hours compared with 36 or 48 hours).,"Pharmacokinetics of oxytetracycline after intramuscular administration with lidocaine in sheep, comparison with a conventional formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9915145/),[μg] / [ml],0.5,122578,DB00281,Lidocaine
,2568441,absorption half-life,The mean absorption half-life was approximately 7 min and the mean bioavailability was slightly in excess of 100%.,Pharmacokinetics of quinacrine after intrapleural instillation in rabbits and man. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568441/),min,7,125120,DB00281,Lidocaine
excess,2568441,bioavailability,The mean absorption half-life was approximately 7 min and the mean bioavailability was slightly in excess of 100%.,Pharmacokinetics of quinacrine after intrapleural instillation in rabbits and man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2568441/),%,100,125121,DB00281,Lidocaine
,9108647,detection limit,A detection limit of 0.005 microgram/ml for lidocaine and nonglucuronidated metabolites and 0.01 microgram/ml for glucuronidated metabolites was achieved.,An improved method for the measurement of lidocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9108647/),[μg] / [ml],0.005,126384,DB00281,Lidocaine
,9108647,detection limit,A detection limit of 0.005 microgram/ml for lidocaine and nonglucuronidated metabolites and 0.01 microgram/ml for glucuronidated metabolites was achieved.,An improved method for the measurement of lidocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9108647/),[μg] / [ml],0.01,126385,DB00281,Lidocaine
,32868484,Tmax,Tmax was 5 min for all the patients.,Pharmacokinetics of lidocaine after bilateral ESP block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32868484/),min,5,127965,DB00281,Lidocaine
,32868484,Cmax,Cmax ranged from 1.2 to 3.8 mg/L (mean: 2.59 mg/L).,Pharmacokinetics of lidocaine after bilateral ESP block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32868484/),[mg] / [l],2.59,127966,DB00281,Lidocaine
,32868484,AUC0-3,"AUC0-3 was high (76%, on average) suggesting an almost complete bioavailability.",Pharmacokinetics of lidocaine after bilateral ESP block. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32868484/),%,76,127967,DB00281,Lidocaine
,658111,t1/2,"Neonates had prolonged t1/2 (neonate mean: 3.16 h; adult mean: 1.80 h), and an increased total volume of distribution (neonate mean: 2.75 l/kg; adult mean: 1.11 l/kg) compared with adults.",The pharmacokinetics and metabolism of the anilide local anaesthetics in neonates. I. Lignocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/658111/),h,3.16,128037,DB00281,Lidocaine
,658111,t1/2,"Neonates had prolonged t1/2 (neonate mean: 3.16 h; adult mean: 1.80 h), and an increased total volume of distribution (neonate mean: 2.75 l/kg; adult mean: 1.11 l/kg) compared with adults.",The pharmacokinetics and metabolism of the anilide local anaesthetics in neonates. I. Lignocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/658111/),h,1.80,128038,DB00281,Lidocaine
,658111,total volume of distribution,"Neonates had prolonged t1/2 (neonate mean: 3.16 h; adult mean: 1.80 h), and an increased total volume of distribution (neonate mean: 2.75 l/kg; adult mean: 1.11 l/kg) compared with adults.",The pharmacokinetics and metabolism of the anilide local anaesthetics in neonates. I. Lignocaine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/658111/),[l] / [kg],2.75,128039,DB00281,Lidocaine
,658111,total volume of distribution,"Neonates had prolonged t1/2 (neonate mean: 3.16 h; adult mean: 1.80 h), and an increased total volume of distribution (neonate mean: 2.75 l/kg; adult mean: 1.11 l/kg) compared with adults.",The pharmacokinetics and metabolism of the anilide local anaesthetics in neonates. I. Lignocaine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/658111/),[l] / [kg],1.11,128040,DB00281,Lidocaine
,658111,Total plasma clearance (Cltp),Total plasma clearance (Cltp) normalised on body weight showed no significant difference between neonates (mean: 0.610 l/h/kg) and adults (mean: 0.550 l/h/kg).,The pharmacokinetics and metabolism of the anilide local anaesthetics in neonates. I. Lignocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/658111/),[l] / [h·kg],0.610,128041,DB00281,Lidocaine
,658111,Total plasma clearance (Cltp),Total plasma clearance (Cltp) normalised on body weight showed no significant difference between neonates (mean: 0.610 l/h/kg) and adults (mean: 0.550 l/h/kg).,The pharmacokinetics and metabolism of the anilide local anaesthetics in neonates. I. Lignocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/658111/),[l] / [h·kg],0.550,128042,DB00281,Lidocaine
,6498050,Peak plasma concentration,Peak plasma concentration was 2.05 +/- 0.08 micrograms ml-1 and occurred at 28.2 +/- 2.9 min after administration.,Pharmacokinetics of lignocaine in children following caudal anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498050/),[μg] / [ml],2.05,132419,DB00281,Lidocaine
,6498050,half-life of elimination,"Pharmacokinetic parameters determined from a two-compartmental model were similar to those observed after the i.v. or extradural administration of lignocaine in adults, except for a longer half-life of elimination (155 +/- 32 min).",Pharmacokinetics of lignocaine in children following caudal anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498050/),min,155,132420,DB00281,Lidocaine
,6498050,total body clearance,"Since the total body clearance of lignocaine was similar in children (15.4 +/- 1.2 ml min-1 kg-1) to that in adults, the longer half-life of elimination was attributed to a larger volume of distribution in the children (3.05 +/- 0.40 litre kg-1).",Pharmacokinetics of lignocaine in children following caudal anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498050/),[ml] / [kg·min],15.4,132421,DB00281,Lidocaine
,6498050,volume of distribution,"Since the total body clearance of lignocaine was similar in children (15.4 +/- 1.2 ml min-1 kg-1) to that in adults, the longer half-life of elimination was attributed to a larger volume of distribution in the children (3.05 +/- 0.40 litre kg-1).",Pharmacokinetics of lignocaine in children following caudal anaesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498050/),[l] / [kg],3.05,132422,DB00281,Lidocaine
,7434856,systemic clearance of,The systemic clearance of Lidocain (Cli.v. = Di.v. divided by AUCi.v.) was significantly increased on ANIT-cholestasis (17 +/- 3) and GalN-hepatitis rats (13 +/- 2) (control rats: 7 +/- 1 ml/min x 100 g bw).,[Lidocain clearance after oral and intravenous application in rats with low grade ANIT-cholestasis and galactosamine-induced hepatitis (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7434856/),,17,132715,DB00281,Lidocaine
,7434856,systemic clearance of,The systemic clearance of Lidocain (Cli.v. = Di.v. divided by AUCi.v.) was significantly increased on ANIT-cholestasis (17 +/- 3) and GalN-hepatitis rats (13 +/- 2) (control rats: 7 +/- 1 ml/min x 100 g bw).,[Lidocain clearance after oral and intravenous application in rats with low grade ANIT-cholestasis and galactosamine-induced hepatitis (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7434856/),[ml] / [min],13,132716,DB00281,Lidocaine
,7434856,systemic clearance of,The systemic clearance of Lidocain (Cli.v. = Di.v. divided by AUCi.v.) was significantly increased on ANIT-cholestasis (17 +/- 3) and GalN-hepatitis rats (13 +/- 2) (control rats: 7 +/- 1 ml/min x 100 g bw).,[Lidocain clearance after oral and intravenous application in rats with low grade ANIT-cholestasis and galactosamine-induced hepatitis (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7434856/),[ml] / [min],7,132717,DB00281,Lidocaine
,7434856,hepatic blood flow,In both groups with experimental liver disease the hepatic blood flow--calculated by comparing the systemic to the oral clearance--was significantly increased (22 +/- 4 and 19 +/- 3 vs 8 +/- 1 ml/min x 100 g bw).,[Lidocain clearance after oral and intravenous application in rats with low grade ANIT-cholestasis and galactosamine-induced hepatitis (author's transl)]. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7434856/),[ml] / [100·bw·g·min],22,132718,DB00281,Lidocaine
,7434856,hepatic blood flow,In both groups with experimental liver disease the hepatic blood flow--calculated by comparing the systemic to the oral clearance--was significantly increased (22 +/- 4 and 19 +/- 3 vs 8 +/- 1 ml/min x 100 g bw).,[Lidocain clearance after oral and intravenous application in rats with low grade ANIT-cholestasis and galactosamine-induced hepatitis (author's transl)]. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7434856/),[ml] / [100·bw·g·min],19,132719,DB00281,Lidocaine
,7434856,hepatic blood flow,In both groups with experimental liver disease the hepatic blood flow--calculated by comparing the systemic to the oral clearance--was significantly increased (22 +/- 4 and 19 +/- 3 vs 8 +/- 1 ml/min x 100 g bw).,[Lidocain clearance after oral and intravenous application in rats with low grade ANIT-cholestasis and galactosamine-induced hepatitis (author's transl)]. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7434856/),[ml] / [100·bw·g·min],8,132720,DB00281,Lidocaine
,7434856,hepatic extraction ratio,"Due to this increase, the hepatic extraction ratio of Lidocain was significantly decreased (ANIT-cholestasis 0.73 +/- 0.07; GalN-hepatitis 0.74 +/- 0.05; controls 0.85 +/- 0.03).",[Lidocain clearance after oral and intravenous application in rats with low grade ANIT-cholestasis and galactosamine-induced hepatitis (author's transl)]. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7434856/),,0.73,132721,DB00281,Lidocaine
,7434856,hepatic extraction ratio,"Due to this increase, the hepatic extraction ratio of Lidocain was significantly decreased (ANIT-cholestasis 0.73 +/- 0.07; GalN-hepatitis 0.74 +/- 0.05; controls 0.85 +/- 0.03).",[Lidocain clearance after oral and intravenous application in rats with low grade ANIT-cholestasis and galactosamine-induced hepatitis (author's transl)]. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7434856/),,0.74,132722,DB00281,Lidocaine
,7434856,hepatic extraction ratio,"Due to this increase, the hepatic extraction ratio of Lidocain was significantly decreased (ANIT-cholestasis 0.73 +/- 0.07; GalN-hepatitis 0.74 +/- 0.05; controls 0.85 +/- 0.03).",[Lidocain clearance after oral and intravenous application in rats with low grade ANIT-cholestasis and galactosamine-induced hepatitis (author's transl)]. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7434856/),,0.85,132723,DB00281,Lidocaine
,2507556,plasma concentration,"Mean FLC plasma concentration values at 0, 1, 2, 4, and 8 h following administration were 562 +/- 271, 342 +/- 129, 270 +/- 90m, 240 +/- 80 and 210 +/- 60 ng/ml, respectively.",Clinical pharmacokinetics of intravenous flecainide in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2507556/),m,562,133193,DB00281,Lidocaine
,2507556,plasma concentration,"Mean FLC plasma concentration values at 0, 1, 2, 4, and 8 h following administration were 562 +/- 271, 342 +/- 129, 270 +/- 90m, 240 +/- 80 and 210 +/- 60 ng/ml, respectively.",Clinical pharmacokinetics of intravenous flecainide in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2507556/),[ng] / [ml],342,133194,DB00281,Lidocaine
,2507556,plasma concentration,"Mean FLC plasma concentration values at 0, 1, 2, 4, and 8 h following administration were 562 +/- 271, 342 +/- 129, 270 +/- 90m, 240 +/- 80 and 210 +/- 60 ng/ml, respectively.",Clinical pharmacokinetics of intravenous flecainide in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2507556/),[ng] / [ml],270,133195,DB00281,Lidocaine
,2507556,plasma concentration,"Mean FLC plasma concentration values at 0, 1, 2, 4, and 8 h following administration were 562 +/- 271, 342 +/- 129, 270 +/- 90m, 240 +/- 80 and 210 +/- 60 ng/ml, respectively.",Clinical pharmacokinetics of intravenous flecainide in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2507556/),[ng] / [ml],240,133196,DB00281,Lidocaine
,2507556,plasma concentration,"Mean FLC plasma concentration values at 0, 1, 2, 4, and 8 h following administration were 562 +/- 271, 342 +/- 129, 270 +/- 90m, 240 +/- 80 and 210 +/- 60 ng/ml, respectively.",Clinical pharmacokinetics of intravenous flecainide in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2507556/),[ng] / [ml],210,133197,DB00281,Lidocaine
,2507556,terminal plasma half-life (t1/2 beta),Mean values for the terminal plasma half-life (t1/2 beta) was 22.0 +/- 9.7 h and the volume of distribution (V beta) was 7.99 +/- 3.02 1/kg.,Clinical pharmacokinetics of intravenous flecainide in critically ill patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2507556/),h,22.0,133198,DB00281,Lidocaine
,2507556,volume of distribution (V beta),Mean values for the terminal plasma half-life (t1/2 beta) was 22.0 +/- 9.7 h and the volume of distribution (V beta) was 7.99 +/- 3.02 1/kg.,Clinical pharmacokinetics of intravenous flecainide in critically ill patients. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2507556/),[1] / [kg],7.99,133199,DB00281,Lidocaine
,25268618,diameter,The average diameter of lidocaine PLGA microspheres was 2.34±0.3 μm.,The pharmacokinetics and pharmacodynamics of lidocaine- loaded biodegradable poly(lactic-co-glycolic acid) microspheres. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25268618/),μm,2.34,133578,DB00281,Lidocaine
,25268618,p,"The poly disperse index was 0.21±0.03, and the zeta potential was +0.34±0.02 mV.",The pharmacokinetics and pharmacodynamics of lidocaine- loaded biodegradable poly(lactic-co-glycolic acid) microspheres. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25268618/),,0.21,133579,DB00281,Lidocaine
,25268618,zeta potential,"The poly disperse index was 0.21±0.03, and the zeta potential was +0.34±0.02 mV.",The pharmacokinetics and pharmacodynamics of lidocaine- loaded biodegradable poly(lactic-co-glycolic acid) microspheres. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25268618/),mv,0.34,133580,DB00281,Lidocaine
,25268618,encapsulation efficiency,The encapsulation efficiency and drug loading of the prepared microspheres were 90.5%±4.3% and 11.2%±1.4%.,The pharmacokinetics and pharmacodynamics of lidocaine- loaded biodegradable poly(lactic-co-glycolic acid) microspheres. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25268618/),%,90.5,133581,DB00281,Lidocaine
,25268618,drug loading,The encapsulation efficiency and drug loading of the prepared microspheres were 90.5%±4.3% and 11.2%±1.4%.,The pharmacokinetics and pharmacodynamics of lidocaine- loaded biodegradable poly(lactic-co-glycolic acid) microspheres. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25268618/),%,11.2,133582,DB00281,Lidocaine
,2111189,peak plasma levels,"The peak plasma levels of the enantiomers, observed at less than or equal to 2 h after dosing, were similar but plasma clearances and terminal half-lives were different after oral administration of (R)-tocainide (195.5 +/- 20.1 ml min-1 and 9.7 +/- 0.8 h) and (S)-tocainide (110.2 +/- 10.5 ml min-1 and 14.5 +/- 1.7 h).",Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111189/),[ml] / [min],195.5,133973,DB00281,Lidocaine
,2111189,plasma clearances,"The peak plasma levels of the enantiomers, observed at less than or equal to 2 h after dosing, were similar but plasma clearances and terminal half-lives were different after oral administration of (R)-tocainide (195.5 +/- 20.1 ml min-1 and 9.7 +/- 0.8 h) and (S)-tocainide (110.2 +/- 10.5 ml min-1 and 14.5 +/- 1.7 h).",Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111189/),[ml] / [min],195.5,133974,DB00281,Lidocaine
,2111189,plasma clearances,"The peak plasma levels of the enantiomers, observed at less than or equal to 2 h after dosing, were similar but plasma clearances and terminal half-lives were different after oral administration of (R)-tocainide (195.5 +/- 20.1 ml min-1 and 9.7 +/- 0.8 h) and (S)-tocainide (110.2 +/- 10.5 ml min-1 and 14.5 +/- 1.7 h).",Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111189/),[ml] / [min],110.2,133975,DB00281,Lidocaine
,2111189,terminal half-lives,"The peak plasma levels of the enantiomers, observed at less than or equal to 2 h after dosing, were similar but plasma clearances and terminal half-lives were different after oral administration of (R)-tocainide (195.5 +/- 20.1 ml min-1 and 9.7 +/- 0.8 h) and (S)-tocainide (110.2 +/- 10.5 ml min-1 and 14.5 +/- 1.7 h).",Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111189/),h,9.7,133976,DB00281,Lidocaine
,2111189,terminal half-lives,"The peak plasma levels of the enantiomers, observed at less than or equal to 2 h after dosing, were similar but plasma clearances and terminal half-lives were different after oral administration of (R)-tocainide (195.5 +/- 20.1 ml min-1 and 9.7 +/- 0.8 h) and (S)-tocainide (110.2 +/- 10.5 ml min-1 and 14.5 +/- 1.7 h).",Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111189/),[ml] / [min],110.2,133977,DB00281,Lidocaine
,2111189,terminal half-lives,"The peak plasma levels of the enantiomers, observed at less than or equal to 2 h after dosing, were similar but plasma clearances and terminal half-lives were different after oral administration of (R)-tocainide (195.5 +/- 20.1 ml min-1 and 9.7 +/- 0.8 h) and (S)-tocainide (110.2 +/- 10.5 ml min-1 and 14.5 +/- 1.7 h).",Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111189/),h,14.5,133978,DB00281,Lidocaine
,2111189,urinary recovery,Over 0-96 h the averaged urinary recovery of (R)-tocainide was 36 per cent and of (S)-tocainide 50 per cent.,Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111189/),%,36,133979,DB00281,Lidocaine
,2111189,urinary recovery,Over 0-96 h the averaged urinary recovery of (R)-tocainide was 36 per cent and of (S)-tocainide 50 per cent.,Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111189/),%,50,133980,DB00281,Lidocaine
,2111189,urinary recovery,Stereoselective metabolism was a likely mechanism for the observed differences as the urinary recovery of the conjugate formed from (R)-tocainide differed substantially from that of (S)-tocainide (45 vs 1.2 per cent of given dose).,Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111189/),%,45,133981,DB00281,Lidocaine
,2111189,urinary recovery,Stereoselective metabolism was a likely mechanism for the observed differences as the urinary recovery of the conjugate formed from (R)-tocainide differed substantially from that of (S)-tocainide (45 vs 1.2 per cent of given dose).,Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111189/),%,1.2,133982,DB00281,Lidocaine
,2111189,Plasma t1/2,"Plasma t1/2 of the (R)- and (S)-conjugate were 9.9 and 18.7 h, respectively, indicating formation rate limited kinetics of the metabolite.",Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111189/),h,9.9,133983,DB00281,Lidocaine
,2111189,Plasma t1/2,"Plasma t1/2 of the (R)- and (S)-conjugate were 9.9 and 18.7 h, respectively, indicating formation rate limited kinetics of the metabolite.",Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111189/),h,18.7,133984,DB00281,Lidocaine
,2111189,renal clearances,The renal clearances of the conjugates were not significantly different (131 vs 97 ml min-1).,Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111189/),[ml] / [min],131,133985,DB00281,Lidocaine
,2111189,renal clearances,The renal clearances of the conjugates were not significantly different (131 vs 97 ml min-1).,Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111189/),[ml] / [min],97,133986,DB00281,Lidocaine
,9717604,elimination half life,The elimination half life of lidocaine was 40.44 +/- 7.99 during hypothermia and 2.01 +/- 4.56 during rewarming.,Lidocaine prolongs the safe duration of circulatory arrest during deep hypothermia in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9717604/),,40.44,134136,DB00281,Lidocaine
,9717604,elimination half life,The elimination half life of lidocaine was 40.44 +/- 7.99 during hypothermia and 2.01 +/- 4.56 during rewarming.,Lidocaine prolongs the safe duration of circulatory arrest during deep hypothermia in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9717604/),,2.01,134137,DB00281,Lidocaine
,11465413,lag time,"Also, lag time decreased from 110 +/- 43 min to 87 +/- 32 min (P = 0.02).",Influence of a microemulsion vehicle on cutaneous bioequivalence of a lipophilic model drug assessed by microdialysis and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11465413/),min,110,134591,DB00281,Lidocaine
,11465413,lag time,"Also, lag time decreased from 110 +/- 43 min to 87 +/- 32 min (P = 0.02).",Influence of a microemulsion vehicle on cutaneous bioequivalence of a lipophilic model drug assessed by microdialysis and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11465413/),min,87,134592,DB00281,Lidocaine
,20371639,pulmonary extraction ratios,"The pulmonary extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the area under the time-plasma concentration curve (AUC) after the intra-arterial and intravenous administrations, were 39.0 +/- 0.5, 18.3 +/- 0.7, and 12.3 +/- 0.3%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,39.0,134661,DB00281,Lidocaine
,20371639,pulmonary extraction ratios,"The pulmonary extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the area under the time-plasma concentration curve (AUC) after the intra-arterial and intravenous administrations, were 39.0 +/- 0.5, 18.3 +/- 0.7, and 12.3 +/- 0.3%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,18.3,134662,DB00281,Lidocaine
,20371639,pulmonary extraction ratios,"The pulmonary extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the area under the time-plasma concentration curve (AUC) after the intra-arterial and intravenous administrations, were 39.0 +/- 0.5, 18.3 +/- 0.7, and 12.3 +/- 0.3%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,12.3,134663,DB00281,Lidocaine
,20371639,hepatic extraction ratios,"The hepatic extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the AUC after the intraportal and intravenous administrations, were 68.0 +/- 3.3, 52.6 +/- 0.4, and 13.5 +/- 0.2%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,68.0,134664,DB00281,Lidocaine
,20371639,hepatic extraction ratios,"The hepatic extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the AUC after the intraportal and intravenous administrations, were 68.0 +/- 3.3, 52.6 +/- 0.4, and 13.5 +/- 0.2%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,52.6,134665,DB00281,Lidocaine
,20371639,hepatic extraction ratios,"The hepatic extraction ratios of lidocaine, midazolam, and nifedipine, calculated from the AUC after the intraportal and intravenous administrations, were 68.0 +/- 3.3, 52.6 +/- 0.4, and 13.5 +/- 0.2%, respectively.","Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371639/),%,13.5,134666,DB00281,Lidocaine
,7175699,terminal half-life,"The range of values for the parameters defining the disposition kinetics of lidocaine were: terminal half-life, 50-231 min; total clearance, 13-17 ml/min/kg; initial dilution space, 0.13-2.5 liters/kg; and volume of distribution at steady state, 0.6-4.5 liters/kg.",Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175699/),min,50-231,135459,DB00281,Lidocaine
,7175699,total clearance,"The range of values for the parameters defining the disposition kinetics of lidocaine were: terminal half-life, 50-231 min; total clearance, 13-17 ml/min/kg; initial dilution space, 0.13-2.5 liters/kg; and volume of distribution at steady state, 0.6-4.5 liters/kg.",Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175699/),[ml] / [kg·min],13-17,135460,DB00281,Lidocaine
,7175699,initial dilution space,"The range of values for the parameters defining the disposition kinetics of lidocaine were: terminal half-life, 50-231 min; total clearance, 13-17 ml/min/kg; initial dilution space, 0.13-2.5 liters/kg; and volume of distribution at steady state, 0.6-4.5 liters/kg.",Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175699/),[l] / [kg],0.13-2.5,135461,DB00281,Lidocaine
,7175699,volume of distribution at steady state,"The range of values for the parameters defining the disposition kinetics of lidocaine were: terminal half-life, 50-231 min; total clearance, 13-17 ml/min/kg; initial dilution space, 0.13-2.5 liters/kg; and volume of distribution at steady state, 0.6-4.5 liters/kg.",Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175699/),[l] / [kg],0.6-4.5,135462,DB00281,Lidocaine
,7175699,hepatic blood flow,"Effective hepatic blood flow, based on total clearance and availability measurements, was estimated to be 18-27 ml/min/kg.",Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175699/),[ml] / [kg·min],18-27,135463,DB00281,Lidocaine
,236703,venous plasma concentration,"Delivery occurred a mean time of 29.83 plus or minus 8.64 minutes after a mean dose of 398.33 plus or minus 63.38 mg to the mother, at which time mean maternal venous plasma concentration was 1.70 plus or minus 0.77 mug/ml.",Lidocaine and its metabolites in the newborn. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/236703/),[μg] / [ml],1.70,136947,DB00281,Lidocaine
,236703,total molar quantity,"Of the total molar quantity of lidocaine and metabolite recovered from the newborns' urine in the first 12 hours of life, 50.63 per cent appeared as unchanged lidocaine, while 49.37 per cent appeared as metabolites.",Lidocaine and its metabolites in the newborn. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/236703/),%,50.63,136948,DB00281,Lidocaine
,236703,total molar quantity,"Of the total molar quantity of lidocaine and metabolite recovered from the newborns' urine in the first 12 hours of life, 50.63 per cent appeared as unchanged lidocaine, while 49.37 per cent appeared as metabolites.",Lidocaine and its metabolites in the newborn. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/236703/),%,49.37,136949,DB00281,Lidocaine
,6834851,total body clearance,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg·mn],"0,178",137594,DB00281,Lidocaine
,6834851,total body clearance,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg·mn],"0,115",137595,DB00281,Lidocaine
,6834851,volume of distribution,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg],"9,32",137596,DB00281,Lidocaine
,6834851,volume of distribution,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg],"6,02",137597,DB00281,Lidocaine
,6834851,half-life,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),mn,"40,25",137598,DB00281,Lidocaine
,6834851,half-life,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),mn,"45,62",137599,DB00281,Lidocaine
,6834851,total body clearance,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg·mn],"3,28",137600,DB00281,Lidocaine
,6834851,total body clearance,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg·mn],"1,43",137601,DB00281,Lidocaine
,6834851,half-life,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),mn,"136,4",137602,DB00281,Lidocaine
,6834851,half-life,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),mn,"324,9",137603,DB00281,Lidocaine
,6834851,volume of distribution,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg],"0,62",137604,DB00281,Lidocaine
,6834851,volume of distribution,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg],"0,62",137605,DB00281,Lidocaine
,1149363,steady-state plasma levels,"Average values for lidocaine steady-state plasma levels (2.3 mug/ml) clearance (12.3 ml/min/kg), terminal half-life (148 min), and total volume of distribution (1.9 L/kg) were found, and are similar to those values reported for normal subjects MFGX and after lidocaine infusion averaged 1/5-2/3 of the corresponding lidocaine level, as in nonuremic subjects, and plateaued by 6-8 hr.",Pharmacokinetics and metabolism of lidocaine in patients with renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1149363/),[μg] / [ml],2.3,138057,DB00281,Lidocaine
,1149363,clearance,"Average values for lidocaine steady-state plasma levels (2.3 mug/ml) clearance (12.3 ml/min/kg), terminal half-life (148 min), and total volume of distribution (1.9 L/kg) were found, and are similar to those values reported for normal subjects MFGX and after lidocaine infusion averaged 1/5-2/3 of the corresponding lidocaine level, as in nonuremic subjects, and plateaued by 6-8 hr.",Pharmacokinetics and metabolism of lidocaine in patients with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1149363/),[ml] / [kg·min],12.3,138058,DB00281,Lidocaine
,1149363,terminal half-life,"Average values for lidocaine steady-state plasma levels (2.3 mug/ml) clearance (12.3 ml/min/kg), terminal half-life (148 min), and total volume of distribution (1.9 L/kg) were found, and are similar to those values reported for normal subjects MFGX and after lidocaine infusion averaged 1/5-2/3 of the corresponding lidocaine level, as in nonuremic subjects, and plateaued by 6-8 hr.",Pharmacokinetics and metabolism of lidocaine in patients with renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1149363/),min,148,138059,DB00281,Lidocaine
,1149363,total volume of distribution,"Average values for lidocaine steady-state plasma levels (2.3 mug/ml) clearance (12.3 ml/min/kg), terminal half-life (148 min), and total volume of distribution (1.9 L/kg) were found, and are similar to those values reported for normal subjects MFGX and after lidocaine infusion averaged 1/5-2/3 of the corresponding lidocaine level, as in nonuremic subjects, and plateaued by 6-8 hr.",Pharmacokinetics and metabolism of lidocaine in patients with renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1149363/),[l] / [kg],1.9,138060,DB00281,Lidocaine
,6144770,Systemic availability,"Systemic availability of lignocaine was the lowest of species so far studied (mean 0.019 +/- 0.001) did not alter with dose, and was very similar to the values in the literature quoted for the isolated perfused liver.",Lignocaine kinetics in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144770/),,0.019,139027,DB00281,Lidocaine
,7439378,maximum concentration,The maximum concentration (2.34 micrograms/kg for a dose of 400 mg) was attained 44 min after the injection.,[Lidocaine pharmacokinetics when administered intramuscularly]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439378/),[μg] / [kg],2.34,141288,DB00281,Lidocaine
,7439378,half-life,"The half-life was 101 min, and the total clearance 0.67 l/min.",[Lidocaine pharmacokinetics when administered intramuscularly]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439378/),min,101,141289,DB00281,Lidocaine
,7439378,total clearance,"The half-life was 101 min, and the total clearance 0.67 l/min.",[Lidocaine pharmacokinetics when administered intramuscularly]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439378/),[l] / [min],0.67,141290,DB00281,Lidocaine
,6879644,absorption constant,The results showed rapid absorption of the anaesthetic by the tracheobronchial mucosa with an average absorption constant of 4.77 +/- 1.99 h-1.,Serum lidocaine levels in patients undergoing fibrobronchoscopy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6879644/),1/[h],4.77,146074,DB00281,Lidocaine
,6879644,Maximum lidocaine levels,"Maximum lidocaine levels in serum averaged 1.21 +/- 0.64 microgram/ml, lower than the levels established as toxic for this anaesthetic.",Serum lidocaine levels in patients undergoing fibrobronchoscopy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6879644/),[μg] / [ml],1.21,146075,DB00281,Lidocaine
,6879644,serum half-life,The serum half-life of lidocaine averaged 1.55 +/- 0.72 h.,Serum lidocaine levels in patients undergoing fibrobronchoscopy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6879644/),h,1.55,146076,DB00281,Lidocaine
,6879644,percentage of dose absorbed,The percentage of dose absorbed in this kind of patient ranged between 20.89 and 60.88% of the dose administered.,Serum lidocaine levels in patients undergoing fibrobronchoscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6879644/),%,20,146077,DB00281,Lidocaine
,17171862,plasma concentrations,"The doses administered gave plasma concentrations of 1.55 microg/mL, which are considered therapeutic.",Compartmental analysis of lidocaine kinetics during extracorporeal circulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17171862/),,1.55,147178,DB00281,Lidocaine
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,589",147638,DB00281,Lidocaine
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,065",147639,DB00281,Lidocaine
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,243",147640,DB00281,Lidocaine
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,254",147641,DB00281,Lidocaine
,21453144,Plasma lidoc,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,206",147642,DB00281,Lidocaine
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,589",147643,DB00281,Lidocaine
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,065",147644,DB00281,Lidocaine
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,243",147645,DB00281,Lidocaine
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,168",147646,DB00281,Lidocaine
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,254",147647,DB00281,Lidocaine
,21453144,concentrations,"Plasma lidocaine concentrations were 2,589 ± 811 ng/mL at the end of the bolus; 2,065 ± 441 ng/mL, 2,243 ± 699 ng/mL, 2,168 ± 339 ng/mL, and 2,254 ± 215 ng/mL at 30, 60, 90, and 120 minutes of infusion, respectively; and 2,206 ± 329 ng/mL at the end of the infusion.",Effects of intravenous administration of lidocaine on the minimum alveolar concentration of sevoflurane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21453144/),[ng] / [ml],"2,206",147648,DB00281,Lidocaine
,7560250,maximal concentration,Lidocaine disposition was modified during head-down tilt: a significant decrease in maximal concentration (1.47 +/- 0.26 mg/L on day 1 and 0.96 +/- 0.30 mg/L on day 2); an increase in elimination clearance from 8.24 +/- 3.22 mL/kg.minutes-1 to 11.63 +/- 3.00 mL/kg.minutes-1; an increase in volume of distribution on day 2 and a decrease to lower than basal value on the other days (2.77 +/- 1.73 L/kg on day 1 and 2.33 +/- 0.48 L/kg on day 7).,Impact of a four-day head-down tilt (-6 degrees) on lidocaine pharmacokinetics used as probe to evaluate hepatic blood flow. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560250/),[mg] / [l],1.47,147817,DB00281,Lidocaine
,7560250,maximal concentration,Lidocaine disposition was modified during head-down tilt: a significant decrease in maximal concentration (1.47 +/- 0.26 mg/L on day 1 and 0.96 +/- 0.30 mg/L on day 2); an increase in elimination clearance from 8.24 +/- 3.22 mL/kg.minutes-1 to 11.63 +/- 3.00 mL/kg.minutes-1; an increase in volume of distribution on day 2 and a decrease to lower than basal value on the other days (2.77 +/- 1.73 L/kg on day 1 and 2.33 +/- 0.48 L/kg on day 7).,Impact of a four-day head-down tilt (-6 degrees) on lidocaine pharmacokinetics used as probe to evaluate hepatic blood flow. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560250/),[mg] / [l],0.96,147818,DB00281,Lidocaine
,7560250,elimination clearance,Lidocaine disposition was modified during head-down tilt: a significant decrease in maximal concentration (1.47 +/- 0.26 mg/L on day 1 and 0.96 +/- 0.30 mg/L on day 2); an increase in elimination clearance from 8.24 +/- 3.22 mL/kg.minutes-1 to 11.63 +/- 3.00 mL/kg.minutes-1; an increase in volume of distribution on day 2 and a decrease to lower than basal value on the other days (2.77 +/- 1.73 L/kg on day 1 and 2.33 +/- 0.48 L/kg on day 7).,Impact of a four-day head-down tilt (-6 degrees) on lidocaine pharmacokinetics used as probe to evaluate hepatic blood flow. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560250/),[ml] / [kg·min],8.24,147819,DB00281,Lidocaine
,7560250,elimination clearance,Lidocaine disposition was modified during head-down tilt: a significant decrease in maximal concentration (1.47 +/- 0.26 mg/L on day 1 and 0.96 +/- 0.30 mg/L on day 2); an increase in elimination clearance from 8.24 +/- 3.22 mL/kg.minutes-1 to 11.63 +/- 3.00 mL/kg.minutes-1; an increase in volume of distribution on day 2 and a decrease to lower than basal value on the other days (2.77 +/- 1.73 L/kg on day 1 and 2.33 +/- 0.48 L/kg on day 7).,Impact of a four-day head-down tilt (-6 degrees) on lidocaine pharmacokinetics used as probe to evaluate hepatic blood flow. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560250/),[ml] / [kg·min],11.63,147820,DB00281,Lidocaine
,7560250,volume of distribution,Lidocaine disposition was modified during head-down tilt: a significant decrease in maximal concentration (1.47 +/- 0.26 mg/L on day 1 and 0.96 +/- 0.30 mg/L on day 2); an increase in elimination clearance from 8.24 +/- 3.22 mL/kg.minutes-1 to 11.63 +/- 3.00 mL/kg.minutes-1; an increase in volume of distribution on day 2 and a decrease to lower than basal value on the other days (2.77 +/- 1.73 L/kg on day 1 and 2.33 +/- 0.48 L/kg on day 7).,Impact of a four-day head-down tilt (-6 degrees) on lidocaine pharmacokinetics used as probe to evaluate hepatic blood flow. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560250/),[l] / [kg],2.77,147821,DB00281,Lidocaine
,7560250,volume of distribution,Lidocaine disposition was modified during head-down tilt: a significant decrease in maximal concentration (1.47 +/- 0.26 mg/L on day 1 and 0.96 +/- 0.30 mg/L on day 2); an increase in elimination clearance from 8.24 +/- 3.22 mL/kg.minutes-1 to 11.63 +/- 3.00 mL/kg.minutes-1; an increase in volume of distribution on day 2 and a decrease to lower than basal value on the other days (2.77 +/- 1.73 L/kg on day 1 and 2.33 +/- 0.48 L/kg on day 7).,Impact of a four-day head-down tilt (-6 degrees) on lidocaine pharmacokinetics used as probe to evaluate hepatic blood flow. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560250/),[l] / [kg],2.33,147822,DB00281,Lidocaine
,7560250,Half-life,Half-life regularly decreased from 264 +/- 210 minutes to 160 +/- 60 minutes between day 1 and day 7.,Impact of a four-day head-down tilt (-6 degrees) on lidocaine pharmacokinetics used as probe to evaluate hepatic blood flow. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560250/),min,264,147823,DB00281,Lidocaine
,7560250,Half-life,Half-life regularly decreased from 264 +/- 210 minutes to 160 +/- 60 minutes between day 1 and day 7.,Impact of a four-day head-down tilt (-6 degrees) on lidocaine pharmacokinetics used as probe to evaluate hepatic blood flow. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7560250/),min,160,147824,DB00281,Lidocaine
,34423354,area under the plasma-time curves,"The area under the plasma-time curves for ticagrelor (1228 vs. 2753 ng h/mL, P < 0.001) and its active metabolite (201 vs. 447 ng h/mL, P = 0.001) were both significantly lower in the fentanyl arm.",Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34423354/),[h·ng] / [ml],1228,148719,DB00281,Lidocaine
,34423354,area under the plasma-time curves,"The area under the plasma-time curves for ticagrelor (1228 vs. 2753 ng h/mL, P < 0.001) and its active metabolite (201 vs. 447 ng h/mL, P = 0.001) were both significantly lower in the fentanyl arm.",Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34423354/),[h·ng] / [ml],2753,148720,DB00281,Lidocaine
,34423354,area under the plasma-time curves,"The area under the plasma-time curves for ticagrelor (1228 vs. 2753 ng h/mL, P < 0.001) and its active metabolite (201 vs. 447 ng h/mL, P = 0.001) were both significantly lower in the fentanyl arm.",Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34423354/),[h·ng] / [ml],201,148721,DB00281,Lidocaine
,34423354,area under the plasma-time curves,"The area under the plasma-time curves for ticagrelor (1228 vs. 2753 ng h/mL, P < 0.001) and its active metabolite (201 vs. 447 ng h/mL, P = 0.001) were both significantly lower in the fentanyl arm.",Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34423354/),[h·ng] / [ml],447,148722,DB00281,Lidocaine
,23230760,retention time,"The retention time of S-DN and R-DN were 15.56 min and 18.41 min, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),min,15.56,150243,DB00281,Lidocaine
,23230760,retention time,"The retention time of S-DN and R-DN were 15.56 min and 18.41 min, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),min,18.41,150244,DB00281,Lidocaine
,23230760,relative recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,95.10,150245,DB00281,Lidocaine
,23230760,relative recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,103.70,150246,DB00281,Lidocaine
,23230760,relative recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,93.58,150247,DB00281,Lidocaine
,23230760,relative recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,98.00,150248,DB00281,Lidocaine
,23230760,relative recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,58.42,150249,DB00281,Lidocaine
,23230760,relative recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,53.24,150250,DB00281,Lidocaine
,23230760,recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,58.42,150251,DB00281,Lidocaine
,23230760,recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,61.08,150252,DB00281,Lidocaine
,23230760,recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,53.24,150253,DB00281,Lidocaine
,23230760,recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,61.87,150254,DB00281,Lidocaine
,24480637,Cmax,"After single-dose intravenous administration of 0.25, 0.50, and 0.75 mg/kg of pilsicainide hydrochloride, mean Cmax was 0.34 (0.11), 0.54 (0.15), and 1.05 (0.19) μg/mL, respectively; AUC0-24 was 0.76 (0.12), 1.61 (0.37), and 2.61 (0.46) h · μg/mL; and AUC0-∞ was 0.79 (0.13), 1.71 (0.46), and 2.72 (0.50) h · μg/mL.","Pharmacokinetics of pilsicainide hydrochloride for injection in healthy Chinese volunteers: a randomized, parallel-group, open-label, single-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24480637/),[μg] / [ml],0.34,150618,DB00281,Lidocaine
,24480637,Cmax,"After single-dose intravenous administration of 0.25, 0.50, and 0.75 mg/kg of pilsicainide hydrochloride, mean Cmax was 0.34 (0.11), 0.54 (0.15), and 1.05 (0.19) μg/mL, respectively; AUC0-24 was 0.76 (0.12), 1.61 (0.37), and 2.61 (0.46) h · μg/mL; and AUC0-∞ was 0.79 (0.13), 1.71 (0.46), and 2.72 (0.50) h · μg/mL.","Pharmacokinetics of pilsicainide hydrochloride for injection in healthy Chinese volunteers: a randomized, parallel-group, open-label, single-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24480637/),[μg] / [ml],0.54,150619,DB00281,Lidocaine
,24480637,Cmax,"After single-dose intravenous administration of 0.25, 0.50, and 0.75 mg/kg of pilsicainide hydrochloride, mean Cmax was 0.34 (0.11), 0.54 (0.15), and 1.05 (0.19) μg/mL, respectively; AUC0-24 was 0.76 (0.12), 1.61 (0.37), and 2.61 (0.46) h · μg/mL; and AUC0-∞ was 0.79 (0.13), 1.71 (0.46), and 2.72 (0.50) h · μg/mL.","Pharmacokinetics of pilsicainide hydrochloride for injection in healthy Chinese volunteers: a randomized, parallel-group, open-label, single-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24480637/),[μg] / [ml],1.05,150620,DB00281,Lidocaine
,24480637,AUC0-24,"After single-dose intravenous administration of 0.25, 0.50, and 0.75 mg/kg of pilsicainide hydrochloride, mean Cmax was 0.34 (0.11), 0.54 (0.15), and 1.05 (0.19) μg/mL, respectively; AUC0-24 was 0.76 (0.12), 1.61 (0.37), and 2.61 (0.46) h · μg/mL; and AUC0-∞ was 0.79 (0.13), 1.71 (0.46), and 2.72 (0.50) h · μg/mL.","Pharmacokinetics of pilsicainide hydrochloride for injection in healthy Chinese volunteers: a randomized, parallel-group, open-label, single-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24480637/),[h·μg] / [ml],0.76,150621,DB00281,Lidocaine
,24480637,AUC0-24,"After single-dose intravenous administration of 0.25, 0.50, and 0.75 mg/kg of pilsicainide hydrochloride, mean Cmax was 0.34 (0.11), 0.54 (0.15), and 1.05 (0.19) μg/mL, respectively; AUC0-24 was 0.76 (0.12), 1.61 (0.37), and 2.61 (0.46) h · μg/mL; and AUC0-∞ was 0.79 (0.13), 1.71 (0.46), and 2.72 (0.50) h · μg/mL.","Pharmacokinetics of pilsicainide hydrochloride for injection in healthy Chinese volunteers: a randomized, parallel-group, open-label, single-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24480637/),[h·μg] / [ml],1.61,150622,DB00281,Lidocaine
,24480637,AUC0-24,"After single-dose intravenous administration of 0.25, 0.50, and 0.75 mg/kg of pilsicainide hydrochloride, mean Cmax was 0.34 (0.11), 0.54 (0.15), and 1.05 (0.19) μg/mL, respectively; AUC0-24 was 0.76 (0.12), 1.61 (0.37), and 2.61 (0.46) h · μg/mL; and AUC0-∞ was 0.79 (0.13), 1.71 (0.46), and 2.72 (0.50) h · μg/mL.","Pharmacokinetics of pilsicainide hydrochloride for injection in healthy Chinese volunteers: a randomized, parallel-group, open-label, single-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24480637/),[h·μg] / [ml],2.61,150623,DB00281,Lidocaine
,24480637,AUC0-∞,"After single-dose intravenous administration of 0.25, 0.50, and 0.75 mg/kg of pilsicainide hydrochloride, mean Cmax was 0.34 (0.11), 0.54 (0.15), and 1.05 (0.19) μg/mL, respectively; AUC0-24 was 0.76 (0.12), 1.61 (0.37), and 2.61 (0.46) h · μg/mL; and AUC0-∞ was 0.79 (0.13), 1.71 (0.46), and 2.72 (0.50) h · μg/mL.","Pharmacokinetics of pilsicainide hydrochloride for injection in healthy Chinese volunteers: a randomized, parallel-group, open-label, single-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24480637/),[h·μg] / [ml],0.79,150624,DB00281,Lidocaine
,24480637,AUC0-∞,"After single-dose intravenous administration of 0.25, 0.50, and 0.75 mg/kg of pilsicainide hydrochloride, mean Cmax was 0.34 (0.11), 0.54 (0.15), and 1.05 (0.19) μg/mL, respectively; AUC0-24 was 0.76 (0.12), 1.61 (0.37), and 2.61 (0.46) h · μg/mL; and AUC0-∞ was 0.79 (0.13), 1.71 (0.46), and 2.72 (0.50) h · μg/mL.","Pharmacokinetics of pilsicainide hydrochloride for injection in healthy Chinese volunteers: a randomized, parallel-group, open-label, single-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24480637/),[h·μg] / [ml],1.71,150625,DB00281,Lidocaine
,24480637,AUC0-∞,"After single-dose intravenous administration of 0.25, 0.50, and 0.75 mg/kg of pilsicainide hydrochloride, mean Cmax was 0.34 (0.11), 0.54 (0.15), and 1.05 (0.19) μg/mL, respectively; AUC0-24 was 0.76 (0.12), 1.61 (0.37), and 2.61 (0.46) h · μg/mL; and AUC0-∞ was 0.79 (0.13), 1.71 (0.46), and 2.72 (0.50) h · μg/mL.","Pharmacokinetics of pilsicainide hydrochloride for injection in healthy Chinese volunteers: a randomized, parallel-group, open-label, single-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24480637/),[h·μg] / [ml],2.72,150626,DB00281,Lidocaine
,24480637,t½z,"The ranges for t½z, CL, and Vz were 5.19 to 5.98 hours, 4.73 to 5.44 mL/min/kg, and 2.23 to 0.58 L/kg, respectively.","Pharmacokinetics of pilsicainide hydrochloride for injection in healthy Chinese volunteers: a randomized, parallel-group, open-label, single-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24480637/),h,5.19 to 5.98,150627,DB00281,Lidocaine
,24480637,CL,"The ranges for t½z, CL, and Vz were 5.19 to 5.98 hours, 4.73 to 5.44 mL/min/kg, and 2.23 to 0.58 L/kg, respectively.","Pharmacokinetics of pilsicainide hydrochloride for injection in healthy Chinese volunteers: a randomized, parallel-group, open-label, single-dose study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24480637/),[ml] / [kg·min],4.73 to 5.44,150628,DB00281,Lidocaine
,24480637,Vz,"The ranges for t½z, CL, and Vz were 5.19 to 5.98 hours, 4.73 to 5.44 mL/min/kg, and 2.23 to 0.58 L/kg, respectively.","Pharmacokinetics of pilsicainide hydrochloride for injection in healthy Chinese volunteers: a randomized, parallel-group, open-label, single-dose study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24480637/),[l] / [kg],2.23 to 0.58,150629,DB00281,Lidocaine
,24480637,urinary recovery rate within,"The mean urinary recovery rate within 24 hours was 75.0% (12.0%), 65.0% (19.2%), and 66.4% (14.1%).","Pharmacokinetics of pilsicainide hydrochloride for injection in healthy Chinese volunteers: a randomized, parallel-group, open-label, single-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24480637/),%,75.0,150630,DB00281,Lidocaine
,24480637,urinary recovery rate within,"The mean urinary recovery rate within 24 hours was 75.0% (12.0%), 65.0% (19.2%), and 66.4% (14.1%).","Pharmacokinetics of pilsicainide hydrochloride for injection in healthy Chinese volunteers: a randomized, parallel-group, open-label, single-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24480637/),%,65.0,150631,DB00281,Lidocaine
,24480637,urinary recovery rate within,"The mean urinary recovery rate within 24 hours was 75.0% (12.0%), 65.0% (19.2%), and 66.4% (14.1%).","Pharmacokinetics of pilsicainide hydrochloride for injection in healthy Chinese volunteers: a randomized, parallel-group, open-label, single-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24480637/),%,66.4,150632,DB00281,Lidocaine
,11396809,formation,"Monoethylglycinexylidide formation was decreased in patients with cystic fibrosis compared with controls (39.4+/-16.9 microg/L versus 70.3+/-45.7 microg/L, mean +/- SD, respectively, P < 0.02).",Assessment of hepatic function in cystic fibrosis by lidocaine metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396809/),[μg] / [l],39.4,150756,DB00281,Lidocaine
,11396809,formation,"Monoethylglycinexylidide formation was decreased in patients with cystic fibrosis compared with controls (39.4+/-16.9 microg/L versus 70.3+/-45.7 microg/L, mean +/- SD, respectively, P < 0.02).",Assessment of hepatic function in cystic fibrosis by lidocaine metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396809/),[μg] / [l],70.3,150757,DB00281,Lidocaine
,11396809,half-life,"Indocyanine green half-life (4.6+/-2.7 min versus 3.0+/-1.0 min), volume of distribution (8.6+/-5.5 L versus 8.3+/-3.4 L), and hepatic blood flow (10.9+/-5.9 ml x kg(-1) x min(-1) versus 7.4+/-2.0 ml x kg(-1) x min(-1)) were similar in both groups.",Assessment of hepatic function in cystic fibrosis by lidocaine metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396809/),min,4.6,150758,DB00281,Lidocaine
,11396809,half-life,"Indocyanine green half-life (4.6+/-2.7 min versus 3.0+/-1.0 min), volume of distribution (8.6+/-5.5 L versus 8.3+/-3.4 L), and hepatic blood flow (10.9+/-5.9 ml x kg(-1) x min(-1) versus 7.4+/-2.0 ml x kg(-1) x min(-1)) were similar in both groups.",Assessment of hepatic function in cystic fibrosis by lidocaine metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396809/),min,3.0,150759,DB00281,Lidocaine
,11396809,volume of distribution,"Indocyanine green half-life (4.6+/-2.7 min versus 3.0+/-1.0 min), volume of distribution (8.6+/-5.5 L versus 8.3+/-3.4 L), and hepatic blood flow (10.9+/-5.9 ml x kg(-1) x min(-1) versus 7.4+/-2.0 ml x kg(-1) x min(-1)) were similar in both groups.",Assessment of hepatic function in cystic fibrosis by lidocaine metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396809/),l,8.6,150760,DB00281,Lidocaine
,11396809,volume of distribution,"Indocyanine green half-life (4.6+/-2.7 min versus 3.0+/-1.0 min), volume of distribution (8.6+/-5.5 L versus 8.3+/-3.4 L), and hepatic blood flow (10.9+/-5.9 ml x kg(-1) x min(-1) versus 7.4+/-2.0 ml x kg(-1) x min(-1)) were similar in both groups.",Assessment of hepatic function in cystic fibrosis by lidocaine metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396809/),l,8.3,150761,DB00281,Lidocaine
,11396809,hepatic blood flow,"Indocyanine green half-life (4.6+/-2.7 min versus 3.0+/-1.0 min), volume of distribution (8.6+/-5.5 L versus 8.3+/-3.4 L), and hepatic blood flow (10.9+/-5.9 ml x kg(-1) x min(-1) versus 7.4+/-2.0 ml x kg(-1) x min(-1)) were similar in both groups.",Assessment of hepatic function in cystic fibrosis by lidocaine metabolism. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396809/),[ml] / [kg·min],10.9,150762,DB00281,Lidocaine
,11396809,hepatic blood flow,"Indocyanine green half-life (4.6+/-2.7 min versus 3.0+/-1.0 min), volume of distribution (8.6+/-5.5 L versus 8.3+/-3.4 L), and hepatic blood flow (10.9+/-5.9 ml x kg(-1) x min(-1) versus 7.4+/-2.0 ml x kg(-1) x min(-1)) were similar in both groups.",Assessment of hepatic function in cystic fibrosis by lidocaine metabolism. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11396809/),[ml] / [kg·min],7.4,150763,DB00281,Lidocaine
,10699514,minimum total volume,"During general anesthesia, 27 elective surgical patients received 2.0 mg/kg lidocaine (diluted as necessary with 0.9% saline to a minimum total volume of 10 mL) via a Combitube (study group, n = 13) or an endotracheal tube (control group, n = 14).",Endotracheal lidocaine administration via an esophageal combitube. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10699514/),ml,10,151131,DB00281,Lidocaine
,10699514,peak concentrations,"Individual patient peak concentrations averaged 1.0+/-0.7 and 2.2+/-1.1 microg/mL in the same two groups, 19+/-16 and 10+/-15 min after lidocaine administration, respectively.",Endotracheal lidocaine administration via an esophageal combitube. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10699514/),[μg] / [ml],1.0,151132,DB00281,Lidocaine
,10699514,peak concentrations,"Individual patient peak concentrations averaged 1.0+/-0.7 and 2.2+/-1.1 microg/mL in the same two groups, 19+/-16 and 10+/-15 min after lidocaine administration, respectively.",Endotracheal lidocaine administration via an esophageal combitube. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10699514/),[μg] / [ml],2.2,151133,DB00281,Lidocaine
,15096108,peak concentration,"Rapid uptake of lidocaine produced a peak concentration of 1.45 +/- 0.36 microg/mL (mean +/- SD, range 0.80-1.86 microg/mL) by 0.37 +/- 0.26 h (range 0.11-0.81) after administration.",Pharmacokinetics of combined intraperitoneal and incisional lidocaine in the dog following ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15096108/),[μg] / [ml],1.45,151705,DB00281,Lidocaine
,15096108,absorption half-life,The absorption half-life was 0.13 +/- 0.1 h.,Pharmacokinetics of combined intraperitoneal and incisional lidocaine in the dog following ovariohysterectomy. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15096108/),h,0.13,151706,DB00281,Lidocaine
,15096108,elimination half-life,Plasma concentrations decreased rapidly and the elimination half-life was 1.17 +/- 0.11 h.,Pharmacokinetics of combined intraperitoneal and incisional lidocaine in the dog following ovariohysterectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15096108/),h,1.17,151707,DB00281,Lidocaine
,4073454,maximum level,The maximum level attained by any puppy was 4.48 ug/ml after 4 mg/kg tracheal lignocaine spray.,The influence of age on plasma lignocaine levels following tracheal spray in young dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4073454/),[ug] / [ml],4.48,151899,DB00281,Lidocaine
,8422740,area under the plasma concentration time curve,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[h·μg] / [ml],81.7,152051,DB00281,Lidocaine
,8422740,area under the plasma concentration time curve,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[h·μg] / [ml],76.3,152052,DB00281,Lidocaine
,8422740,systemic,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[ml] / [kg·min],9.53,152053,DB00281,Lidocaine
,8422740,systemic,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[ml] / [kg·min],10.27,152054,DB00281,Lidocaine
,8422740,volume of distribution at steady state,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[l] / [kg],2.48,152055,DB00281,Lidocaine
,8422740,volume of distribution at steady state,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[l] / [kg],2.64,152056,DB00281,Lidocaine
,8422740,mean residence time,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),h,4.37,152057,DB00281,Lidocaine
,8422740,mean residence time,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),h,4.47,152058,DB00281,Lidocaine
,9862241,plasma clearance,The lignocaine plasma clearance increased from 7.5+/-1.2 ml min(-1) kg(-1) before to 8.6+/-2ml min(-1) kg(-1) (P=0.026) after induction.,The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862241/),[ml] / [kg·min],7.5,153171,DB00281,Lidocaine
,9862241,plasma clearance,The lignocaine plasma clearance increased from 7.5+/-1.2 ml min(-1) kg(-1) before to 8.6+/-2ml min(-1) kg(-1) (P=0.026) after induction.,The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862241/),[ml] / [kg·min],8.6,153172,DB00281,Lidocaine
,9862241,concentrations,The normalised MEGX30min concentrations increased from 61+/-14 (day 7) to 82+/-34 microg l(-1) (day 14) by a mean of 21 microg l(-1) (95% confidence interval: -3 to 44 microg l(-1)) (P=0.055).,The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862241/),[μg] / [l],61,153173,DB00281,Lidocaine
,9862241,concentrations,The normalised MEGX30min concentrations increased from 61+/-14 (day 7) to 82+/-34 microg l(-1) (day 14) by a mean of 21 microg l(-1) (95% confidence interval: -3 to 44 microg l(-1)) (P=0.055).,The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862241/),[μg] / [l],82,153174,DB00281,Lidocaine
,3701908,total dose,An estimated total dose of 1.2 gm.,Intravenous lidocaine overdosage in a child. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3701908/),gm,1.2,154160,DB00281,Lidocaine
,3195730,volume of the central compartment,The volume of the central compartment was greater in pregnant than in nonpregnant ewes (1.51 +/- 0.20 vs. 0.96 +/- 0.16 L/kg) as was the volume of distribution at steady state (Vdss): 3.24 +/- 0.40 vs. 1.88 +/- 0.32 L/kg.,Pharmacokinetics of lidocaine in nonpregnant and pregnant ewes. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3195730/),[l] / [kg],1.51,154465,DB00281,Lidocaine
,3195730,volume of the central compartment,The volume of the central compartment was greater in pregnant than in nonpregnant ewes (1.51 +/- 0.20 vs. 0.96 +/- 0.16 L/kg) as was the volume of distribution at steady state (Vdss): 3.24 +/- 0.40 vs. 1.88 +/- 0.32 L/kg.,Pharmacokinetics of lidocaine in nonpregnant and pregnant ewes. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3195730/),[l] / [kg],0.96,154466,DB00281,Lidocaine
,3195730,volume of distribution at steady state (Vdss),The volume of the central compartment was greater in pregnant than in nonpregnant ewes (1.51 +/- 0.20 vs. 0.96 +/- 0.16 L/kg) as was the volume of distribution at steady state (Vdss): 3.24 +/- 0.40 vs. 1.88 +/- 0.32 L/kg.,Pharmacokinetics of lidocaine in nonpregnant and pregnant ewes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3195730/),[l] / [kg],3.24,154467,DB00281,Lidocaine
,3195730,volume of distribution at steady state (Vdss),The volume of the central compartment was greater in pregnant than in nonpregnant ewes (1.51 +/- 0.20 vs. 0.96 +/- 0.16 L/kg) as was the volume of distribution at steady state (Vdss): 3.24 +/- 0.40 vs. 1.88 +/- 0.32 L/kg.,Pharmacokinetics of lidocaine in nonpregnant and pregnant ewes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3195730/),[l] / [kg],1.88,154468,DB00281,Lidocaine
,3195730,volume of distribution during the terminal exponential phase of drug elimination (Vd beta),"The volume of distribution during the terminal exponential phase of drug elimination (Vd beta) and total clearance of lidocaine (Cl) were also higher in pregnant animals: 4.17 +/- 0.50 L/kg and 99.6 +/- 8.5 ml.min-1.kg-1, respectively; compared to 2.46 +/- 0.48 L/kg and 44.1 +/- 6.5 ml.min-1.kg-1, in nonpregnant ewes.",Pharmacokinetics of lidocaine in nonpregnant and pregnant ewes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3195730/),[l] / [kg],4.17,154469,DB00281,Lidocaine
,3195730,volume of distribution during the terminal exponential phase of drug elimination (Vd beta),"The volume of distribution during the terminal exponential phase of drug elimination (Vd beta) and total clearance of lidocaine (Cl) were also higher in pregnant animals: 4.17 +/- 0.50 L/kg and 99.6 +/- 8.5 ml.min-1.kg-1, respectively; compared to 2.46 +/- 0.48 L/kg and 44.1 +/- 6.5 ml.min-1.kg-1, in nonpregnant ewes.",Pharmacokinetics of lidocaine in nonpregnant and pregnant ewes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3195730/),[l] / [kg],2.46,154470,DB00281,Lidocaine
,3195730,total clearance,"The volume of distribution during the terminal exponential phase of drug elimination (Vd beta) and total clearance of lidocaine (Cl) were also higher in pregnant animals: 4.17 +/- 0.50 L/kg and 99.6 +/- 8.5 ml.min-1.kg-1, respectively; compared to 2.46 +/- 0.48 L/kg and 44.1 +/- 6.5 ml.min-1.kg-1, in nonpregnant ewes.",Pharmacokinetics of lidocaine in nonpregnant and pregnant ewes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3195730/),[l] / [kg],4.17,154471,DB00281,Lidocaine
,3195730,total clearance,"The volume of distribution during the terminal exponential phase of drug elimination (Vd beta) and total clearance of lidocaine (Cl) were also higher in pregnant animals: 4.17 +/- 0.50 L/kg and 99.6 +/- 8.5 ml.min-1.kg-1, respectively; compared to 2.46 +/- 0.48 L/kg and 44.1 +/- 6.5 ml.min-1.kg-1, in nonpregnant ewes.",Pharmacokinetics of lidocaine in nonpregnant and pregnant ewes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3195730/),[ml] / [kg·min],99.6,154472,DB00281,Lidocaine
,3195730,total clearance,"The volume of distribution during the terminal exponential phase of drug elimination (Vd beta) and total clearance of lidocaine (Cl) were also higher in pregnant animals: 4.17 +/- 0.50 L/kg and 99.6 +/- 8.5 ml.min-1.kg-1, respectively; compared to 2.46 +/- 0.48 L/kg and 44.1 +/- 6.5 ml.min-1.kg-1, in nonpregnant ewes.",Pharmacokinetics of lidocaine in nonpregnant and pregnant ewes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3195730/),[l] / [kg],2.46,154473,DB00281,Lidocaine
,3195730,total clearance,"The volume of distribution during the terminal exponential phase of drug elimination (Vd beta) and total clearance of lidocaine (Cl) were also higher in pregnant animals: 4.17 +/- 0.50 L/kg and 99.6 +/- 8.5 ml.min-1.kg-1, respectively; compared to 2.46 +/- 0.48 L/kg and 44.1 +/- 6.5 ml.min-1.kg-1, in nonpregnant ewes.",Pharmacokinetics of lidocaine in nonpregnant and pregnant ewes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3195730/),[ml] / [kg·min],44.1,154474,DB00281,Lidocaine
,3195730,Cl,"However, the balance between these changes in Vd beta and Cl did not result in a significant difference in the elimination half-life of lidocaine (38.1 +/- 2.1 minutes in nonpregnant and 31.9 +/- 3.0 minutes in pregnant ewes).",Pharmacokinetics of lidocaine in nonpregnant and pregnant ewes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3195730/),min,38.1,154475,DB00281,Lidocaine
,3195730,elimination half-life,"However, the balance between these changes in Vd beta and Cl did not result in a significant difference in the elimination half-life of lidocaine (38.1 +/- 2.1 minutes in nonpregnant and 31.9 +/- 3.0 minutes in pregnant ewes).",Pharmacokinetics of lidocaine in nonpregnant and pregnant ewes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3195730/),min,38.1,154476,DB00281,Lidocaine
,3195730,elimination half-life,"However, the balance between these changes in Vd beta and Cl did not result in a significant difference in the elimination half-life of lidocaine (38.1 +/- 2.1 minutes in nonpregnant and 31.9 +/- 3.0 minutes in pregnant ewes).",Pharmacokinetics of lidocaine in nonpregnant and pregnant ewes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3195730/),min,31.9,154477,DB00281,Lidocaine
,15509291,Minimum alveolar concentration,Minimum alveolar concentration of I was 1.34 +/- 0.11 (%; mean +/- SD) for both types of stimulus.,Effect of lidocaine on the minimum alveolar concentration of isoflurane in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509291/),%,1.34,156139,DB00281,Lidocaine
,15509291,Plasma concentrations,"Plasma concentrations (ng mL(-1), median; value below and above MAC, respectively) for LCRI were: lidocaine, 1465 and 1537; glycinexylidide (GX), 111 and 181; monoethylglycinexylidide (MEGX), 180 and 471 and for HCRI were: lidocaine, 4350 and 4691; GX, 784 and 862; MEGX, 714 and 710.",Effect of lidocaine on the minimum alveolar concentration of isoflurane in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509291/),[ng] / [ml],146,156140,DB00281,Lidocaine
,15509291,Plasma concentrations,"Plasma concentrations (ng mL(-1), median; value below and above MAC, respectively) for LCRI were: lidocaine, 1465 and 1537; glycinexylidide (GX), 111 and 181; monoethylglycinexylidide (MEGX), 180 and 471 and for HCRI were: lidocaine, 4350 and 4691; GX, 784 and 862; MEGX, 714 and 710.",Effect of lidocaine on the minimum alveolar concentration of isoflurane in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509291/),[ng] / [ml],435,156141,DB00281,Lidocaine
,8214738,Plasma concentrations,Plasma concentrations at 1.5 and 2 min after drug administration were higher (P < 0.05) after instillation into the endotracheal tube (1.40 +/- 0.19 and 1.26 +/- 0.14 microgram/mL) than after deep endobronchial administration (1.00 +/- 0.08 and 0.83 +/- 0.05 microgram/mL).,Pharmacokinetics and technique of endotracheal and deep endobronchial lidocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214738/),[μg] / [ml],1.40,157693,DB00281,Lidocaine
,8214738,Plasma concentrations,Plasma concentrations at 1.5 and 2 min after drug administration were higher (P < 0.05) after instillation into the endotracheal tube (1.40 +/- 0.19 and 1.26 +/- 0.14 microgram/mL) than after deep endobronchial administration (1.00 +/- 0.08 and 0.83 +/- 0.05 microgram/mL).,Pharmacokinetics and technique of endotracheal and deep endobronchial lidocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214738/),[μg] / [ml],1.26,157694,DB00281,Lidocaine
,8214738,Plasma concentrations,Plasma concentrations at 1.5 and 2 min after drug administration were higher (P < 0.05) after instillation into the endotracheal tube (1.40 +/- 0.19 and 1.26 +/- 0.14 microgram/mL) than after deep endobronchial administration (1.00 +/- 0.08 and 0.83 +/- 0.05 microgram/mL).,Pharmacokinetics and technique of endotracheal and deep endobronchial lidocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214738/),[μg] / [ml],1.00,157695,DB00281,Lidocaine
,8214738,Plasma concentrations,Plasma concentrations at 1.5 and 2 min after drug administration were higher (P < 0.05) after instillation into the endotracheal tube (1.40 +/- 0.19 and 1.26 +/- 0.14 microgram/mL) than after deep endobronchial administration (1.00 +/- 0.08 and 0.83 +/- 0.05 microgram/mL).,Pharmacokinetics and technique of endotracheal and deep endobronchial lidocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214738/),[μg] / [ml],0.83,157696,DB00281,Lidocaine
,8214738,AUC1/AUCtot ratio,"After tube instillation, the AUC1/AUCtot ratio (2.6%) was higher (P < 0.05) than after deep endobronchial instillation (1.1%).",Pharmacokinetics and technique of endotracheal and deep endobronchial lidocaine administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214738/),,2,157697,DB00281,Lidocaine
,8214738,AUC1/AUCtot ratio,"After tube instillation, the AUC1/AUCtot ratio (2.6%) was higher (P < 0.05) than after deep endobronchial instillation (1.1%).",Pharmacokinetics and technique of endotracheal and deep endobronchial lidocaine administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214738/),,1,157698,DB00281,Lidocaine
,11324717,constant flow rate,The liver was perfused in a recirculating system at a constant flow rate of 20 ml/min.,The effects of norepinephrine and prostaglandin E1 on pharmacokinetics of lidocaine in isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11324717/),[ml] / [min],20,159488,DB00281,Lidocaine
,19301938,maximum serum concentration (C(max)),"The means +/- SD and medians of pharmacokinetic parameters for lidocaine were as follows: maximum serum concentration (C(max)) 245.1 +/- 370.8 ng/mL, 73.6 ng/mL; time to reach C(max) (t(max)) 69.2 +/- 78.3 minutes, 40 minutes; area under the serum concentration-time curve from 0 to 6 hours (AUC(6)) 756.5 +/- 1254.1 ng.h/mL, 238.2 ng.h/mL.","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),[ng] / [ml],245.1,160184,DB00281,Lidocaine
,19301938,maximum serum concentration (C(max)),"The means +/- SD and medians of pharmacokinetic parameters for lidocaine were as follows: maximum serum concentration (C(max)) 245.1 +/- 370.8 ng/mL, 73.6 ng/mL; time to reach C(max) (t(max)) 69.2 +/- 78.3 minutes, 40 minutes; area under the serum concentration-time curve from 0 to 6 hours (AUC(6)) 756.5 +/- 1254.1 ng.h/mL, 238.2 ng.h/mL.","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),[ng] / [ml],73.6,160185,DB00281,Lidocaine
,19301938,time to reach C(max) (t(max)),"The means +/- SD and medians of pharmacokinetic parameters for lidocaine were as follows: maximum serum concentration (C(max)) 245.1 +/- 370.8 ng/mL, 73.6 ng/mL; time to reach C(max) (t(max)) 69.2 +/- 78.3 minutes, 40 minutes; area under the serum concentration-time curve from 0 to 6 hours (AUC(6)) 756.5 +/- 1254.1 ng.h/mL, 238.2 ng.h/mL.","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),min,69.2,160186,DB00281,Lidocaine
,19301938,time to reach C(max) (t(max)),"The means +/- SD and medians of pharmacokinetic parameters for lidocaine were as follows: maximum serum concentration (C(max)) 245.1 +/- 370.8 ng/mL, 73.6 ng/mL; time to reach C(max) (t(max)) 69.2 +/- 78.3 minutes, 40 minutes; area under the serum concentration-time curve from 0 to 6 hours (AUC(6)) 756.5 +/- 1254.1 ng.h/mL, 238.2 ng.h/mL.","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),min,40,160187,DB00281,Lidocaine
,19301938,area under the serum concentration-time curve from 0 to 6 hours (AUC(6)),"The means +/- SD and medians of pharmacokinetic parameters for lidocaine were as follows: maximum serum concentration (C(max)) 245.1 +/- 370.8 ng/mL, 73.6 ng/mL; time to reach C(max) (t(max)) 69.2 +/- 78.3 minutes, 40 minutes; area under the serum concentration-time curve from 0 to 6 hours (AUC(6)) 756.5 +/- 1254.1 ng.h/mL, 238.2 ng.h/mL.","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),[h·ng] / [ml],756.5,160188,DB00281,Lidocaine
,19301938,area under the serum concentration-time curve from 0 to 6 hours (AUC(6)),"The means +/- SD and medians of pharmacokinetic parameters for lidocaine were as follows: maximum serum concentration (C(max)) 245.1 +/- 370.8 ng/mL, 73.6 ng/mL; time to reach C(max) (t(max)) 69.2 +/- 78.3 minutes, 40 minutes; area under the serum concentration-time curve from 0 to 6 hours (AUC(6)) 756.5 +/- 1254.1 ng.h/mL, 238.2 ng.h/mL.","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),[h·ng] / [ml],238.2,160189,DB00281,Lidocaine
above,19301938,maximum serum concentrations,"Only three patients had maximum serum concentrations above 1000 ng/mL (1037.8, 1044.75 and 1364.1 ng/mL).","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),[ng] / [ml],1000,160190,DB00281,Lidocaine
,19301938,maximum serum concentrations,"Only three patients had maximum serum concentrations above 1000 ng/mL (1037.8, 1044.75 and 1364.1 ng/mL).","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),[ng] / [ml],1037.8,160191,DB00281,Lidocaine
,19301938,maximum serum concentrations,"Only three patients had maximum serum concentrations above 1000 ng/mL (1037.8, 1044.75 and 1364.1 ng/mL).","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),[ng] / [ml],1044.75,160192,DB00281,Lidocaine
,19301938,maximum serum concentrations,"Only three patients had maximum serum concentrations above 1000 ng/mL (1037.8, 1044.75 and 1364.1 ng/mL).","Pharmacokinetics of anorectal nifedipine and lidocaine (lignocaine) ointment following haemorrhoidectomy: an open-label, single-dose, phase IV clinical study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19301938/),[ng] / [ml],1364.1,160193,DB00281,Lidocaine
,8068867,clearances,"For the 6-hydroxylation of chlorzoxazone (P450 2E1) the predicted and actual clearances were 110 +/- 77 mL min-1 and 110 mL min-1, respectively.",Predicting the hepatic clearance of xenobiotics in humans from in vitro data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068867/),[ml] / [min],110,162611,DB00281,Lidocaine
,8068867,clearances,"For the 6-hydroxylation of chlorzoxazone (P450 2E1) the predicted and actual clearances were 110 +/- 77 mL min-1 and 110 mL min-1, respectively.",Predicting the hepatic clearance of xenobiotics in humans from in vitro data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068867/),[ml] / [min],110,162612,DB00281,Lidocaine
,8068867,CLH,An increase to 72 +/- 25 mL min-1 in the CLH of cortisol to 6 beta-hydroxycortisol was calculated following rifampicin treatment.,Predicting the hepatic clearance of xenobiotics in humans from in vitro data. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068867/),[ml] / [min],72,162613,DB00281,Lidocaine
,11050747,time of half-life of elimination phase (t1/2),"After intravenous administration of product A the mean time of half-life of elimination phase (t1/2) for sulphadoxine was 12.9 h, steady-state volume of distribution (Vd(ss)) was 0.44 L.kg-1 and clearance was 0.024 L.kg-1.h-1.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,12.9,162744,DB00281,Lidocaine
,11050747,steady-state volume of distribution (Vd(ss)),"After intravenous administration of product A the mean time of half-life of elimination phase (t1/2) for sulphadoxine was 12.9 h, steady-state volume of distribution (Vd(ss)) was 0.44 L.kg-1 and clearance was 0.024 L.kg-1.h-1.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),[l] / [kg],0.44,162745,DB00281,Lidocaine
,11050747,clearance,"After intravenous administration of product A the mean time of half-life of elimination phase (t1/2) for sulphadoxine was 12.9 h, steady-state volume of distribution (Vd(ss)) was 0.44 L.kg-1 and clearance was 0.024 L.kg-1.h-1.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),[l] / [h·kg],0.024,162746,DB00281,Lidocaine
,11050747,bioavailability,"After subcutaneous administration, the bioavailability of sulphadoxine was 96% and 98% and the time to reach a maximum concentration was 6.3 and 8.0 h for products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),%,96,162747,DB00281,Lidocaine
,11050747,bioavailability,"After subcutaneous administration, the bioavailability of sulphadoxine was 96% and 98% and the time to reach a maximum concentration was 6.3 and 8.0 h for products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),%,98,162748,DB00281,Lidocaine
,11050747,time to reach a maximum concentration,"After subcutaneous administration, the bioavailability of sulphadoxine was 96% and 98% and the time to reach a maximum concentration was 6.3 and 8.0 h for products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,6.3,162749,DB00281,Lidocaine
,11050747,time to reach a maximum concentration,"After subcutaneous administration, the bioavailability of sulphadoxine was 96% and 98% and the time to reach a maximum concentration was 6.3 and 8.0 h for products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,8.0,162750,DB00281,Lidocaine
,11050747,Cmax,The Cmax for trimethoprim was higher for product A (0.49 microgram.,Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),μg,0.49,162751,DB00281,Lidocaine
,11050747,apparent elimination t1/2,"Slow absorption from the injection site appeared to delay the elimination of trimethoprim after subcutaneous administration when compared to that after intravenous administration: apparent elimination t1/2 for trimethoprim after intravenous administration of product A was 1.9 h compared to 3.9 h and 3.6 h after subcutaneous administration of products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,1.9,162752,DB00281,Lidocaine
,11050747,apparent elimination t1/2,"Slow absorption from the injection site appeared to delay the elimination of trimethoprim after subcutaneous administration when compared to that after intravenous administration: apparent elimination t1/2 for trimethoprim after intravenous administration of product A was 1.9 h compared to 3.9 h and 3.6 h after subcutaneous administration of products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,3.9,162753,DB00281,Lidocaine
,11050747,apparent elimination t1/2,"Slow absorption from the injection site appeared to delay the elimination of trimethoprim after subcutaneous administration when compared to that after intravenous administration: apparent elimination t1/2 for trimethoprim after intravenous administration of product A was 1.9 h compared to 3.9 h and 3.6 h after subcutaneous administration of products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,3.6,162754,DB00281,Lidocaine
,11050747,mean residence time,Also the mean residence time was significantly shorter (p < 0.05) after intravenous administration (2.4 h) than that after subcutaneous administration of product A (6.9 h) and B (7.1 h).,Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,2.4,162755,DB00281,Lidocaine
,11050747,mean residence time,Also the mean residence time was significantly shorter (p < 0.05) after intravenous administration (2.4 h) than that after subcutaneous administration of product A (6.9 h) and B (7.1 h).,Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,6.9,162756,DB00281,Lidocaine
,11050747,mean residence time,Also the mean residence time was significantly shorter (p < 0.05) after intravenous administration (2.4 h) than that after subcutaneous administration of product A (6.9 h) and B (7.1 h).,Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),h,7.1,162757,DB00281,Lidocaine
,11050747,bioavailability,"The bioavailability of trimethoprim was lower than that of sulphadoxine: 76% and 74% for products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),%,76,162758,DB00281,Lidocaine
,11050747,bioavailability,"The bioavailability of trimethoprim was lower than that of sulphadoxine: 76% and 74% for products A and B, respectively.",Pharmacokinetics of sulphadoxine and trimethoprim and tissue irritation caused by two sulphadoxine-trimethoprim containing products after subcutaneous administration in pre-ruminant calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11050747/),%,74,162759,DB00281,Lidocaine
,21616681,V(2),"The final pharmacokinetic parameters were V(1)(L) = 0.0619*weight, V(2)(L) = 187, CL(1) (L/min) = 0.00419*weight, and CL(2) (L/min) = 8.92.",Population pharmacokinetics of lidocaine administered during and after cardiac surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21616681/),l,187,163115,DB00281,Lidocaine
,21616681,CL(2),"The final pharmacokinetic parameters were V(1)(L) = 0.0619*weight, V(2)(L) = 187, CL(1) (L/min) = 0.00419*weight, and CL(2) (L/min) = 8.92.",Population pharmacokinetics of lidocaine administered during and after cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21616681/),[l] / [min],8.92,163116,DB00281,Lidocaine
,9373813,onset time,The mean onset time of surgical analgesia of lidocaine was 11.2 +/- 5.1 min and that of prilocaine was 10.9 +/- 6.0 min.,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,11.2,164808,DB00281,Lidocaine
,9373813,onset time,The mean onset time of surgical analgesia of lidocaine was 11.2 +/- 5.1 min and that of prilocaine was 10.9 +/- 6.0 min.,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,10.9,164809,DB00281,Lidocaine
,9373813,t1/2 alpha,"After releasing the tourniquet, lidocaine is bi-exponentially eliminated with a t1/2 alpha of 4.3 +/- 2.1 min and a t1/2 beta of 79.1 +/- 31.2 min.",Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,4.3,164810,DB00281,Lidocaine
,9373813,t1/2 beta,"After releasing the tourniquet, lidocaine is bi-exponentially eliminated with a t1/2 alpha of 4.3 +/- 2.1 min and a t1/2 beta of 79.1 +/- 31.2 min.",Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,79.1,164811,DB00281,Lidocaine
,9373813,Total body clearance,Total body clearance was 0.86 +/- 0.39 litres/min.,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),[l] / [min],0.86,164812,DB00281,Lidocaine
,9373813,t1/2 alpha,Prilocaine is rapidly and bi-exponentially eliminated with a t1/2 alpha of 3.0 +/- 1.6 min and a t1/2 beta of 29.9 +/- 15.7 min.,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,3.0,164813,DB00281,Lidocaine
,9373813,t1/2 beta,Prilocaine is rapidly and bi-exponentially eliminated with a t1/2 alpha of 3.0 +/- 1.6 min and a t1/2 beta of 29.9 +/- 15.7 min.,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,29.9,164814,DB00281,Lidocaine
,9373813,total body clearance,"The total body clearance of prilocaine is higher than that of lidocaine, 4.15 +/- 1.31 vs.",Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),,4.15,164815,DB00281,Lidocaine
,9373813,t1/2 alpha,"Both compounds show comparable volumes of distribution (Vd, Vss and V beta) and a comparable t1/2 alpha (4.3 +/- 2.1 vs. 3.0 +/- 1.6 min; P = 0.1780).",Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,4.3,164816,DB00281,Lidocaine
,9373813,t1/2 alpha,"Both compounds show comparable volumes of distribution (Vd, Vss and V beta) and a comparable t1/2 alpha (4.3 +/- 2.1 vs. 3.0 +/- 1.6 min; P = 0.1780).",Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,3.0,164817,DB00281,Lidocaine
,9373813,t1/2 beta,The t1/2 beta for the two compounds were different (P = 0031); 79.1 +/- 31.2 min for lidocaine and 29.9 +/- 15.7 min for prilocaine.,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,79.1,164818,DB00281,Lidocaine
,9373813,t1/2 beta,The t1/2 beta for the two compounds were different (P = 0031); 79.1 +/- 31.2 min for lidocaine and 29.9 +/- 15.7 min for prilocaine.,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,29.9,164819,DB00281,Lidocaine
,9373813,mean residence time (MRT),The mean residence time (MRT) of lidocaine (193 +/- 233 min) also differed significantly from that of prilocaine (33.4 +/- 19.9 min; P = 0.0022).,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,193,164820,DB00281,Lidocaine
,9373813,mean residence time (MRT),The mean residence time (MRT) of lidocaine (193 +/- 233 min) also differed significantly from that of prilocaine (33.4 +/- 19.9 min; P = 0.0022).,Comparison of the disposition kinetics of lidocaine and (+/-)prilocaine in 20 patients undergoing intravenous regional anaesthesia during day case surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373813/),min,33.4,164821,DB00281,Lidocaine
,3954113,peak arterial plasma lidocaine concentration,"Despite a large total dose of topical lidocaine (5.3 +/- 2.1 mg/kg), the mean peak arterial plasma lidocaine concentration was low (0.6 +/- 2.1 micrograms/ml).",Cardiovascular responses and lidocaine absorption in fiberoptic-assisted awake intubation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954113/),[μg] / [ml],0.6,164985,DB00281,Lidocaine
,29561515,area under the concentration time curve0-8,"The median area under the concentration time curve0-8 and median maximum plasma concentration of amikacin were 109.0 μg × h/mL (IQR, 84.7-121.3) and 36.7 μg/mL (IQR, 34.1-40.5) with lidocaine compared with 103.3 μg × h/mL (IQR, 81.7-135.0; P = 0.814) and 34.1 μg/mL (IQR, 35.6-46.4; P = 0.638) without lidocaine, respectively.",Effect of Coadministration of Lidocaine on the Pain and Pharmacokinetics of Intramuscular Amikacin in Children With Multidrug-Resistant Tuberculosis: A Randomized Crossover Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29561515/),[h·μg] / [ml],109.0,165224,DB00281,Lidocaine
,29561515,area under the concentration time curve0-8,"The median area under the concentration time curve0-8 and median maximum plasma concentration of amikacin were 109.0 μg × h/mL (IQR, 84.7-121.3) and 36.7 μg/mL (IQR, 34.1-40.5) with lidocaine compared with 103.3 μg × h/mL (IQR, 81.7-135.0; P = 0.814) and 34.1 μg/mL (IQR, 35.6-46.4; P = 0.638) without lidocaine, respectively.",Effect of Coadministration of Lidocaine on the Pain and Pharmacokinetics of Intramuscular Amikacin in Children With Multidrug-Resistant Tuberculosis: A Randomized Crossover Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29561515/),[h·μg] / [ml],103.3,165225,DB00281,Lidocaine
,29561515,maximum plasma concentration,"The median area under the concentration time curve0-8 and median maximum plasma concentration of amikacin were 109.0 μg × h/mL (IQR, 84.7-121.3) and 36.7 μg/mL (IQR, 34.1-40.5) with lidocaine compared with 103.3 μg × h/mL (IQR, 81.7-135.0; P = 0.814) and 34.1 μg/mL (IQR, 35.6-46.4; P = 0.638) without lidocaine, respectively.",Effect of Coadministration of Lidocaine on the Pain and Pharmacokinetics of Intramuscular Amikacin in Children With Multidrug-Resistant Tuberculosis: A Randomized Crossover Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29561515/),[μg] / [ml],36.7,165226,DB00281,Lidocaine
,29561515,maximum plasma concentration,"The median area under the concentration time curve0-8 and median maximum plasma concentration of amikacin were 109.0 μg × h/mL (IQR, 84.7-121.3) and 36.7 μg/mL (IQR, 34.1-40.5) with lidocaine compared with 103.3 μg × h/mL (IQR, 81.7-135.0; P = 0.814) and 34.1 μg/mL (IQR, 35.6-46.4; P = 0.638) without lidocaine, respectively.",Effect of Coadministration of Lidocaine on the Pain and Pharmacokinetics of Intramuscular Amikacin in Children With Multidrug-Resistant Tuberculosis: A Randomized Crossover Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29561515/),[μg] / [ml],34.1,165227,DB00281,Lidocaine
,4057054,terminal half-life,"After intravenous dosing, the plasma levels of cefotaxime declined in a biphasic manner with a terminal half-life varying between 0.92 and 1.65 hr.",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),h,0.92 and 1.65,165915,DB00281,Lidocaine
,4057054,volume of distribution based on area,"Moreover, the pharmacokinetics were linear up to at least a 2.0 g dose for volume of distribution based on area (23.3-31.3 l), plasma clearance (249-2.88 ml/min), and renal clearance (151-177 ml/min).",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),l,23.3-31.3,165916,DB00281,Lidocaine
,4057054,plasma clearance,"Moreover, the pharmacokinetics were linear up to at least a 2.0 g dose for volume of distribution based on area (23.3-31.3 l), plasma clearance (249-2.88 ml/min), and renal clearance (151-177 ml/min).",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),[ml] / [min],249-2.88,165917,DB00281,Lidocaine
,4057054,renal clearance,"Moreover, the pharmacokinetics were linear up to at least a 2.0 g dose for volume of distribution based on area (23.3-31.3 l), plasma clearance (249-2.88 ml/min), and renal clearance (151-177 ml/min).",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),[ml] / [min],151-177,165918,DB00281,Lidocaine
,4057054,ratio,"Renal tubular secretion of intact cefotaxime and each of its metabolites was demonstrated by its interaction with probenecid, although the ratio of drug to metabolites ultimately excreted in urine after probenecid was similar to that seen normally (54 +/- 6, 19 +/- 4, 6.5 +/- 0.7 and 5.5 +/- 0.7% for cefotaxime, DACM, M2, and M3, respectively, when calculated as a percentage of the dose).",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),,54,165919,DB00281,Lidocaine
,4057054,ratio,"Renal tubular secretion of intact cefotaxime and each of its metabolites was demonstrated by its interaction with probenecid, although the ratio of drug to metabolites ultimately excreted in urine after probenecid was similar to that seen normally (54 +/- 6, 19 +/- 4, 6.5 +/- 0.7 and 5.5 +/- 0.7% for cefotaxime, DACM, M2, and M3, respectively, when calculated as a percentage of the dose).",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),,19,165920,DB00281,Lidocaine
,4057054,ratio,"Renal tubular secretion of intact cefotaxime and each of its metabolites was demonstrated by its interaction with probenecid, although the ratio of drug to metabolites ultimately excreted in urine after probenecid was similar to that seen normally (54 +/- 6, 19 +/- 4, 6.5 +/- 0.7 and 5.5 +/- 0.7% for cefotaxime, DACM, M2, and M3, respectively, when calculated as a percentage of the dose).",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),,6,165921,DB00281,Lidocaine
,4057054,ratio,"Renal tubular secretion of intact cefotaxime and each of its metabolites was demonstrated by its interaction with probenecid, although the ratio of drug to metabolites ultimately excreted in urine after probenecid was similar to that seen normally (54 +/- 6, 19 +/- 4, 6.5 +/- 0.7 and 5.5 +/- 0.7% for cefotaxime, DACM, M2, and M3, respectively, when calculated as a percentage of the dose).",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),,5,165922,DB00281,Lidocaine
,4057054,half-lives,"The observed half-lives of DACM, M2, and M3 were 2.3 +/- 0.4, 2.2 +/- 0.1 and 2.2 hr, respectively.",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),h,2.3,165923,DB00281,Lidocaine
,4057054,half-lives,"The observed half-lives of DACM, M2, and M3 were 2.3 +/- 0.4, 2.2 +/- 0.1 and 2.2 hr, respectively.",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),h,2.2,165924,DB00281,Lidocaine
,4057054,half-lives,"The observed half-lives of DACM, M2, and M3 were 2.3 +/- 0.4, 2.2 +/- 0.1 and 2.2 hr, respectively.",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),h,2.2,165925,DB00281,Lidocaine
,4057054,half-life,"However, when the true half-life of DACM was calculated (0.83 +/- 0.23 hr) it was not only significantly shorter than that observed but also shorter than that for intact cefotaxime.",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),h,0.83,165926,DB00281,Lidocaine
,4057054,plasma clearance,The plasma clearance of DACM (744 +/- 226 ml/min) was much higher than that of cefotaxime while the volume of distribution was of a similar order (56 +/- 24 l).,The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),[ml] / [min],744,165927,DB00281,Lidocaine
,4057054,volume of distribution,The plasma clearance of DACM (744 +/- 226 ml/min) was much higher than that of cefotaxime while the volume of distribution was of a similar order (56 +/- 24 l).,The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),l,56,165928,DB00281,Lidocaine
,4057054,maximum plasma levels,"When administered intramuscularly, there was good absorption of cefotaxime from the site of injection (92-94%) giving maximum plasma levels of the drug of between 30 and 35 mg/l at approximately 40 min after dosing.",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),[mg] / [l],30 and 35,165929,DB00281,Lidocaine
,4057054,half-life,"Thereafter, the plasma levels of cefotaxime declined in a monophasic manner with a half-life (1.0-1.2 hr) similar to that of the terminal half-life seen after intravenous administration.",The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057054/),h,1.0-1.2,165930,DB00281,Lidocaine
,6420165,terminal plasma half-life,"In one patient with active hepatic necrosis the terminal plasma half-life was 57.4, and in the others the half life ranged from 16.0 to 29.0 h.",Pharmacokinetics of tocainide in patients with combined hepatic and renal dysfunction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6420165/),,57.4,166442,DB00281,Lidocaine
,6420165,half life,"In one patient with active hepatic necrosis the terminal plasma half-life was 57.4, and in the others the half life ranged from 16.0 to 29.0 h.",Pharmacokinetics of tocainide in patients with combined hepatic and renal dysfunction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6420165/),h,16.0 to 29.0,166443,DB00281,Lidocaine
,1464113,absolute bioavailability (F(oral)),The absolute bioavailability (F(oral)) was 5.63%.,Preparation and evaluation of eudragit gels. V. Rectal gel preparations for sustained release and avoidance of first-pass metabolism of lidocaine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1464113/),%,5.63,166978,DB00281,Lidocaine
,1464113,absolute bioavailabilities,"The absolute bioavailabilities were 21.3 and 29.6%, respectively.",Preparation and evaluation of eudragit gels. V. Rectal gel preparations for sustained release and avoidance of first-pass metabolism of lidocaine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1464113/),%,21.3,166979,DB00281,Lidocaine
,1464113,absolute bioavailabilities,"The absolute bioavailabilities were 21.3 and 29.6%, respectively.",Preparation and evaluation of eudragit gels. V. Rectal gel preparations for sustained release and avoidance of first-pass metabolism of lidocaine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1464113/),%,29.6,166980,DB00281,Lidocaine
,3254976,plasma concentration,"The plasma concentration of lidocaine at the steady state, after a loading dose (7.62 mg/kg body weight) followed by an infusion (0.16 mg/min/kg), increased from 1.62 to 2.69 micrograms/ml after cimetidine treatment.",Effects of cimetidine on lidocaine distribution in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3254976/),[μg] / [ml],1.62,167755,DB00281,Lidocaine
,3254976,plasma concentration,"The plasma concentration of lidocaine at the steady state, after a loading dose (7.62 mg/kg body weight) followed by an infusion (0.16 mg/min/kg), increased from 1.62 to 2.69 micrograms/ml after cimetidine treatment.",Effects of cimetidine on lidocaine distribution in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3254976/),[μg] / [ml],2.69,167756,DB00281,Lidocaine
,18370545,onset time,The mean onset time of surgical analgesia of both lidocaine and prilocaine was 10 minutes.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),min,10,167805,DB00281,Lidocaine
,18370545,elimination phase half-life (t((1/2)alpha)),Lidocaine was biexponentially eliminated with a rapid elimination phase half-life (t((1/2)alpha)) of 9.95 +/- 14.3 minutes and a terminal elimination phase half-life (t((1/2)beta)) of 2.86 +/- 1.55 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),min,9.95,167806,DB00281,Lidocaine
,18370545,terminal elimination phase half-life (t((1/2)beta)),Lidocaine was biexponentially eliminated with a rapid elimination phase half-life (t((1/2)alpha)) of 9.95 +/- 14.3 minutes and a terminal elimination phase half-life (t((1/2)beta)) of 2.86 +/- 1.55 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),h,2.86,167807,DB00281,Lidocaine
,18370545,time to reach maximum plasma concentration (tmax),Lidocaine was metabolised to MEGX (monoethylglycylxylidide); time to reach maximum plasma concentration (tmax) 2.3 +/- 0.8 hours; maximum plasma concentration (C(max)) 0.32 +/- 0.13 mg/L; t((1/2)beta) 2.4 +/- 2.4 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),h,2.3,167808,DB00281,Lidocaine
,18370545,maximum plasma concentration (C(max)),Lidocaine was metabolised to MEGX (monoethylglycylxylidide); time to reach maximum plasma concentration (tmax) 2.3 +/- 0.8 hours; maximum plasma concentration (C(max)) 0.32 +/- 0.13 mg/L; t((1/2)beta) 2.4 +/- 2.4 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),[mg] / [l],0.32,167809,DB00281,Lidocaine
,18370545,t((1/2)beta),Lidocaine was metabolised to MEGX (monoethylglycylxylidide); time to reach maximum plasma concentration (tmax) 2.3 +/- 0.8 hours; maximum plasma concentration (C(max)) 0.32 +/- 0.13 mg/L; t((1/2)beta) 2.4 +/- 2.4 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),h,2.4,167810,DB00281,Lidocaine
,18370545,total body clearance,Lidocaine total body clearance was 67.8 +/- 28.8 L/h.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),[l] / [h],67.8,167811,DB00281,Lidocaine
,18370545,t((1/2)alpha),Prilocaine was rapidly and biexponentially eliminated with a t((1/2)alpha) of 9.4 +/- 18.4 minutes and a t((1/2)beta) of 2.12 +/- 1.28 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),min,9.4,167812,DB00281,Lidocaine
,18370545,t((1/2)beta),Prilocaine was rapidly and biexponentially eliminated with a t((1/2)alpha) of 9.4 +/- 18.4 minutes and a t((1/2)beta) of 2.12 +/- 1.28 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),h,2.12,167813,DB00281,Lidocaine
,18370545,total body clearance,The total body clearance of prilocaine (150 +/- 53 L/h) was higher than that of lidocaine (p = 0.0255).,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),[l] / [h],150,167814,DB00281,Lidocaine
,6437721,apparent volume of distribution,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),l,"1300 to 11,000",168376,DB00281,Lidocaine
,6437721,elimination half-life,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),d,53,168377,DB00281,Lidocaine
,6437721,elimination half-life,"Although it has a short elimination half-life (1 to 3h), 2 major metabolites with antiarrhythmic effects accumulate in the plasma of patients during long term therapy.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,1 to 3,168378,DB00281,Lidocaine
,6437721,elimination half-life,"Flecainide, another class Ic antiarrhythmic agent, has an elimination half-life of 14 hours which makes it suitable for twice daily dosing.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,14,168379,DB00281,Lidocaine
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,9,168380,DB00281,Lidocaine
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,28,168381,DB00281,Lidocaine
,6437721,apparent volume of distribution,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),[l] / [kg],5.0 to 6.6,168382,DB00281,Lidocaine
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,6 to 12,168383,DB00281,Lidocaine
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,11 to 17,168384,DB00281,Lidocaine
,9408858,apparent pulmonary tissue volume,The apparent pulmonary tissue volume of lidocaine (39 ml/kg) was nearly ninefold greater than that of antipyrine (4.5 ml/kg).,A recirculatory model of the pulmonary uptake and pharmacokinetics of lidocaine based on analysis of arterial and mixed venous data from dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408858/),[ml] / [kg],39,168422,DB00281,Lidocaine
,9408858,apparent pulmonary tissue volume,The apparent pulmonary tissue volume of lidocaine (39 ml/kg) was nearly ninefold greater than that of antipyrine (4.5 ml/kg).,A recirculatory model of the pulmonary uptake and pharmacokinetics of lidocaine based on analysis of arterial and mixed venous data from dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9408858/),[ml] / [kg],4.5,168423,DB00281,Lidocaine
,11900338,Total hepatic blood flow,"Total hepatic blood flow was significantly decreased (36.2 +/- 8.4 mL/min/100 g tissue vs. 120.4 +/- 10.6 mL/min/100 g tissue), which was due to the decreased portal blood flow.",Endotoxic shock alters the pharmacokinetics of lidocaine and monoethylglycinexylidide. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11900338/),[ml] / [100·g·min],36.2,168664,DB00281,Lidocaine
,11900338,Total hepatic blood flow,"Total hepatic blood flow was significantly decreased (36.2 +/- 8.4 mL/min/100 g tissue vs. 120.4 +/- 10.6 mL/min/100 g tissue), which was due to the decreased portal blood flow.",Endotoxic shock alters the pharmacokinetics of lidocaine and monoethylglycinexylidide. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11900338/),[ml] / [100·g·min],120.4,168665,DB00281,Lidocaine
,11900338,Serum concentrations,Serum concentrations of lidocaine were higher in endotoxic shock versus control animals at 2 h following lidocaine administration (1.5 +/- 0.13 mg/L vs. 0.11 +/- 0.03 mg/L).,Endotoxic shock alters the pharmacokinetics of lidocaine and monoethylglycinexylidide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11900338/),[mg] / [l],1.5,168666,DB00281,Lidocaine
,11900338,Serum concentrations,Serum concentrations of lidocaine were higher in endotoxic shock versus control animals at 2 h following lidocaine administration (1.5 +/- 0.13 mg/L vs. 0.11 +/- 0.03 mg/L).,Endotoxic shock alters the pharmacokinetics of lidocaine and monoethylglycinexylidide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11900338/),[mg] / [l],0.11,168667,DB00281,Lidocaine
,6407848,plasma half-life,"In 9 with total renal failure, the plasma half-life ranged from 16.6 to 42.7 h and total plasma clearance from 35 to 94 ml/min.",Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),h,16.6 to 42.7,170295,DB00281,Lidocaine
,6407848,total plasma clearance,"In 9 with total renal failure, the plasma half-life ranged from 16.6 to 42.7 h and total plasma clearance from 35 to 94 ml/min.",Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),[ml] / [min],35 to 94,170296,DB00281,Lidocaine
,6407848,half-life,The mean half-life in the remaining patients was 22.3 +/- 4.8 h (+/- SD).,Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),h,22.3,170297,DB00281,Lidocaine
,6407848,half-life,"During a 4 h haemodialysis, the half-life in the 9 patients decreased to 8.5 +/- 4.6 h, which was calculated to correspond to removal of 25 +/- 14% of the drug from the body.",Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),h,8.5,170298,DB00281,Lidocaine
,6407848,half-life,In 6 patients with impaired renal function (creatinine clearance 10-55 ml/min) the tocainide half-life ranged from 13.2 to 22.0 h and total plasma clearance from 72 to 122 ml/min.,Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),h,13.2 to 22.0,170299,DB00281,Lidocaine
,6407848,total plasma clearance,In 6 patients with impaired renal function (creatinine clearance 10-55 ml/min) the tocainide half-life ranged from 13.2 to 22.0 h and total plasma clearance from 72 to 122 ml/min.,Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),[ml] / [min],72 to 122,170300,DB00281,Lidocaine
,6407848,half-life,"One patient was taking allopurinol and 1 dihydralazine, and the mean half-life in the others was 19.2 +/- 4.0 h.",Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6407848/),h,19.2,170301,DB00281,Lidocaine
,2111573,half-life,The hydantoin was synthesized and its hydrolysis in sodium hydroxide (pH greater than 12) was found to follow first-order kinetics with an estimated half-life of 24.6 minutes.,"A gas chromatographic assay for tocainide carbamoyl-O-beta-D-glucuronide:quantitation of the base hydrolyzed product, 3-(2',6'-xylyl)-5-methylhydantoin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111573/),min,24.6,171885,DB00281,Lidocaine
,2111573,elimination half-life,"From urine data, the elimination half-life of tocainide was approximately 15.5 hours.","A gas chromatographic assay for tocainide carbamoyl-O-beta-D-glucuronide:quantitation of the base hydrolyzed product, 3-(2',6'-xylyl)-5-methylhydantoin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111573/),h,15.5,171886,DB00281,Lidocaine
,2111573,urinary excretion half-life,The urinary excretion half-life of the tocainide carbamoyl glucuronide was approximately 13.8 hours.,"A gas chromatographic assay for tocainide carbamoyl-O-beta-D-glucuronide:quantitation of the base hydrolyzed product, 3-(2',6'-xylyl)-5-methylhydantoin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111573/),h,13.8,171887,DB00281,Lidocaine
,6440790,elimination half-life,The elimination half-life of RS-tocainide was found to be 14.3 hours.,Stereoselective disposition of RS-tocainide in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6440790/),h,14.3,174172,DB00281,Lidocaine
,6440790,elimination half-lives,"The elimination half-lives of the two stereoisomers of tocainide differed significantly, i.e. R(-) tocainide 10 hours, and S(+) tocainide 16.7 hours.",Stereoselective disposition of RS-tocainide in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6440790/),h,10,174173,DB00281,Lidocaine
,6440790,elimination half-lives,"The elimination half-lives of the two stereoisomers of tocainide differed significantly, i.e. R(-) tocainide 10 hours, and S(+) tocainide 16.7 hours.",Stereoselective disposition of RS-tocainide in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6440790/),h,16.7,174174,DB00281,Lidocaine
,6440790,t1/2,"The observed t1/2 for the tocainide conjugate of 10.3 hours was close to that of R(-) tocainide, indicating that the metabolite was preferably formed from the R(-) stereoisomer of tocainide.",Stereoselective disposition of RS-tocainide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6440790/),h,10.3,174175,DB00281,Lidocaine
,1724536,Infarct size,Infarct size was 16.3 +/- 14.7% in the lidocaine group as compared with 68.6 +/- 12.6% (p less than 0.01) in the bretylium group.,Differences in infarct size with lidocaine as compared with bretylium tosylate in acute myocardial ischemia and reperfusion in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1724536/),%,16.3,175974,DB00281,Lidocaine
,1724536,Infarct size,Infarct size was 16.3 +/- 14.7% in the lidocaine group as compared with 68.6 +/- 12.6% (p less than 0.01) in the bretylium group.,Differences in infarct size with lidocaine as compared with bretylium tosylate in acute myocardial ischemia and reperfusion in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1724536/),%,68.6,175975,DB00281,Lidocaine
,1724536,peak chemiluminescence response,"Lidocaine significantly reduced the peak chemiluminescence response to zymosan from 3.34 +/- 0.44 without lidocaine to 2.23 +/- 0.46 (p less than 0.01) and 1.06 +/- 0.17 mV (p less than 0.001), with lidocaine concentrations of 20 and 200 micrograms/ml, respectively.",Differences in infarct size with lidocaine as compared with bretylium tosylate in acute myocardial ischemia and reperfusion in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1724536/),mv,3.34,175976,DB00281,Lidocaine
,1724536,peak chemiluminescence response,"Lidocaine significantly reduced the peak chemiluminescence response to zymosan from 3.34 +/- 0.44 without lidocaine to 2.23 +/- 0.46 (p less than 0.01) and 1.06 +/- 0.17 mV (p less than 0.001), with lidocaine concentrations of 20 and 200 micrograms/ml, respectively.",Differences in infarct size with lidocaine as compared with bretylium tosylate in acute myocardial ischemia and reperfusion in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1724536/),mv,2.23,175977,DB00281,Lidocaine
,1724536,peak chemiluminescence response,"Lidocaine significantly reduced the peak chemiluminescence response to zymosan from 3.34 +/- 0.44 without lidocaine to 2.23 +/- 0.46 (p less than 0.01) and 1.06 +/- 0.17 mV (p less than 0.001), with lidocaine concentrations of 20 and 200 micrograms/ml, respectively.",Differences in infarct size with lidocaine as compared with bretylium tosylate in acute myocardial ischemia and reperfusion in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1724536/),mv,1.06,175978,DB00281,Lidocaine
,1724536,Adherence,"Adherence of porcine granulocytes to plastic was also reduced from 332 +/- 32 cells/mm2 (no lidocaine) to 247 +/- 35 and 206 +/- 26 cells/mm2 with lidocaine concentrations of 20 and 200 micrograms/ml, respectively (p less than 0.001).",Differences in infarct size with lidocaine as compared with bretylium tosylate in acute myocardial ischemia and reperfusion in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1724536/),[cells] / [mm2],332,175979,DB00281,Lidocaine
,1724536,Adherence,"Adherence of porcine granulocytes to plastic was also reduced from 332 +/- 32 cells/mm2 (no lidocaine) to 247 +/- 35 and 206 +/- 26 cells/mm2 with lidocaine concentrations of 20 and 200 micrograms/ml, respectively (p less than 0.001).",Differences in infarct size with lidocaine as compared with bretylium tosylate in acute myocardial ischemia and reperfusion in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1724536/),[cells] / [mm2],247,175980,DB00281,Lidocaine
,1724536,Adherence,"Adherence of porcine granulocytes to plastic was also reduced from 332 +/- 32 cells/mm2 (no lidocaine) to 247 +/- 35 and 206 +/- 26 cells/mm2 with lidocaine concentrations of 20 and 200 micrograms/ml, respectively (p less than 0.001).",Differences in infarct size with lidocaine as compared with bretylium tosylate in acute myocardial ischemia and reperfusion in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1724536/),[cells] / [mm2],206,175981,DB00281,Lidocaine
,1724536,Infract size,Infract size in the granulocyte-depleted pigs was 26.6 +/- 5.6% as compared with 51.4 +/- 5.5% in pigs that received nonimmune serum (p less than 0.01).,Differences in infarct size with lidocaine as compared with bretylium tosylate in acute myocardial ischemia and reperfusion in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1724536/),,26,175982,DB00281,Lidocaine
,1724536,Infract size,Infract size in the granulocyte-depleted pigs was 26.6 +/- 5.6% as compared with 51.4 +/- 5.5% in pigs that received nonimmune serum (p less than 0.01).,Differences in infarct size with lidocaine as compared with bretylium tosylate in acute myocardial ischemia and reperfusion in pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1724536/),%,51,175983,DB00281,Lidocaine
,32440099,IC50,"In vitro study revealed that simvastatin, among the statins, had the most significant inhibitory effect on lidocaine metabolism with IC50 of 39.31 µM, 50 µM and 15.77 µM for RLM, HLM and CYP3A4.1, respectively.",Investigation of the Inhibitory Effect of Simvastatin on the Metabolism of Lidocaine Both in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32440099/),μM,39.31,176348,DB00281,Lidocaine
,32440099,IC50,"In vitro study revealed that simvastatin, among the statins, had the most significant inhibitory effect on lidocaine metabolism with IC50 of 39.31 µM, 50 µM and 15.77 µM for RLM, HLM and CYP3A4.1, respectively.",Investigation of the Inhibitory Effect of Simvastatin on the Metabolism of Lidocaine Both in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32440099/),μM,50,176349,DB00281,Lidocaine
,32440099,IC50,"In vitro study revealed that simvastatin, among the statins, had the most significant inhibitory effect on lidocaine metabolism with IC50 of 39.31 µM, 50 µM and 15.77 µM for RLM, HLM and CYP3A4.1, respectively.",Investigation of the Inhibitory Effect of Simvastatin on the Metabolism of Lidocaine Both in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32440099/),μM,15.77,176350,DB00281,Lidocaine
,15616060,plasma concentrations,"Actual lidocaine plasma concentrations were 1.06 +/- 0.12, 2.83 +/- 0.39, 4.93 +/- 0.64, 6.86 +/- 0.97, 8.86 +/- 2.10, and 9.84 +/- 1.34 microg/mL for the target concentrations of 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),[μg] / [ml],1.06,176933,DB00281,Lidocaine
,15616060,plasma concentrations,"Actual lidocaine plasma concentrations were 1.06 +/- 0.12, 2.83 +/- 0.39, 4.93 +/- 0.64, 6.86 +/- 0.97, 8.86 +/- 2.10, and 9.84 +/- 1.34 microg/mL for the target concentrations of 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),[μg] / [ml],2.83,176934,DB00281,Lidocaine
,15616060,plasma concentrations,"Actual lidocaine plasma concentrations were 1.06 +/- 0.12, 2.83 +/- 0.39, 4.93 +/- 0.64, 6.86 +/- 0.97, 8.86 +/- 2.10, and 9.84 +/- 1.34 microg/mL for the target concentrations of 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),[μg] / [ml],4.93,176935,DB00281,Lidocaine
,15616060,plasma concentrations,"Actual lidocaine plasma concentrations were 1.06 +/- 0.12, 2.83 +/- 0.39, 4.93 +/- 0.64, 6.86 +/- 0.97, 8.86 +/- 2.10, and 9.84 +/- 1.34 microg/mL for the target concentrations of 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),[μg] / [ml],6.86,176936,DB00281,Lidocaine
,15616060,plasma concentrations,"Actual lidocaine plasma concentrations were 1.06 +/- 0.12, 2.83 +/- 0.39, 4.93 +/- 0.64, 6.86 +/- 0.97, 8.86 +/- 2.10, and 9.84 +/- 1.34 microg/mL for the target concentrations of 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),[μg] / [ml],8.86,176937,DB00281,Lidocaine
,15616060,plasma concentrations,"Actual lidocaine plasma concentrations were 1.06 +/- 0.12, 2.83 +/- 0.39, 4.93 +/- 0.64, 6.86 +/- 0.97, 8.86 +/- 2.10, and 9.84 +/- 1.34 microg/mL for the target concentrations of 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),[μg] / [ml],9.84,176938,DB00281,Lidocaine
,15616060,MAC,"The MAC of isoflurane in this study was 2.21% +/- 0.17%, 2.14% +/- 0.14%, 1.88% +/- 0.18%, 1.66% +/- 0.16%, 1.47% +/- 0.13%, 1.33% +/- 0.23%, and 1.06% +/- 0.19% at lidocaine target plasma concentrations of 0, 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),%,2.21,176939,DB00281,Lidocaine
,15616060,MAC,"The MAC of isoflurane in this study was 2.21% +/- 0.17%, 2.14% +/- 0.14%, 1.88% +/- 0.18%, 1.66% +/- 0.16%, 1.47% +/- 0.13%, 1.33% +/- 0.23%, and 1.06% +/- 0.19% at lidocaine target plasma concentrations of 0, 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),%,2.14,176940,DB00281,Lidocaine
,15616060,MAC,"The MAC of isoflurane in this study was 2.21% +/- 0.17%, 2.14% +/- 0.14%, 1.88% +/- 0.18%, 1.66% +/- 0.16%, 1.47% +/- 0.13%, 1.33% +/- 0.23%, and 1.06% +/- 0.19% at lidocaine target plasma concentrations of 0, 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),%,1.88,176941,DB00281,Lidocaine
,15616060,MAC,"The MAC of isoflurane in this study was 2.21% +/- 0.17%, 2.14% +/- 0.14%, 1.88% +/- 0.18%, 1.66% +/- 0.16%, 1.47% +/- 0.13%, 1.33% +/- 0.23%, and 1.06% +/- 0.19% at lidocaine target plasma concentrations of 0, 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),%,1.66,176942,DB00281,Lidocaine
,15616060,MAC,"The MAC of isoflurane in this study was 2.21% +/- 0.17%, 2.14% +/- 0.14%, 1.88% +/- 0.18%, 1.66% +/- 0.16%, 1.47% +/- 0.13%, 1.33% +/- 0.23%, and 1.06% +/- 0.19% at lidocaine target plasma concentrations of 0, 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),%,1.47,176943,DB00281,Lidocaine
,15616060,MAC,"The MAC of isoflurane in this study was 2.21% +/- 0.17%, 2.14% +/- 0.14%, 1.88% +/- 0.18%, 1.66% +/- 0.16%, 1.47% +/- 0.13%, 1.33% +/- 0.23%, and 1.06% +/- 0.19% at lidocaine target plasma concentrations of 0, 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),%,1.33,176944,DB00281,Lidocaine
,15616060,MAC,"The MAC of isoflurane in this study was 2.21% +/- 0.17%, 2.14% +/- 0.14%, 1.88% +/- 0.18%, 1.66% +/- 0.16%, 1.47% +/- 0.13%, 1.33% +/- 0.23%, and 1.06% +/- 0.19% at lidocaine target plasma concentrations of 0, 1, 3, 5, 7, 9, and 11 microg/mL, respectively.",The effects of intravenous lidocaine administration on the minimum alveolar concentration of isoflurane in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15616060/),%,1.06,176945,DB00281,Lidocaine
>,11375834,plasma concentrations,Therapeutic plasma concentrations (>1.4 microg/mL) could be achieved in 10 of 10 patients after endotracheal tube instillation but in only 4 of 10 patients after laryngeal mask instillation (P < 0.05).,A comparison of the endotracheal tube and the laryngeal mask airway as a route for endobronchial lidocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11375834/),μg,1.,177064,DB00281,Lidocaine
,11375834,Peak lidocaine concentrations,Peak lidocaine concentrations (2.47 and 1.09 microg/mL) (P < 0.05) and the area under the time versus plasma concentration curve (117.7 and 91.2 microg x min x mL(-1)) (P < 0.05) were higher after lidocaine administration into the endotracheal tube than into the laryngeal mask airway.,A comparison of the endotracheal tube and the laryngeal mask airway as a route for endobronchial lidocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11375834/),[μg] / [ml],2.47,177065,DB00281,Lidocaine
,11375834,Peak lidocaine concentrations,Peak lidocaine concentrations (2.47 and 1.09 microg/mL) (P < 0.05) and the area under the time versus plasma concentration curve (117.7 and 91.2 microg x min x mL(-1)) (P < 0.05) were higher after lidocaine administration into the endotracheal tube than into the laryngeal mask airway.,A comparison of the endotracheal tube and the laryngeal mask airway as a route for endobronchial lidocaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11375834/),[μg] / [ml],1.09,177066,DB00281,Lidocaine
,11375834,area under the time versus plasma concentration curve,Peak lidocaine concentrations (2.47 and 1.09 microg/mL) (P < 0.05) and the area under the time versus plasma concentration curve (117.7 and 91.2 microg x min x mL(-1)) (P < 0.05) were higher after lidocaine administration into the endotracheal tube than into the laryngeal mask airway.,A comparison of the endotracheal tube and the laryngeal mask airway as a route for endobronchial lidocaine administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11375834/),[min·μg] / [ml],117.7,177067,DB00281,Lidocaine
,11375834,area under the time versus plasma concentration curve,Peak lidocaine concentrations (2.47 and 1.09 microg/mL) (P < 0.05) and the area under the time versus plasma concentration curve (117.7 and 91.2 microg x min x mL(-1)) (P < 0.05) were higher after lidocaine administration into the endotracheal tube than into the laryngeal mask airway.,A comparison of the endotracheal tube and the laryngeal mask airway as a route for endobronchial lidocaine administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11375834/),[min·μg] / [ml],91.2,177068,DB00281,Lidocaine
,11226108,peak concentrations,"Observed peak concentrations were larger in the Ropivacaine group (4.25 [2.07-6.59 mg/L] vs 3.02 [0.98-5.82 mg/L]), but time to reach peak concentrations was comparable (5 [1-15 min] vs 5 [0-45 min] in the Ropivacaine and Bupivacaine groups, respectively).",A comparison of ropivacaine and bupivacaine for cervical plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11226108/),[mg] / [l],4.25,178162,DB00281,Lidocaine
,11226108,peak concentrations,"Observed peak concentrations were larger in the Ropivacaine group (4.25 [2.07-6.59 mg/L] vs 3.02 [0.98-5.82 mg/L]), but time to reach peak concentrations was comparable (5 [1-15 min] vs 5 [0-45 min] in the Ropivacaine and Bupivacaine groups, respectively).",A comparison of ropivacaine and bupivacaine for cervical plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11226108/),[mg] / [l],3.02,178163,DB00281,Lidocaine
,11226108,time to reach peak concentrations,"Observed peak concentrations were larger in the Ropivacaine group (4.25 [2.07-6.59 mg/L] vs 3.02 [0.98-5.82 mg/L]), but time to reach peak concentrations was comparable (5 [1-15 min] vs 5 [0-45 min] in the Ropivacaine and Bupivacaine groups, respectively).",A comparison of ropivacaine and bupivacaine for cervical plexus block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11226108/),,5,178164,DB00281,Lidocaine
,11226108,time to reach peak concentrations,"Observed peak concentrations were larger in the Ropivacaine group (4.25 [2.07-6.59 mg/L] vs 3.02 [0.98-5.82 mg/L]), but time to reach peak concentrations was comparable (5 [1-15 min] vs 5 [0-45 min] in the Ropivacaine and Bupivacaine groups, respectively).",A comparison of ropivacaine and bupivacaine for cervical plexus block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11226108/),,5,178165,DB00281,Lidocaine
,2245677,Peak SLC,Peak SLC were 1-3.5 (mean +/- SEM = 2.5 +/- 0.2) micrograms/ml.,Serum lidocaine concentrations in children during bronchoscopy with topical anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2245677/),[μg] / [ml],1-3.5,179742,DB00281,Lidocaine
,2245677,Peak SLC,Peak SLC were 1-3.5 (mean +/- SEM = 2.5 +/- 0.2) micrograms/ml.,Serum lidocaine concentrations in children during bronchoscopy with topical anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2245677/),[μg] / [ml],2.5,179743,DB00281,Lidocaine
,2245677,Vd beta,"The Vd beta was 1.79 +/- 0.19 L/kg, the t1/2 beta was 109 +/- 12 minutes, and the total body clearance 12.2 +/- 1.1 ml/min/kg.",Serum lidocaine concentrations in children during bronchoscopy with topical anesthesia. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2245677/),[l] / [kg],1.79,179744,DB00281,Lidocaine
,2245677,t1/2 beta,"The Vd beta was 1.79 +/- 0.19 L/kg, the t1/2 beta was 109 +/- 12 minutes, and the total body clearance 12.2 +/- 1.1 ml/min/kg.",Serum lidocaine concentrations in children during bronchoscopy with topical anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2245677/),min,109,179745,DB00281,Lidocaine
,2245677,total body clearance,"The Vd beta was 1.79 +/- 0.19 L/kg, the t1/2 beta was 109 +/- 12 minutes, and the total body clearance 12.2 +/- 1.1 ml/min/kg.",Serum lidocaine concentrations in children during bronchoscopy with topical anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2245677/),[ml] / [kg·min],12.2,179746,DB00281,Lidocaine
,12455305,maximum plasma lidocaine concentrations at steady state,"The mean maximum plasma lidocaine concentrations at steady state with lidocaine patches applied in groups 1 and 2 were 186 and 225 ng/mL, respectively, compared with the reported mean maximum plasma concentration of 130 ng/ml. with the labeled dosage (12 hr/day).",Pharmacokinetics and safety of continuously applied lidocaine patches 5%. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12455305/),[ng] / [ml],186,180609,DB00281,Lidocaine
,12455305,maximum plasma lidocaine concentrations at steady state,"The mean maximum plasma lidocaine concentrations at steady state with lidocaine patches applied in groups 1 and 2 were 186 and 225 ng/mL, respectively, compared with the reported mean maximum plasma concentration of 130 ng/ml. with the labeled dosage (12 hr/day).",Pharmacokinetics and safety of continuously applied lidocaine patches 5%. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12455305/),[ng] / [ml],225,180610,DB00281,Lidocaine
,12455305,maximum plasma concentration,"The mean maximum plasma lidocaine concentrations at steady state with lidocaine patches applied in groups 1 and 2 were 186 and 225 ng/mL, respectively, compared with the reported mean maximum plasma concentration of 130 ng/ml. with the labeled dosage (12 hr/day).",Pharmacokinetics and safety of continuously applied lidocaine patches 5%. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12455305/),[ng] / [ml],130,180611,DB00281,Lidocaine
,12455305,area under the concentration-time curve,"The area under the concentration-time curve for one dosage interval at steady state was 3550 and 4506 ng.hr/mL for groups 1 and 2, respectively.",Pharmacokinetics and safety of continuously applied lidocaine patches 5%. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12455305/),[h·ng] / [ml],3550,180612,DB00281,Lidocaine
,12455305,area under the concentration-time curve,"The area under the concentration-time curve for one dosage interval at steady state was 3550 and 4506 ng.hr/mL for groups 1 and 2, respectively.",Pharmacokinetics and safety of continuously applied lidocaine patches 5%. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12455305/),[h·ng] / [ml],4506,180613,DB00281,Lidocaine
under,3623743,tmax,All the tmax observed were under 2 h and the dose independence of the kinetic of BU is not admissible in this study.,Pharmacokinetics of bupivacaine after axillary brachial plexus block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3623743/),h,2,180682,DB00281,Lidocaine
,8650905,maximum concentration,A mean maximum concentration of 232 ng/ml was observed after 20 minutes.,Pharmacokinetics of lignocaine in Icelandic horses after infiltration anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8650905/),[ng] / [ml],232,181014,DB00281,Lidocaine
,8650905,half-life of the distribution phase (alpha),The mean half-life of the distribution phase (alpha) was 9.8 minutes and that of the elimination phase (beta) 48.4 minutes.,Pharmacokinetics of lignocaine in Icelandic horses after infiltration anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8650905/),min,9.8,181015,DB00281,Lidocaine
,8650905,elimination phase (beta),The mean half-life of the distribution phase (alpha) was 9.8 minutes and that of the elimination phase (beta) 48.4 minutes.,Pharmacokinetics of lignocaine in Icelandic horses after infiltration anaesthesia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8650905/),min,48.4,181016,DB00281,Lidocaine
,3612496,clearance,"When administered in combination with MEGX, lignocaine clearance was significantly reduced from 58 +/- 18 to 48 +/- 13 L hr-1 (p less than 0.02).",The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612496/),[l] / [h],58,181557,DB00281,Lidocaine
,3612496,clearance,"When administered in combination with MEGX, lignocaine clearance was significantly reduced from 58 +/- 18 to 48 +/- 13 L hr-1 (p less than 0.02).",The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612496/),[l] / [h],48,181558,DB00281,Lidocaine
,25525759,run-time,"The chromatography run-time was 5.5 minutes for lidocaine and 3.3 minutes for prilocaine, and the lower limit of quantification was 0.05 ng/mL for both drugs.",Pharmacokinetic and pharmacodynamic evaluation of a nanotechnological topical formulation of lidocaine/prilocaine (nanorap) in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25525759/),min,5.5,184169,DB00281,Lidocaine
,25525759,run-time,"The chromatography run-time was 5.5 minutes for lidocaine and 3.3 minutes for prilocaine, and the lower limit of quantification was 0.05 ng/mL for both drugs.",Pharmacokinetic and pharmacodynamic evaluation of a nanotechnological topical formulation of lidocaine/prilocaine (nanorap) in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25525759/),min,3.3,184170,DB00281,Lidocaine
,25525759,Cmax,"Mean Cmax was 6.62 and 1.72 ng/mL for lidocaine and prilocaine, respectively.",Pharmacokinetic and pharmacodynamic evaluation of a nanotechnological topical formulation of lidocaine/prilocaine (nanorap) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25525759/),[ng] / [ml],6.62,184171,DB00281,Lidocaine
,25525759,Cmax,"Mean Cmax was 6.62 and 1.72 ng/mL for lidocaine and prilocaine, respectively.",Pharmacokinetic and pharmacodynamic evaluation of a nanotechnological topical formulation of lidocaine/prilocaine (nanorap) in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25525759/),[ng] / [ml],1.72,184172,DB00281,Lidocaine
,25525759,Tmax,Median Tmax was 6.5 hours for both drugs.,Pharmacokinetic and pharmacodynamic evaluation of a nanotechnological topical formulation of lidocaine/prilocaine (nanorap) in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25525759/),h,6.5,184173,DB00281,Lidocaine
,3942298,area under the concentration time curve,The calculated area under the concentration time curve in preeclamptic patients (18.5 +/- 4.7 micrograms X hr X ml-1) was significantly greater than in normotensive mothers (14.1 +/- 1.3 micrograms X hr X ml-1) (P less than 0.02).,The pharmacokinetics and maternal and neonatal effects of epidural lidocaine in preeclampsia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3942298/),[h·μg] / [ml],18.5,185516,DB00281,Lidocaine
,3942298,area under the concentration time curve,The calculated area under the concentration time curve in preeclamptic patients (18.5 +/- 4.7 micrograms X hr X ml-1) was significantly greater than in normotensive mothers (14.1 +/- 1.3 micrograms X hr X ml-1) (P less than 0.02).,The pharmacokinetics and maternal and neonatal effects of epidural lidocaine in preeclampsia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3942298/),[h·μg] / [ml],14.1,185517,DB00281,Lidocaine
,3942298,Total maternal body clearance,Total maternal body clearance in preeclamptic patients (24.5 +/- 7.1 L/hr) was significantly lower than in normotensives (31.1 +/- 4.4 L/hr) (P less than 0.05).,The pharmacokinetics and maternal and neonatal effects of epidural lidocaine in preeclampsia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3942298/),[l] / [h],24.5,185518,DB00281,Lidocaine
,3942298,Total maternal body clearance,Total maternal body clearance in preeclamptic patients (24.5 +/- 7.1 L/hr) was significantly lower than in normotensives (31.1 +/- 4.4 L/hr) (P less than 0.05).,The pharmacokinetics and maternal and neonatal effects of epidural lidocaine in preeclampsia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3942298/),[l] / [h],31.1,185519,DB00281,Lidocaine
,15861085,time to reach peak lidocaine concentration,"The average time to reach peak lidocaine concentration after neck injection was 5.8 hours, whereas peak lidocaine concentration after thigh injection did not occur until 12.0 hours.",Rapid absorption of tumescent lidocaine above the clavicles: a prospective clinical study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15861085/),h,5.8,187607,DB00281,Lidocaine
,15861085,peak concentration,"The average peak concentration after neck injection was 16 percent greater than that after thigh injection (0.94 microg/ml versus 0.81 microg/ml), with the difference approaching significance (p = 0.06).",Rapid absorption of tumescent lidocaine above the clavicles: a prospective clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15861085/),[μg] / [ml],0.94,187608,DB00281,Lidocaine
,15861085,peak concentration,"The average peak concentration after neck injection was 16 percent greater than that after thigh injection (0.94 microg/ml versus 0.81 microg/ml), with the difference approaching significance (p = 0.06).",Rapid absorption of tumescent lidocaine above the clavicles: a prospective clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15861085/),[μg] / [ml],0.81,187609,DB00281,Lidocaine
,3177919,distribution,The distribution and elimination half-lives of the deuterium-labelled analogues were 25 +/- 13 min (mean +/- SD) and 121 +/- 31 min for lidocaine and 19 +/- 10 min and 131 +/- 33 min for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),min,25,188511,DB00281,Lidocaine
,3177919,distribution,The distribution and elimination half-lives of the deuterium-labelled analogues were 25 +/- 13 min (mean +/- SD) and 121 +/- 31 min for lidocaine and 19 +/- 10 min and 131 +/- 33 min for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),min,19,188512,DB00281,Lidocaine
,3177919,distribution,The distribution and elimination half-lives of the deuterium-labelled analogues were 25 +/- 13 min (mean +/- SD) and 121 +/- 31 min for lidocaine and 19 +/- 10 min and 131 +/- 33 min for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),min,131,188513,DB00281,Lidocaine
,3177919,elimination half-lives,The distribution and elimination half-lives of the deuterium-labelled analogues were 25 +/- 13 min (mean +/- SD) and 121 +/- 31 min for lidocaine and 19 +/- 10 min and 131 +/- 33 min for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),min,121,188514,DB00281,Lidocaine
,3177919,elimination half-lives,The distribution and elimination half-lives of the deuterium-labelled analogues were 25 +/- 13 min (mean +/- SD) and 121 +/- 31 min for lidocaine and 19 +/- 10 min and 131 +/- 33 min for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),min,131,188515,DB00281,Lidocaine
,3177919,volumes of the central compartment,"The volumes of the central compartment and steady-state volumes of distribution were: lidocaine 57 +/- 10 l and 105 +/- 25 l, bupivacaine 25 +/- 6 l and 63 +/- 22 l.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),l,57,188516,DB00281,Lidocaine
,3177919,volumes of the central compartment,"The volumes of the central compartment and steady-state volumes of distribution were: lidocaine 57 +/- 10 l and 105 +/- 25 l, bupivacaine 25 +/- 6 l and 63 +/- 22 l.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),l,25,188517,DB00281,Lidocaine
,3177919,steady-state volumes of distribution,"The volumes of the central compartment and steady-state volumes of distribution were: lidocaine 57 +/- 10 l and 105 +/- 25 l, bupivacaine 25 +/- 6 l and 63 +/- 22 l.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),l,105,188518,DB00281,Lidocaine
,3177919,steady-state volumes of distribution,"The volumes of the central compartment and steady-state volumes of distribution were: lidocaine 57 +/- 10 l and 105 +/- 25 l, bupivacaine 25 +/- 6 l and 63 +/- 22 l.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),l,63,188519,DB00281,Lidocaine
,3177919,Total plasma clearance,Total plasma clearance values averaged 0.97 +/- 0.21 l/min for lidocaine and 0.56 +/- 0.14 l/min for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),[l] / [min],0.97,188520,DB00281,Lidocaine
,3177919,Total plasma clearance,Total plasma clearance values averaged 0.97 +/- 0.21 l/min for lidocaine and 0.56 +/- 0.14 l/min for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),[l] / [min],0.56,188521,DB00281,Lidocaine
,3177919,half-life,"The absorption of lidocaine could be described by a single first order absorption process, characterized by a half-life of 71 +/- 17 min in five out of six patients.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),min,71,188522,DB00281,Lidocaine
,3177919,half-lives,"The half-lives, characterizing the fast and slow absorption processes of bupivacaine, were 50 +/- 27 min and 408 +/- 275 min, respectively.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),min,50,188523,DB00281,Lidocaine
,3177919,half-lives,"The half-lives, characterizing the fast and slow absorption processes of bupivacaine, were 50 +/- 27 min and 408 +/- 275 min, respectively.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),min,408,188524,DB00281,Lidocaine
,3177919,fractions of,"The fractions of the dose, absorbed in the fast and slow processes, were 0.35 +/- 0.17 and 0.61 +/- 0.16, respectively.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),,0.35,188525,DB00281,Lidocaine
,3177919,fractions of,"The fractions of the dose, absorbed in the fast and slow processes, were 0.35 +/- 0.17 and 0.61 +/- 0.16, respectively.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),,0.61,188526,DB00281,Lidocaine
,4028870,peak serum concentrations,Following subcutaneous application peak serum concentrations of 37.1 +/- 5.6 mg/1 were found after 138 +/- 49 min and a mean serum concentration of 6.6 +/- 1.6 mg/1 after 24 h.,Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028870/),mg,37.1,189579,DB00281,Lidocaine
,4028870,serum concentration,Following subcutaneous application peak serum concentrations of 37.1 +/- 5.6 mg/1 were found after 138 +/- 49 min and a mean serum concentration of 6.6 +/- 1.6 mg/1 after 24 h.,Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028870/),mg,6.6,189580,DB00281,Lidocaine
,4028870,Cumulated urine recoveries,"Cumulated urine recoveries over a period of 24 h were: 51.2 +/- 8.9% (2 g i.v.), 47.1 +/- 7.9% (0.5 g i.v.) and 39.7 +/- 9.5% (0.5 g s.c.).",Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028870/),%,51.2,189581,DB00281,Lidocaine
,4028870,Cumulated urine recoveries,"Cumulated urine recoveries over a period of 24 h were: 51.2 +/- 8.9% (2 g i.v.), 47.1 +/- 7.9% (0.5 g i.v.) and 39.7 +/- 9.5% (0.5 g s.c.).",Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028870/),%,47.1,189582,DB00281,Lidocaine
,4028870,Cumulated urine recoveries,"Cumulated urine recoveries over a period of 24 h were: 51.2 +/- 8.9% (2 g i.v.), 47.1 +/- 7.9% (0.5 g i.v.) and 39.7 +/- 9.5% (0.5 g s.c.).",Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028870/),%,39.7,189583,DB00281,Lidocaine
,4028870,t beta 1/2,"Comparison of pharmacokinetic parameters for the 0.5 g dose did not show relevant differences between intravenous and subcutaneous administration (using an open two-compartment model): t beta 1/2 (min) 514 +/- 104 (s.c.), 592 +/- 133 (i.v.), VD,Area (1) 11.9 +/- 3.8 (s.c.), 13.3 +/- 3.8 (i.v.) and AUCtot (mg X h/1) 515 +/- 106 (s.c.) and 549 +/- 125 (i.v.).",Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028870/),min,514,189584,DB00281,Lidocaine
,4028870,t beta 1/2,"Comparison of pharmacokinetic parameters for the 0.5 g dose did not show relevant differences between intravenous and subcutaneous administration (using an open two-compartment model): t beta 1/2 (min) 514 +/- 104 (s.c.), 592 +/- 133 (i.v.), VD,Area (1) 11.9 +/- 3.8 (s.c.), 13.3 +/- 3.8 (i.v.) and AUCtot (mg X h/1) 515 +/- 106 (s.c.) and 549 +/- 125 (i.v.).",Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028870/),min,592,189585,DB00281,Lidocaine
,4028870,Area (1),"Comparison of pharmacokinetic parameters for the 0.5 g dose did not show relevant differences between intravenous and subcutaneous administration (using an open two-compartment model): t beta 1/2 (min) 514 +/- 104 (s.c.), 592 +/- 133 (i.v.), VD,Area (1) 11.9 +/- 3.8 (s.c.), 13.3 +/- 3.8 (i.v.) and AUCtot (mg X h/1) 515 +/- 106 (s.c.) and 549 +/- 125 (i.v.).",Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028870/),,11.9,189586,DB00281,Lidocaine
,4028870,Area (1),"Comparison of pharmacokinetic parameters for the 0.5 g dose did not show relevant differences between intravenous and subcutaneous administration (using an open two-compartment model): t beta 1/2 (min) 514 +/- 104 (s.c.), 592 +/- 133 (i.v.), VD,Area (1) 11.9 +/- 3.8 (s.c.), 13.3 +/- 3.8 (i.v.) and AUCtot (mg X h/1) 515 +/- 106 (s.c.) and 549 +/- 125 (i.v.).",Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028870/),,13.3,189587,DB00281,Lidocaine
,4028870,AUCtot,"Comparison of pharmacokinetic parameters for the 0.5 g dose did not show relevant differences between intravenous and subcutaneous administration (using an open two-compartment model): t beta 1/2 (min) 514 +/- 104 (s.c.), 592 +/- 133 (i.v.), VD,Area (1) 11.9 +/- 3.8 (s.c.), 13.3 +/- 3.8 (i.v.) and AUCtot (mg X h/1) 515 +/- 106 (s.c.) and 549 +/- 125 (i.v.).",Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028870/),h·mg,515,189588,DB00281,Lidocaine
,4028870,AUCtot,"Comparison of pharmacokinetic parameters for the 0.5 g dose did not show relevant differences between intravenous and subcutaneous administration (using an open two-compartment model): t beta 1/2 (min) 514 +/- 104 (s.c.), 592 +/- 133 (i.v.), VD,Area (1) 11.9 +/- 3.8 (s.c.), 13.3 +/- 3.8 (i.v.) and AUCtot (mg X h/1) 515 +/- 106 (s.c.) and 549 +/- 125 (i.v.).",Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028870/),h·mg,549,189589,DB00281,Lidocaine
,4028870,Bioavailability,Bioavailability of the subcutaneous application was 0.96 +/- 0.26.,Comparative pharmacokinetics of ceftriaxone after subcutaneous and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028870/),,0.96,189590,DB00281,Lidocaine
,2305231,Cardiac output,Cardiac output increased from 2.94 +/- 0.68 to 4.77 +/- 1.1 l/min and stroke volume from 35 +/- 10 to 56 +/- 12 ml (p less than 0.001).,[Short-term dobutamine therapy in severe cardiac insufficiency]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305231/),[l] / [min],2.94,189869,DB00281,Lidocaine
,2305231,Cardiac output,Cardiac output increased from 2.94 +/- 0.68 to 4.77 +/- 1.1 l/min and stroke volume from 35 +/- 10 to 56 +/- 12 ml (p less than 0.001).,[Short-term dobutamine therapy in severe cardiac insufficiency]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305231/),[l] / [min],4.77,189870,DB00281,Lidocaine
,2305231,stroke volume,Cardiac output increased from 2.94 +/- 0.68 to 4.77 +/- 1.1 l/min and stroke volume from 35 +/- 10 to 56 +/- 12 ml (p less than 0.001).,[Short-term dobutamine therapy in severe cardiac insufficiency]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305231/),ml,35,189871,DB00281,Lidocaine
,2305231,stroke volume,Cardiac output increased from 2.94 +/- 0.68 to 4.77 +/- 1.1 l/min and stroke volume from 35 +/- 10 to 56 +/- 12 ml (p less than 0.001).,[Short-term dobutamine therapy in severe cardiac insufficiency]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305231/),ml,56,189872,DB00281,Lidocaine
,2305231,Pulmonary capillary wedge pressure,Pulmonary capillary wedge pressure decreased from 28.5 +/- 5 to 21 +/- 6 and central venous pressure from 14 +/- 6 to 7 +/- 3 mm Hg (p less than 0.007).,[Short-term dobutamine therapy in severe cardiac insufficiency]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305231/),,28.5,189873,DB00281,Lidocaine
,2305231,Pulmonary capillary wedge pressure,Pulmonary capillary wedge pressure decreased from 28.5 +/- 5 to 21 +/- 6 and central venous pressure from 14 +/- 6 to 7 +/- 3 mm Hg (p less than 0.007).,[Short-term dobutamine therapy in severe cardiac insufficiency]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305231/),,21,189874,DB00281,Lidocaine
,2305231,central venous pressure,Pulmonary capillary wedge pressure decreased from 28.5 +/- 5 to 21 +/- 6 and central venous pressure from 14 +/- 6 to 7 +/- 3 mm Hg (p less than 0.007).,[Short-term dobutamine therapy in severe cardiac insufficiency]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305231/),hg·mm,14,189875,DB00281,Lidocaine
,2305231,central venous pressure,Pulmonary capillary wedge pressure decreased from 28.5 +/- 5 to 21 +/- 6 and central venous pressure from 14 +/- 6 to 7 +/- 3 mm Hg (p less than 0.007).,[Short-term dobutamine therapy in severe cardiac insufficiency]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305231/),hg·mm,7,189876,DB00281,Lidocaine
,2305231,cardiac output,"However, after withdrawal of dobutamine a significantly higher cardiac output and stroke volume (3.73 +/- 0.43 l/min, 42 +/- 7 mm Hg. p less than 0.05) persisted.",[Short-term dobutamine therapy in severe cardiac insufficiency]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305231/),[l] / [min],3.73,189877,DB00281,Lidocaine
,2305231,stroke volume,"However, after withdrawal of dobutamine a significantly higher cardiac output and stroke volume (3.73 +/- 0.43 l/min, 42 +/- 7 mm Hg. p less than 0.05) persisted.",[Short-term dobutamine therapy in severe cardiac insufficiency]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305231/),h·mm,42,189878,DB00281,Lidocaine
,2305231,half life,"Both clearance and distribution volume of lidocaine increased, while half life decreased significantly (6.61 +/- 1.43 to 5.33 +/- 0.77 h. p less than 0.05).",[Short-term dobutamine therapy in severe cardiac insufficiency]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305231/),h,6.61,189879,DB00281,Lidocaine
,2305231,half life,"Both clearance and distribution volume of lidocaine increased, while half life decreased significantly (6.61 +/- 1.43 to 5.33 +/- 0.77 h. p less than 0.05).",[Short-term dobutamine therapy in severe cardiac insufficiency]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305231/),h,5.33,189880,DB00281,Lidocaine
,2495879,elimination rate constant,"Significant differences in elimination rate constant (average increase, 0.0545 to 0.0748 hr-1), elimination half-life (average reduction, 13.2 to 9.4 hours), oral clearance, and area under the concentration-time curve (average reduction, 76.8 to 55.0 mg.hr/L) between the control and rifampin treatment phases were observed.",Influence of rifampin on tocainide pharmacokinetics in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495879/),1/[h],0.0545 to 0.0748,189987,DB00281,Lidocaine
,8818566,AUCL(O-infinity),"The area under lidocaine plasma concentration-time curve [AUCL(O-infinity)] corrected by the dose, when injected into the jugular vein, was equal to that estimated when injected into the thoracic aorta, but was larger than the AUCL(O-infinity) corrected by the dose of lidocaine injected into a mesenteric vein [i.e. 0.0047 +/- 0.0005 vs. 0.0030 +/- 0.0004 min/ml, respectively (p < 0.05)].",First-pass metabolism of lidocaine in the anesthetized rabbit. Contribution of the small intestine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818566/),[min] / [ml],0.0047,190152,DB00281,Lidocaine
,8818566,AUCL(O-infinity),"The area under lidocaine plasma concentration-time curve [AUCL(O-infinity)] corrected by the dose, when injected into the jugular vein, was equal to that estimated when injected into the thoracic aorta, but was larger than the AUCL(O-infinity) corrected by the dose of lidocaine injected into a mesenteric vein [i.e. 0.0047 +/- 0.0005 vs. 0.0030 +/- 0.0004 min/ml, respectively (p < 0.05)].",First-pass metabolism of lidocaine in the anesthetized rabbit. Contribution of the small intestine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818566/),[min] / [ml],0.0030,190153,DB00281,Lidocaine
,8818566,AUCL(O-infinity),"Moreover, the latter was greater (p < 0.05) than the AUCL(O-infinity) corrected by the dose of lidocaine instilled into the duodenum (0.0024 +/- 0.0003 min/ml).",First-pass metabolism of lidocaine in the anesthetized rabbit. Contribution of the small intestine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818566/),[min] / [ml],0.0024,190154,DB00281,Lidocaine
,8818566,Liver,"Liver and intestinal extractions of lidocaine were 36 and 20%, respectively.",First-pass metabolism of lidocaine in the anesthetized rabbit. Contribution of the small intestine. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818566/),%,36,190155,DB00281,Lidocaine
,8818566,extractions,"Liver and intestinal extractions of lidocaine were 36 and 20%, respectively.",First-pass metabolism of lidocaine in the anesthetized rabbit. Contribution of the small intestine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818566/),%,36,190156,DB00281,Lidocaine
,8818566,extractions,"Liver and intestinal extractions of lidocaine were 36 and 20%, respectively.",First-pass metabolism of lidocaine in the anesthetized rabbit. Contribution of the small intestine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818566/),%,20,190157,DB00281,Lidocaine
,8818566,Oral systemic bioavailability,Oral systemic bioavailability was 0.49.,First-pass metabolism of lidocaine in the anesthetized rabbit. Contribution of the small intestine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8818566/),,0.49,190158,DB00281,Lidocaine
,7291727,maximum A/V ratios,"The maximum A/V ratios shortly after a rapid intravenous bolus dose were 277-, 15-, 34-, 33-, 5.4- and 3240-fold, respectively, for the above six drugs.",Arterial-venous plasma concentration differences of six drugs in the dog and rabbit after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7291727/),,27,190508,DB00281,Lidocaine
,7291727,maximum A/V ratios,"The maximum A/V ratios shortly after a rapid intravenous bolus dose were 277-, 15-, 34-, 33-, 5.4- and 3240-fold, respectively, for the above six drugs.",Arterial-venous plasma concentration differences of six drugs in the dog and rabbit after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7291727/),,15,190509,DB00281,Lidocaine
,773580,elimination half-life,"Drug plasma levels at 1 and 2 hr after administration and the area under the plasma concentration-time curve were proportional to dose, and the drug disappeared with a mean elimination half-life of 14.7 +/- 1.7 hr (mean +/- SD).","Antiarrhythmic effects of a lidocaine congener, tocainide, 2-amino-2',6'-propionoxylidide, in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/773580/),h,14.7,191175,DB00281,Lidocaine
,773580,Plasma levels,Plasma levels resulting in suppression of PVCs ranged from 1 to 5 mug/ml.,"Antiarrhythmic effects of a lidocaine congener, tocainide, 2-amino-2',6'-propionoxylidide, in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/773580/),[μg] / [ml],1 to 5,191176,DB00281,Lidocaine
,14706243,relative in vivo recoveries,The relative in vivo recoveries in striatum (11.3%) and blood (24.0%) were significantly lower than in vitro (31.3 and 44.9%).,A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14706243/),%,11.3,192565,DB00281,Lidocaine
,14706243,relative in vivo recoveries,The relative in vivo recoveries in striatum (11.3%) and blood (24.0%) were significantly lower than in vitro (31.3 and 44.9%).,A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14706243/),%,24.0,192566,DB00281,Lidocaine
,14706243,relative in vivo recoveries,The relative in vivo recoveries in striatum (11.3%) and blood (24.0%) were significantly lower than in vitro (31.3 and 44.9%).,A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14706243/),%,31.3,192567,DB00281,Lidocaine
,14706243,relative in vivo recoveries,The relative in vivo recoveries in striatum (11.3%) and blood (24.0%) were significantly lower than in vitro (31.3 and 44.9%).,A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14706243/),%,44.9,192568,DB00281,Lidocaine
,14706243,nasal bioavailabilities,"The average nasal bioavailabilities of lidocaine in blood, left and right striatum were 85, 103 and 129%, respectively.",A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14706243/),%,85,192569,DB00281,Lidocaine
,14706243,nasal bioavailabilities,"The average nasal bioavailabilities of lidocaine in blood, left and right striatum were 85, 103 and 129%, respectively.",A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14706243/),%,103,192570,DB00281,Lidocaine
,14706243,nasal bioavailabilities,"The average nasal bioavailabilities of lidocaine in blood, left and right striatum were 85, 103 and 129%, respectively.",A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14706243/),%,129,192571,DB00281,Lidocaine
,15966499,half-lives of elimination (t1/2alpha,"The half-lives of elimination (t1/2alpha and t1/2beta) of articaine are 0.6 and 2.5 hours, whereas the apparent half-life of the metabolite articainic acid is 2.5 hours.",Clinical pharmacology and the use of articaine for local and regional anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966499/),h,0.6,192815,DB00281,Lidocaine
,15966499,t1/2beta),"The half-lives of elimination (t1/2alpha and t1/2beta) of articaine are 0.6 and 2.5 hours, whereas the apparent half-life of the metabolite articainic acid is 2.5 hours.",Clinical pharmacology and the use of articaine for local and regional anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966499/),h,2.5,192816,DB00281,Lidocaine
,15966499,apparent half-life,"The half-lives of elimination (t1/2alpha and t1/2beta) of articaine are 0.6 and 2.5 hours, whereas the apparent half-life of the metabolite articainic acid is 2.5 hours.",Clinical pharmacology and the use of articaine for local and regional anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966499/),h,2.5,192817,DB00281,Lidocaine
,15966499,t1/2alpha,"Intrinsic half-lives of articainic acid are: t1/2alpha 12 minutes, and t1/2beta 64 minutes (1 hour).",Clinical pharmacology and the use of articaine for local and regional anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966499/),min,12,192818,DB00281,Lidocaine
,15966499,t1/2beta,"Intrinsic half-lives of articainic acid are: t1/2alpha 12 minutes, and t1/2beta 64 minutes (1 hour).",Clinical pharmacology and the use of articaine for local and regional anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966499/),min,64,192819,DB00281,Lidocaine
,8942594,apparent t1/2,"The dog exhibited ""flip-flop"" pharmacokinetics and absorption was biphasic after epidural administration of lidocaine solution (apparent t1/2 of the fast and slow absorption phases were 4 min and 131 min, respectively).",Biphasic drug absorption from the epidural space of the dog may limit the utility of a slow release medium molecular weight hyaluronic acid-lidocaine ionic complex formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8942594/),min,4,193560,DB00281,Lidocaine
,8942594,apparent t1/2,"The dog exhibited ""flip-flop"" pharmacokinetics and absorption was biphasic after epidural administration of lidocaine solution (apparent t1/2 of the fast and slow absorption phases were 4 min and 131 min, respectively).",Biphasic drug absorption from the epidural space of the dog may limit the utility of a slow release medium molecular weight hyaluronic acid-lidocaine ionic complex formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8942594/),min,131,193561,DB00281,Lidocaine
,8942594,apparent t1/2,"The L-HA formulation markedly altered the absorption kinetics such that a single, slow absorption phase was evident (apparent t1/2 of 56 min), although this rate was more rapid than the slow phase observed after lidocaine solution.",Biphasic drug absorption from the epidural space of the dog may limit the utility of a slow release medium molecular weight hyaluronic acid-lidocaine ionic complex formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8942594/),min,56,193562,DB00281,Lidocaine
,21642610,Cmax,Epidural lidocaine administration (20-35 mL) 1 hour before epidural EREM administration increased the Cmax in group E (11.1 ± 4.9) compared with group SE (8.3 ± 7.1 ng/mL) (P = 0.038).,Prior epidural lidocaine alters the pharmacokinetics and drug effects of extended-release epidural morphine (DepoDur®) after cesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21642610/),[ng] / [ml],11.1,195168,DB00281,Lidocaine
,21642610,Cmax,Epidural lidocaine administration (20-35 mL) 1 hour before epidural EREM administration increased the Cmax in group E (11.1 ± 4.9) compared with group SE (8.3 ± 7.1 ng/mL) (P = 0.038).,Prior epidural lidocaine alters the pharmacokinetics and drug effects of extended-release epidural morphine (DepoDur®) after cesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21642610/),[ng] / [ml],8.3,195169,DB00281,Lidocaine
,24628898,maximum plasma detomidine concentration,The maximum plasma detomidine concentration after GEL was 2.1 ± 1.2 ng mL(-1) (mean ±SD) and the time of maximum concentration was 66.0 ± 36.9 minutes.,Sublingual administration of detomidine to calves prior to disbudding: a comparison with the intravenous route. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628898/),[ng] / [ml],2.1,195779,DB00281,Lidocaine
,24628898,time of maximum concentration,The maximum plasma detomidine concentration after GEL was 2.1 ± 1.2 ng mL(-1) (mean ±SD) and the time of maximum concentration was 66.0 ± 36.9 minutes.,Sublingual administration of detomidine to calves prior to disbudding: a comparison with the intravenous route. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628898/),min,66.0,195780,DB00281,Lidocaine
,24628898,bioavailability,The bioavailability of detomidine was approximately 34% with GEL.,Sublingual administration of detomidine to calves prior to disbudding: a comparison with the intravenous route. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24628898/),%,34,195781,DB00281,Lidocaine
,2098858,t max,Absorption from epidural space is equally fast for both anesthetic agents (t max 20 +/- 7 minutes for MPV and 25 +/- 12 minutes for LDC) resulting in high values of Cmax: 7.8 +/- 3.3 microg/ml for MPV and 2.6 +/- 0.7 microg/ml for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),min,20,197017,DB00281,Lidocaine
,2098858,t max,Absorption from epidural space is equally fast for both anesthetic agents (t max 20 +/- 7 minutes for MPV and 25 +/- 12 minutes for LDC) resulting in high values of Cmax: 7.8 +/- 3.3 microg/ml for MPV and 2.6 +/- 0.7 microg/ml for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),min,25,197018,DB00281,Lidocaine
,2098858,Cmax,Absorption from epidural space is equally fast for both anesthetic agents (t max 20 +/- 7 minutes for MPV and 25 +/- 12 minutes for LDC) resulting in high values of Cmax: 7.8 +/- 3.3 microg/ml for MPV and 2.6 +/- 0.7 microg/ml for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),[μg] / [ml],7.8,197019,DB00281,Lidocaine
,2098858,Cmax,Absorption from epidural space is equally fast for both anesthetic agents (t max 20 +/- 7 minutes for MPV and 25 +/- 12 minutes for LDC) resulting in high values of Cmax: 7.8 +/- 3.3 microg/ml for MPV and 2.6 +/- 0.7 microg/ml for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),[μg] / [ml],2.6,197020,DB00281,Lidocaine
,2098858,K,Mean values of K and Vd were 0.0076 +/- 0.0020 minutes-1 for MPV versus 0.0087 +/- 0.0032 minutes-1 for LDC and 0.9 +/- 0.7 1/kg for MPV versus 1.8 +/- 0.6 1/kg for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),1/[min],0.0076,197021,DB00281,Lidocaine
,2098858,K,Mean values of K and Vd were 0.0076 +/- 0.0020 minutes-1 for MPV versus 0.0087 +/- 0.0032 minutes-1 for LDC and 0.9 +/- 0.7 1/kg for MPV versus 1.8 +/- 0.6 1/kg for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),1/[min],0.0087,197022,DB00281,Lidocaine
,2098858,K,Mean values of K and Vd were 0.0076 +/- 0.0020 minutes-1 for MPV versus 0.0087 +/- 0.0032 minutes-1 for LDC and 0.9 +/- 0.7 1/kg for MPV versus 1.8 +/- 0.6 1/kg for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),[1] / [kg],0.9,197023,DB00281,Lidocaine
,2098858,Vd,Mean values of K and Vd were 0.0076 +/- 0.0020 minutes-1 for MPV versus 0.0087 +/- 0.0032 minutes-1 for LDC and 0.9 +/- 0.7 1/kg for MPV versus 1.8 +/- 0.6 1/kg for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),[1] / [kg],0.9,197024,DB00281,Lidocaine
,2098858,Vd,Mean values of K and Vd were 0.0076 +/- 0.0020 minutes-1 for MPV versus 0.0087 +/- 0.0032 minutes-1 for LDC and 0.9 +/- 0.7 1/kg for MPV versus 1.8 +/- 0.6 1/kg for LDC (p less than 0.001).,[Pharmacokinetics of mepivacaine and lidocaine after epidural administration]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2098858/),[1] / [kg],1.8,197025,DB00281,Lidocaine
,9872341,Fh,Fh was about 30% and did not vary with increasing i.p.v. dose.,Avoidance of hepatic first-pass effect in the rabbit via rectal route of administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872341/),%,30,197687,DB00281,Lidocaine
,9872341,Fm,"With i.d. administration, lidocaine was absorbed completely with negligible first-pass effect in the mucosa (Fm=1).",Avoidance of hepatic first-pass effect in the rabbit via rectal route of administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9872341/),,1,197688,DB00281,Lidocaine
,1808237,Kp,The Kp value increased in the following order; procaine (1.1) less than PABA-Et (1.9) less than lidocaine (2.2) less than PABA-Pr (2.7) less than PABA-Bu (3.6).,Study on brain uptake of local anesthetics in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1808237/),,1.1,198236,DB00281,Lidocaine
,1808237,Kp,The Kp value increased in the following order; procaine (1.1) less than PABA-Et (1.9) less than lidocaine (2.2) less than PABA-Pr (2.7) less than PABA-Bu (3.6).,Study on brain uptake of local anesthetics in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1808237/),,1.9,198237,DB00281,Lidocaine
,1808237,Kp,The Kp value increased in the following order; procaine (1.1) less than PABA-Et (1.9) less than lidocaine (2.2) less than PABA-Pr (2.7) less than PABA-Bu (3.6).,Study on brain uptake of local anesthetics in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1808237/),,2.2,198238,DB00281,Lidocaine
,1808237,Kp,The Kp value increased in the following order; procaine (1.1) less than PABA-Et (1.9) less than lidocaine (2.2) less than PABA-Pr (2.7) less than PABA-Bu (3.6).,Study on brain uptake of local anesthetics in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1808237/),,2.7,198239,DB00281,Lidocaine
,1808237,Kp,The Kp value increased in the following order; procaine (1.1) less than PABA-Et (1.9) less than lidocaine (2.2) less than PABA-Pr (2.7) less than PABA-Bu (3.6).,Study on brain uptake of local anesthetics in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1808237/),,3.6,198240,DB00281,Lidocaine
,1821461,total clearance,"In the group of patients with cirrhosis of the liver the total clearance of the drug was lower (8.7 +/- 5.0 1.h-1), as compared with the group of patients without liver damage (34.7 +/- 19.4 1.h-1).",[Changes in pharmacokinetics of trimecaine in patients with liver cirrhosis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1821461/),[1] / [h],8.7,199014,DB00281,Lidocaine
,1821461,total clearance,"In the group of patients with cirrhosis of the liver the total clearance of the drug was lower (8.7 +/- 5.0 1.h-1), as compared with the group of patients without liver damage (34.7 +/- 19.4 1.h-1).",[Changes in pharmacokinetics of trimecaine in patients with liver cirrhosis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1821461/),[1] / [h],34.7,199015,DB00281,Lidocaine
,11371877,peak,Healthy volunteers and patients with interstitial cystitis had similar lidocaine absorption profiles with a peak of 1.06 microg/ml. (range 0.66 to 1.71) and 1.3 (range 0.2 to 2.0) at about 30 minutes.,Absorption of alkalized intravesical lidocaine in normal and inflamed bladders: a simple method for improving bladder anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11371877/),[μg] / [ml],1.06,201267,DB00281,Lidocaine
,11371877,peak,Healthy volunteers and patients with interstitial cystitis had similar lidocaine absorption profiles with a peak of 1.06 microg/ml. (range 0.66 to 1.71) and 1.3 (range 0.2 to 2.0) at about 30 minutes.,Absorption of alkalized intravesical lidocaine in normal and inflamed bladders: a simple method for improving bladder anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11371877/),[μg] / [ml],1.3,201268,DB00281,Lidocaine
,2905709,area under the concentration-time curve,"After a 400-mg oral dose of tocainide, the area under the concentration-time curve decreased from (mean +/- SD) 31.64 +/- 14.16 micrograms.hr/mL during placebo, to 23.10 +/- 7.33 micrograms.hr/mL during cimetidine (P less than .05).",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),[h·μg] / [ml],31.64,201770,DB00281,Lidocaine
,2905709,area under the concentration-time curve,"After a 400-mg oral dose of tocainide, the area under the concentration-time curve decreased from (mean +/- SD) 31.64 +/- 14.16 micrograms.hr/mL during placebo, to 23.10 +/- 7.33 micrograms.hr/mL during cimetidine (P less than .05).",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),[h·μg] / [ml],23.10,201771,DB00281,Lidocaine
,2905709,peak tocainide concentrations,"Similarly, the peak tocainide concentrations were 2.81 +/- 0.89 micrograms/mL and 1.70 +/- 0.44 micrograms/mL with placebo and cimetidine, respectively (P less than .05).",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),[μg] / [ml],2.81,201772,DB00281,Lidocaine
,2905709,peak tocainide concentrations,"Similarly, the peak tocainide concentrations were 2.81 +/- 0.89 micrograms/mL and 1.70 +/- 0.44 micrograms/mL with placebo and cimetidine, respectively (P less than .05).",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),[μg] / [ml],1.70,201773,DB00281,Lidocaine
,2905709,total amount,"However, the total amount of tocainide excreted unchanged in the urine, decreased from 159.8 +/- 14.7 mg with placebo to 136.8 +/- 26.8 mg with cimetidine (P less than .05), whereas there was no change with ranitidine.",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),,159,201774,DB00281,Lidocaine
,2905709,total amount,"However, the total amount of tocainide excreted unchanged in the urine, decreased from 159.8 +/- 14.7 mg with placebo to 136.8 +/- 26.8 mg with cimetidine (P less than .05), whereas there was no change with ranitidine.",The effect of histamine-2 receptor antagonists on tocainide pharmacokinetics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905709/),,136,201775,DB00281,Lidocaine
,3954094,distribution half-life (t 1/2 alpha),"Using standard formulas, we derived the following data: Children: distribution half-life (t 1/2 alpha) 3.2 min, elimination half-life (t 1/2 beta) 58 min, volume of the central compartment (V1) 0.22 L/kg, volume of distribution (Vd area) 1.1 L/kg, and total plasma clearance (Cl) 11.1 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),min,3.2,201929,DB00281,Lidocaine
,3954094,elimination half-life (t 1/2 beta),"Using standard formulas, we derived the following data: Children: distribution half-life (t 1/2 alpha) 3.2 min, elimination half-life (t 1/2 beta) 58 min, volume of the central compartment (V1) 0.22 L/kg, volume of distribution (Vd area) 1.1 L/kg, and total plasma clearance (Cl) 11.1 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),min,58,201930,DB00281,Lidocaine
,3954094,volume of the central compartment (V1),"Using standard formulas, we derived the following data: Children: distribution half-life (t 1/2 alpha) 3.2 min, elimination half-life (t 1/2 beta) 58 min, volume of the central compartment (V1) 0.22 L/kg, volume of distribution (Vd area) 1.1 L/kg, and total plasma clearance (Cl) 11.1 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),[l] / [kg],0.22,201931,DB00281,Lidocaine
,3954094,volume of distribution (Vd area),"Using standard formulas, we derived the following data: Children: distribution half-life (t 1/2 alpha) 3.2 min, elimination half-life (t 1/2 beta) 58 min, volume of the central compartment (V1) 0.22 L/kg, volume of distribution (Vd area) 1.1 L/kg, and total plasma clearance (Cl) 11.1 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),[l] / [kg],1.1,201932,DB00281,Lidocaine
,3954094,total plasma clearance (Cl),"Using standard formulas, we derived the following data: Children: distribution half-life (t 1/2 alpha) 3.2 min, elimination half-life (t 1/2 beta) 58 min, volume of the central compartment (V1) 0.22 L/kg, volume of distribution (Vd area) 1.1 L/kg, and total plasma clearance (Cl) 11.1 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),[ml] / [kg·min],11.1,201933,DB00281,Lidocaine
,3954094,t 1/2 alpha,"Adults: t 1/2 alpha 3.6 min, t 1/2 beta 43 min, V1 0.16 L/kg, Vd area 0.71 L/kg, and Cl 9.8 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),min,3.6,201934,DB00281,Lidocaine
,3954094,t 1/2 beta,"Adults: t 1/2 alpha 3.6 min, t 1/2 beta 43 min, V1 0.16 L/kg, Vd area 0.71 L/kg, and Cl 9.8 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),min,43,201935,DB00281,Lidocaine
,3954094,V1,"Adults: t 1/2 alpha 3.6 min, t 1/2 beta 43 min, V1 0.16 L/kg, Vd area 0.71 L/kg, and Cl 9.8 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),[l] / [kg],0.16,201936,DB00281,Lidocaine
,3954094,Vd area,"Adults: t 1/2 alpha 3.6 min, t 1/2 beta 43 min, V1 0.16 L/kg, Vd area 0.71 L/kg, and Cl 9.8 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),[l] / [kg],0.71,201937,DB00281,Lidocaine
,3954094,Cl,"Adults: t 1/2 alpha 3.6 min, t 1/2 beta 43 min, V1 0.16 L/kg, Vd area 0.71 L/kg, and Cl 9.8 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),[ml] / [kg·min],9.8,201938,DB00281,Lidocaine
,10447050,maximal lidocaine concentrations,"Under HBO, lidocaine injection caused marked dizziness and buzzing in the ears, sweating, tremor and coordination-disturbances, even though maximal lidocaine concentrations (0.63 mg x L(-1) and 0.70 mg x L(-1)) were far below therapeutic serum concentrations (1.5-5.0 mg x L(-1)).",Lidocaine pharmacokinetics during hyperbaric hyperoxia in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447050/),[mg] / [l],0.63,202118,DB00281,Lidocaine
,10447050,maximal lidocaine concentrations,"Under HBO, lidocaine injection caused marked dizziness and buzzing in the ears, sweating, tremor and coordination-disturbances, even though maximal lidocaine concentrations (0.63 mg x L(-1) and 0.70 mg x L(-1)) were far below therapeutic serum concentrations (1.5-5.0 mg x L(-1)).",Lidocaine pharmacokinetics during hyperbaric hyperoxia in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447050/),[mg] / [l],0.70,202119,DB00281,Lidocaine
,10447050,T1/2beta,Pharmacokinetic parameters of lidocaine were similar to those published earlier (T1/2beta: 110+/-16 min; CI: 12.6+/-2.9 ml x min(-1) x kg(-1); Vss: 1.73+/-0.18 L x kg(-1)).,Lidocaine pharmacokinetics during hyperbaric hyperoxia in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447050/),min,110,202120,DB00281,Lidocaine
,10447050,CI,Pharmacokinetic parameters of lidocaine were similar to those published earlier (T1/2beta: 110+/-16 min; CI: 12.6+/-2.9 ml x min(-1) x kg(-1); Vss: 1.73+/-0.18 L x kg(-1)).,Lidocaine pharmacokinetics during hyperbaric hyperoxia in humans. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447050/),[ml] / [kg·min],12.6,202121,DB00281,Lidocaine
,10447050,Vss,Pharmacokinetic parameters of lidocaine were similar to those published earlier (T1/2beta: 110+/-16 min; CI: 12.6+/-2.9 ml x min(-1) x kg(-1); Vss: 1.73+/-0.18 L x kg(-1)).,Lidocaine pharmacokinetics during hyperbaric hyperoxia in humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447050/),[l] / [kg],1.73,202122,DB00281,Lidocaine
,8843047,Peak plasma concentration,Peak plasma concentration was 1.83 +/- 0.17 mg/l.,Pharmacokinetics of lidocaine with epinephrine in piglets following epidural anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843047/),[mg] / [l],1.83,203216,DB00281,Lidocaine
,8843047,time taken to reach the maximum concentration,"Pharmacokinetic parameters determined from an independent compartment model were not different from those observed after an epidural administration of lidocaine via the sacrococcygeal space in children, except for a wide variability in the time taken to reach the maximum concentration (27.3 +/- 7.4 min) and a shorter half-life of elimination (82.8 +/- 7.0 min).",Pharmacokinetics of lidocaine with epinephrine in piglets following epidural anaesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843047/),min,27.3,203217,DB00281,Lidocaine
,8843047,half-life of elimination,"Pharmacokinetic parameters determined from an independent compartment model were not different from those observed after an epidural administration of lidocaine via the sacrococcygeal space in children, except for a wide variability in the time taken to reach the maximum concentration (27.3 +/- 7.4 min) and a shorter half-life of elimination (82.8 +/- 7.0 min).",Pharmacokinetics of lidocaine with epinephrine in piglets following epidural anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843047/),min,82.8,203218,DB00281,Lidocaine
,8843047,total body clearance,The total body clearance of lidocaine was similar in piglets (17.3 +/- 1.6 ml/min/kg) to that in children.,Pharmacokinetics of lidocaine with epinephrine in piglets following epidural anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843047/),[ml] / [kg·min],17.3,203219,DB00281,Lidocaine
,8843047,volume of distribution,The shorter half-life of elimination was therefore attributed to a smaller volume of distribution in piglets (2.0 +/- 0.2 l/kg).,Pharmacokinetics of lidocaine with epinephrine in piglets following epidural anaesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843047/),[l] / [kg],2.0,203220,DB00281,Lidocaine
,16580907,renal clearance,"A pharmacokinetic study in 6 healthy male volunteers after a single dose of either cetirizine (20 mg) or pilsicainide (50 mg), or both, found that the renal clearance of each drug was significantly decreased by the coadministration of the drugs (from 475 +/- 101 mL/min to 279 +/- 117 mL/min for pilsicainide and from 189 +/- 37 mL/min to 118 +/- 28 mL/min for cetirizine; P = .008 and .009, respectively).",Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580907/),[ml] / [min],475,203570,DB00281,Lidocaine
,16580907,renal clearance,"A pharmacokinetic study in 6 healthy male volunteers after a single dose of either cetirizine (20 mg) or pilsicainide (50 mg), or both, found that the renal clearance of each drug was significantly decreased by the coadministration of the drugs (from 475 +/- 101 mL/min to 279 +/- 117 mL/min for pilsicainide and from 189 +/- 37 mL/min to 118 +/- 28 mL/min for cetirizine; P = .008 and .009, respectively).",Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580907/),[ml] / [min],279,203571,DB00281,Lidocaine
,16580907,renal clearance,"A pharmacokinetic study in 6 healthy male volunteers after a single dose of either cetirizine (20 mg) or pilsicainide (50 mg), or both, found that the renal clearance of each drug was significantly decreased by the coadministration of the drugs (from 475 +/- 101 mL/min to 279 +/- 117 mL/min for pilsicainide and from 189 +/- 37 mL/min to 118 +/- 28 mL/min for cetirizine; P = .008 and .009, respectively).",Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580907/),[ml] / [min],189,203572,DB00281,Lidocaine
,16580907,renal clearance,"A pharmacokinetic study in 6 healthy male volunteers after a single dose of either cetirizine (20 mg) or pilsicainide (50 mg), or both, found that the renal clearance of each drug was significantly decreased by the coadministration of the drugs (from 475 +/- 101 mL/min to 279 +/- 117 mL/min for pilsicainide and from 189 +/- 37 mL/min to 118 +/- 28 mL/min for cetirizine; P = .008 and .009, respectively).",Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580907/),[ml] / [min],118,203573,DB00281,Lidocaine
,28416162,Maximum concentration,"Maximum concentration was 23.92 ± 8.64 ng mL-1 at 1 minute (maximum time); elimination half-life was 41.87 ± 17.35 minutes; area under the curve was 486.68 ± 125.66 minutes ng-1 mL-1; clearance was 33.61 ± 13.01 mL minute-1 kg-1, and volume of distribution at steady state was 1.77 ± 0.50 L kg-1.",Pharmacokinetics of buprenorphine following constant rate infusion for postoperative analgesia in dogs undergoing ovariectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416162/),[ng] / [ml],23.92,204605,DB00281,Lidocaine
,28416162,elimination half-life,"Maximum concentration was 23.92 ± 8.64 ng mL-1 at 1 minute (maximum time); elimination half-life was 41.87 ± 17.35 minutes; area under the curve was 486.68 ± 125.66 minutes ng-1 mL-1; clearance was 33.61 ± 13.01 mL minute-1 kg-1, and volume of distribution at steady state was 1.77 ± 0.50 L kg-1.",Pharmacokinetics of buprenorphine following constant rate infusion for postoperative analgesia in dogs undergoing ovariectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416162/),min,41.87,204606,DB00281,Lidocaine
,28416162,area under the curve,"Maximum concentration was 23.92 ± 8.64 ng mL-1 at 1 minute (maximum time); elimination half-life was 41.87 ± 17.35 minutes; area under the curve was 486.68 ± 125.66 minutes ng-1 mL-1; clearance was 33.61 ± 13.01 mL minute-1 kg-1, and volume of distribution at steady state was 1.77 ± 0.50 L kg-1.",Pharmacokinetics of buprenorphine following constant rate infusion for postoperative analgesia in dogs undergoing ovariectomy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416162/),[min] / [ml·ng],486.68,204607,DB00281,Lidocaine
,28416162,clearance,"Maximum concentration was 23.92 ± 8.64 ng mL-1 at 1 minute (maximum time); elimination half-life was 41.87 ± 17.35 minutes; area under the curve was 486.68 ± 125.66 minutes ng-1 mL-1; clearance was 33.61 ± 13.01 mL minute-1 kg-1, and volume of distribution at steady state was 1.77 ± 0.50 L kg-1.",Pharmacokinetics of buprenorphine following constant rate infusion for postoperative analgesia in dogs undergoing ovariectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416162/),[ml] / [kg·min],33.61,204608,DB00281,Lidocaine
,28416162,volume of distribution at steady state,"Maximum concentration was 23.92 ± 8.64 ng mL-1 at 1 minute (maximum time); elimination half-life was 41.87 ± 17.35 minutes; area under the curve was 486.68 ± 125.66 minutes ng-1 mL-1; clearance was 33.61 ± 13.01 mL minute-1 kg-1, and volume of distribution at steady state was 1.77 ± 0.50 L kg-1.",Pharmacokinetics of buprenorphine following constant rate infusion for postoperative analgesia in dogs undergoing ovariectomy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416162/),[l] / [kg],1.77,204609,DB00281,Lidocaine
,3662055,peak plasma concentration,"Addition of epinephrine to the local anesthetic solution reduced the mean peak plasma concentration of lidocaine from 526 to 376 ng/ml, but did not significantly reduce the mean peak plasma concentration of bupivacaine (70 vs 56 ng/ml).",Spinal anesthesia with hyperbaric lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662055/),[ng] / [ml],526,204683,DB00281,Lidocaine
,3662055,peak plasma concentration,"Addition of epinephrine to the local anesthetic solution reduced the mean peak plasma concentration of lidocaine from 526 to 376 ng/ml, but did not significantly reduce the mean peak plasma concentration of bupivacaine (70 vs 56 ng/ml).",Spinal anesthesia with hyperbaric lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662055/),[ng] / [ml],376,204684,DB00281,Lidocaine
,3662055,peak plasma concentration,"Addition of epinephrine to the local anesthetic solution reduced the mean peak plasma concentration of lidocaine from 526 to 376 ng/ml, but did not significantly reduce the mean peak plasma concentration of bupivacaine (70 vs 56 ng/ml).",Spinal anesthesia with hyperbaric lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662055/),[ng] / [ml],70,204685,DB00281,Lidocaine
,3662055,peak plasma concentration,"Addition of epinephrine to the local anesthetic solution reduced the mean peak plasma concentration of lidocaine from 526 to 376 ng/ml, but did not significantly reduce the mean peak plasma concentration of bupivacaine (70 vs 56 ng/ml).",Spinal anesthesia with hyperbaric lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662055/),[ng] / [ml],56,204686,DB00281,Lidocaine
,17385349,remission time,Mean remission time was 61 +/- 30 months.,Assessment of liver function in children with acute lymphoblastic leukemia in remission. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17385349/),month,61,205035,DB00281,Lidocaine
,18638297,rate,"Approximately, constant rate absorption was observed from 12-72 h after patch application at a mean +/- SD rate of 109 +/- 49 microg/kg/h, resulting in steady-state lidocaine plasma concentrations of 0.083 +/- 0.032 microg/mL and MEGX concentrations of 0.012 +/- 0.009 microg/mL.",Pharmacokinetics of lidocaine following the application of 5% lidocaine patches to cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638297/),[μg] / [h·kg],109,205224,DB00281,Lidocaine
,18638297,steady-state lidocaine plasma concentrations,"Approximately, constant rate absorption was observed from 12-72 h after patch application at a mean +/- SD rate of 109 +/- 49 microg/kg/h, resulting in steady-state lidocaine plasma concentrations of 0.083 +/- 0.032 microg/mL and MEGX concentrations of 0.012 +/- 0.009 microg/mL.",Pharmacokinetics of lidocaine following the application of 5% lidocaine patches to cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638297/),[μg] / [ml],0.083,205225,DB00281,Lidocaine
,18638297,concentrations,"Approximately, constant rate absorption was observed from 12-72 h after patch application at a mean +/- SD rate of 109 +/- 49 microg/kg/h, resulting in steady-state lidocaine plasma concentrations of 0.083 +/- 0.032 microg/mL and MEGX concentrations of 0.012 +/- 0.009 microg/mL.",Pharmacokinetics of lidocaine following the application of 5% lidocaine patches to cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638297/),μ,0.,205226,DB00281,Lidocaine
,18638297,Overall bioavailability,"Overall bioavailability of transdermal lidocaine was 6.3 +/- 2.7%, and only 56 +/- 29% of the total lidocaine dose delivered by the patch reached systemic circulation.",Pharmacokinetics of lidocaine following the application of 5% lidocaine patches to cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638297/),%,6.3,205227,DB00281,Lidocaine
,18638297,Overall bioavailability,"Overall bioavailability of transdermal lidocaine was 6.3 +/- 2.7%, and only 56 +/- 29% of the total lidocaine dose delivered by the patch reached systemic circulation.",Pharmacokinetics of lidocaine following the application of 5% lidocaine patches to cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18638297/),%,56,205228,DB00281,Lidocaine
,17583875,analytical recovery,"The analytical recovery of prilocaine HCl and IS from plasma has averaged 94.79 and 96.8%, respectively.",Development and validation of gas chromatography-mass spectroscopy method for determination of prilocaine HCl in human plasma using internal standard methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583875/),%,94.79,205244,DB00281,Lidocaine
,17583875,analytical recovery,"The analytical recovery of prilocaine HCl and IS from plasma has averaged 94.79 and 96.8%, respectively.",Development and validation of gas chromatography-mass spectroscopy method for determination of prilocaine HCl in human plasma using internal standard methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583875/),%,96.8,205245,DB00281,Lidocaine
,17583875,LOQ,"LOQ and LOD values for plasma were found to be 20 and 10 ng/mL, respectively.",Development and validation of gas chromatography-mass spectroscopy method for determination of prilocaine HCl in human plasma using internal standard methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583875/),[ng] / [ml],20,205246,DB00281,Lidocaine
,17583875,LOD,"LOQ and LOD values for plasma were found to be 20 and 10 ng/mL, respectively.",Development and validation of gas chromatography-mass spectroscopy method for determination of prilocaine HCl in human plasma using internal standard methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583875/),[ng] / [ml],10,205247,DB00281,Lidocaine
,18679666,Cmax,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ng] / [ml],879.11,206161,DB00281,Lidocaine
,18679666,Cmax,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ng] / [ml],"1,145.58",206162,DB00281,Lidocaine
,18679666,AUC(0-infinity),"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[μg] / [min·ml],256.01,206163,DB00281,Lidocaine
,18679666,AUC(0-infinity),"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[μg] / [min·ml],455.95,206164,DB00281,Lidocaine
,18679666,Cl/f/kg,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ml] / [kg·min],10.61,206165,DB00281,Lidocaine
,18679666,Cl/f/kg,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ml] / [kg·min],5.64,206166,DB00281,Lidocaine
,18679666,Vd/f/kg,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[l] / [kg],3.26,206167,DB00281,Lidocaine
,18679666,Vd/f/kg,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[l] / [kg],2.19,206168,DB00281,Lidocaine
,18679666,Cmax,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ng] / [ml],82.71,206169,DB00281,Lidocaine
,18679666,Cmax,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ng] / [ml],141.38,206170,DB00281,Lidocaine
,18679666,Tmax,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),min,44.71,206171,DB00281,Lidocaine
,18679666,Tmax,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),min,193.14,206172,DB00281,Lidocaine
,18679666,t(1/2)alpha,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),min,7.64,206173,DB00281,Lidocaine
,18679666,t(1/2)alpha,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),min,59.77,206174,DB00281,Lidocaine
,18679666,alpha,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),1/[min],0.097,206175,DB00281,Lidocaine
,18679666,alpha,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),1/[min],0.012,206176,DB00281,Lidocaine
,18679666,AUC(0-infinity),"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[μg] / [min·ml],29.91,206177,DB00281,Lidocaine
,18679666,AUC(0-infinity),"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[μg] / [min·ml],108.23,206178,DB00281,Lidocaine
,28902942,peak of plasma concentrations,The peak of plasma concentrations appeared difference (Group LG: 1.39 ± 0.23 mg/L; Group LS: 1.47 ± 0.29 mg/L and Group LE: 0.99 ± 0.08 mg/L).,A study on reducing the absorption of lidocaine from the airway in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28902942/),[mg] / [l],1.39,206195,DB00281,Lidocaine
,28902942,peak of plasma concentrations,The peak of plasma concentrations appeared difference (Group LG: 1.39 ± 0.23 mg/L; Group LS: 1.47 ± 0.29 mg/L and Group LE: 0.99 ± 0.08 mg/L).,A study on reducing the absorption of lidocaine from the airway in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28902942/),[mg] / [l],1.47,206196,DB00281,Lidocaine
,28902942,peak of plasma concentrations,The peak of plasma concentrations appeared difference (Group LG: 1.39 ± 0.23 mg/L; Group LS: 1.47 ± 0.29 mg/L and Group LE: 0.99 ± 0.08 mg/L).,A study on reducing the absorption of lidocaine from the airway in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28902942/),[mg] / [l],0.99,206197,DB00281,Lidocaine
,552293,serum clearance,The serum clearance (mean +/- s.d.) was slightly higher in the patients (0.85 +/- 0.09 v 0.77 +/- 0.07 l/min) but the difference was not statistically significant.,Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/552293/),[l] / [min],0.85,206410,DB00281,Lidocaine
,552293,serum clearance,The serum clearance (mean +/- s.d.) was slightly higher in the patients (0.85 +/- 0.09 v 0.77 +/- 0.07 l/min) but the difference was not statistically significant.,Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/552293/),[l] / [min],0.77,206411,DB00281,Lidocaine
,552293,bioavailability,"3. Lignocaine bioavailability after oral administration was more than two-fold in the patients than in the normal subjects (0.15 +/- 0.06 v 0.37 +/- 0.09, P < 0.001).",Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/552293/),,0.15,206412,DB00281,Lidocaine
,552293,bioavailability,"3. Lignocaine bioavailability after oral administration was more than two-fold in the patients than in the normal subjects (0.15 +/- 0.06 v 0.37 +/- 0.09, P < 0.001).",Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/552293/),,0.37,206413,DB00281,Lidocaine
,8891878,Ki,"Lidocaine inhibited amiodarone N-monodesethylation (Ki = 120 microM) competitively; inversely, amiodarone suppressed lidocaine N-monodesethylase activity in the same manner (Ki = 47 microM).",Interaction between amiodarone and lidocaine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8891878/),μM,120,206607,DB00281,Lidocaine
,8891878,Ki,"Lidocaine inhibited amiodarone N-monodesethylation (Ki = 120 microM) competitively; inversely, amiodarone suppressed lidocaine N-monodesethylase activity in the same manner (Ki = 47 microM).",Interaction between amiodarone and lidocaine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8891878/),μM,47,206608,DB00281,Lidocaine
greater,6652007,Plasma concentrations,"Plasma concentrations greater than 1.5 micrograms ml-1 were found briefly and inconsistently in patients receiving the usually recommended dose (1.5 mg kg-1), but reliably for 14 min in those receiving 2.5 mg kg-1.",Lignocaine kinetics during cardiopulmonary bypass. Optimum dosage and the effects of haemodilution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6652007/),[μg] / [ml],1.5,207444,DB00281,Lidocaine
,22358767,clearance,"Lidocaine clearance and extraction ratio of hepatocytes in the DMS corresponded to 1.354 ± 0.318 ml/min/g-liver and 0.677 ± 0.0159/g-liver, respectively (N=4).",Prolonged lidocaine metabolizing activity of primary hepatocytes with spheroid culture using polyurethane foam as a culture substratum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358767/),[ml] / [g-liver·min],1.354,208295,DB00281,Lidocaine
,22358767,extraction ratio,"Lidocaine clearance and extraction ratio of hepatocytes in the DMS corresponded to 1.354 ± 0.318 ml/min/g-liver and 0.677 ± 0.0159/g-liver, respectively (N=4).",Prolonged lidocaine metabolizing activity of primary hepatocytes with spheroid culture using polyurethane foam as a culture substratum. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22358767/),1/[g-liver],0.677,208296,DB00281,Lidocaine
,16021436,t(1/2)alpha,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),min,13.5,211876,DB00281,Lidocaine
,16021436,t(1/2)beta,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),min,192.5,211877,DB00281,Lidocaine
,16021436,t(1/2)gamma,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),min,620,211878,DB00281,Lidocaine
,16021436,AUC(0-infinity),"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),[min·ng] / [milliliter],137.404,211879,DB00281,Lidocaine
,16021436,C(l)/f,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),[ml] / [min],464.984,211880,DB00281,Lidocaine
,16021436,V(d)/f,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),l,299.974,211881,DB00281,Lidocaine
,16021436,C(l)/f/kg,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),[ml] / [kg·min],6.875,211882,DB00281,Lidocaine
,16021436,V(d)/f/kg,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),[l] / [kg],4.441,211883,DB00281,Lidocaine
,16021436,latency,"The latency between drug administration and birth was 28.5 min, with a maternal and fetal plasma concentration of 0.310 and 0.245 ng/ml, respectively, at a median fetal/maternal ratio of 0.892.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),min,28.5,211884,DB00281,Lidocaine
,10599952,onset time of sensory block,The mean onset time of sensory block of the median nerve of both lidocaine and articaine were approximately 10 min.,Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),min,10,212028,DB00281,Lidocaine
,10599952,t1/2alpha,Lidocaine is biexponentially eliminated with a t1/2alpha of 9.95 +/- 14.3 min and a t1/2beta of 2.86 +/- 1.55 h.,Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),min,9.95,212029,DB00281,Lidocaine
,10599952,t1/2beta,Lidocaine is biexponentially eliminated with a t1/2alpha of 9.95 +/- 14.3 min and a t1/2beta of 2.86 +/- 1.55 h.,Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),h,2.86,212030,DB00281,Lidocaine
,10599952,t(max),Lidocaine is metabolized into MEGX (mono-ethyl-glycyl-xilidide) (t(max) 2.31 +/- 0.84 h; C(max) 0.32 +/- 0.13 mg/l; t1/2beta 2.36 +/- 2.35 h).,Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),h,2.31,212031,DB00281,Lidocaine
,10599952,C(max),Lidocaine is metabolized into MEGX (mono-ethyl-glycyl-xilidide) (t(max) 2.31 +/- 0.84 h; C(max) 0.32 +/- 0.13 mg/l; t1/2beta 2.36 +/- 2.35 h).,Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),[mg] / [l],0.32,212032,DB00281,Lidocaine
,10599952,t1/2beta,Lidocaine is metabolized into MEGX (mono-ethyl-glycyl-xilidide) (t(max) 2.31 +/- 0.84 h; C(max) 0.32 +/- 0.13 mg/l; t1/2beta 2.36 +/- 2.35 h).,Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),h,2.36,212033,DB00281,Lidocaine
,10599952,total body clearance,Lidocaine total body clearance was 67.9 +/- 28.9 l/h.,Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),[l] / [h],67.9,212034,DB00281,Lidocaine
,10599952,t1/2beta,Articaine is rapidly and monoexponentially eliminated with a t1/2beta of 0.95 +/- 0.39 h.,Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),h,0.95,212035,DB00281,Lidocaine
,10599952,total body clearance,"The total body clearance of articaine is higher than that of lidocaine, 1,133 +/- 582 l/h vs 67.9 +/- 28.9 l/h, respectively (p < 0.0001).",Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),[l] / [h],"1,133",212036,DB00281,Lidocaine
,10599952,total body clearance,"The total body clearance of articaine is higher than that of lidocaine, 1,133 +/- 582 l/h vs 67.9 +/- 28.9 l/h, respectively (p < 0.0001).",Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),[l] / [h],67.9,212037,DB00281,Lidocaine
,517996,maximum plasma lidocaine concentration,"The mean maximum plasma lidocaine concentration in group I 1.99 +/- 1.45 (SD) microgram/ml, in group II 1.33 +/- 0.54 microgram/ml and in group III 1.56 +/- 0.88 microgram/ml (P greater than 0.05) was below the toxic concentrations reported in the literature.",Plasma lidocaine concentrations after different methods of releasing the tourniquet during intravenous regional anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/517996/),[μg] / [ml],1.99,212279,DB00281,Lidocaine
,517996,maximum plasma lidocaine concentration,"The mean maximum plasma lidocaine concentration in group I 1.99 +/- 1.45 (SD) microgram/ml, in group II 1.33 +/- 0.54 microgram/ml and in group III 1.56 +/- 0.88 microgram/ml (P greater than 0.05) was below the toxic concentrations reported in the literature.",Plasma lidocaine concentrations after different methods of releasing the tourniquet during intravenous regional anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/517996/),[μg] / [ml],1.33,212280,DB00281,Lidocaine
,517996,maximum plasma lidocaine concentration,"The mean maximum plasma lidocaine concentration in group I 1.99 +/- 1.45 (SD) microgram/ml, in group II 1.33 +/- 0.54 microgram/ml and in group III 1.56 +/- 0.88 microgram/ml (P greater than 0.05) was below the toxic concentrations reported in the literature.",Plasma lidocaine concentrations after different methods of releasing the tourniquet during intravenous regional anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/517996/),[μg] / [ml],1.56,212281,DB00281,Lidocaine
,1456524,steady-state plasma concentrations,"To obtain steady-state plasma concentrations of 0.5, 1.0, 2.0, 4.0, and 8.0 micrograms/ml, loading doses and constant infusions for ketamine were calculated for each horse on the basis of data from other studies in which the pharmacokinetic properties of ketamine were investigated.",Effects of ketamine infusion on halothane minimal alveolar concentration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1456524/),[μg] / [ml],0.5,213228,DB00281,Lidocaine
,1456524,steady-state plasma concentrations,"To obtain steady-state plasma concentrations of 0.5, 1.0, 2.0, 4.0, and 8.0 micrograms/ml, loading doses and constant infusions for ketamine were calculated for each horse on the basis of data from other studies in which the pharmacokinetic properties of ketamine were investigated.",Effects of ketamine infusion on halothane minimal alveolar concentration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1456524/),[μg] / [ml],1.0,213229,DB00281,Lidocaine
,1456524,steady-state plasma concentrations,"To obtain steady-state plasma concentrations of 0.5, 1.0, 2.0, 4.0, and 8.0 micrograms/ml, loading doses and constant infusions for ketamine were calculated for each horse on the basis of data from other studies in which the pharmacokinetic properties of ketamine were investigated.",Effects of ketamine infusion on halothane minimal alveolar concentration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1456524/),[μg] / [ml],2.0,213230,DB00281,Lidocaine
,1456524,steady-state plasma concentrations,"To obtain steady-state plasma concentrations of 0.5, 1.0, 2.0, 4.0, and 8.0 micrograms/ml, loading doses and constant infusions for ketamine were calculated for each horse on the basis of data from other studies in which the pharmacokinetic properties of ketamine were investigated.",Effects of ketamine infusion on halothane minimal alveolar concentration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1456524/),[μg] / [ml],4.0,213231,DB00281,Lidocaine
,1456524,steady-state plasma concentrations,"To obtain steady-state plasma concentrations of 0.5, 1.0, 2.0, 4.0, and 8.0 micrograms/ml, loading doses and constant infusions for ketamine were calculated for each horse on the basis of data from other studies in which the pharmacokinetic properties of ketamine were investigated.",Effects of ketamine infusion on halothane minimal alveolar concentration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1456524/),[μg] / [ml],8.0,213232,DB00281,Lidocaine
,7650234,Cmax,The drug was quickly absorbed into the plasma in the control group (Cmax = 2.76 +/- 0.10 microgram/mL at 0.33 +/- 0.14 hours after administration); whereas drug access to CSF was decreased and occurred slowly (Cmax = 0.32 +/- 0.07 microgram/mL at 1.66 +/- 1.35 hours).,The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),[μg] / [ml],2.76,214079,DB00281,Lidocaine
,7650234,Cmax,The drug was quickly absorbed into the plasma in the control group (Cmax = 2.76 +/- 0.10 microgram/mL at 0.33 +/- 0.14 hours after administration); whereas drug access to CSF was decreased and occurred slowly (Cmax = 0.32 +/- 0.07 microgram/mL at 1.66 +/- 1.35 hours).,The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),[μg] / [ml],0.32,214080,DB00281,Lidocaine
,7650234,half-lives,"The drug was eliminated more quickly from plasma than from CSF, with half-lives of 1.71 +/- 0.43 hours and 3.86 +/- 1.27 hours, respectively.",The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),h,1.71,214081,DB00281,Lidocaine
,7650234,half-lives,"The drug was eliminated more quickly from plasma than from CSF, with half-lives of 1.71 +/- 0.43 hours and 3.86 +/- 1.27 hours, respectively.",The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),h,3.86,214082,DB00281,Lidocaine
,7650234,tmax,The simultaneous administration of adrenalin delayed absorption (tmax = 0.91 +/- 0.52 hours).,The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),h,0.91,214083,DB00281,Lidocaine
,7650234,elimination half-lives,"The drug elimination half-lives in plasma and CSF of this group increased to 3.22 +/- 1.22 hours and 8.71 +/- 3.28 hours, respectively.",The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),h,3.22,214084,DB00281,Lidocaine
,7650234,elimination half-lives,"The drug elimination half-lives in plasma and CSF of this group increased to 3.22 +/- 1.22 hours and 8.71 +/- 3.28 hours, respectively.",The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),h,8.71,214085,DB00281,Lidocaine
,7650234,duration,"The duration of the analgesia, evaluated as the time until the patient needed another dose, increased from 8.2 +/- 1.5 hours in the control group to 9.7 +/- 1.3 hours in the group that received adrenalin.",The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),h,8.2,214086,DB00281,Lidocaine
,7650234,duration,"The duration of the analgesia, evaluated as the time until the patient needed another dose, increased from 8.2 +/- 1.5 hours in the control group to 9.7 +/- 1.3 hours in the group that received adrenalin.",The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),h,9.7,214087,DB00281,Lidocaine
,9052295,elimination half-life,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),min,113.9,214660,DB00281,Lidocaine
,9052295,elimination half-life,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),min,110.4,214661,DB00281,Lidocaine
,9052295,plasma clearance,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[ml] / [kg·min],6.1,214662,DB00281,Lidocaine
,9052295,plasma clearance,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[ml] / [kg·min],13.6,214663,DB00281,Lidocaine
,9052295,volume of distribution,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[l] / [kg],0.98,214664,DB00281,Lidocaine
,9052295,volume of distribution,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[l] / [kg],1.67,214665,DB00281,Lidocaine
,9052295,time to peak concentration,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),min,31,214666,DB00281,Lidocaine
,9052295,time to peak concentration,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),min,40.5,214667,DB00281,Lidocaine
,9052295,peak Ma concentration,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[μg] / [ml],6.4,214668,DB00281,Lidocaine
,9052295,peak Ma concentration,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[μg] / [ml],0.8,214669,DB00281,Lidocaine
,2611092,peak plasma concentration,"The mean (+/- s.e. mean) peak plasma concentration of lignocaine following intranasal administration was 144 +/- 48 ng ml-1, and the time to peak was 0.92 +/- 0.12 h.",The bioavailability of intranasal lignocaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611092/),[ng] / [ml],144,214906,DB00281,Lidocaine
,2611092,time to peak,"The mean (+/- s.e. mean) peak plasma concentration of lignocaine following intranasal administration was 144 +/- 48 ng ml-1, and the time to peak was 0.92 +/- 0.12 h.",The bioavailability of intranasal lignocaine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611092/),h,0.92,214907,DB00281,Lidocaine
,2611092,AUC,"The mean AUC values for intranasal and intravenous routes were 421 +/- 121 vs 1616 +/- 30 ng ml-1 h, respectively, and the mean bioavailability of the intranasal formulation (AUC ratio) was 0.26 +/- 0.08.",The bioavailability of intranasal lignocaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611092/),[h·ng] / [ml],421,214908,DB00281,Lidocaine
,2611092,AUC,"The mean AUC values for intranasal and intravenous routes were 421 +/- 121 vs 1616 +/- 30 ng ml-1 h, respectively, and the mean bioavailability of the intranasal formulation (AUC ratio) was 0.26 +/- 0.08.",The bioavailability of intranasal lignocaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611092/),[h·ng] / [ml],1616,214909,DB00281,Lidocaine
,2611092,bioavailability of the,"The mean AUC values for intranasal and intravenous routes were 421 +/- 121 vs 1616 +/- 30 ng ml-1 h, respectively, and the mean bioavailability of the intranasal formulation (AUC ratio) was 0.26 +/- 0.08.",The bioavailability of intranasal lignocaine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611092/),,0.26,214910,DB00281,Lidocaine
,2611092,bioavailability,"In all subjects, intranasal absorption was less than 50% complete, and bioavailability varied from 0.05 to 0.48 between individuals.",The bioavailability of intranasal lignocaine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611092/),,0,214911,DB00281,Lidocaine
,3342287,distribution,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,8.4,215411,DB00281,Lidocaine
,3342287,distribution,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,9.2,215412,DB00281,Lidocaine
,3342287,distribution,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,15.3,215413,DB00281,Lidocaine
,3342287,distribution,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,15.2,215414,DB00281,Lidocaine
,3342287,elimination half-lives,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,96,215415,DB00281,Lidocaine
,3342287,elimination half-lives,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,15.3,215416,DB00281,Lidocaine
,3342287,elimination half-lives,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,111,215417,DB00281,Lidocaine
,3342287,elimination half-lives,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,15.2,215418,DB00281,Lidocaine
,3342287,elimination half-lives,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,109,215419,DB00281,Lidocaine
,3342287,volumes of the central compartment,"The mean volumes of the central compartment and mean steady state volumes of distribution were: lidocaine 37 +/- 151 and 97 +/- 201, deuterium-labelled lidocaine 39 +/- 161 and 98 +/- 181, bupivacaine 27 +/- 111 and 66 +/- 231 and deuterium-labelled bupivacaine 28 +/- 121, and 65 +/- 221, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),,37,215420,DB00281,Lidocaine
,3342287,volumes of the central compartment,"The mean volumes of the central compartment and mean steady state volumes of distribution were: lidocaine 37 +/- 151 and 97 +/- 201, deuterium-labelled lidocaine 39 +/- 161 and 98 +/- 181, bupivacaine 27 +/- 111 and 66 +/- 231 and deuterium-labelled bupivacaine 28 +/- 121, and 65 +/- 221, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),,27,215421,DB00281,Lidocaine
,3342287,volumes of the central compartment,"The mean volumes of the central compartment and mean steady state volumes of distribution were: lidocaine 37 +/- 151 and 97 +/- 201, deuterium-labelled lidocaine 39 +/- 161 and 98 +/- 181, bupivacaine 27 +/- 111 and 66 +/- 231 and deuterium-labelled bupivacaine 28 +/- 121, and 65 +/- 221, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),,28,215422,DB00281,Lidocaine
,3342287,steady state volumes of distribution,"The mean volumes of the central compartment and mean steady state volumes of distribution were: lidocaine 37 +/- 151 and 97 +/- 201, deuterium-labelled lidocaine 39 +/- 161 and 98 +/- 181, bupivacaine 27 +/- 111 and 66 +/- 231 and deuterium-labelled bupivacaine 28 +/- 121, and 65 +/- 221, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),,27,215423,DB00281,Lidocaine
,3342287,steady state volumes of distribution,"The mean volumes of the central compartment and mean steady state volumes of distribution were: lidocaine 37 +/- 151 and 97 +/- 201, deuterium-labelled lidocaine 39 +/- 161 and 98 +/- 181, bupivacaine 27 +/- 111 and 66 +/- 231 and deuterium-labelled bupivacaine 28 +/- 121, and 65 +/- 221, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),,66,215424,DB00281,Lidocaine
,3342287,steady state volumes of distribution,"The mean volumes of the central compartment and mean steady state volumes of distribution were: lidocaine 37 +/- 151 and 97 +/- 201, deuterium-labelled lidocaine 39 +/- 161 and 98 +/- 181, bupivacaine 27 +/- 111 and 66 +/- 231 and deuterium-labelled bupivacaine 28 +/- 121, and 65 +/- 221, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),,28,215425,DB00281,Lidocaine
,3342287,steady state volumes of distribution,"The mean volumes of the central compartment and mean steady state volumes of distribution were: lidocaine 37 +/- 151 and 97 +/- 201, deuterium-labelled lidocaine 39 +/- 161 and 98 +/- 181, bupivacaine 27 +/- 111 and 66 +/- 231 and deuterium-labelled bupivacaine 28 +/- 121, and 65 +/- 221, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),,65,215426,DB00281,Lidocaine
,3342287,plasma clearances,"The respective mean plasma clearances were 0.88 +/- 0.181 min-1, 0.87 +/- 0.181 min-1, 0.61 +/- 0.151 min-1, and 0.62 +/- 0.171 min-1.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),1/[min],0.88,215427,DB00281,Lidocaine
,3342287,plasma clearances,"The respective mean plasma clearances were 0.88 +/- 0.181 min-1, 0.87 +/- 0.181 min-1, 0.61 +/- 0.151 min-1, and 0.62 +/- 0.171 min-1.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),1/[min],0.87,215428,DB00281,Lidocaine
,3342287,plasma clearances,"The respective mean plasma clearances were 0.88 +/- 0.181 min-1, 0.87 +/- 0.181 min-1, 0.61 +/- 0.151 min-1, and 0.62 +/- 0.171 min-1.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),1/[min],0.61,215429,DB00281,Lidocaine
,3342287,plasma clearances,"The respective mean plasma clearances were 0.88 +/- 0.181 min-1, 0.87 +/- 0.181 min-1, 0.61 +/- 0.151 min-1, and 0.62 +/- 0.171 min-1.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),1/[min],0.62,215430,DB00281,Lidocaine
,7448106,clearance,"2. Mean +/- s.d. values of lignocaine clearance (ml min-1 kg-1) were higher in patients without heart failure (11.8 +/- 2.6, n = 9) than in those with heart failure (7.2 +/- 1.9, n = 9) (P < 0002).",Lignocaine and indocyanine green kinetics in patients following myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448106/),[ml] / [kg·min],11.8,215500,DB00281,Lidocaine
,7448106,clearance,"2. Mean +/- s.d. values of lignocaine clearance (ml min-1 kg-1) were higher in patients without heart failure (11.8 +/- 2.6, n = 9) than in those with heart failure (7.2 +/- 1.9, n = 9) (P < 0002).",Lignocaine and indocyanine green kinetics in patients following myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448106/),[ml] / [kg·min],7.2,215501,DB00281,Lidocaine
,7448106,terminal half-life,5. The mean +/- s.d. post-infusion terminal half-life of lignocaine in four patients whose lignocaine infusions lasted 30h or longer was 7.2 +/- 2.1 h.,Lignocaine and indocyanine green kinetics in patients following myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448106/),h,7.2,215502,DB00281,Lidocaine
,8268538,clearance,"Lidocaine clearance was 7.0 +/- 0.6 ml/min, and the half-life of lidocaine was 5.6 +/- 0.8 hr under in vitro conditions.",Pharmacokinetic analysis verifies P450 function during in vitro and in vivo application of a bioartificial liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268538/),[ml] / [min],7.0,215974,DB00281,Lidocaine
,8268538,half-life,"Lidocaine clearance was 7.0 +/- 0.6 ml/min, and the half-life of lidocaine was 5.6 +/- 0.8 hr under in vitro conditions.",Pharmacokinetic analysis verifies P450 function during in vitro and in vivo application of a bioartificial liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268538/),h,5.6,215975,DB00281,Lidocaine
,7285479,ClH,"Our randomized crossover study demonstrated that mean ClH rose from 1245 to 1477 ml/min (P less than 0.03) as a result of the meal (i.e., mean area under the blood concentration-time curve decreased 20%).",Effect of food on lidocaine kinetics: mechanism of food-related alteration in high intrinsic clearance drug elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285479/),[ml] / [min],124,216818,DB00281,Lidocaine
,7285479,ClH,"Our randomized crossover study demonstrated that mean ClH rose from 1245 to 1477 ml/min (P less than 0.03) as a result of the meal (i.e., mean area under the blood concentration-time curve decreased 20%).",Effect of food on lidocaine kinetics: mechanism of food-related alteration in high intrinsic clearance drug elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285479/),[ml] / [min],147,216819,DB00281,Lidocaine
,7285479,free fraction,"In a separate study, it was observed that the meal did not influence lidocaine serum protein binding; the free fraction of lidocaine in samples drawn from the subjects in the fasting state averaged 0.305 +/- 0.027 while that from subjects who had eaten was 0.321 +/- 0.042.",Effect of food on lidocaine kinetics: mechanism of food-related alteration in high intrinsic clearance drug elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285479/),,0.305,216820,DB00281,Lidocaine
,7285479,free fraction,"In a separate study, it was observed that the meal did not influence lidocaine serum protein binding; the free fraction of lidocaine in samples drawn from the subjects in the fasting state averaged 0.305 +/- 0.027 while that from subjects who had eaten was 0.321 +/- 0.042.",Effect of food on lidocaine kinetics: mechanism of food-related alteration in high intrinsic clearance drug elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285479/),,0.321,216821,DB00281,Lidocaine
,3674474,arterial oxygen saturation,Shunts were prepared by anastomosing the pulmonary artery to the left atrial appendage to achieve arterial oxygen saturation of 65-75%.,The influence of a right-to-left cardiac shunt on lidocaine pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674474/),%,65-75,219031,DB00281,Lidocaine
,3674474,Peak arterial whole blood concentration,Peak arterial whole blood concentration of lidocaine in the shunted animals was 37.0 +/- 2.1 micrograms/ml compared to 21.1 +/- 0.1 microgram/ml in the control animals; P less than .01.,The influence of a right-to-left cardiac shunt on lidocaine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674474/),[μg] / [ml],37.0,219032,DB00281,Lidocaine
,3674474,Peak arterial whole blood concentration,Peak arterial whole blood concentration of lidocaine in the shunted animals was 37.0 +/- 2.1 micrograms/ml compared to 21.1 +/- 0.1 microgram/ml in the control animals; P less than .01.,The influence of a right-to-left cardiac shunt on lidocaine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674474/),[μg] / [ml],21.1,219033,DB00281,Lidocaine
,3674474,peak arterial concentrations,The peak arterial concentrations during the lidocaine infusion were 12.6 +/- 3.5 micrograms/ml in the RLS and 5.8 +/- 1.5 micrograms/ml in the controls.,The influence of a right-to-left cardiac shunt on lidocaine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674474/),[μg] / [ml],12.6,219034,DB00281,Lidocaine
,3674474,peak arterial concentrations,The peak arterial concentrations during the lidocaine infusion were 12.6 +/- 3.5 micrograms/ml in the RLS and 5.8 +/- 1.5 micrograms/ml in the controls.,The influence of a right-to-left cardiac shunt on lidocaine pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674474/),[μg] / [ml],5.8,219035,DB00281,Lidocaine
,3674474,Total body clearance,Total body clearance of lidocaine was decreased in the shunted animals to 30.7 +/- 13.2 ml.kg-1.min-1 from 68.1 +/- 12.1 ml.kg-1.min-1 in the control animals; P less than .001.,The influence of a right-to-left cardiac shunt on lidocaine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674474/),[ml] / [kg·min],30.7,219036,DB00281,Lidocaine
,3674474,Total body clearance,Total body clearance of lidocaine was decreased in the shunted animals to 30.7 +/- 13.2 ml.kg-1.min-1 from 68.1 +/- 12.1 ml.kg-1.min-1 in the control animals; P less than .001.,The influence of a right-to-left cardiac shunt on lidocaine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674474/),[ml] / [kg·min],68.1,219037,DB00281,Lidocaine
,3674474,steady-state volume of distribution,"The steady-state volume of distribution was also decreased in the shunted animals, 1.0 +/- 0.2 l/kg versus 2.0 +/- 0.7 l/kg in the controls; P less than .02.",The influence of a right-to-left cardiac shunt on lidocaine pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674474/),[l] / [kg],1.0,219038,DB00281,Lidocaine
,3674474,steady-state volume of distribution,"The steady-state volume of distribution was also decreased in the shunted animals, 1.0 +/- 0.2 l/kg versus 2.0 +/- 0.7 l/kg in the controls; P less than .02.",The influence of a right-to-left cardiac shunt on lidocaine pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3674474/),[l] / [kg],2.0,219039,DB00281,Lidocaine
,2316876,Peak lidocaine serum concentrations,"Peak lidocaine serum concentrations, 1.9 +/- 0.7 micrograms/mL, were present 9 +/- 3 min after injection of the loading dose.",Continuous intercostal blockade with lidocaine after thoracic surgery. Clinical and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316876/),[μg] / [ml],1.9,219268,DB00281,Lidocaine
,2316876,Serum concentrations,"Serum concentrations of lidocaine under steady state conditions averaged 4.8 +/- 0.9 micrograms/mL (range, 3.5-5.8 micrograms/mL).",Continuous intercostal blockade with lidocaine after thoracic surgery. Clinical and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316876/),[μg] / [ml],4.8,219269,DB00281,Lidocaine
,442753,threshold concentration,The antiarrhythmically effective threshold concentration in plasma (1.5 mg/l) was reached after an average time of 5.5 min by 9 out of 10 patients.,[Pharmacokinetics of lidocaine after intramuscular injection in patients with acute myocardial infarction (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/442753/),[mg] / [l],1.5,219712,DB00281,Lidocaine
,442753,maximum concentration,The mean value of maximum concentration after 30 min was 3.6 mg/l in 10 patients and the mean duration for exceeding the threshold (1.5 mg/l) was about 2 hrs.,[Pharmacokinetics of lidocaine after intramuscular injection in patients with acute myocardial infarction (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/442753/),[mg] / [l],3.6,219713,DB00281,Lidocaine
,442753,elimination half-life,The elimination half-life for lidocaine valued 1.77 hrs.,[Pharmacokinetics of lidocaine after intramuscular injection in patients with acute myocardial infarction (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/442753/),h,1.77,219714,DB00281,Lidocaine
,442753,toxic threshold concentration,The toxic threshold concentration of 6 mg/l was exceeded for a short time by 3 patients without any side effects; in three other patients suffering from side-effects no relation to high plasma levels of lidocaine was observed.,[Pharmacokinetics of lidocaine after intramuscular injection in patients with acute myocardial infarction (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/442753/),[mg] / [l],6,219715,DB00281,Lidocaine
,10967444,in,"The intrathecal bioavailability of bupivacaine and lidocaine was 12.3 and 17.9%, respectively, while it was 5.5 and 17.7% following the separate administration of each agent [Clément, R., Malinovsky, J.M., Le Corre, P., Dollo, G., Chevanne, F., Le Verge, R., 1999.",Spinal biopharmaceutics of bupivacaine and lidocaine by microdialysis after their simultaneous administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10967444/),%,12.3,220072,DB00281,Lidocaine
,10967444,in,"The intrathecal bioavailability of bupivacaine and lidocaine was 12.3 and 17.9%, respectively, while it was 5.5 and 17.7% following the separate administration of each agent [Clément, R., Malinovsky, J.M., Le Corre, P., Dollo, G., Chevanne, F., Le Verge, R., 1999.",Spinal biopharmaceutics of bupivacaine and lidocaine by microdialysis after their simultaneous administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10967444/),%,17.9,220073,DB00281,Lidocaine
,10967444,in,"The intrathecal bioavailability of bupivacaine and lidocaine was 12.3 and 17.9%, respectively, while it was 5.5 and 17.7% following the separate administration of each agent [Clément, R., Malinovsky, J.M., Le Corre, P., Dollo, G., Chevanne, F., Le Verge, R., 1999.",Spinal biopharmaceutics of bupivacaine and lidocaine by microdialysis after their simultaneous administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10967444/),%,5.5,220074,DB00281,Lidocaine
,10967444,in,"The intrathecal bioavailability of bupivacaine and lidocaine was 12.3 and 17.9%, respectively, while it was 5.5 and 17.7% following the separate administration of each agent [Clément, R., Malinovsky, J.M., Le Corre, P., Dollo, G., Chevanne, F., Le Verge, R., 1999.",Spinal biopharmaceutics of bupivacaine and lidocaine by microdialysis after their simultaneous administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10967444/),%,17.7,220075,DB00281,Lidocaine
,10967444,bioavailability,"The intrathecal bioavailability of bupivacaine and lidocaine was 12.3 and 17.9%, respectively, while it was 5.5 and 17.7% following the separate administration of each agent [Clément, R., Malinovsky, J.M., Le Corre, P., Dollo, G., Chevanne, F., Le Verge, R., 1999.",Spinal biopharmaceutics of bupivacaine and lidocaine by microdialysis after their simultaneous administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10967444/),%,12.3,220076,DB00281,Lidocaine
,10967444,bioavailability,"The intrathecal bioavailability of bupivacaine and lidocaine was 12.3 and 17.9%, respectively, while it was 5.5 and 17.7% following the separate administration of each agent [Clément, R., Malinovsky, J.M., Le Corre, P., Dollo, G., Chevanne, F., Le Verge, R., 1999.",Spinal biopharmaceutics of bupivacaine and lidocaine by microdialysis after their simultaneous administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10967444/),%,17.9,220077,DB00281,Lidocaine
,10967444,bioavailability,"The intrathecal bioavailability of bupivacaine and lidocaine was 12.3 and 17.9%, respectively, while it was 5.5 and 17.7% following the separate administration of each agent [Clément, R., Malinovsky, J.M., Le Corre, P., Dollo, G., Chevanne, F., Le Verge, R., 1999.",Spinal biopharmaceutics of bupivacaine and lidocaine by microdialysis after their simultaneous administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10967444/),%,5.5,220078,DB00281,Lidocaine
,10967444,bioavailability,"The intrathecal bioavailability of bupivacaine and lidocaine was 12.3 and 17.9%, respectively, while it was 5.5 and 17.7% following the separate administration of each agent [Clément, R., Malinovsky, J.M., Le Corre, P., Dollo, G., Chevanne, F., Le Verge, R., 1999.",Spinal biopharmaceutics of bupivacaine and lidocaine by microdialysis after their simultaneous administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10967444/),%,17.7,220079,DB00281,Lidocaine
,18547152,Tmax,The phentolamine Tmax occurred earlier following the intravenous administration of 1Piv (7 minutes than following its submucosal administration in treatment 1L1P (15 minutes) or 4L2P (11 minutes).,Pharmacokinetics of lidocaine with epinephrine following local anesthesia reversal with phentolamine mesylate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18547152/),min,7,220621,DB00281,Lidocaine
,18547152,Tmax,The phentolamine Tmax occurred earlier following the intravenous administration of 1Piv (7 minutes than following its submucosal administration in treatment 1L1P (15 minutes) or 4L2P (11 minutes).,Pharmacokinetics of lidocaine with epinephrine following local anesthesia reversal with phentolamine mesylate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18547152/),min,15,220622,DB00281,Lidocaine
,18547152,Tmax,The phentolamine Tmax occurred earlier following the intravenous administration of 1Piv (7 minutes than following its submucosal administration in treatment 1L1P (15 minutes) or 4L2P (11 minutes).,Pharmacokinetics of lidocaine with epinephrine following local anesthesia reversal with phentolamine mesylate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18547152/),min,11,220623,DB00281,Lidocaine
,7073151,systemic clearance,Cimetidine reduced the systemic clearance of lidocaine from 766 +/- 50 mL/min to 576 +/- 47 mL/min (p less than 0.05); the apparent volume of distribution at steady-state and the degree of plasma protein binding of lidocaine also were decreased.,Increased toxicity and reduced clearance of lidocaine by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7073151/),[ml] / [min],766,220871,DB00281,Lidocaine
,7073151,systemic clearance,Cimetidine reduced the systemic clearance of lidocaine from 766 +/- 50 mL/min to 576 +/- 47 mL/min (p less than 0.05); the apparent volume of distribution at steady-state and the degree of plasma protein binding of lidocaine also were decreased.,Increased toxicity and reduced clearance of lidocaine by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7073151/),[ml] / [min],576,220872,DB00281,Lidocaine
,24941827,flow rate,"The analysis was performed on a column of ultimate C18 (50 mm x 4.6 mm, 5 microm) with the mobile phase consisting of methyl alcohol-water-formic acid = 75:25 : 0.05 at a flow rate of 0. 2 mL/min.",[Determination of dimemorfan in human plasma and urine with HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24941827/),[ml] / [min],0. 2,222620,DB00281,Lidocaine
,24941827,(,The ion pairs being detected were (m/z) 256.4-->155.,[Determination of dimemorfan in human plasma and urine with HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24941827/),,256.4,222621,DB00281,Lidocaine
,24941827,m/z),The ion pairs being detected were (m/z) 256.4-->155.,[Determination of dimemorfan in human plasma and urine with HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24941827/),,256.4,222622,DB00281,Lidocaine
,24941827,m/z),The ion pairs being detected were (m/z) 256.4-->155.,[Determination of dimemorfan in human plasma and urine with HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24941827/),,155,222623,DB00281,Lidocaine
,24941827,recoveries,"The method recoveries of dimemorfan in plasma and urine were ranging from 103.38% to 106.88% and 90.05% to 101.40%, respectively.",[Determination of dimemorfan in human plasma and urine with HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24941827/),%,103.38,222624,DB00281,Lidocaine
,24941827,recoveries,"The method recoveries of dimemorfan in plasma and urine were ranging from 103.38% to 106.88% and 90.05% to 101.40%, respectively.",[Determination of dimemorfan in human plasma and urine with HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24941827/),%,106.88,222625,DB00281,Lidocaine
,24941827,recoveries,"The method recoveries of dimemorfan in plasma and urine were ranging from 103.38% to 106.88% and 90.05% to 101.40%, respectively.",[Determination of dimemorfan in human plasma and urine with HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24941827/),%,90.05,222626,DB00281,Lidocaine
,24941827,recoveries,"The method recoveries of dimemorfan in plasma and urine were ranging from 103.38% to 106.88% and 90.05% to 101.40%, respectively.",[Determination of dimemorfan in human plasma and urine with HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24941827/),%,101.40,222627,DB00281,Lidocaine
,20108649,drug targeting index (DTI),"Moreover, the drug targeting index (DTI) of olfactory/ventricle after nasal gel and spray administration was 2.15/1.51 and 1.66/1.26, respectively.",Hydrophilic nasal gel of lidocaine hydrochloride. 2nd communication: Improved bioavailability and brain delivery in rats with low ciliotoxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108649/),-1,2.15,223131,DB00281,Lidocaine
,20108649,drug targeting index (DTI),"Moreover, the drug targeting index (DTI) of olfactory/ventricle after nasal gel and spray administration was 2.15/1.51 and 1.66/1.26, respectively.",Hydrophilic nasal gel of lidocaine hydrochloride. 2nd communication: Improved bioavailability and brain delivery in rats with low ciliotoxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108649/),-1,1.51,223132,DB00281,Lidocaine
,20108649,drug targeting index (DTI),"Moreover, the drug targeting index (DTI) of olfactory/ventricle after nasal gel and spray administration was 2.15/1.51 and 1.66/1.26, respectively.",Hydrophilic nasal gel of lidocaine hydrochloride. 2nd communication: Improved bioavailability and brain delivery in rats with low ciliotoxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108649/),-1,1.66,223133,DB00281,Lidocaine
,20108649,drug targeting index (DTI),"Moreover, the drug targeting index (DTI) of olfactory/ventricle after nasal gel and spray administration was 2.15/1.51 and 1.66/1.26, respectively.",Hydrophilic nasal gel of lidocaine hydrochloride. 2nd communication: Improved bioavailability and brain delivery in rats with low ciliotoxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108649/),-1,1.26,223134,DB00281,Lidocaine
,3312572,clearance,"In the normal state, the clearance of methylprednisolone succinate was 1.64 +/- 0.499 L/h/kg and its half-life was 15.33 +/- 3.84 min.","Pharmacokinetics of methylprednisolone succinate, methylprednisolone, and lidocaine in the normal dog and during hemorrhagic shock. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3312572/),[l] / [h·kg],1.64,224589,DB00281,Lidocaine
,3312572,half-life,"In the normal state, the clearance of methylprednisolone succinate was 1.64 +/- 0.499 L/h/kg and its half-life was 15.33 +/- 3.84 min.","Pharmacokinetics of methylprednisolone succinate, methylprednisolone, and lidocaine in the normal dog and during hemorrhagic shock. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3312572/),min,15.33,224590,DB00281,Lidocaine
,3312572,systemic availability,"The systemic availability of methylprednisolone from methylprednisolone succinate was 59.9 +/- 8.3%, and the maximal methylprednisolone concentration was observed after a delay of 7.68 +/- 6.31 min.","Pharmacokinetics of methylprednisolone succinate, methylprednisolone, and lidocaine in the normal dog and during hemorrhagic shock. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3312572/),%,59.9,224591,DB00281,Lidocaine
,3312572,clearance,"The clearance of methylprednisolone succinate decreased to 0.488 +/- 0.240 L/kg/h, and the half-life increased to 40.66 +/- 23.48 min.","Pharmacokinetics of methylprednisolone succinate, methylprednisolone, and lidocaine in the normal dog and during hemorrhagic shock. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3312572/),[l] / [h·kg],0.488,224592,DB00281,Lidocaine
,3312572,half-life,"The clearance of methylprednisolone succinate decreased to 0.488 +/- 0.240 L/kg/h, and the half-life increased to 40.66 +/- 23.48 min.","Pharmacokinetics of methylprednisolone succinate, methylprednisolone, and lidocaine in the normal dog and during hemorrhagic shock. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3312572/),min,40.66,224593,DB00281,Lidocaine
,6653615,Elimination constant rate: max,2.97 +/- 0.29 micrograms X ml-1 at 04.00.--Elimination constant rate: max.,Effect of the hour of administration on the pharmacokinetics of lidocaine in the rat. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653615/),[μg] / [ml],2.97,224743,DB00281,Lidocaine
,6653615,Apparent volume of distribution: max,7.45 +/- 0.84 micrograms X kg-1 X h-1 at 04.00.--Apparent volume of distribution: max.,Effect of the hour of administration on the pharmacokinetics of lidocaine in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6653615/),[μg] / [h·kg],7.45,224744,DB00281,Lidocaine
,11684406,recovery,The mean recovery of the drug from plasma samples was 95.71+/-2.82%.,Determination of pethidine in rabbit plasma by capillary gas chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11684406/),%,95.71,224780,DB00281,Lidocaine
,12805913,t1/2alpha,Lidocaine is eliminated biexponentially with a t1/2alpha of 9.95 +/- 14.3 min and a t1/2beta of 2.86 +/- 1.55 h.,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),min,9.95,225154,DB00281,Lidocaine
,12805913,t1/2beta,Lidocaine is eliminated biexponentially with a t1/2alpha of 9.95 +/- 14.3 min and a t1/2beta of 2.86 +/- 1.55 h.,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,2.86,225155,DB00281,Lidocaine
,12805913,tmax,Lidocaine is metabolised into MEGX (tmax 2.31 +/- 0.84 h; Cmax 0.32 +/- 0.13 mg l(-1); t1/2beta 2.36 +/- 2.35 h; total body clearance was 67.9 +/- 28.9 l h(-1)).,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,2.31,225156,DB00281,Lidocaine
,12805913,Cmax,Lidocaine is metabolised into MEGX (tmax 2.31 +/- 0.84 h; Cmax 0.32 +/- 0.13 mg l(-1); t1/2beta 2.36 +/- 2.35 h; total body clearance was 67.9 +/- 28.9 l h(-1)).,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[mg] / [l],0.32,225157,DB00281,Lidocaine
,12805913,t1/2beta,Lidocaine is metabolised into MEGX (tmax 2.31 +/- 0.84 h; Cmax 0.32 +/- 0.13 mg l(-1); t1/2beta 2.36 +/- 2.35 h; total body clearance was 67.9 +/- 28.9 l h(-1)).,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,2.36,225158,DB00281,Lidocaine
,12805913,total body clearance,Lidocaine is metabolised into MEGX (tmax 2.31 +/- 0.84 h; Cmax 0.32 +/- 0.13 mg l(-1); t1/2beta 2.36 +/- 2.35 h; total body clearance was 67.9 +/- 28.9 l h(-1)).,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[l] / [h],67.9,225159,DB00281,Lidocaine
,12805913,t1/2,"Mepivacaine is eliminated rapidly and monoexponentially with a t1/2 of 4.78 +/- 2.38 h, a Cmax of 3.89 +/- 0.83 mg l(-1), and a tmax of 0.41 +/- 0.19 h.",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,4.78,225160,DB00281,Lidocaine
,12805913,Cmax,"Mepivacaine is eliminated rapidly and monoexponentially with a t1/2 of 4.78 +/- 2.38 h, a Cmax of 3.89 +/- 0.83 mg l(-1), and a tmax of 0.41 +/- 0.19 h.",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[mg] / [l],3.89,225161,DB00281,Lidocaine
,12805913,tmax,"Mepivacaine is eliminated rapidly and monoexponentially with a t1/2 of 4.78 +/- 2.38 h, a Cmax of 3.89 +/- 0.83 mg l(-1), and a tmax of 0.41 +/- 0.19 h.",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,0.41,225162,DB00281,Lidocaine
,12805913,total body clearance,"The total body clearance of mepivacaine is 50% of that of lidocaine, 26.9 +/- 10.6 l h(-1) vs. 67.9 +/- 28.9 l h-1, respectively (p < 0.0001).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[l] / [h],26.9,225163,DB00281,Lidocaine
,12805913,total body clearance,"The total body clearance of mepivacaine is 50% of that of lidocaine, 26.9 +/- 10.6 l h(-1) vs. 67.9 +/- 28.9 l h-1, respectively (p < 0.0001).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[l] / [h],67.9,225164,DB00281,Lidocaine
,12805913,Cmax,"(+/-)mepivacaine is metabolised into (+/-)4-OHmepivacaine (Cmax 0.45 +/- 0.25 mg l(-1); t1/2beta 6.48 +/- 6.57 h) and (+/-)2,6-pipecoloxylidide (Cmax 0.56 +/- 0.30 mg l(-1); t1/2beta 1.48 +/- 0.74 h).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[mg] / [l],0.45,225165,DB00281,Lidocaine
,12805913,t1/2beta,"(+/-)mepivacaine is metabolised into (+/-)4-OHmepivacaine (Cmax 0.45 +/- 0.25 mg l(-1); t1/2beta 6.48 +/- 6.57 h) and (+/-)2,6-pipecoloxylidide (Cmax 0.56 +/- 0.30 mg l(-1); t1/2beta 1.48 +/- 0.74 h).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,6.48,225166,DB00281,Lidocaine
,12805913,Cmax,"(+/-)mepivacaine is metabolised into (+/-)4-OHmepivacaine (Cmax 0.45 +/- 0.25 mg l(-1); t1/2beta 6.48 +/- 6.57 h) and (+/-)2,6-pipecoloxylidide (Cmax 0.56 +/- 0.30 mg l(-1); t1/2beta 1.48 +/- 0.74 h).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[mg] / [l],0.56,225167,DB00281,Lidocaine
,12805913,t1/2beta,"(+/-)mepivacaine is metabolised into (+/-)4-OHmepivacaine (Cmax 0.45 +/- 0.25 mg l(-1); t1/2beta 6.48 +/- 6.57 h) and (+/-)2,6-pipecoloxylidide (Cmax 0.56 +/- 0.30 mg l(-1); t1/2beta 1.48 +/- 0.74 h).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,1.48,225168,DB00281,Lidocaine
,3665324,distribution,"The mean distribution and elimination half-lives were 12 minutes and 100 minutes for lignocaine, and 22 minutes and 143 minutes for bupivacaine.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),min,12,228762,DB00281,Lidocaine
,3665324,distribution,"The mean distribution and elimination half-lives were 12 minutes and 100 minutes for lignocaine, and 22 minutes and 143 minutes for bupivacaine.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),min,22,228763,DB00281,Lidocaine
,3665324,elimination half-lives,"The mean distribution and elimination half-lives were 12 minutes and 100 minutes for lignocaine, and 22 minutes and 143 minutes for bupivacaine.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),min,100,228764,DB00281,Lidocaine
,3665324,elimination half-lives,"The mean distribution and elimination half-lives were 12 minutes and 100 minutes for lignocaine, and 22 minutes and 143 minutes for bupivacaine.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),min,143,228765,DB00281,Lidocaine
,3665324,volumes of the central compartment,"The mean volumes of the central compartment and the mean steady-state volumes of distribution were: lignocaine, 43L and 99L; bupivacaine, 33L and 68L.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),l,43,228766,DB00281,Lidocaine
,3665324,steady-state volumes of distribution,"The mean volumes of the central compartment and the mean steady-state volumes of distribution were: lignocaine, 43L and 99L; bupivacaine, 33L and 68L.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,99,228767,DB00281,Lidocaine
,3665324,steady-state volumes of distribution,"The mean volumes of the central compartment and the mean steady-state volumes of distribution were: lignocaine, 43L and 99L; bupivacaine, 33L and 68L.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),l,33,228768,DB00281,Lidocaine
,3665324,steady-state volumes of distribution,"The mean volumes of the central compartment and the mean steady-state volumes of distribution were: lignocaine, 43L and 99L; bupivacaine, 33L and 68L.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,68,228769,DB00281,Lidocaine
,3665324,Total plasma clearances,Total plasma clearances averaged 0.95 L/min (57 L/h) for lignocaine and 0.52 L/min (31.2 L/h) for bupivacaine.,Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),[l] / [min],0.95,228770,DB00281,Lidocaine
,3665324,Total plasma clearances,Total plasma clearances averaged 0.95 L/min (57 L/h) for lignocaine and 0.52 L/min (31.2 L/h) for bupivacaine.,Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),[l] / [min],0.52,228771,DB00281,Lidocaine
,3665324,half-lives,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),min,9.3,228772,DB00281,Lidocaine
,3665324,half-lives,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),min,82,228773,DB00281,Lidocaine
,3665324,half-lives,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),min,7.0,228774,DB00281,Lidocaine
,3665324,half-lives,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),min,362,228775,DB00281,Lidocaine
,3665324,half-lives,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,0.38,228776,DB00281,Lidocaine
,3665324,half-lives,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,0.58,228777,DB00281,Lidocaine
,3665324,half-lives,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,0.28,228778,DB00281,Lidocaine
,3665324,half-lives,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,0.66,228779,DB00281,Lidocaine
,3665324,fractions,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,0.38,228780,DB00281,Lidocaine
,3665324,fractions,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,0.58,228781,DB00281,Lidocaine
,3665324,fractions,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,0.28,228782,DB00281,Lidocaine
,3665324,fractions,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,0.66,228783,DB00281,Lidocaine
,2189614,bioavailability,Pharmacokinetic studies have shown that oral absorption is rapid with bioavailability of 80-90%.,Mexiletine: pharmacology and therapeutic use. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189614/),%,80-90,228858,DB00281,Lidocaine
,2189614,elimination half-life,Mexiletine is predominantly metabolized by the liver with elimination half-life of 9 to 12 hours.,Mexiletine: pharmacology and therapeutic use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2189614/),h,9 to 12,228859,DB00281,Lidocaine
,9661557,peak plasma lidocaine concentrations,"The SGB group showed significantly higher peak plasma lidocaine concentrations than other groups (SGB 1.65 +/- 0.21 microgram/mL, ICNB 0.89 +/- 0.12 microgram/mL, EB 0.91 +/- 0.19 microgram/mL; P < 0.01).","Comparison of plasma lidocaine concentrations after injection of a fixed small volume in the stellate ganglion, the lumbar epidural space, or a single intercostal nerve. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661557/),[μg] / [ml],1.65,230852,DB00281,Lidocaine
,9661557,peak plasma lidocaine concentrations,"The SGB group showed significantly higher peak plasma lidocaine concentrations than other groups (SGB 1.65 +/- 0.21 microgram/mL, ICNB 0.89 +/- 0.12 microgram/mL, EB 0.91 +/- 0.19 microgram/mL; P < 0.01).","Comparison of plasma lidocaine concentrations after injection of a fixed small volume in the stellate ganglion, the lumbar epidural space, or a single intercostal nerve. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661557/),[μg] / [ml],0.89,230853,DB00281,Lidocaine
,9661557,peak plasma lidocaine concentrations,"The SGB group showed significantly higher peak plasma lidocaine concentrations than other groups (SGB 1.65 +/- 0.21 microgram/mL, ICNB 0.89 +/- 0.12 microgram/mL, EB 0.91 +/- 0.19 microgram/mL; P < 0.01).","Comparison of plasma lidocaine concentrations after injection of a fixed small volume in the stellate ganglion, the lumbar epidural space, or a single intercostal nerve. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661557/),[μg] / [ml],0.91,230854,DB00281,Lidocaine
,9661557,ICNB,"The SGB group showed significantly higher peak plasma lidocaine concentrations than other groups (SGB 1.65 +/- 0.21 microgram/mL, ICNB 0.89 +/- 0.12 microgram/mL, EB 0.91 +/- 0.19 microgram/mL; P < 0.01).","Comparison of plasma lidocaine concentrations after injection of a fixed small volume in the stellate ganglion, the lumbar epidural space, or a single intercostal nerve. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661557/),[μg] / [ml],0.89,230855,DB00281,Lidocaine
,9661557,ICNB,"The SGB group showed significantly higher peak plasma lidocaine concentrations than other groups (SGB 1.65 +/- 0.21 microgram/mL, ICNB 0.89 +/- 0.12 microgram/mL, EB 0.91 +/- 0.19 microgram/mL; P < 0.01).","Comparison of plasma lidocaine concentrations after injection of a fixed small volume in the stellate ganglion, the lumbar epidural space, or a single intercostal nerve. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661557/),[μg] / [ml],0.91,230856,DB00281,Lidocaine
,29909577,apparent volume,"The estimates (between subject variability; relative standard error, %) of apparent volume, apparent clearance, tumescent absorption rate, and instillation absorption rate were 195.0 (46.3; 14.5%) L, 24.7 (48.9; 13.3%) L h-1, 0.28 (39.6; 13.8%) h-1, and 2.56 (135.3; 44.9%) h-1, respectively.",Population pharmacokinetic model for tumescent lidocaine in women undergoing breast cancer surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29909577/),,195.0,232436,DB00281,Lidocaine
,29909577,apparent clearance,"The estimates (between subject variability; relative standard error, %) of apparent volume, apparent clearance, tumescent absorption rate, and instillation absorption rate were 195.0 (46.3; 14.5%) L, 24.7 (48.9; 13.3%) L h-1, 0.28 (39.6; 13.8%) h-1, and 2.56 (135.3; 44.9%) h-1, respectively.",Population pharmacokinetic model for tumescent lidocaine in women undergoing breast cancer surgery. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29909577/),[l] / [h],24.7,232437,DB00281,Lidocaine
,29909577,instillation absorption rate,"The estimates (between subject variability; relative standard error, %) of apparent volume, apparent clearance, tumescent absorption rate, and instillation absorption rate were 195.0 (46.3; 14.5%) L, 24.7 (48.9; 13.3%) L h-1, 0.28 (39.6; 13.8%) h-1, and 2.56 (135.3; 44.9%) h-1, respectively.",Population pharmacokinetic model for tumescent lidocaine in women undergoing breast cancer surgery. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29909577/),,2.56,232438,DB00281,Lidocaine
,2960397,Bioavailability,"Bioavailability of lidocaine in 5 normal volunteers ranged from 26 to 36% (mean 31 +/- SD 5%) and in a cirrhotic with an end-to-side portacaval shunt it approached 100%, as anticipated.",Bioavailability determination of lidocaine by capillary gas chromatography ammonia chemical ionization mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960397/),%,26 to 36,235514,DB00281,Lidocaine
,2960397,Bioavailability,"Bioavailability of lidocaine in 5 normal volunteers ranged from 26 to 36% (mean 31 +/- SD 5%) and in a cirrhotic with an end-to-side portacaval shunt it approached 100%, as anticipated.",Bioavailability determination of lidocaine by capillary gas chromatography ammonia chemical ionization mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960397/),%,31,235515,DB00281,Lidocaine
,2960397,Bioavailability,"Bioavailability of lidocaine in 5 normal volunteers ranged from 26 to 36% (mean 31 +/- SD 5%) and in a cirrhotic with an end-to-side portacaval shunt it approached 100%, as anticipated.",Bioavailability determination of lidocaine by capillary gas chromatography ammonia chemical ionization mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960397/),%,100,235516,DB00281,Lidocaine
,2326518,tmax,LDC absorption from epidural space is fairly rapid (tmax = 17 +/- 4 min and t1/2a = 6.2 +/- 1.7 min).,[Systemic absorption of 2% lidocaine from the lumbar epidural space]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2326518/),min,17,236388,DB00281,Lidocaine
,2326518,t1/2a,LDC absorption from epidural space is fairly rapid (tmax = 17 +/- 4 min and t1/2a = 6.2 +/- 1.7 min).,[Systemic absorption of 2% lidocaine from the lumbar epidural space]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2326518/),min,6.2,236389,DB00281,Lidocaine
,2326518,peak plasma levels,This results in very shape peak plasma levels (2.97 +/- 0.87 micrograms/ml with 2% LDC).,[Systemic absorption of 2% lidocaine from the lumbar epidural space]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2326518/),[μg] / [ml],2.97,236390,DB00281,Lidocaine
,2326518,Ke,The remaining pharmacokinetic parameters were: Ke = 0.0057 +/- 0.0022 min-1 and Vd = 1.5 +/- 0.5 l/kg.,[Systemic absorption of 2% lidocaine from the lumbar epidural space]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2326518/),1/[min],0.0057,236391,DB00281,Lidocaine
,2326518,Vd,The remaining pharmacokinetic parameters were: Ke = 0.0057 +/- 0.0022 min-1 and Vd = 1.5 +/- 0.5 l/kg.,[Systemic absorption of 2% lidocaine from the lumbar epidural space]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2326518/),[l] / [kg],1.5,236392,DB00281,Lidocaine
,3985850,peak levels,"During trial C, the mean peak levels of lidocaine and MEGX, respectively, were 0.5 and 0.6 microgram/mL after the first dose, and 0.8 and 1.3 microgram/mL after the eighth dose.",Lidocaine plasma concentrations following administration of intraoral lidocaine solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3985850/),[μg] / [ml],0.5,236915,DB00281,Lidocaine
,3985850,peak levels,"During trial C, the mean peak levels of lidocaine and MEGX, respectively, were 0.5 and 0.6 microgram/mL after the first dose, and 0.8 and 1.3 microgram/mL after the eighth dose.",Lidocaine plasma concentrations following administration of intraoral lidocaine solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3985850/),[μg] / [ml],0.6,236916,DB00281,Lidocaine
,3985850,peak levels,"During trial C, the mean peak levels of lidocaine and MEGX, respectively, were 0.5 and 0.6 microgram/mL after the first dose, and 0.8 and 1.3 microgram/mL after the eighth dose.",Lidocaine plasma concentrations following administration of intraoral lidocaine solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3985850/),[μg] / [ml],0.8,236917,DB00281,Lidocaine
,3985850,peak levels,"During trial C, the mean peak levels of lidocaine and MEGX, respectively, were 0.5 and 0.6 microgram/mL after the first dose, and 0.8 and 1.3 microgram/mL after the eighth dose.",Lidocaine plasma concentrations following administration of intraoral lidocaine solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3985850/),[μg] / [ml],1.3,236918,DB00281,Lidocaine
,1467100,half-life,"Mean half-life was 72.9 (SEM 9.9) min, similar to that found previously in adults and children.",Pharmacokinetics of lignocaine in children after infiltration for cleft palate surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467100/),min,72.9,237824,DB00281,Lidocaine
,1467100,clearance,However differences in mean clearance (24.6 (2.04) ml kg-1 min-1) and volume of distribution (0.80 (0.07) litre kg-1) were found between this and previous studies.,Pharmacokinetics of lignocaine in children after infiltration for cleft palate surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467100/),[ml] / [kg·min],24.6,237825,DB00281,Lidocaine
,1467100,volume of distribution,However differences in mean clearance (24.6 (2.04) ml kg-1 min-1) and volume of distribution (0.80 (0.07) litre kg-1) were found between this and previous studies.,Pharmacokinetics of lignocaine in children after infiltration for cleft palate surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467100/),[l] / [kg],0.80,237826,DB00281,Lidocaine
,3668853,initial volume of distribution,"Although verapamil did not affect lidocaine pharmacokinetics, in the presence of the steady-state lidocaine we recorded an increase in verapamil initial volume of distribution of 44% from 40 +/- 4 liters, and intercompartmental clearance increased by 88% from 101 +/- 20 liters/hr, combined with an increase in verapamil total clearance of 47% from 54 +/- 6 liters/hr (n = 6).",Pharmacodynamic and pharmacokinetic interactions between lidocaine and verapamil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668853/),l,40,238620,DB00281,Lidocaine
,3668853,intercompartmental clearance,"Although verapamil did not affect lidocaine pharmacokinetics, in the presence of the steady-state lidocaine we recorded an increase in verapamil initial volume of distribution of 44% from 40 +/- 4 liters, and intercompartmental clearance increased by 88% from 101 +/- 20 liters/hr, combined with an increase in verapamil total clearance of 47% from 54 +/- 6 liters/hr (n = 6).",Pharmacodynamic and pharmacokinetic interactions between lidocaine and verapamil. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668853/),[l] / [h],101,238621,DB00281,Lidocaine
,3668853,total clearance,"Although verapamil did not affect lidocaine pharmacokinetics, in the presence of the steady-state lidocaine we recorded an increase in verapamil initial volume of distribution of 44% from 40 +/- 4 liters, and intercompartmental clearance increased by 88% from 101 +/- 20 liters/hr, combined with an increase in verapamil total clearance of 47% from 54 +/- 6 liters/hr (n = 6).",Pharmacodynamic and pharmacokinetic interactions between lidocaine and verapamil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668853/),[l] / [h],54,238622,DB00281,Lidocaine
,25846945,AUC,"Mean ± SD AUC and CMAX were 3054.29 ± 1095.93 ng·h/mL and 54.1 ± 15.84 ng/mL in the Incision Group, and 2269.9 ± 1037.08 ng·h/mL and 44.5 ± 16.34 ng/mL in the No-Incision Group, respectively.",Plasma concentrations of lidocaine in dogs following lidocaine patch application over an incision compared to intact skin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25846945/),[h·ng] / [ml],3054.29,239008,DB00281,Lidocaine
,25846945,AUC,"Mean ± SD AUC and CMAX were 3054.29 ± 1095.93 ng·h/mL and 54.1 ± 15.84 ng/mL in the Incision Group, and 2269.9 ± 1037.08 ng·h/mL and 44.5 ± 16.34 ng/mL in the No-Incision Group, respectively.",Plasma concentrations of lidocaine in dogs following lidocaine patch application over an incision compared to intact skin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25846945/),[h·ng] / [ml],2269.9,239009,DB00281,Lidocaine
,25846945,CMAX,"Mean ± SD AUC and CMAX were 3054.29 ± 1095.93 ng·h/mL and 54.1 ± 15.84 ng/mL in the Incision Group, and 2269.9 ± 1037.08 ng·h/mL and 44.5 ± 16.34 ng/mL in the No-Incision Group, respectively.",Plasma concentrations of lidocaine in dogs following lidocaine patch application over an incision compared to intact skin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25846945/),[ng] / [ml],54.1,239010,DB00281,Lidocaine
,25846945,CMAX,"Mean ± SD AUC and CMAX were 3054.29 ± 1095.93 ng·h/mL and 54.1 ± 15.84 ng/mL in the Incision Group, and 2269.9 ± 1037.08 ng·h/mL and 44.5 ± 16.34 ng/mL in the No-Incision Group, respectively.",Plasma concentrations of lidocaine in dogs following lidocaine patch application over an incision compared to intact skin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25846945/),[ng] / [ml],44.5,239011,DB00281,Lidocaine
,2171117,Po2,"Each dog was given the same dose of endotracheal lidocaine by the same technique of administration while in both a normal control state (Group I = 'Non-hypoxemia', mean Po2 = 98) and during hypoxemia (Group II = ""Hypoxemia"", mean Po2 = 36).",Effect of hypoxemia on pharmacokinetics of endotracheal lidocaine in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2171117/),,98,241546,DB00281,Lidocaine
,2171117,Po2,"Each dog was given the same dose of endotracheal lidocaine by the same technique of administration while in both a normal control state (Group I = 'Non-hypoxemia', mean Po2 = 98) and during hypoxemia (Group II = ""Hypoxemia"", mean Po2 = 36).",Effect of hypoxemia on pharmacokinetics of endotracheal lidocaine in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2171117/),,36,241547,DB00281,Lidocaine
,31134628,peak concentrations,Peak serum concentration occurred within 30 min with average peak concentrations of 1.65 μg/ml.,Rectus sheath single-injection blocks: a study to quantify local anaesthetic absorption using serial ultrasound measurements and lidocaine serum concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31134628/),[μg] / [ml],1.65,243027,DB00281,Lidocaine
,9522138,onset time,The onset time of the local anaesthetic action of lignocaine was 11.2 +/- 5.1 min.,Disposition of lignocaine for intravenous regional anaesthesia during day-case surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9522138/),min,11.2,243099,DB00281,Lidocaine
,9522138,t1/2a,"After releasing the tourniquet lignocaine is rapidly and biexponentially eliminated, with a t1/2a of 4.3 +/- 2.1 min and a t1/2 beta of 79.1 +/- 31.2 min.",Disposition of lignocaine for intravenous regional anaesthesia during day-case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9522138/),min,4.3,243100,DB00281,Lidocaine
,9522138,t1/2 beta,"After releasing the tourniquet lignocaine is rapidly and biexponentially eliminated, with a t1/2a of 4.3 +/- 2.1 min and a t1/2 beta of 79.1 +/- 31.2 min.",Disposition of lignocaine for intravenous regional anaesthesia during day-case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9522138/),min,79.1,243101,DB00281,Lidocaine
,9522138,Total body clearance,Total body clearance was 0.86 +/- 0.39 L min-1.,Disposition of lignocaine for intravenous regional anaesthesia during day-case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9522138/),[l] / [min],0.86,243102,DB00281,Lidocaine
,791536,plasma half-life,The drug was found to have linear kinetics over the dose range studied and a plasma half-life of 13.5 +/- 2 hours.,"Clinical efficacy and pharmacokinetics of a new orally effective antiarrhythmic, tocainide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/791536/),h,13.5,243854,DB00281,Lidocaine
,10215682,unbound CSF fraction,"The CSF binding of BUP and LID was linear in a range from 50 to 500 micrograms/ml, and the mean unbound CSF fraction at a concentration of 100 micrograms/ml was 39.",Cerebrospinal fluid bioavailability and pharmacokinetics of bupivacaine and lidocaine after intrathecal and epidural administrations in rabbits using microdialysis. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215682/),,39,243919,DB00281,Lidocaine
,10215682,bioavailability,"Although the absorption rate of BUP appeared higher than that of LID, the mean CSF bioavailability of epidural BUP and LID was 5.5 and 17.7%, respectively.",Cerebrospinal fluid bioavailability and pharmacokinetics of bupivacaine and lidocaine after intrathecal and epidural administrations in rabbits using microdialysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215682/),%,5.5,243920,DB00281,Lidocaine
,10215682,bioavailability,"Although the absorption rate of BUP appeared higher than that of LID, the mean CSF bioavailability of epidural BUP and LID was 5.5 and 17.7%, respectively.",Cerebrospinal fluid bioavailability and pharmacokinetics of bupivacaine and lidocaine after intrathecal and epidural administrations in rabbits using microdialysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215682/),%,17.7,243921,DB00281,Lidocaine
,2726591,plasma concentrations,Lidocaine plasma concentrations averaged in the range of 3.04-0.88 micrograms/ml from the beginning of the procedure to the end of blood sampling.,Systemic absorption of topical lidocaine in elderly and young adults undergoing bronchoscopy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2726591/),[μg] / [ml],3.04-0.88,243929,DB00281,Lidocaine
,16411907,peak plasma lidocaine concentration,"In dogs with clipped hair, a mean peak plasma lidocaine concentration of 62.94 ng/ml was obtained after 10.67 h.",Pharmacokinetics of a lidocaine patch 5% in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411907/),[ng] / [ml],62.94,244335,DB00281,Lidocaine
,16411907,peak plasma concentration,"In the depilatory group, a mean peak plasma concentration of 103.55 ng/ml was reached after 9.27 h.",Pharmacokinetics of a lidocaine patch 5% in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411907/),[ng] / [ml],103.55,244336,DB00281,Lidocaine
,16411907,peak lidocaine plasma concentration,"There, the mean peak lidocaine plasma concentration was 45.18 ng/ml achieved after 24 h and a final concentration of 29.37 ng/ml was obtained at 60 h.",Pharmacokinetics of a lidocaine patch 5% in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411907/),[ng] / [ml],45.18,244337,DB00281,Lidocaine
,16411907,final concentration,"There, the mean peak lidocaine plasma concentration was 45.18 ng/ml achieved after 24 h and a final concentration of 29.37 ng/ml was obtained at 60 h.",Pharmacokinetics of a lidocaine patch 5% in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411907/),[ng] / [ml],29.37,244338,DB00281,Lidocaine
,19282712,basal rate,"The PCEA regimen was prepared as 0.15% ropivacaine and fentanyl 2 microg/mL (basal rate, 6 mL/h; demand dose, 4 mL/20 min).",Excretion of ropivacaine in breast milk during patient-controlled epidural analgesia after cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19282712/),[ml] / [h],6,244767,DB00281,Lidocaine
,19282712,demand dose,"The PCEA regimen was prepared as 0.15% ropivacaine and fentanyl 2 microg/mL (basal rate, 6 mL/h; demand dose, 4 mL/20 min).",Excretion of ropivacaine in breast milk during patient-controlled epidural analgesia after cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19282712/),-1·ml,4,244768,DB00281,Lidocaine
,19282712,milk-plasma ratios,"Ropivacaine excretion into the breast milk produced concentrations that significantly correlated with those in the plasma 18 and 24 hrs after administration, achieving milk-plasma ratios (mean +/- SD) of 0.25 +/- 0.08 and 0.23 +/- 0.07, respectively.",Excretion of ropivacaine in breast milk during patient-controlled epidural analgesia after cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19282712/),,0.25,244769,DB00281,Lidocaine
,19282712,milk-plasma ratios,"Ropivacaine excretion into the breast milk produced concentrations that significantly correlated with those in the plasma 18 and 24 hrs after administration, achieving milk-plasma ratios (mean +/- SD) of 0.25 +/- 0.08 and 0.23 +/- 0.07, respectively.",Excretion of ropivacaine in breast milk during patient-controlled epidural analgesia after cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19282712/),,0.23,244770,DB00281,Lidocaine
,31887082,terminal half-life,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),h,4.1,247369,DB00281,Lidocaine
,31887082,terminal half-life,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),h,0.98,247370,DB00281,Lidocaine
,31887082,terminal half-life,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),h,1.55,247371,DB00281,Lidocaine
,31887082,area under the concentration-time curve,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[h·μg] / [ml],41,247372,DB00281,Lidocaine
,31887082,area under the concentration-time curve,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[h·μg] / [ml],"14,494",247373,DB00281,Lidocaine
,31887082,area under the concentration-time curve,"Mean terminal half-life was 4.1, 0.98, and 1.55 hours and area under the concentration-time curve was 41, 14,494, and 7,426 h•μg/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[h·μg] / [ml],"7,426",247374,DB00281,Lidocaine
,31887082,serum drug concentration at steady state,"After the CRI, the mean serum drug concentration at steady state was 6.3, 616.7, and 328 ng/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[ng] / [ml],6.3,247375,DB00281,Lidocaine
,31887082,serum drug concentration at steady state,"After the CRI, the mean serum drug concentration at steady state was 6.3, 616.7, and 328 ng/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[ng] / [ml],616.7,247376,DB00281,Lidocaine
,31887082,serum drug concentration at steady state,"After the CRI, the mean serum drug concentration at steady state was 6.3, 616.7, and 328 ng/mL for morphine, lidocaine, and ketamine, respectively.",Pharmacokinetics of an intravenous constant rate infusion of a morphine-lidocaine-ketamine combination in Holstein calves undergoing umbilical herniorrhaphy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31887082/),[ng] / [ml],328,247377,DB00281,Lidocaine
,1688484,Time to placement,"Time to placement of the intraosseous needle varied from 15 seconds to 5 minutes, with a mean of 60 seconds.","Comparison study of intraosseous, central intravenous, and peripheral intravenous infusions of emergency drugs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688484/),min,5,247741,DB00281,Lidocaine
,1688484,Time to placement,"Time to placement of the intraosseous needle varied from 15 seconds to 5 minutes, with a mean of 60 seconds.","Comparison study of intraosseous, central intravenous, and peripheral intravenous infusions of emergency drugs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688484/),seconds,60,247742,DB00281,Lidocaine
,11442278,absorption coefficient,The microemulsion formulations were shown to increase the absorption coefficient of lidocaine more than eight times (753 microg/l/min) compared with a conventional oil-in-water emulsion-based cream (89 microg/l/min) and prilocaine hydrochloride almost two times (8.9 microg/l/min) compared with hydrogel (5.2 microg/l/min).,Dermal pharmacokinetics of microemulsion formulations determined by in vivo microdialysis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442278/),[μg] / [l·min],753,248532,DB00281,Lidocaine
,11442278,absorption coefficient,The microemulsion formulations were shown to increase the absorption coefficient of lidocaine more than eight times (753 microg/l/min) compared with a conventional oil-in-water emulsion-based cream (89 microg/l/min) and prilocaine hydrochloride almost two times (8.9 microg/l/min) compared with hydrogel (5.2 microg/l/min).,Dermal pharmacokinetics of microemulsion formulations determined by in vivo microdialysis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442278/),[μg] / [l·min],89,248533,DB00281,Lidocaine
,11442278,absorption coefficient,The microemulsion formulations were shown to increase the absorption coefficient of lidocaine more than eight times (753 microg/l/min) compared with a conventional oil-in-water emulsion-based cream (89 microg/l/min) and prilocaine hydrochloride almost two times (8.9 microg/l/min) compared with hydrogel (5.2 microg/l/min).,Dermal pharmacokinetics of microemulsion formulations determined by in vivo microdialysis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442278/),[μg] / [l·min],8.9,248534,DB00281,Lidocaine
,11442278,absorption coefficient,The microemulsion formulations were shown to increase the absorption coefficient of lidocaine more than eight times (753 microg/l/min) compared with a conventional oil-in-water emulsion-based cream (89 microg/l/min) and prilocaine hydrochloride almost two times (8.9 microg/l/min) compared with hydrogel (5.2 microg/l/min).,Dermal pharmacokinetics of microemulsion formulations determined by in vivo microdialysis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442278/),[μg] / [l·min],5.2,248535,DB00281,Lidocaine
,14756696,log Poct,"3. Ropivacaine, with a log Poct of 2.9, exhibited a tmax of 61.6 min.",Lipophilicity affects the pharmacokinetics and toxicity of local anaesthetic agents administered by caudal block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756696/),,2.9,249667,DB00281,Lidocaine
,14756696,tmax,"3. Ropivacaine, with a log Poct of 2.9, exhibited a tmax of 61.6 min.",Lipophilicity affects the pharmacokinetics and toxicity of local anaesthetic agents administered by caudal block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756696/),min,61.6,249668,DB00281,Lidocaine
,14756696,log Poct,"At log Poct of approximately 3.0, the toxicity of these local anaesthetic agents was substantially increased.",Lipophilicity affects the pharmacokinetics and toxicity of local anaesthetic agents administered by caudal block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756696/),,3.0,249669,DB00281,Lidocaine
higher,14756696,log Poct,"Toxicity, due to plasma availability of these local anaesthetic agents, seems to be increased at log Poct equal or higher than 3.0 secondary to the highest transfer from plasma into the central nervous system.",Lipophilicity affects the pharmacokinetics and toxicity of local anaesthetic agents administered by caudal block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756696/),,3.0,249670,DB00281,Lidocaine
,6834271,elimination half-life,The average elimination half-life was about the same for all routes of administration (approximately 27 min).,"Avoidance of ""first-pass"" elimination of rectally administered lidocaine in relation to the site of absorption in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834271/),min,27,249851,DB00281,Lidocaine
,6834271,Systemic availability,Systemic availability of lidocaine when given by the oral route was 16%; a similar value was found after rectal administration at 4 cm distance from the anus.,"Avoidance of ""first-pass"" elimination of rectally administered lidocaine in relation to the site of absorption in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834271/),%,16,249852,DB00281,Lidocaine
,6834271,systemic availability,"At 2 cm distance from the anus the mean systemic availability was 21%, at 1 cm, 45% and as closely as possible to the anus, 72%.","Avoidance of ""first-pass"" elimination of rectally administered lidocaine in relation to the site of absorption in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834271/),%,21,249853,DB00281,Lidocaine
,6834271,systemic availability,"At 2 cm distance from the anus the mean systemic availability was 21%, at 1 cm, 45% and as closely as possible to the anus, 72%.","Avoidance of ""first-pass"" elimination of rectally administered lidocaine in relation to the site of absorption in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834271/),%,45,249854,DB00281,Lidocaine
,6834271,systemic availability,"At 2 cm distance from the anus the mean systemic availability was 21%, at 1 cm, 45% and as closely as possible to the anus, 72%.","Avoidance of ""first-pass"" elimination of rectally administered lidocaine in relation to the site of absorption in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834271/),%,72,249855,DB00281,Lidocaine
,3373418,total body clearances,"Lignocaine and procainamide mean total body clearances were 2.9 L/min (SD 1.1) and 1.3 L/min (SD 0.2), respectively.",The uptake and elution of lignocaine and procainamide in the hindquarters of the sheep described using mass balance principles. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3373418/),[l] / [min],2.9,250746,DB00281,Lidocaine
,3373418,total body clearances,"Lignocaine and procainamide mean total body clearances were 2.9 L/min (SD 1.1) and 1.3 L/min (SD 0.2), respectively.",The uptake and elution of lignocaine and procainamide in the hindquarters of the sheep described using mass balance principles. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3373418/),[l] / [min],1.3,250747,DB00281,Lidocaine
,8150879,extraction yield,"The extraction yield of bupivacaine from plasma was 73.5 +/- 5.1% (mean +/- S.D., n = 10).",High-performance liquid chromatographic determination of bupivacaine in plasma samples for biopharmaceutical studies and application to seven other local anaesthetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150879/),%,73.5,253252,DB00281,Lidocaine
,8150879,signal-to-noise ratio,"The limit of detection, defined by a signal-to-noise ratio of 3:1, was 2 ng/ml.",High-performance liquid chromatographic determination of bupivacaine in plasma samples for biopharmaceutical studies and application to seven other local anaesthetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150879/),[ng] / [ml],3:1,253253,DB00281,Lidocaine
,8150879,signal-to-noise ratio,"The limit of detection, defined by a signal-to-noise ratio of 3:1, was 2 ng/ml.",High-performance liquid chromatographic determination of bupivacaine in plasma samples for biopharmaceutical studies and application to seven other local anaesthetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150879/),[ng] / [ml],2,253254,DB00281,Lidocaine
,8610868,Tmax,The Tmax of lidocaine was shorter in the presence of hyaluronidase (17.1 +/- 2.6 min vs 32.7 +/- 6.0 min) as well as the Tmax of bupivacaine (16.8 +/- 3.0 min vs 26.5 +/- 4.4 min).,The role of hyaluronidase on lidocaine and bupivacaine pharmacokinetics after peribulbar blockade. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610868/),min,17.1,253407,DB00281,Lidocaine
,8610868,Tmax,The Tmax of lidocaine was shorter in the presence of hyaluronidase (17.1 +/- 2.6 min vs 32.7 +/- 6.0 min) as well as the Tmax of bupivacaine (16.8 +/- 3.0 min vs 26.5 +/- 4.4 min).,The role of hyaluronidase on lidocaine and bupivacaine pharmacokinetics after peribulbar blockade. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610868/),min,32.7,253408,DB00281,Lidocaine
,8610868,Tmax,The Tmax of lidocaine was shorter in the presence of hyaluronidase (17.1 +/- 2.6 min vs 32.7 +/- 6.0 min) as well as the Tmax of bupivacaine (16.8 +/- 3.0 min vs 26.5 +/- 4.4 min).,The role of hyaluronidase on lidocaine and bupivacaine pharmacokinetics after peribulbar blockade. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610868/),min,16.8,253409,DB00281,Lidocaine
,8610868,Tmax,The Tmax of lidocaine was shorter in the presence of hyaluronidase (17.1 +/- 2.6 min vs 32.7 +/- 6.0 min) as well as the Tmax of bupivacaine (16.8 +/- 3.0 min vs 26.5 +/- 4.4 min).,The role of hyaluronidase on lidocaine and bupivacaine pharmacokinetics after peribulbar blockade. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610868/),min,26.5,253410,DB00281,Lidocaine
,16918719,t1/2,"Fluvoxamine alone had no statistically significant effect on the half-life of lidocaine (t1/2), but during the combination phase t1/2 (3.8 hr) was significantly longer than during the placebo phase (2.4 hr; P<0.01).",Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918719/),h,3.8,253817,DB00281,Lidocaine
,16918719,t1/2,"Fluvoxamine alone had no statistically significant effect on the half-life of lidocaine (t1/2), but during the combination phase t1/2 (3.8 hr) was significantly longer than during the placebo phase (2.4 hr; P<0.01).",Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16918719/),h,2.4,253818,DB00281,Lidocaine
,8437971,Plasma drug concentration,"Plasma drug concentration measured shortly after seizure, and at 4 and 22 hours after seizure were 12.0, 7.6, and 1.4 mg/L, respectively.",Seizure after lidocaine for bronchoscopy: case report and review of the use of lidocaine in airway anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8437971/),[mg] / [l],12.0,255265,DB00281,Lidocaine
,8437971,Plasma drug concentration,"Plasma drug concentration measured shortly after seizure, and at 4 and 22 hours after seizure were 12.0, 7.6, and 1.4 mg/L, respectively.",Seizure after lidocaine for bronchoscopy: case report and review of the use of lidocaine in airway anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8437971/),[mg] / [l],7.6,255266,DB00281,Lidocaine
,8437971,Plasma drug concentration,"Plasma drug concentration measured shortly after seizure, and at 4 and 22 hours after seizure were 12.0, 7.6, and 1.4 mg/L, respectively.",Seizure after lidocaine for bronchoscopy: case report and review of the use of lidocaine in airway anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8437971/),[mg] / [l],1.4,255267,DB00281,Lidocaine
,19393851,C(max),Pilsicainide reached C(max) 0.5 to 1.5 hours after dosing in both the Korean and Japanese subjects.,"An open-label, single-dose, parallel-group, dose-increasing study comparing the pharmacokinetics and tolerability of pilsicainide hydrochloride in healthy Korean and Japanese male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19393851/),h,0.5 to 1.5,256418,DB00281,Lidocaine
,19393851,C(max),"The mean (SD) dose-normalized values for C(max) for the Korean and Japanese subjects were 9.4 (1.9) and 9.2 (1.6) ng/mL/mg, respectively.","An open-label, single-dose, parallel-group, dose-increasing study comparing the pharmacokinetics and tolerability of pilsicainide hydrochloride in healthy Korean and Japanese male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19393851/),[ng] / [mg·ml],9.4,256419,DB00281,Lidocaine
,19393851,C(max),"The mean (SD) dose-normalized values for C(max) for the Korean and Japanese subjects were 9.4 (1.9) and 9.2 (1.6) ng/mL/mg, respectively.","An open-label, single-dose, parallel-group, dose-increasing study comparing the pharmacokinetics and tolerability of pilsicainide hydrochloride in healthy Korean and Japanese male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19393851/),[ng] / [mg·ml],9.2,256420,DB00281,Lidocaine
,19393851,AUC(0-infinity),The mean (SD) dose-normalized values for AUC(0-infinity) were 56.0 (8.0) ng . h/mL/mg in the Korean subjects and 53.8 (8.1) ng . h/mL/mg in the Japanese subjects.,"An open-label, single-dose, parallel-group, dose-increasing study comparing the pharmacokinetics and tolerability of pilsicainide hydrochloride in healthy Korean and Japanese male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19393851/),[h·ng] / [mg·ml],56.0,256421,DB00281,Lidocaine
,19393851,AUC(0-infinity),The mean (SD) dose-normalized values for AUC(0-infinity) were 56.0 (8.0) ng . h/mL/mg in the Korean subjects and 53.8 (8.1) ng . h/mL/mg in the Japanese subjects.,"An open-label, single-dose, parallel-group, dose-increasing study comparing the pharmacokinetics and tolerability of pilsicainide hydrochloride in healthy Korean and Japanese male subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19393851/),[h·ng] / [mg·ml],53.8,256422,DB00281,Lidocaine
,1269216,Renal clearance,"Renal clearance of tocainide averaged 59 ml/min when urinary pH was uncontrolled or acidified, while it was reduced to 13 ml/min during intense sodium bicarbonate loading.","Kinetics of the oral antiarrhythmic lidocaine congener, tocainide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269216/),[ml] / [min],59,257268,DB00281,Lidocaine
,1269216,Renal clearance,"Renal clearance of tocainide averaged 59 ml/min when urinary pH was uncontrolled or acidified, while it was reduced to 13 ml/min during intense sodium bicarbonate loading.","Kinetics of the oral antiarrhythmic lidocaine congener, tocainide. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269216/),[ml] / [min],13,257269,DB00281,Lidocaine
,1269216,volume of the central compartment,Blood levels following intravenous infusion were well described by a 2-compartment open model with a volume of the central compartment of 0.92 L/kg.,"Kinetics of the oral antiarrhythmic lidocaine congener, tocainide. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269216/),[l] / [kg],0.92,257270,DB00281,Lidocaine
,1269216,t 1/2 beta,The t 1/2 beta was 11 hr and total body clearance was 166 ml/min.,"Kinetics of the oral antiarrhythmic lidocaine congener, tocainide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269216/),h,11,257271,DB00281,Lidocaine
,1269216,total body clearance,The t 1/2 beta was 11 hr and total body clearance was 166 ml/min.,"Kinetics of the oral antiarrhythmic lidocaine congener, tocainide. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269216/),[ml] / [min],166,257272,DB00281,Lidocaine
,1269216,Bioavailability,Bioavailability approached 100%.,"Kinetics of the oral antiarrhythmic lidocaine congener, tocainide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1269216/),%,100,257273,DB00281,Lidocaine
,4041336,systemic clearance,Lignocaine systemic clearance was reduced by 9% (1.11 to 0.99 1 h-1 kg-1; P less than 0.01) following ranitidine pretreatment.,The effect of ranitidine on the disposition of lignocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041336/),[1] / [h·kg],1.11 to 0.99,257423,DB00281,Lidocaine
,4041336,volume of distribution at steady-state,The volume of distribution at steady-state was reduced by 15% (3.34 to 2.85 1 kg-1; P less than 0.005).,The effect of ranitidine on the disposition of lignocaine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041336/),[1] / [kg],3.34 to 2.85,257424,DB00281,Lidocaine
,6772381,Plasma half-time of elimination,Plasma half-time of elimination was 19.1 +/- 6.8 hours (r = 0.9).,"Antiarrhythmic efficacy, pharmacokinetics and clinical safety of tocainide in convalescent myocardial infarction patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6772381/),h,19.1,258041,DB00281,Lidocaine
,1969949,binding,The binding of verapamil was ca 85%.,Influence of lignocaine on plasma protein binding and pharmacokinetics of verapamil in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1969949/),%,85,258238,DB00281,Lidocaine
,6713782,Vdss,"Women had larger Vdss (64% +/- 19%), longer t 1/2 (50% +/- 18%), and greater oral lidocaine bioavailability (63% +/- 29%) than did men.",Lidocaine disposition--sex differences and effects of cimetidine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713782/),%,64,258546,DB00281,Lidocaine
,6713782,t 1/2,"Women had larger Vdss (64% +/- 19%), longer t 1/2 (50% +/- 18%), and greater oral lidocaine bioavailability (63% +/- 29%) than did men.",Lidocaine disposition--sex differences and effects of cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713782/),%,50,258547,DB00281,Lidocaine
,6713782,bioavailability,"Women had larger Vdss (64% +/- 19%), longer t 1/2 (50% +/- 18%), and greater oral lidocaine bioavailability (63% +/- 29%) than did men.",Lidocaine disposition--sex differences and effects of cimetidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713782/),%,63,258548,DB00281,Lidocaine
,1526669,terminal half-life,"Serum concentrations were adequately described by three exponential functions, with a terminal half-life of about 4 h.",Pharmacokinetic profile of cefodizime. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526669/),h,4,260272,DB00281,Lidocaine
,1526669,bioavailable,CDZ is 100% bioavailable after i.m. administration.,Pharmacokinetic profile of cefodizime. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526669/),%,100,260273,DB00281,Lidocaine
,1526669,Cmax,"Following administration of 1 and 2 g i.m., Cmax was reached after 1.2 h and amounted to 60 and 140 mg/l, respectively.",Pharmacokinetic profile of cefodizime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526669/),[mg] / [l],60,260274,DB00281,Lidocaine
,1526669,Cmax,"Following administration of 1 and 2 g i.m., Cmax was reached after 1.2 h and amounted to 60 and 140 mg/l, respectively.",Pharmacokinetic profile of cefodizime. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1526669/),[mg] / [l],140,260275,DB00281,Lidocaine
>,9262698,PO2S,Mean PO2S remained > 340 torr throughout each method of administration.,The impact of an endotracheal side port on the absorption of lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9262698/),torr,340,263643,DB00281,Lidocaine
,31414038,flow rate,"The reconstituted samples were chromatographed on Phenomenex Kinetex EVO 4.6*100 mm 2.6 μ 100A column by using a mixture of acetonitrile and 5 mM ammonium acetate buffer (80:20, v/v) as the mobile phase at a flow rate of 0.6 mL/min.",Simultaneous quantification of lidocaine and prilocaine in human plasma by LC-MS/MS and its application in a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31414038/),[ml] / [min],0.6,265647,DB00281,Lidocaine
,31414038,run time,"A run time of 3.0 min for each sample, make it possible to analyze more than 350 human plasma samples per day.",Simultaneous quantification of lidocaine and prilocaine in human plasma by LC-MS/MS and its application in a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31414038/),min,3.0,265648,DB00281,Lidocaine
,31477360,heart rate,"Vital signs were: BP, 66 mmHg/palpation; heart rate, 115/min; respirations 18/min; oxygen saturation, 100% on room air.",Toxicokinetics of hydroxychloroquine following a massive overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),1/[min],115,265920,DB00281,Lidocaine
,31477360,respirations,"Vital signs were: BP, 66 mmHg/palpation; heart rate, 115/min; respirations 18/min; oxygen saturation, 100% on room air.",Toxicokinetics of hydroxychloroquine following a massive overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),1/[min],18,265921,DB00281,Lidocaine
,31477360,half-life,Serial concentrations demonstrated apparent first-order elimination with a half-life of 11.6 h.,Toxicokinetics of hydroxychloroquine following a massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),h,11.6,265922,DB00281,Lidocaine
,31477360,apparent,The apparent 11.6 hour half-life of hydroxychloroquine was shorter than previously described.,Toxicokinetics of hydroxychloroquine following a massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),h,11.6,265923,DB00281,Lidocaine
,22417024,maximum plasma concentration,Application of gel in doses between 2.7 and 5.8 mg/kg of lignocaine resulted in a maximum plasma concentration in any patient of 1520 ng/ml lignocaine and 240 ng/ml monoethyl-glycinexylidide.,Lignocaine plasma levels following topical gel application in laparoscopic and hysteroscopic procedures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417024/),[ng] / [ml],1520,266756,DB00281,Lidocaine
,22417024,maximum plasma concentration,Application of gel in doses between 2.7 and 5.8 mg/kg of lignocaine resulted in a maximum plasma concentration in any patient of 1520 ng/ml lignocaine and 240 ng/ml monoethyl-glycinexylidide.,Lignocaine plasma levels following topical gel application in laparoscopic and hysteroscopic procedures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417024/),[ng] / [ml],240,266757,DB00281,Lidocaine
,22417024,maximum observed concentrations,These maximum concentrations were recorded in a patient undergoing a laparoscopic procedure and patients undergoing hysteroscopic procedures all recorded lower maximum concentrations compared with patients undergoing laparoscopy; the maximum observed concentrations in a patient having a hysteroscopy were 420 ng/ml lignocaine and 56 ng/ml of monoethyl-glycinexylidide.,Lignocaine plasma levels following topical gel application in laparoscopic and hysteroscopic procedures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417024/),[ng] / [ml],420,266758,DB00281,Lidocaine
,22417024,maximum observed concentrations,These maximum concentrations were recorded in a patient undergoing a laparoscopic procedure and patients undergoing hysteroscopic procedures all recorded lower maximum concentrations compared with patients undergoing laparoscopy; the maximum observed concentrations in a patient having a hysteroscopy were 420 ng/ml lignocaine and 56 ng/ml of monoethyl-glycinexylidide.,Lignocaine plasma levels following topical gel application in laparoscopic and hysteroscopic procedures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22417024/),[ng] / [ml],56,266759,DB00281,Lidocaine
,458558,total body clearances (ClT),"The total body clearances (ClT) of PA in slow and fast acetylators were 22.6 and 34.8 liters/hr, respectively.",Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/458558/),[l] / [h],22.6,267921,DB00281,Lidocaine
,458558,total body clearances (ClT),"The total body clearances (ClT) of PA in slow and fast acetylators were 22.6 and 34.8 liters/hr, respectively.",Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/458558/),[l] / [h],34.8,267922,DB00281,Lidocaine
,458558,fraction of,The fraction of PA cleared by the formation of NAPA in the corresponding acetylator group was 0.2 and 0.4.,Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/458558/),,0.2,267923,DB00281,Lidocaine
,458558,fraction of,The fraction of PA cleared by the formation of NAPA in the corresponding acetylator group was 0.2 and 0.4.,Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/458558/),,0.4,267924,DB00281,Lidocaine
,458558,ClT's,"Renal impairment affected the pharmacokinetics of PA more profoundly as the ClT's of PA in patients with and without renal impairment were 17.9 and 31.2 liters/hr, respectively.",Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/458558/),[l] / [h],17.9,267925,DB00281,Lidocaine
,458558,ClT's,"Renal impairment affected the pharmacokinetics of PA more profoundly as the ClT's of PA in patients with and without renal impairment were 17.9 and 31.2 liters/hr, respectively.",Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/458558/),[l] / [h],31.2,267926,DB00281,Lidocaine
,2646847,first-stage elimination half-life (t1/2 beta),The first-stage elimination half-life (t1/2 beta) of propofol in children was shorter (mean 9.3 +/- 3.8 (s.d.) min) than the values found in adults.,Propofol as an induction agent in children: pain on injection and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2646847/),min,9.3,268515,DB00281,Lidocaine
,15102415,V(1),"The best parameters of a three-compartment mammillary model fit to the measured concentration using the pooled data approach were: V(1) = 7.44, V(2) =11.5 and V(3) = 97.71; Cl(1) = 0.585, Cl(2) = 2.23 and Cl(3) =1.64 l/min.",The pharmacokinetics of lignocaine in humans during a computer-controlled infusion. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102415/),,7.44,269895,DB00281,Lidocaine
,15102415,V(2),"The best parameters of a three-compartment mammillary model fit to the measured concentration using the pooled data approach were: V(1) = 7.44, V(2) =11.5 and V(3) = 97.71; Cl(1) = 0.585, Cl(2) = 2.23 and Cl(3) =1.64 l/min.",The pharmacokinetics of lignocaine in humans during a computer-controlled infusion. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102415/),,11.5,269896,DB00281,Lidocaine
,15102415,V(3),"The best parameters of a three-compartment mammillary model fit to the measured concentration using the pooled data approach were: V(1) = 7.44, V(2) =11.5 and V(3) = 97.71; Cl(1) = 0.585, Cl(2) = 2.23 and Cl(3) =1.64 l/min.",The pharmacokinetics of lignocaine in humans during a computer-controlled infusion. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102415/),,97.71,269897,DB00281,Lidocaine
,15102415,Cl(1),"The best parameters of a three-compartment mammillary model fit to the measured concentration using the pooled data approach were: V(1) = 7.44, V(2) =11.5 and V(3) = 97.71; Cl(1) = 0.585, Cl(2) = 2.23 and Cl(3) =1.64 l/min.",The pharmacokinetics of lignocaine in humans during a computer-controlled infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102415/),,0.585,269898,DB00281,Lidocaine
,15102415,Cl(2),"The best parameters of a three-compartment mammillary model fit to the measured concentration using the pooled data approach were: V(1) = 7.44, V(2) =11.5 and V(3) = 97.71; Cl(1) = 0.585, Cl(2) = 2.23 and Cl(3) =1.64 l/min.",The pharmacokinetics of lignocaine in humans during a computer-controlled infusion. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102415/),,2.23,269899,DB00281,Lidocaine
,15102415,Cl(3),"The best parameters of a three-compartment mammillary model fit to the measured concentration using the pooled data approach were: V(1) = 7.44, V(2) =11.5 and V(3) = 97.71; Cl(1) = 0.585, Cl(2) = 2.23 and Cl(3) =1.64 l/min.",The pharmacokinetics of lignocaine in humans during a computer-controlled infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102415/),[l] / [min],1.64,269900,DB00281,Lidocaine
,15102415,V(1),"Similarly calculated parameters using NONMEM were V(1) = 6.99, V(2) =12.2 and V(3) =1341; Cl(1) = 0.703, Cl(2) =1.24 and Cl(3) =1.49 l/min.",The pharmacokinetics of lignocaine in humans during a computer-controlled infusion. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102415/),,6.99,269901,DB00281,Lidocaine
,15102415,V(2),"Similarly calculated parameters using NONMEM were V(1) = 6.99, V(2) =12.2 and V(3) =1341; Cl(1) = 0.703, Cl(2) =1.24 and Cl(3) =1.49 l/min.",The pharmacokinetics of lignocaine in humans during a computer-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102415/),,12.2,269902,DB00281,Lidocaine
,15102415,V(3),"Similarly calculated parameters using NONMEM were V(1) = 6.99, V(2) =12.2 and V(3) =1341; Cl(1) = 0.703, Cl(2) =1.24 and Cl(3) =1.49 l/min.",The pharmacokinetics of lignocaine in humans during a computer-controlled infusion. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102415/),,1341,269903,DB00281,Lidocaine
,15102415,Cl(1),"Similarly calculated parameters using NONMEM were V(1) = 6.99, V(2) =12.2 and V(3) =1341; Cl(1) = 0.703, Cl(2) =1.24 and Cl(3) =1.49 l/min.",The pharmacokinetics of lignocaine in humans during a computer-controlled infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102415/),,0.703,269904,DB00281,Lidocaine
,15102415,Cl(2),"Similarly calculated parameters using NONMEM were V(1) = 6.99, V(2) =12.2 and V(3) =1341; Cl(1) = 0.703, Cl(2) =1.24 and Cl(3) =1.49 l/min.",The pharmacokinetics of lignocaine in humans during a computer-controlled infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102415/),[l] / [min],1.24,269905,DB00281,Lidocaine
,15102415,Cl(3),"Similarly calculated parameters using NONMEM were V(1) = 6.99, V(2) =12.2 and V(3) =1341; Cl(1) = 0.703, Cl(2) =1.24 and Cl(3) =1.49 l/min.",The pharmacokinetics of lignocaine in humans during a computer-controlled infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102415/),[l] / [min],1.49,269906,DB00281,Lidocaine
,9010628,bioavailability,"After oral administration, D2624 was found to be well absorbed (93%), but underwent extensive first-pass metabolism in the rat, thus resulting in 5.3% bioavailability.","Pharmacokinetics and metabolism of the novel anticonvulsant agent N-(2,6-dimethylphenyl)-5-methyl-3-isoxazolecarboxamide (D2624) in rats and humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010628/),%,5.3,269986,DB00281,Lidocaine
,9010628,half-life,"D3017 was detected after all doses of parent drug, with approximate dose proportionality in AUC and a half-life of 1.3-2.2 hr.","Pharmacokinetics and metabolism of the novel anticonvulsant agent N-(2,6-dimethylphenyl)-5-methyl-3-isoxazolecarboxamide (D2624) in rats and humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010628/),h,1.3-2.2,269987,DB00281,Lidocaine
,3695734,systemic bioavailability,"The systemic bioavailability after P.O. was 31%, and between 32% and 53% for the rectal dosage forms.",Rectal bioavailability of lidocaine in the dog: evaluation of first-pass elimination. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3695734/),%,31,270394,DB00281,Lidocaine
,3695734,systemic bioavailability,"The systemic bioavailability after P.O. was 31%, and between 32% and 53% for the rectal dosage forms.",Rectal bioavailability of lidocaine in the dog: evaluation of first-pass elimination. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3695734/),%,32,270395,DB00281,Lidocaine
,3695734,systemic bioavailability,"The systemic bioavailability after P.O. was 31%, and between 32% and 53% for the rectal dosage forms.",Rectal bioavailability of lidocaine in the dog: evaluation of first-pass elimination. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3695734/),%,53,270396,DB00281,Lidocaine
,8701403,half-life,"A drawback in the use of rFVIIa has been its half-life of only about 2 h, which necessitates very frequent and punctual injections.",Feasibility of using recombinant factor VIIa in continuous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701403/),h,2,270452,DB00281,Lidocaine
,8701403,clearance,The second patient had a progressive decrease of the clearance from 86.4 to 24.7 ml/h/kg.,Feasibility of using recombinant factor VIIa in continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701403/),[ml] / [h·kg],86.4,270453,DB00281,Lidocaine
,8701403,clearance,The second patient had a progressive decrease of the clearance from 86.4 to 24.7 ml/h/kg.,Feasibility of using recombinant factor VIIa in continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701403/),[ml] / [h·kg],24.7,270454,DB00281,Lidocaine
,498711,rect,The mean rectal systemic availability was higher than the oral: 63% vs 31% (whole blood) and 71% vs 34% (plasma).,"Rectal bioavailability of lidocaine in man: partial avoidance of ""first-pass"" metabolism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/498711/),%,63,272520,DB00281,Lidocaine
,498711,rect,The mean rectal systemic availability was higher than the oral: 63% vs 31% (whole blood) and 71% vs 34% (plasma).,"Rectal bioavailability of lidocaine in man: partial avoidance of ""first-pass"" metabolism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/498711/),%,31,272521,DB00281,Lidocaine
,498711,rect,The mean rectal systemic availability was higher than the oral: 63% vs 31% (whole blood) and 71% vs 34% (plasma).,"Rectal bioavailability of lidocaine in man: partial avoidance of ""first-pass"" metabolism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/498711/),%,71,272522,DB00281,Lidocaine
,498711,rect,The mean rectal systemic availability was higher than the oral: 63% vs 31% (whole blood) and 71% vs 34% (plasma).,"Rectal bioavailability of lidocaine in man: partial avoidance of ""first-pass"" metabolism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/498711/),%,34,272523,DB00281,Lidocaine
,498711,rectal systemic availability,"The mean rectal systemic availability, based on plasma concentrations, was then 67% vs 27% orally.","Rectal bioavailability of lidocaine in man: partial avoidance of ""first-pass"" metabolism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/498711/),%,67,272524,DB00281,Lidocaine
,498711,rectal systemic availability,"The mean rectal systemic availability, based on plasma concentrations, was then 67% vs 27% orally.","Rectal bioavailability of lidocaine in man: partial avoidance of ""first-pass"" metabolism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/498711/),%,27,272525,DB00281,Lidocaine
,9269873,blood clearance,"Despite similar blood clearance (27.5 +/- 6.0 mL/min/kg vs 27.5 +/- 3.5 mL/min/kg), volume of distribution at steady state (1.38 +/- 0.08 L/kg vs 1.36 +/- 0.17 L/kg), and free fraction values of LD between days 1 and 10 (p > 0.05), intrinsic clearance values were consistently reduced (1224 +/- 859 mL/ min/kg vs 285 +/- 104 mL/min/kg; p = 0.034).",Effects of intravenous infusion of lidocaine on its pharmacokinetics in conscious instrumented dogs. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269873/),[ml] / [kg·min],27.5,273606,DB00281,Lidocaine
,9269873,blood clearance,"Despite similar blood clearance (27.5 +/- 6.0 mL/min/kg vs 27.5 +/- 3.5 mL/min/kg), volume of distribution at steady state (1.38 +/- 0.08 L/kg vs 1.36 +/- 0.17 L/kg), and free fraction values of LD between days 1 and 10 (p > 0.05), intrinsic clearance values were consistently reduced (1224 +/- 859 mL/ min/kg vs 285 +/- 104 mL/min/kg; p = 0.034).",Effects of intravenous infusion of lidocaine on its pharmacokinetics in conscious instrumented dogs. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269873/),[ml] / [kg·min],27.5,273607,DB00281,Lidocaine
,9269873,volume of distribution at steady state,"Despite similar blood clearance (27.5 +/- 6.0 mL/min/kg vs 27.5 +/- 3.5 mL/min/kg), volume of distribution at steady state (1.38 +/- 0.08 L/kg vs 1.36 +/- 0.17 L/kg), and free fraction values of LD between days 1 and 10 (p > 0.05), intrinsic clearance values were consistently reduced (1224 +/- 859 mL/ min/kg vs 285 +/- 104 mL/min/kg; p = 0.034).",Effects of intravenous infusion of lidocaine on its pharmacokinetics in conscious instrumented dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269873/),[l] / [kg],1.38,273608,DB00281,Lidocaine
,9269873,volume of distribution at steady state,"Despite similar blood clearance (27.5 +/- 6.0 mL/min/kg vs 27.5 +/- 3.5 mL/min/kg), volume of distribution at steady state (1.38 +/- 0.08 L/kg vs 1.36 +/- 0.17 L/kg), and free fraction values of LD between days 1 and 10 (p > 0.05), intrinsic clearance values were consistently reduced (1224 +/- 859 mL/ min/kg vs 285 +/- 104 mL/min/kg; p = 0.034).",Effects of intravenous infusion of lidocaine on its pharmacokinetics in conscious instrumented dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269873/),[l] / [kg],1.36,273609,DB00281,Lidocaine
,9269873,intrinsic clearance,"Despite similar blood clearance (27.5 +/- 6.0 mL/min/kg vs 27.5 +/- 3.5 mL/min/kg), volume of distribution at steady state (1.38 +/- 0.08 L/kg vs 1.36 +/- 0.17 L/kg), and free fraction values of LD between days 1 and 10 (p > 0.05), intrinsic clearance values were consistently reduced (1224 +/- 859 mL/ min/kg vs 285 +/- 104 mL/min/kg; p = 0.034).",Effects of intravenous infusion of lidocaine on its pharmacokinetics in conscious instrumented dogs. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269873/),[ml] / [kg·min],1224,273610,DB00281,Lidocaine
,9269873,intrinsic clearance,"Despite similar blood clearance (27.5 +/- 6.0 mL/min/kg vs 27.5 +/- 3.5 mL/min/kg), volume of distribution at steady state (1.38 +/- 0.08 L/kg vs 1.36 +/- 0.17 L/kg), and free fraction values of LD between days 1 and 10 (p > 0.05), intrinsic clearance values were consistently reduced (1224 +/- 859 mL/ min/kg vs 285 +/- 104 mL/min/kg; p = 0.034).",Effects of intravenous infusion of lidocaine on its pharmacokinetics in conscious instrumented dogs. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269873/),[ml] / [kg·min],285,273611,DB00281,Lidocaine
,9269873,hepatic tissue uptake,"Furthermore, hepatic tissue uptake of LD and/or its metabolites was less on day 10 than on day 1 (39.7 +/- 14.5 micromol vs 30.1 +/- 15.1 micromol; p = 0.072).",Effects of intravenous infusion of lidocaine on its pharmacokinetics in conscious instrumented dogs. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269873/),μM,39.7,273612,DB00281,Lidocaine
,9269873,hepatic tissue uptake,"Furthermore, hepatic tissue uptake of LD and/or its metabolites was less on day 10 than on day 1 (39.7 +/- 14.5 micromol vs 30.1 +/- 15.1 micromol; p = 0.072).",Effects of intravenous infusion of lidocaine on its pharmacokinetics in conscious instrumented dogs. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269873/),μM,30.1,273613,DB00281,Lidocaine
